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Abstract 
Chronic obstructive pulmonary disease (COPD) is an incurable global health burden 
and is characterised by progressive airflow limitation and loss of lung function.  In 
addition to the pulmonary impact of the disease, COPD patients often develop comorbid 
diseases such as cardiovascular disease and skeletal muscle wasting, lung cancer and 
osteoporosis.  One key feature of COPD, yet often underappreciated, is the contribution 
of oxidative stress in the onset and development of the disease.  Patients experience an 
increased burden of oxidative stress due to the combined effects of excess reactive 
oxygen (ROS) and nitrogen species (RNS) generation, antioxidant depletion and 
reduced antioxidant enzyme activity.  Currently, there is a lack of effective treatments 
for COPD, and an even greater lack of research regarding interventions that treat both 
COPD and its comorbidities.  Due to the involvement of oxidative stress in the 
pathogenesis of COPD and many of its comorbidities, a unique therapeutic opportunity 
arises where the treatment of a multitude of diseases may be possible with only one 
therapeutic target.  
 
In this thesis, we used an established smoke exposure preclinical model of COPD to 
assess the effectiveness of two novel antioxidant therapies ebeselen and apocynin. 
Using these compounds, we aimed to determine whether targeting the oxidant-
dependent mechanisms that drive COPD and its co-morbidities would have a positive 
impact on the pulmonary and extrapulmonary manifestations of the disease, specifically 
in comorbid skeletal muscle wasting. Using this smoke exposure model, we were able 
to induce several of the key characteristics of COPD including lung inflammation, 
systemic inflammation, skeletal muscle wasting and oxidative damage. 
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We assessed the effectiveness of two antioxidant therapies that act on different levels of 
the reactive oxygen species cascade via differing mechanisms of action. In Chapter 3, 
we first assessed the efficacy of the Gpx-1 mimetic ebselen, exploring the impact of 
enhanced hydrogen peroxide reduction in an established animal model of COPD. 
Ebselen successfully reduced smoke-induced increases in lung inflammation, lung 
inflammatory cytokine and chemokine mRNA expression. In contrast, Ebselen had no 
effect on smoke-induced skeletal muscle and WAT wasting, expression of muscle 
growth signaling pathways, muscle contractility and function. 
 
In Chapter 4, apocynin was used to reduce superoxide production via inhibition of 
NOX-2 in the same in vivo model of COPD. Apocynin proved to be the more effective 
compound, as it was able to treat both pulmonary and skeletal muscle manifestations in 
this model. Apocynin successfully reduced CS-induced increases in lung inflammation, 
lung inflammatory cytokine and chemokine mRNA expression, and lung mass. 
Apocynin also reduced smoke-induced skeletal muscle and WAT wasting, improved 
muscle contractility and function, and reduced oxidative damage to muscle tissue. In 
addition to this, we explored the use of an in vitro hydrogen peroxide exposure model in 
C2C12 myotube cells to investigate the mechanisms behind oxidant-dependent 
alterations in skeletal muscle. 
 
In Chapter 5, we designed, developed and validated a novel methodology of assessing 
cardiac morphology and function in rodents using transthoracic echocardiography, and 
aimed to eventually use this methodology to assess the effect of antioxidant therapy in 
cardiovascular comorbidities of COPD. We demonstrated that examination using the 
modified mid-right ventricle views has the potential to provide a comprehensive 
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assessment of the RV particularly when standard transthoracic views are often 
suboptimal. We found that these views enable a large section of the right ventricle free 
wall to be imaged, enabling assessment of dilatation, wall hypertrophy and also 
demonstrated that strain analysis is feasible in rodent models of disease. 
 
Because of the unique interplay between oxidative stress and these diseases, oxidative 
stress represents a novel target for the treatment of COPD and its comorbidities. The 
primary findings of this thesis highlight the use of novel antioxidant compounds as 
viable therapeutic alternatives for the treatment of both pulmonary and extrapulmonary 
manifestations of COPD. Additionally, validated methods for the identification of the 
mechanisms that drive the onset and development of comorbidities were established, 
providing a framework for future studies. 
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Chapter 1: General Introduction
  2 
This general introduction chapter was published as a literature review in the Journal of 
Pharmacology and Therapeutics in 2015 and entitled “Targeting oxidant-dependent 
mechanisms for the treatment of COPD and its comorbidities.”  It has been adapted for this 
thesis. 
1. Introduction 
 
An increased burden of oxidative stress is an important feature of the pathogenesis of chronic 
obstructive pulmonary disease (COPD) and its associated comorbid diseases (comorbidities). 
Current forms of therapy for COPD are largely ineffective and the development of effective 
treatments for COPD have been severely hampered as the mechanisms and mediators that 
drive the induction and progression of chronic inflammation, emphysema, altered lung 
function, defective lung immunity and many extrapulmonary comorbidities are still poorly 
understood.  What is known is that four primary mechanisms have been implicated in the 
pathophysiological alterations observed in COPD: oxidative stress; inflammation; protease-
antiprotease imbalance; and apoptosis [1-3].  Although mostly underappreciated, oxidative 
stress has been recognized as a central component in the pathogenesis of COPD as it can 
trigger and further potentiate the other three mechanisms.  In this review we focus on the role 
of oxidative stress in the pathogenesis of COPD and its comorbidities.  Given its pivotal role 
in the onset and development of COPD, oxidative stress may be a novel target for the 
treatment of COPD and its comorbidities. 
 
1.1. COPD Overview 
COPD represents an increasing global burden, afflicting over 600 million people and 
corresponding to approximately 5% of all deaths globally [4].  It is currently the third leading 
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cause of death [5].  It is well known that lower/middle income countries bear most of the 
burden of COPD with almost 90% of COPD-related deaths worldwide taking place in these 
countries [6].  Although the incidence rate of COPD is likely to escalate in both developed 
and developing countries, COPD poses a heavier burden on the Asia-pacific and African 
regions where smoking is still widespread and gradually increasing [7, 8].  Cigarette smoke is 
inarguably the biggest risk factor for COPD, with 90% of deaths from COPD directly 
attributable to smoking [9].  Other risk factors include exposure to air pollutants and biomass 
fuels [10].  In addition, there is generally a long latency period between exposure to smoke 
and clinically-evident disease and as such, there is a high incidence of COPD in the older 
population and ex-smokers [11].  This latency period generally lasts a number of years and by 
the time patients become symptomatic, the damage is already irreversible. 
COPD is characterized by persistent airflow limitation and lung inflammation 
resulting in a progressive decline in lung function [12].  The main symptoms of the disease 
are chronic cough (smokers cough), excessive mucus production and dyspnoea (particularly 
during exercise) [11]. In addition to the pulmonary manifestation of COPD, many systemic 
manifestations occur in the form of comorbid diseases, such as skeletal muscle wasting, 
cardiac dysfunction, osteoporosis and lung cancer [13-15]. These comorbidities have been 
associated with increased oxidative stress and are known to affect, or are strong predictors of, 
the mortality of COPD patients independent of the decline in lung function [16-19]. 
Although COPD is a largely preventable disease, the numbers of diagnoses continue 
to increase resulting in ever increasing medical costs to patients, communities and 
governments [5, 20].  COPD patients generally have long hospital stays, require long-term 
treatments, and in addition to these medical costs, other “costs” such as an increase in days 
missed from work and limitations to quality of life, are important consequences of this 
disease [21, 22]. 
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1.1.1. Acute exacerbations of COPD 
Patients with COPD often experience episodes of sudden worsening of symptoms, known as 
acute exacerbations (AECOPD).  The Global initiative for Chronic Obstructive Lung Disease 
(GOLD) defines an exacerbation as ‘‘a change in the patient’s baseline dyspnoea, cough, 
and/or sputum and beyond normal day-to-day variations, that is acute in onset and may 
warrant a change in regular medication in a patient with underlying COPD”. These 
exacerbations are considered to be part of the natural progression and chronicity of the 
disease and as COPD progresses, exacerbations become increasingly more frequent [23, 24]. 
Exacerbations result in a dramatic increase in lung inflammation and are associated with 
increased systemic inflammation compared to stable disease where there is only an increase 
in oxidative stress markers [25]. This contributes to the worsening of symptoms and it has 
been shown that following hospitalisation for AECOPD, patients have increased mortality 
rates [26]. 
AECOPD is often triggered by respiratory infections, such as those caused by the 
bacteria Streptococcus Pneumoniae and Influenza A Virus, or acute exposure to airborne 
irritants [24, 27]. There are also many non-aetiological risk factors that contribute to the 
frequency of exacerbations such as age, frequent past exacerbations and the presence of 
comorbid diseases (especially cardiovascular disease) [28].  The rates of exacerbations vary 
dramatically depending on the parameters used to define an exacerbation, however, rates of 
severe AECOPD measured by hospitalisations occur at an approximate rate of 0.5 to 
3.6/person-year depending on the study cited [29, 30].  The outcomes of AECOPD can vary 
from the return to near baseline spirometric parameters to respiratory failure and death.  
Exacerbations are the largest direct cost for the treatment of COPD due to the length of 
hospital stays and the frequency of the exacerbations per patient [24, 31, 32].  
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1.2. Oxidative Stress in COPD 
1.2.1. What is oxidative stress? 
Oxidative stress refers to the imbalance between the oxidant and antioxidant levels in favour 
of a pro-oxidant environment in cells and tissues [33].  An oxidant is a species that causes or 
promotes oxidation and an antioxidant is a molecule that inhibits either the formation of 
oxidants or inhibits oxidation itself.  Oxidative stress arises from the inability of innate 
antioxidant mechanisms to neutralise oxidants generated endo- or exogenously resulting in an 
imbalance between oxidant and antioxidant factors [34]. Consequentially, the oxidants 
predominate and chronic oxidative stress occurs, leading to the modification of lipids, 
proteins, and DNA [35, 36].  The harmful modifications caused by oxidative stress are 
referred to as oxidative damage. 
Oxidative stress can result from increased production of oxidants (in the form of free 
radicals/reactive oxygen and nitrogen species) or from diminished antioxidant levels or 
reduced antioxidant enzyme activity [33]. The depletion of dietary antioxidants (e.g., 
vitamins E, C, and D, flavonoids and carotenoids) and micronutrients (e.g., iron, copper, zinc, 
selenium) can also contribute to oxidative stress insufficient amounts impair antioxidant 
enzyme activity [37].  In chronic inflammatory conditions, such as COPD, oxidative stress 
primarily results from the increased production of reactive oxygen species (ROS) from 
exposure to toxins (e.g. cigarette smoke, infection) and continuous activation of endogenous 
enzymes (e.g. NADPH oxidases) (Figure 1). 
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Figure 1.  Overview of oxidative stress in the pathogenesis of COPD.   
The generation of reactive oxidant species both exogenously and endogenously can lead to 
the onset and development of COPD and its comorbidities.  Reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) are found in cigarette smoke but in COPD the primary 
sources of ROS and RNS are from inflammatory cells including macrophages, neutrophils 
and epithelial cells.  When activated by inhaled irritants (e.g. cigarette smoke), enzymatic 
(e.g. NADPH oxidase) generation of oxidants leads to the depletion of scavenging 
antioxidants (e.g. vitamin E), resulting in oxidative stress. 
 
 
1.2.2. COPD and oxidative stress 
The prolonged increase in oxidative stress is a major factor in potentiating both the airway 
and systemic inflammation in COPD and is known to play a key role in the onset and 
development of COPD and its comorbidities [38-40].  Direct damage occurs due to the 
oxidants found in cigarette smoke and from excessive levels of ROS and reactive nitrogen 
species (RNS) produced as a result of both pulmonary and systemic inflammation. An 
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increase in ROS production in the airways is reflected by elevated levels of markers of 
oxidative stress (e.g. superoxide and malondialdehyde) in the airspaces, sputum, breath, 
lungs, and blood in patients with COPD [25, 35].  These levels of oxidative stress markers are 
also dramatically increased during exacerbations of COPD [41].  Due to the nature of the 
oxidative burden and its consequences in the progression of COPD, this review is primarily 
focused on the role of ROS/RNS in the pathogenesis of COPD and its comorbidities, and the 
potential pharmacological targets related to ROS signalling. 
 
1.2.3. Environmentally-derived ROS 
Each puff of cigarette smoke contains more than 1015-17 oxidant/free radical molecules and 
over 4,700 highly reactive chemical compounds, such as aldehydes and quinones, which 
increases the oxidant burden in smokers [35, 40, 42-45].  The nature of ROS found within 
cigarette smoke varies from short-lived oxidants, such as the superoxide radical (O2•-) and the 
nitric oxide radical (NO•), to long-lived organic radicals, such as semiquinones that can 
undergo redox cycling within the epithelial lining fluid of smokers for some considerable 
period of time [43, 46]. Lung and systemic formation of protein carbonyls in response to 
cigarette smoke-derived lipid peroxides/carbonyls have also been implicated in the 
pathogenesis of COPD [38].  
In addition to the release of oxidants, cigarette smoking is also associated with an 
increased amount of myeloperoxidase (MPO) in neutrophils, an oxidising factor that forms 
hypochlorous acid and converts tyrosine to tyrosyl radical [47].  Studies have shown a 
correlation between the content of MPO in neutrophils and the degree of pulmonary 
dysfunction observed in patients [48].  In addition, studies suggest that neutrophil MPO-
mediated oxidative stress plays a role in lung inflammation [49].  It is also known that 
cigarette smoke can cause the activation of alveolar macrophages, which is observed in the 
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bronchoalveolar lavage fluid (BALF) from the lungs of smokers and COPD patients but not 
present in non-smokers.  The activation of macrophages contributes to the endogenous 
generation of ROS in the respiratory tract [50, 51]. 
 
1.2.4. Cellular derived ROS 
Cellular-derived ROS is enzymatically produced by inflammatory and epithelial cells within 
the lung and/or systemically as part of an inflammatory-immune response towards a pathogen 
or irritant [52].  Production of ROS by phagocytes can be enhanced by oxidants present in 
cigarette smoke leading to the release of inflammatory mediators [45].  Several sources for 
ROS production exist within a cell; however, the primary ROS generator is the enzyme 
NADPH oxidase (NOX), which comes in various isoforms: NOX-1, NOX-2, and NOX-4 [53, 
54].  In humans, NOX-1 and 2 are significant ROS-generators which are made up of an 
enzyme complex which is present in phagocytic and non-phagocytic cells including epithelial 
cells, macrophages, and skeletal muscles [55, 56]. Although NOX is found in many cell 
types, it is latent in neutrophils under normal circumstances [57]. Once activated, neutrophils 
and macrophages can generate ROS via the NADPH oxidase system, leading to further 
augmentation of oxidative stress in the lungs of smokers and COPD patients (Figure 2).  
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Figure 2.  Cellular generation of reactive oxygen and nitrogen species in COPD.   
Cigarette smoke acts on inflammatory cells in the lung (e.g. macrophages, neutrophils, 
epithelium) where activation of NADPH oxidase 2 (Nox2) generates superoxide radicals 
(O2•-) which can then either react with nitric oxide (NO•) to form the reactive peroxynitrite 
molecule (ONOO-) or be rapidly converted to hydrogen peroxide (H2O2) via the enzymatic 
activity of superoxide dismutase (SOD).  In the presence of Fe2+, H2O2 can be converted into 
the more damaging hydroxyl radical (•OH) via the Fenton reaction.  This reaction causes the 
oxidation of Fe2+ to Fe3+, and in this oxidation state, the presence of iron can directly generate 
•OH from O2•-.  These iron reactions have increased importance in COPD as a higher 
concentration of iron has been reported in the lungs of smokers, thereby increasing the 
potential ROS burden [58]. The glutathione peroxidase (Gpx) family of enzymes, and 
catalase (CAT) are responsible for the conversion of H2O2 into harmless water and oxygen, 
which effectively reduces circulating ROS and thus reduces the oxidative burden [59]. 
 
 
NOX-generated ROS have long been recognized to play key roles in the pathogenesis 
of a number of diverse chronic lung disorders that result in obstructive physiology, in 
particular asthma, cystic fibrosis, and emphysema [56].  Mice deficient in p47phox or NOX-2 
exhibit increased cigarette smoke–induced lung inflammation and emphysema despite 
decreased ROS production compared with control mice [60]. The lung responses in p47phox- 
and NOX2-null mice were associated with increased production of pro-inflammatory 
O2•-
NO•
H2O2
ONOO-
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H2O + O2
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cytokines and chemokines via a TLR4-NF-kB pathway, indicating that NOX-2 may mediate 
anti-inflammatory functions by restraining TLR4 activation [60].  However, another group 
reported that p47phox-null mice have less inflammation, IL-6, keratinocyte-derived 
chemokine, and monocyte chemoattractant protein-1 in lung-lavage specimens after cigarette-
smoke exposure compared with WT mice [61].  The differences observed by these groups 
may be due to variability in lung compartment sampling, cellular distributions, and chronicity 
of cigarette-smoke exposure. 
 
1.2.5. Reactive nitrogen species 
Although increased production of ROS is the primary mechanism of oxidative stress in 
COPD/chronic lung diseases/acute lung diseases, there is compelling evidence to suggest that 
RNS also play a role in disease [62, 63].  Reactive nitrogen species include nitric oxide 
(NO•), a nitrogen free radical, and its derivative species such as peroxynitrite and nitrogen 
dioxide (Figure 3).  As with ROS, in addition to generation endogenously, RNS are present in 
cigarette smoke and air pollutants in the form of NO• and has many of the same harmful 
effects as ROS [64].  Endogenously, NO• is associated with a multitude of signalling 
pathways in mammalian physiological and pathological processes; however, in excess it too 
causes indiscriminate damage to surrounding tissues and can react with O2•- forming the even 
more harmful peroxynitrite radical (ONOO-). 
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Figure 3.  The reactive nitrogen species cascade.   
In addition to its ability to cause direct damage, ONOO− can also react with carbon dioxide 
(CO2) in vivo.  The reaction between ONOO- and CO2 occurs rapidly under physiological 
conditions, forming nitrosoperoxycarbonate (ONOOCO2-).  ONOOCO2− homolyzes (the 
molecule dissociates into 2 free radicals) to form the carbonate radical (•CO32-) and nitrogen 
dioxide (•NO2) [33].  It is these radicals (•CO32- and •NO2) that are believed to cause 
peroxynitrite-related cellular damage.  The conjugate acid of peroxynitrite, peroxynitrous 
acid (HNO3) also homolyzes into •OH and •NO2 radicals, adding to the oxidative burden 
caused by peroxynitrite [65]. 
 
 
Nitric oxide  
For years, NO• had only been considered as a toxic, unstable free radical gas that was just a 
constituent of air pollutant and cigarette smoke.  However, it is now known that NO• can be 
generated endogenously in several types of cells [66]. This implicated NO• in various 
physiological roles and pathways, including host defense, vascular regulation and neuronal 
communication [33]. NO• has been well characterized in human biology and is perhaps the 
most important endogenous vasoprotective molecule in addition to its role in cardiovascular 
function [67-70]. NO• inhibits vascular smooth muscle contraction and growth, platelet 
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aggregation, and leukocyte adhesion to the endothelium, contributing to vascular homeostasis 
[67-72]. Individuals with hypertension, atherosclerosis and/or diabetes often show impaired 
NO• signalling, highlighting the importance of NO• with regards to comorbid cardiovascular 
disease [73] (see below). 
 Nitric oxide is generated by phagocytes and is biosynthesized endogenously from 
the amino acid L-arginine, oxygen, and NADPH by various nitric oxide synthase (NOS) 
enzymes [74].  In addition to its signalling roles, NO• has both pro-oxidant and antioxidant 
activities; excessive NO• can cause direct oxidative damage, however, NO• can also scavenge 
circulating ROS [75, 76].  More importantly, O2•- can react directly with endothelium-derived 
NO• forming the harmful peroxynitrite (ONOO-) molecule. 
 
Peroxynitrite 
Peroxynitrite is formed by the reaction between O2•- and NO• in vivo.  The pairing of these 2 
radicals results in ONOO- anion, which is not a free radical but is still a very potent oxidant.  
ONOO- is both an oxidizing and nitrating agent and can thus damage a wide array of 
molecules, including DNA and proteins [77, 78].  The formation of ONOO- is of particular 
relevance to the comorbidities of COPD as its formation involves the consumption of NO•, 
reducing the bioavailability of NO• for physiological processes (see Section 3.2.3). 
 
1.2.6. Depletion of antioxidants 
ROS/RNS generated exogenously or endogenously, whether circulating or in pulmonary 
vasculature, are scavenged by blood antioxidants and antioxidant enzymes.  Accordingly, the 
ability to protect against the deleterious effects of oxidative stress depends greatly on the 
antioxidant capacity of the blood and the tissues [79, 80]. Studies have shown that in addition 
to the increased levels of circulating oxidants, there is also an observed decrease in systemic 
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antioxidant capacity in smokers and patients with COPD [81]. This is due to the saturation of 
lung antioxidants, plasma antioxidants and protein sulfhydryls by the excessive amounts of 
circulating ROS released by neutrophils and macrophages [81].  The saturation of many of 
these antioxidants, such as uric acid, glutathione (GSH), vitamin E, and ascorbate is also 
associated with the severity of COPD exacerbations [82].  Cigarette smoke, the main 
etiological risk factor for COPD, has also been shown to irreversibly modify glutathione to 
glutathione conjugates in the airway epithelium resulting in antioxidant deficiency and 
injurious lung response [83].  Cigarette smoking also inhibits the protective expression of the 
Nrf2/antioxidant response element pathway in peripheral mononuclear cells of smokers, 
favouring a pro-inflammatory state [84].  In addition to the antioxidant saturation, studies 
have also shown a decrease in anti-oxidative enzyme function in COPD patients; specifically 
reduced SOD and Gpx activity [85].  
There is evidence to suggest that the anti-oxidant enzyme glutathione peroxidase-1 
(Gpx-1) may have a role in regulating the inflammatory response to cigarette smoke 
exposure.  Elevated levels of H2O2 are measured in the exhaled breath condensate of COPD 
patients, particularly during exacerbations [86]. There is upregulation of Gpx-1 gene 
expression in the lungs of smokers [87] and depletion of Gpx activity in COPD patients and 
smokers [88-90].  With respect to reduced Gpx activity in COPD patients and smokers, 
erythrocyte Gpx activity was significantly lower in patients with severe COPD compared 
with patients with moderate COPD and there is a direct relationship between systemic Gpx 
activity and [90].  In addition, Gpx activity was decreased in plasma from COPD patients and 
oxidative stress correlates with both lung function and body mass index in COPD [88].  
Moreover, Gpx activity was decreased in total blood from smokers and ex-smokers [89]. 
However, these studies did not identify the isoform of Gpx that was involved in reduced 
activity of Gpx. 
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1.3. Oxidative modifications 
Oxidative stress causes a wide array of physiological and pathological consequences not 
necessarily limited to just COPD patients.  In COPD, increased oxidative stress can cause cell 
damage, cell necrosis, apoptosis, autophagy, remodelling of extracellular matrix and blood 
vessels, endothelial dysfunction, inactivation of antiproteases, premature cellular senescence, 
elevated mucus secretion, steroid resistance, unfolded protein response, cell proliferation, 
epigenetic changes, and autoimmunity [35, 40, 91].  Oxidative modifications of DNA, 
proteins and lipids all contribute to the pathophysiology of the disease. 
 
DNA 
Unlike the other ROS and RNS which do not react with DNA bases or deoxyribose, the 
hydroxyl radical and peroxynitrite can react with both purine (adenine & guanine) and 
pyrimidine (cytosine & thymine), forming specific products [92].  This oxidative damage can 
lead to mutation of DNA bases caused by AT-GC transition and GC-TA transversion and, if 
left unrepaired, can result in changes in protein gene expression [33].  In addition to this, 
ROS/RNS-induced DNA damage also involves single- or double-stranded DNA breaks and 
DNA cross-links, DNA damage inducing either arrest or induction of transcription, induction 
of signal transduction pathways, replication errors, and genomic instability [93]. 
 
Protein 
Oxidative modifications to proteins caused by ROS/RNS include protein fragmentation, 
oxidation of amino acids, the formation of carbonyls, dityrosine and nitrated and chlorinated 
tyrosines [94, 95].  In COPD and other inflammatory diseases, elevated levels of nitrated, 
chlorinated and brominated tyrosines have been detected in the tissues of patients [96]. These 
oxidative changes to proteins can result in various functional consequences, such as 
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inhibition of enzymatic and binding activities, increased susceptibility to aggregation and 
proteolysis, modifications in uptake by cells, and altered immunogenicity [97]. 
 
Lipids 
In the presence of ROS/RNS and oxygen, lipids undergo a chain oxidation reaction leading to 
peroxidation.  This chain reaction is initiated by oxidants, primarily the hydroxyl radical and 
leads to the formation of lipid peroxide and lipid radicals, which can then reinitiate the chain 
reaction [98]. This process continues indefinitely unless terminated by phenolic antioxidants, 
also known as chain-breaking antioxidants (e.g. vitamin E) [33] (Figure 4).  This is especially 
important in comorbid cardiovascular disease where the formation of plaques in the arteries is 
initiated from lipid peroxidation [99]. 
  
  16 
 
Figure 4. Oxidants (•OH) abstract the allylic hydrogen from lipid molecules (LH) 
forming the carbon-centered lipid radical.  
This radical then undergoes molecular rearrangement to form a more stable form of the 
carbon-centered radical (L•). In the presence of oxygen, L• rapidly forms a lipid peroxy 
radical (LOO•). This new radical can then abstract an allylic hydrogen from another lipid 
molecule generating a new L•. This process can be terminated by the donation of a hydrogen 
atom from vitamin E to the LOO• species forming a vitamin E radical. The vitamin E radical 
then reacts with another LOO• forming non-radical products and thus terminating the 
reaction. 
 
 
1.4. Effects of oxidative stress 
ROS and RNS normally play roles in cell signalling and homeostasis; however, in excess 
they become increasingly toxic.  The ROS and RNS O2•-, ONOO-, H2O2 and •OH, in addition 
to their indiscriminate oxidization of proteins, lipids and DNA [100], can result in direct lung 
damage or induce an assortment of cellular responses.  Additionally, these oxidants also 
influence the inflammatory responses in the lungs via various pathways such as the activation 
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of transcription factor NF-κB, and transcription of pro-inflammatory mediator genes, further 
potentiating the inflammatory response in COPD [58].  This induces a pro-inflammatory state 
that drives the sustained production of more ROS, leading to a vicious cycle of oxidative 
stress and inflammation.  The oxidative damage and modifications caused by ROS are known 
to precede the characteristic respiratory changes seen in COPD such as airway remodelling 
and emphysema [101].  Recent studies have also shown a decrease in glucocorticosteroid 
receptor expression as a result of prolonged oxidative stress indicating that in a pro-oxidant 
environment, such as in COPD patients, steroid therapy is of limited therapeutic benefit 
highlighting the need for new treatments [102]. 
 
1.4.1. Systemic oxidative stress 
Even after smoke cessation, systemic oxidative stress still persists in COPD patients [103].  
This is reflected by an elevation in circulating ROS and a depletion of antioxidants [104].  
The increased oxidative stress is likely due to the persistent low grade systemic inflammation 
resulting in the production of ROS systemically [105].  This systemic oxidative stress has 
been implicated in various systemic manifestations of COPD, with many studies associating 
this increased burden of oxidative stress with skeletal muscle wasting and cardiovascular 
disease in COPD [105-107].  In addition to the links between oxidative stress in COPD and 
comorbid diseases, increased extrapulmonary oxidative stress is also an independent risk 
factor of many comorbidities such as cardiovascular disease, osteoporosis and depressive 
disorders in patients without COPD [108-110]. 
 
1.5. Oxidative stress in comorbidities of COPD  
A prominent feature of COPD is the presence of comorbid diseases (or comorbidities) in 
patients [13, 15].  These diseases can range from more “mild” or indirectly fatal conditions 
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that affect quality of life such as osteoporosis and depression, to more directly fatal diseases 
such as ischaemic heart disease and cancer.  COPD-related mortality is likely underestimated 
due to these comorbidities as their presence makes it difficult to determine the precise cause 
of death.  Respiratory failure is considered to be the major cause of death in advanced COPD; 
however, comorbidities such as cardiovascular disease and lung cancer are also major causes 
of death.  In early/mid stages of COPD, comorbidities are the leading causes of mortality 
[19].  Comprehensive studies on the specific cause of deaths in COPD patients have found 
that rather than dying from progressive respiratory failure, many COPD patients die from a 
complex web of interconnected comorbidities [102].  For the purpose of this review, 
comorbidities are defined as the presence of one or more distinct diseases or disorders that 
are not directly related to COPD or are not part of the natural history/progression of the 
disease (e.g. respiratory infections resulting in AECOPD).  The underlying mechanisms 
resulting in these systemic manifestations in COPD are not fully understood; however, they 
have been linked to the persistent low-grade systemic inflammation and persistent oxidative 
stress in COPD as discussed earlier. 
1.6. Skeletal Muscle Wasting 
1.6.1. Skeletal muscle wasting overview 
Skeletal muscle wasting, also referred to as cachexia or skeletal muscle atrophy, occurs in 
approximately 20 to 40% of all COPD patients [17, 111, 112].  Muscle wasting is 
characterized by a marked decrease in skeletal muscle mass, an increase in proportion of type 
I muscle fibres in the diaphragm and type 2 muscle fibres in the periphery, and associated 
with low exercise capacity and skeletal muscle weakness [112].  Skeletal muscle wasting in 
COPD is a strong predictor of mortality, independent of decline in lung function [16-18].  
Although present in a large population of patients, the prevalence of muscle wasting can only 
be approximated as there are no simple techniques to measure muscle mass.  Knowing this, 
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the actual prevalence and extent of muscle wasting in the COPD population is likely 
underestimated.  This is because the data is extrapolated from body weight measurements and 
lean body mass, an index of muscle mass, may be reduced despite the preservation of total 
body weight.  This is further supported by the fact that patients have a proportionally greater 
reduction in thigh muscle cross-sectional area compared to reduction in body weight [16].  
This indicates that a preferential loss of muscle tissue exists in emaciated patients with COPD 
[96]. 
Skeletal muscle wasting, although not a directly fatal condition, reduces health-related 
quality of life and decreases survivability for COPD patients.  The main feature of comorbid 
skeletal muscle wasting is a reduction in fat free mass (FFM) and is associated with weaker 
peripheral muscles, impaired functional status, as well as poor health-related quality of life 
[113, 114].  In COPD, the reduction in muscle mass is proportional to that of the reduction in 
strength indicating that the remaining contractile apparatus may be functionally preserved.  
However, in patients chronically treated with glucocorticosteroids, it is possible for the loss 
of strength to be disproportional to the reduction in muscle mass. 
 Deteriorations in FFM have also been described following acute exacerbations.  These 
COPD patients also experience a reduction in exercise capabilities, with skeletal muscle 
alterations contributing to limitations in exercise in addition to pulmonary dysfunction [115].  
It should be noted that the strength of the quadriceps is a key determinant of exercise 
tolerance in COPD.  This is explained by the influence that muscle strength has on the 
perceived leg effort required during exercise, which is considered to be the main limiting 
symptom in 40–45% of patients with COPD [116]. 
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1.6.2. Mechanisms of skeletal muscle dysfunction 
The pathophysiological interaction between COPD and alterations in skeletal muscle tissue is 
poorly understood and represents an important gap in knowledge of the disease.  Skeletal 
muscle wasting in COPD is multifactorial in nature with several of these factors likely 
interacting.  Many factors (e.g. inflammation, oxidative stress, and poor nutrition) can initiate 
or enhance alterations in skeletal muscle, such as change in fibre type phenotypic expression 
and regenerative defects in peripheral muscles of patients with COPD [112].  In this review, 
multiple risk factors will be briefly discussed along with a more in depth discussion regarding 
the role of oxidative stress and ROS. 
 
Smoking 
Cigarette smoking or exposure to other airborne irritants is unlikely to be the primary 
mechanism involved in skeletal muscle wasting in COPD, as seen in several studies where 
patients and control subjects were matched for smoking history [112].  Nevertheless, smoking 
does have some effect on muscle biology and it may predispose patients to the development 
of skeletal muscle dysfunction [117, 118].  Smoking is also associated with skeletal muscle 
weakness in otherwise healthy individuals [119-121]. 
 
Disuse 
Peripheral (or limb) muscle dysfunction in COPD has been partly attributed to a reduction in 
physical activity, or “deconditioning.”  In general, the disuse of muscle can lead to many of 
the features and alterations of skeletal muscle in COPD patients: muscle weakness, muscle 
atrophy, loss of type I fibres, decreased cross-sectional area of muscle fibres, reduced 
oxidative enzyme activity, reduced capillary-to-fibre ratio, early lactate release, reduced rate 
of phosphocreatine synthesis after exercise and altered redox status [122-125].  In healthy 
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adults these changes are fully reversible in response to training and increased exercise; 
however, full recovery is unusual in COPD patients [125-128]. 
 
Inflammation 
A low body mass index (BMI) has been linked to systemic inflammation in COPD patients. 
As seen in Figure 5, inflammation plays a key role in the activation of protein breakdown in 
skeletal muscle.  Inflammation results in the production of key cytokines, such as IL-8, that 
can generate an array of cellular responses.  This includes the induction of the ubiquitin 
proteasome (UbP) system through the transcriptional activities of NK-κB and FOXOs, 
apoptosis, and macroautophagy, all of which have been linked to the muscle atrophy [129].  
In COPD patients, there is a lack of evidence with regards to inflammation in skeletal muscle 
during stable disease [130, 131]; however, increased inflammation is seen during periods of 
exacerbation [132, 133].  Because of this, the role of inflammation as the key event for the 
development of skeletal muscle dysfunction in COPD is still widely debated. 
 
Hypoxia 
In humans [134] and animals [135] muscle mass decreases under hypoxic conditions.  COPD 
patients that have low arterial O2 and reduced O2 delivery tend to have lower body mass than 
those with normal levels of arterial O2 and sufficient O2 delivery [136].  Hypoxia may be a 
factor driving changes in limb muscle tissue as hypoxia can induce downstream effects 
leading to the activation of the UbP system and reduced myogenesis [137]. 
 
1.7. Oxidative stress in skeletal muscle wasting 
In addition to chronic inflammation, hypoxia, cigarette smoke, sepsis and an increased cost of 
breathing cause the increased generation of oxidants in the lungs (e.g. H2O2, O2•-, MDA) [35].  
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It is suggested that, in addition to inflammatory mediators, these oxidants can spill into 
circulation, increasing the systemic oxidative stress burden of COPD patients [138].  In in 
vivo models of skeletal muscle wasting in COPD, increased oxidative stress has been 
observed [118].  This increase in oxidative stress can modify muscle proteins, reducing their 
integrity and enhancing their degradation [139].  Direct exposure to oxidative stress from 
environmentally derived oxidants, or indirect exposure via cellular-derived ROS due to 
inflammation, can induce proteolysis.  Acute bouts of physical exercise and acute 
exacerbations can also increase the level of oxidative stress [25, 140, 141].  It is suggested 
that oxidative stress may acutely affect skeletal muscle function by inhibiting the activity of 
the sodium/potassium pump, sarcoplasmic reticulum function, myosin ATPase and 
mitochondrial respiration [115].  In addition to these acute effects, chronic oxidative stress 
also contributes to muscle wasting and dysfunction in both respiratory and peripheral muscle.  
The increased presence of ROS associated with COPD causes an increase in the expression of 
UbP components leading to increased protein breakdown in skeletal muscle (Figure 5) [112].   
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Figure 5:  Regulation of muscle mass relies on various hypertrophy and atrophy 
signalling pathways.   
In skeletal muscle wasting, there is an imbalance between these anabolic and catabolic 
processes resulting in enhanced muscle degradation as a result of protein breakdown.  
Myostatin (a negative regulator of muscle mass) can inhibit muscle growth. Inflammatory 
mediators and ROS can lead to the downstream activation of atrophagy-related genes (e.g. 
Atrogin-1, MuRF-1) resulting in enhanced protein degradation.  Inflammation and oxidative 
stress have also been implicated in the activation of the ubiquitin-proteasome (UbP) system.  
The UbP system is the primary mechanism of the protein catabolism in mammalian skeletal 
muscle.  Refer to Maltais et al. 2014 for an exhaustive overview of the signalling pathways 
involved. 
 
 
There is evidence that COPD patients with muscle wasting experience a more severe 
abnormal oxidative stress response to submaximal and maximal exercise compared to non-
muscle-wasted patients with COPD [142].  Although most studies focus on the increased 
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signalling of atrophy pathways as the major driving force of comorbid skeletal muscle 
wasting, it should be noted that decreases in hypertrophy signalling may also contribute 
greatly to the pathology of the disease.  Further studies are required to determine the exact 
contribution of these various pathways to the disease. 
 
1.7.1. Current treatments and antioxidant therapies 
There are currently no effective drug treatments for skeletal muscle wasting in COPD [112].  
Pharmacological treatments that have been explored include, anabolic steroids, growth 
hormone, other growth anabolic compounds and bioactive nutrients (e.g. ghrelin, creatine) 
and antioxidants [143-145].  Most of these treatments have only shown little to modest 
benefits when treating skeletal muscle wasting and weakness in COPD, or have significant 
adverse effects.   As with CVD, skeletal muscle wasting and COPD also overlap with regards 
to their non-pharmacological management.  Currently, the most potent treatment for limb 
muscle dysfunction is exercise training, which is already a key component for the 
management of COPD [112].  Some treatments such as lifestyle modifications (diet and 
exercise) and anabolic steroids have shown improvement in patients; however, they do not 
reverse the progression of muscle loss and may only increase muscle growth without 
substantial improvements in strength or endurance [146, 147].  Therefore, new treatments are 
needed as limiting muscle wasting in COPD will lead to improved quality of life and 
increased survivability of patients.  Because of its role in the pathogenesis of comorbid 
skeletal muscle wasting, targeting oxidative stress may be able to slow the progression or 
onset of the disease, giving patients an improved quality of life while managing their other 
symptoms.  Furthermore, it has been reported that increasing antioxidant potential can 
improve muscle performance whilst attenuating muscle fatigue [112]. Traditional antioxidant 
therapy using scavenging molecules has shown limited improvements in preclinical murine 
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models of skeletal muscle wasting induced by cigarette smoke. Further pre-clinical and 
clinical studies are required to determine the effectiveness of targeting oxidative stress in 
comorbid skeletal muscle wasting. 
1.8. Cardiovascular Disease (CVD) 
1.8.1. CVD overview 
CVD is a broad term used to describe any disease involving the heart and/or blood vessels.  
The presence of CVD is very common in COPD patients and is the leading cause of 
morbidity and mortality in younger patients and patients with mild-to-moderate COPD [19]. 
Comorbid CVD can manifest itself in one or more various disorders such as angina, stroke, 
arrhythmias, hypertrophy of the heart, and myocardial infarction, and its presence greatly 
reduces the survivability of COPD patients [107]. 
 
1.8.2. CVD and COPD links 
It is well documented that COPD and CVD share many of the same risk factors, such as 
smoking, poor diet, and pre-existing hypertension.  When considering these risk factors it is 
of significance that many, if not all, contribute to disease progression at least in part via 
oxidative stress.  Multiple studies have shown links between COPD and classical 
cardiovascular risk factors such as family history of coronary heart disease and diabetes [148-
151].  Persistent low-grade systemic inflammation is present in both COPD and CVD and 
oxidative stress, which plays a major role in COPD, has also been implicated in CVD [106].  
This indicates that the systemic inflammation and increased oxidative stress in COPD may 
lead to the onset and development of comorbid CVD. 
In addition to this, acute inflammatory lung conditions, such as bacterial/viral 
infection or acute exposure to airborne irritants, are also associated with vascular dysfunction 
[152, 153].  Increased systemic inflammation, as a result of these lung conditions, is capable 
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of destabilizing vulnerable plaques, inducing a prothrombotic state [154].  COPD patients 
generally do not tolerate cardiac injury or intervention as well as healthy individuals.  COPD 
patients with acute myocardial infarction have a five-year survival rate of 46% compared to 
68% in those without COPD [149].  
 
1.8.3. CVD and AECOPD 
Although many factors have been associated with poor outcomes from AECOPD, CVD is 
becoming increasingly recognized as a strong predictor of in-hospital mortality.  Studies have 
shown that over 50% of patients hospitalized for AECOPD have a high prevalence of 
coexisting cardiovascular disease [155].  Comorbid cardiovascular disease is independently 
associated with increased risk of AECOPD [156].  The severity of airway obstruction is a 
major predictor of AECOPD, and is also an independent risk factor for cardiovascular disease 
[26, 157-159].  There is also mounting evidence associating a high frequency of acute CVD 
with acute respiratory illness, such as pneumonia or AECOPD.  Studies have shown that in 
the general population, subjects with respiratory tract infections are more likely to experience 
a myocardial infarction within 2 weeks of infection [160, 161].  A retrospective review 
examining 24 hour mortality following AECOPD hospitalisation found that approximately 
60% of deaths that occurred resulted from cardiovascular causes [162]. 
 
1.8.4. Pulmonary hypertension, hypertrophy and heart failure  
There are two principal pathological features in the pulmonary vasculature common to most 
forms of pulmonary hypertension: excessive vasoconstriction and remodelling of the 
pulmonary arteriolar wall, which primarily occurs by a mechanism of smooth muscle 
proliferation within the medial layer [163].  Because ROS may promote vasoconstriction, 
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smooth muscle cell proliferation, and vascular remodelling, oxidative stress likely plays a 
critical role in many forms of pulmonary hypertension. 
Multiple studies have shown that 25-70% of COPD patients have pulmonary 
hypertension, depending on the definition used [164, 165].  In addition to this, it is estimated 
that 25% of patients with moderate-to-severe COPD develop pulmonary hypertension within 
6 years if they have no hypertension at baseline [166].  The pathological changes implicated 
in the development of pulmonary hypertension can also be seen in tissue samples of COPD 
patients who do not have a diagnosis of pulmonary hypertension [167, 168]. 
A major feature of COPD is emphysema, contributing to airway obstruction.  The 
destruction of alveolar walls and enlargement of airspaces results in a reduction in gas 
exchange [83].  To compensate for this, blood pressure is increased to facilitate more 
pulmonary blood flow leading to pulmonary hypertension.  This results in increased work in 
right heart and over time this increased workload can lead to concentric hypertrophy of the 
right ventricle (RV) [169].  This can lead to reduced ejection fraction, elevated end diastolic 
RV pressure, impedance of the right heart and, if left unchecked, can lead to heart failure.  
These changes can be detected in COPD patients, especially in end-stage COPD patients, 
using transthoracic echocardiography, which allows for the measurement of various 
parameters in the heart such as systolic and diastolic wall thickness, and chamber size.  Both 
pulmonary hypertension and right heart failure are associated with an increase in morbidity 
and mortality in COPD patients, independent of the decline in lung function [170].  
 
1.9. Oxidative stress in CVD 
The presence of oxidative stress in the form of increased ROS/RNS formation (e.g. O2-, 
ONOO-) has been observed both clinically and in animal models of CVD [171, 172].  
Although implicated in CVD, the cause-effect relationship of oxidative stress with any of the 
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different cardiovascular diseases has yet to be established.  The increased generation of ROS 
due to impaired mitochondrial reduction of molecular oxygen, secretion of ROS by 
inflammatory cells, endothelial dysfunction, auto-oxidation of catecholamines, as well as 
exposure to radiation or air pollution can drive the oxidative stress in cardiac and vascular 
myocytes [173].  In addition to the increased oxidant production, depression in the 
antioxidant reserve has also been implicated in CVD.  These typically phenolic antioxidants 
(e.g. vitamin E) act as a protective mechanism in cardiac and vascular myocytes, and their 
reduced levels appear to be due to both the saturation of by excess ROS/RNS and/or changes 
in gene expression.  The harmful effects caused by ROS/RNS in cardiovascular tissues are 
mainly due to ability of the oxidant species to drive changes in subcellular organelles (e.g. 
mitochondria), reduce NO• bioavailability, and induce intracellular Ca2+-overload [173]. 
 
1.9.1. Cardiovascular generation of ROS/RNS  
As stated earlier, in addition to phagocytising cells, NOX-dependent ROS-generation has 
been observed in numerous non-phagocytising cells, though at a lower level. In the 
cardiovascular system these include vascular smooth muscle cells (VSMC), endothelial cells, 
adventitial and cardiac fibroblasts and cardiomyocytes [174].  Normally, these cells 
continuously generate low levels of ROS even in the absence of external stimuli, and ROS 
derived from vascular NOX act as second messengers in VSMC signalling.  Over long 
periods of time, vascular NOX complexes only produce low levels of O2•- , with much of it 
generated intracellularly where it participates in cell signalling (compared to phagocyte O2•- 
which is generated extracellularly) [175]. When stimulated however, there is a significant 
increase in NOX-driven ROS production by these cells.  It is important to recognise that both 
vascular and phagocytic NOX play an important role in superoxide production as phagocytes 
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can infiltrate cardiovascular tissues and facilitate the functional and structural alterations 
observed in CVD [176]. 
 
1.9.2. Oxidative stress in the pathogenesis of CVD 
Damage to the endothelium is the initiating step in CVD.  This damage can expose 
endothelial cells, along with the underlying cell layers, to the deleterious effects of the 
inflammatory process, which can ultimately lead to the formation of atherosclerotic lesions. 
Cellular oxidative stress caused by excess ROS/RNS production is considered to be intrinsic 
to atherosclerotic lesion formation [177].  Exogenous factors contributing to oxidative stress 
such as smoking and comorbid diabetes also contribute to vascular oxidative stress and are 
strong risk factors for CVD [178]. Cigarette smoke has been associated with the down-
regulation of key exogenous and endogenous antioxidants such as vitamin C (ascorbic acid), 
carotene, Gpx and SOD [179, 180]. This can lead to dysfunction in endothelial cells, 
monocytes and VSMCs as well as mitochondrial damage.  In addition to this, DNA damage 
can be caused by oxidised lipids and this may also contribute to the dysfunction of 
endothelial cells, VSMCs, T lymphocytes and macrophages [181].  
Oxidative stress has also been associated with the apoptosis or programmed cell death 
of cardio myocytes [182].  The loss of myocytes via apoptosis has been observed in the 
infarct regions of myocardium from patients that have suffered from heart failure or a 
myocardial infarction (MI) [183].  Both in vitro studies and in vivo animal model studies 
found that apoptosis occurs in response to cardiovascular complications, such as MI, and 
chronic pressure overload [184].  The common factor in all of these conditions is the 
generation of oxidative stress and oxidative stress is known to play a role in the initiation of 
apoptosis [185]. Additionally, the apoptosis of myocytes is inhibited by antioxidants such as 
vitamin E and SOD, implicating ROS/RNS in the pathological pathways of CVD [186].  
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Although studies have implicated a role for ROS/RNS in CVD related apoptosis, the exact 
contribution of oxidative stress in the loss of myocardial function and heart failure remains to 
be established. 
 
1.9.3. Nitric oxide in CVD 
The role of nitric oxide NO• in vascular homeostasis and signalling has been well 
characterized.  As stated early, NO• plays a pivotal role in the maintenance of vascular tone 
and vasoreactivity.  In contrast to this distinct role in cell physiology, NO• can also contribute 
to CVD pathology.  Under certain conditions eNOS (the endothelial isoform of the nitric 
oxide synthase) becomes uncoupled from a NO• to an O2−producing state [187].  The excess 
O2 produced can react with NO• resulting in the formation of excessive ONOO-.  This 
reaction reduces the bioavailability of NO•, leading to cardiovascular dysfunction and 
reduced endothelial vasoregulatory capacity [188]. ONOO- has also been shown to promote 
the uncoupling of eNOS, propagating the increased ONOO- formation and decreased NO• 
bioavailability [189]. 
 
1.9.4. Current treatments and antioxidant therapies 
The current treatments for comorbid CVD are the same treatments used for CVD independent 
of COPD, such as β receptor blockers, ACE inhibitors, or angiotensin receptor blockers. 
However, the benefit of these drugs in COPD patients with CVD is conflicting.  Some studies 
have found that these treatments may be detrimental for COPD patients, worsening the 
pulmonary symptoms of the disease [190].  However, others have shown that when given to 
COPD patients with and without comorbid COPD, these treatments have shown notable 
benefits with regards to airway symptoms [191].  This may be due to the fact that both ACE 
inhibitors and angiotensin receptor blockers have displayed pleiotropic antioxidant effects in 
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addition to their antihypertensive effects [192].  Thus, this presents a unique opportunity for 
dual action therapy using CVD-specific treatments and antioxidants, and understandably 
warrants further research. 
CVD and COPD also overlap with regards to their non-pharmacological management.  
Cardiovascular modifying factors such as physical activity and diet modification are reported 
to decrease hospital readmission for COPD [193].  The recognition of the importance of 
oxidative stress in CVD has led to the fervent use of antioxidants in the treatment and 
prevention of the disease, however, the results of prospective, randomized clinical trials have 
been generally disappointing [194, 195].  In contradiction, studies have shown that 
antioxidant therapy is beneficial in non-comorbid hypertension, atherosclerosis, ischemic 
heart disease, cardiomyopathies and congestive heart failure [173].  It should be noted that 
almost all antioxidant clinical studies only explored the effectiveness of traditional 
scavenging antioxidants such as vitamin E. 
With regards to antioxidant treatments, the protective role of exercise in preventing 
oxidative stress is noteworthy.  Acutely, it is known that exercise causes oxidative stress 
[196].  However, exercise also leads to longer-term activation and enhanced synthesis of 
antioxidants and antioxidant enzymes (e.g. SOD, Gpx-1), as well as decreasing oxidant 
production [197].  This may explain the links between prolonged exercise and the beneficial 
effects to both COPD and CVD patients, and highlights the potential benefits of targeting 
oxidative stress in comorbid CVD. To our knowledge, the effectiveness of antioxidant 
therapy on cardiac structure and function has not been explored in murine models of COPD. 
Additionally, current non-invasive techniques of measuring cardiovascular morphology and 
function are inadequate for measuring changes in the right ventricle of rodents in a non-
terminal manner, limiting in vivo experimental design. 
  32 
Overall, it appears that targeting oxidative stress with antioxidant enzyme modifying 
treatments may have great potential in COPD and comorbid CVD by providing beneficial 
effects with regards to both the pulmonary and cardiovascular aspects. 
 
1.10. Novel antioxidant approaches for the treatment of COPD 
Besides never smoking, smoke cessation is the only effective method for preventing the 
onset and progression of COPD.  The progression of airway inflammation, increased 
oxidative stress, and protease burden even months/years after cessation, and non-
responsiveness to glucocorticosteroids have been documented as therapeutic challenges for 
the treatment of COPD [33].  Because of this, there is a lack of effective treatments for 
COPD and its comorbidities. 
As stated throughout this review, tissue injury and inflammation as a result of 
oxidative stress are common to COPD and many of its comorbidities.  A common theme 
throughout this review is the similarity and interplay between the pathological mechanisms 
of each condition and it is this similarity that provides a unique therapeutic opportunity 
(Figure 6).  Treatment with antioxidants may be able to progressively prevent and treat 
multiple diseases by supressing the generation of ROS/RNS, neutralizing oxidants or both.  
Due to the overwhelming evidence implicating oxidative stress in the pathogenesis of 
COPD and its comorbidities, it is only logical to consider antioxidant intervention in this 
patient population.  It is important that such interventions not only neutralize the excessive 
ROS and RNS generated, inhibit peroxidation of lipids, and the subsequent inflammatory 
response, but to also identify the source of these oxidants and inhibit their generation [53].  
Due to the imbalance in oxidants and antioxidants, this can be achieved by two approaches: 
increasing the endogenous antioxidant enzyme activity via enzyme modulators/mimetics, or 
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by replenishing the depleted non-enzymatic defences through dietary or pharmacological 
means.  
It should be noted that typical radical scavenging treatments, such as Vitamin E and 
other dietary antioxidants, have shown minimal improvements in either COPD or the 
comorbidities outlined in this review.  This may be due to the dose, route of administration, 
or the specific antioxidant given and thus more research is required to determine the 
efficacy of these compounds with certainty.  In addition, traditional antioxidants act in a 
“sacrificial manner,” due to the fact that once they have scavenged a radical, they are 
essentially consumed.  
Undoubtedly, the most damaging of all the ROS/RNS are the hydroxyl radical and 
peroxynitrite.  These species are extremely reactive and indiscriminate to the point that they 
basically react with the first substrate they come into contact with.  Knowing this, the most 
effective form of protection would be to prevent their generation in the first place and this 
cannot be performed by traditional antioxidants (scavengers).  Therefore, a pharmacological 
approach that inhibits the production of oxidant species is required.  In addition to this, it 
may also prove beneficial to use combination therapy and treat patients with the 
pharmacological enzymatic antioxidants (e.g. NOX inhibitors) whilst also supplementing 
them with dietary antioxidants (e.g. vitamin E supplements). 
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Figure 6.  Points of therapeutic intervention in COPD and its comorbidities.   
Oxidative stress indiscriminately damages a number of tissues and, as such, has been 
implicated in the onset and development of multiple diseases regardless of COPD diagnosis.  
Using novel antioxidant therapies it may be possible to treat COPD, AECOPD and 
comorbidities of COPD.  Inhibiting the generation of ROS and RNS with pharmacological 
compounds could reduce lung and systemic inflammation, reduce the severity and 
progression of COPD and comorbidities, improve the quality of life of patients, and increase 
their survival. 
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1.10.1. Novel antioxidants 
As shown on the ROS cascade (Figure 2), there are 3 key enzymes that can be targeted in 
order to reduce oxidative stress; NOX, SOD, and Gpx/Cat.  These enzymes can either be 
inhibited to reduce their activity (e.g. NOX inhibitor - apocynin) or amplified/mimicked to 
increase their activity (e.g. Gpx mimetics – ebselen).  Outlined below are just some of the 
enzymatic compounds that may be of therapeutic benefit to COPD patients (see Table 1). 
Antioxidant compounds Examples 
Thiol compounds N-acetyl-L-cysteine (NAC) 
Glutathione esters 
Fudosteine 
Thioredoxin 
 
Inducers of glutathione biosynthesis 
Nrf2 activators CDDO-imidazolide 
Sulforaphane 
 
NOX, SOD, Gpx 
Mimetics Salen compounds 
Metaloporphyrins 
Ebselen 
 
Inhibitors Apocynin 
 
Lipid 
peroxidation/protein 
carbonylation 
inhibitors/blockers 
Lazaroids/tirilazad 
Edaravone 
 
Other 
antioxidants/enzymes 
and oxidant scavengers 
Nitrone spin traps 
Peroxynitrite decomposition catalysts 
Porphyrins 
 
Polyphenols, natural 
products, and dietary 
agents 
Polyphenols/flavonoids/natural compounds 
(Apocynin, vitamin D, vitamin E, omega-3-fatty acid) 
 
Source: [198] 
Table 1.  Various antioxidant compounds that have been studied in the context of COPD 
and/or its comorbidities.   
Pre-clinical and clinical tests are investigating, or have investigated, the effectiveness of 
intervention with various small-molecular weight antioxidant compounds that target oxidant 
generation, or quench inflammation/cigarette smoke-derived oxidants and aldehydes.  Refer 
to Rahman & MacNee (2012) for an in-depth analysis of these various compounds. 
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1.10.2. NOX inhibitors 
As stated earlier, NOX-1 and -2 are the primary generators of O2•- and are responsible for the 
initiation of the ROS cascade (Figure 2).  NOX is a unique target in the sense that inhibiting 
the activity of the enzyme would not only reduce the generation of a single oxidant species 
but also reduce the generation of all other ROS and RNS.  Inhibiting NOX would reduce O2•- 
production which would result in less available O2•- for the generation of H2O2 and ONOO-, 
subsequently reducing •OH generation and increasing •NO bioavailability as a result. 
 
Current studies 
There are several NOX inhibitors currently being studied, however the most common is 
apocynin, which is a NOX inhibitor that preferentially blocks NOX-2 at low doses.  It 
inhibits NOX by preventing the assembly of the NOX enzyme subunits, resulting in the 
reduced formation of NOX complexes [53, 54].  We have shown that apocynin reduces 
cigarette smoke-induced lung inflammation in mice (refer to Chapter 4).  Additionally, the 
inhibition of NOX-2 activity ameliorates influenza A virus-induced lung inflammation, 
indicating that pharmacologically targeting NOX-2 may also have therapeutic potential in 
seasonal and possibly pandemic influenza infection [199, 200].  Because of this, the possible 
therapeutic utility of NOX-2 inhibitors may extend to AECOPD.  Clinically, COPD patients 
treated with apocynin had reduced H2O2 and NO2- in their exhaled breath concentrate 
compared to placebo control [201]. 
 
1.10.3. Gpx mimetics 
The Gpx family of enzymes, along with catalase, are responsible for the termination of the 
ROS cascade.  There are 8 known isoforms of Gpx (1 to 8) but the most abundant isoform is 
Gpx-1, which is found in the cytoplasm of almost all mammalian cells and whose preferred 
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substrate is H2O2 [59].  The main function of Gpx is the reduction of H2O2 to H2O and O2; 
however, Gpx is also known to reduce lipid peroxides to their corresponding alcohols.  
Additionally, it has been reported that Gpx-2 is a major cigarette smoke-inducible isoform 
found in the lung [202].  As with SOD, it is possible to increase the reduction of H2O2 by 
introducing Gpx (or catalase) mimetics.  This would result in the termination of the ROS 
cascade by increasing conversion of H2O2 to H2O and O2, and subsequently reduced levels of 
•OH and the decreased levels of lipid peroxides.  
 
Current studies 
There is currently a limited amount of studies exploring the effectiveness of Gpx mimetics in 
COPD.  When exposed to cigarette smoke, Gpx-1 knockout mice exhibited increased BALF 
neutrophils, macrophages, proteolytic burden, whole lung IL-17A, and MIP1 mRNA 
compared with WT mice [203].  When treated prophylactically with the Gpx-1 mimetic 
ebselen, the cigarette smoke-induced increases in BALF macrophages, neutrophils, 
proteolytic burden, and macrophage and neutrophil chemotactic factor gene expression were 
all inhibited in both the WT and knockout mice.  In addition, ebselen inhibited established 
BALF inflammation when administered therapeutically, suggesting that Gpx-1 mimetics may 
have therapeutic utility in inflammatory lung diseases where cigarette smoke plays a role 
such as COPD [59].  In addition, we have shown that ebselen caused a reduction in influenza 
A virus-induced lung inflammation in mice, suggesting that targeting Gpx-1 may be of 
therapeutic benefit for AECOPD [204]. 
Ebselen has also been shown to be protective in vivo in disease situations hallmarked 
by oxidative stress such as diabetes-associated atherosclerosis and cerebral ischaemia–
reperfusion injury [205].  Additionally, ebselen has been used in clinical trials of acute 
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ischaemic stroke and was found to improve the outcome of patients when administered 
within 24 hours of stroke [206]. 
 
1.11. Hypothesis and Aims of this Thesis 
COPD is a major incurable global health burden and is the 4th largest cause of death in the 
world.  Exacerbations are a common occurrence in COPD patients and contribute mainly to 
morbidity, death and health-related quality of life.  Comorbid diseases, in particular 
cardiovascular disease and skeletal muscle wasting, are also common in COPD and potentiate 
the morbidity of COPD, leading to increased hospitalisations, mortality and healthcare costs.  
Current treatments have limited efficacy and fail to modify the factors that initiate and drive 
the long-term progression of COPD, its exacerbations and its co-morbidities.  In addition, no 
pharmacological treatment has been shown to reduce the risk of death in COPD in 
prospective clinical trials.  Moreover, sophisticated non-invasive methods of assessing 
cardiac function and morphology to explore cardiovascular changes in experimental rodent 
(and in particular mice) models of COPD are lacking. 
 
It is now evident that increased oxidative stress within the local lung 
microenvironment is a major driving mechanism in the pathophysiology of COPD and that it 
may directly influence peripheral organ (e.g. heart and skeletal muscle) behaviour in a 
‘COPD-specific manner’.  Therefore, I hypothesise that targeting oxidant-dependent 
mechanisms that drive COPD and its co-morbidities may have great therapeutic potential in 
treating both pulmonary and extrapulmonary manifestations of the disease. Thus, the primary 
aims of this thesis were: 
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Aim 1: To determine if the Gpx-1 mimetic ebselen could improve both lung inflammation 
and skeletal muscle wasting in an in vivo model of COPD. 
To test this aim, we explored the effects of ebselen in an 8-week sub-chronic cigarette smoke 
exposure protocol in 8-week old Balb/C mice. To assess the impact of ebselen on lung 
inflammation, we measured inflammation in the BALF and cytokine and chemokine mRNA 
expression in the lung tissue. To assess the impact of ebselen on skeletal muscle, we 
measured contractile function of the tibialis anterior, whole skeletal muscle tissue weight, 
hypertrophy, atrophy, and inflammatory mRNA expression in the tibialis anterior and 
gastrocnemius, and oxidative damage in the tibialis anterior. 
 
Aim 2: To determine if the NADPH oxidase 2 inhibitor apocynin could improve both lung 
inflammation and skeletal muscle wasting in an experimental model of COPD. 
To test this aim, we explored the effects of apocynin in an 8-week sub-chronic cigarette 
smoke exposure protocol in 8-week old Balb/C mice. To assess the impact of apocynin on 
lung inflammation, we measured inflammation in the BALF and cytokine and chemokine 
mRNA expression in the lung tissue. To assess the impact of apocynin on skeletal muscle, we 
measured contractile function of the tibialis anterior, whole skeletal muscle tissue weight, 
hypertrophy, atrophy, and inflammatory mRNA expression in the tibialis anterior and 
gastrocnemius, and oxidative damage in the tibialis anterior. 
 
Aim 3: To design, develop and validate a non-invasive method of assessing cardiac 
function and morphology to explore cardiovascular changes of COPD in experimental 
rodent models. 
To test this aim, we adapted existing transthoracic echocardiographic views to examine right 
ventricular function and morphology in Wistar Kyoto rats. Functional and morphological 
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parameters were measured and validated by comparing values derived from traditional 
echocardiographic techniques and measurements taken during dissection. The viability of 
strain analysis using this modified view was also investigated.  
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Chapter 2: General Methods, Materials 
and Experimental Design 
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2. Methods 
 
This general methods chapter describes in detail the various materials and experimental 
techniques used throughout this thesis. Chapter-specific information can be found in the 
methods sections of each respective chapter. 
2.1. In vivo animal studies 
2.1.1. Mice 
Eight-week old male Balb/c mice (Animal Resource Centre, Perth, WA) were housed at 20°C 
in sterile micro-isolator cages under a 12:12h light dark cycle. Mice were given ad libitum 
access to food and water. Experimental protocols and procedures were approved by the 
Animal Experimental Ethics Committee of the University of Melbourne (AEC 1413348, 
1112185, 1212675), and the RMIT Animal Ethics Committee (AEC 1521). 
2.1.2. Rats 
300gm Male Wistar Kyoto Rats (Animal Resource Centre, Perth, WA) were house at 20°C 
under a 12:12h light dark cycle. Rats were given ad libitum access to food and water. All 
experimental protocols and procedures were approved by the Animal Experimental Ethics 
Committee of the University of Melbourne (AEC 1212675).  
2.2. Experimental procedures 
2.2.1. Cigarette smoke exposure 
Briefly, mice were placed in an 18 L perspex container in a class II biosafety cabinet, and 
were exposed to the smoke produced by 3 cigarettes (Winfield Red, ≤16 mg of tar, ≤1.2 mg 
of nicotine, and ≤15 mg of carbon monoxide; Philip Morris, Melbourne, Australia,), 2 times a 
day, 5 days per week (10:00AM, 4:00 PM) over a 56 day period as previously described 
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[207]. Sham-exposed mice were handled identically, but exposed to room air instead of 
cigarette smoke 
2.2.2. Chronic cigarette smoke exposure and apocynin groups 
Following a 1-week acclimatisation period, mice were divided into four groups (n = 8 per 
group) that were matched for body weight. The groups were allocated as sham + vehicle 
(SV), sham + apocynin (SA), cigarette smoke + vehicle (CSV) and cigarette smoke + 
apocynin (CSA). Body weight was measured 3 times each week (Monday, Wednesday, 
Friday) at 10:00AM during the experimental period. Food intake was measured daily by 
weighing the food remaining in the animal cage and subtracting from the previous day’s 
amount. This amount was divided by the number of animals per cage to determine the 
average intake per mouse per day. 
 
2.2.3. Chronic cigarette smoke exposure and ebselen groups 
Following a 1-week acclimatisation period, mice were divided into four groups (n = 10 per 
group) that were matched for body weight. The groups were allocated as sham + vehicle 
(SV), sham + ebselen (SE), cigarette smoke + vehicle (CSV) and cigarette smoke + ebselen 
(CSE). Body weight was measured 3 times each week (Monday, Wednesday, Friday) at 
10:00AM during the experimental period. Food intake was measured daily. 
 
2.2.4. Apocynin preparation and administration 
Mice were treated with apocynin (5 mg/kg; Sigma-Aldrich, Sydney, Australia) or vehicle 
(0.1% DMSO in Saline) via intraperitoneal (i.p) injection at 9 am per weekday throughout the 
56 day period. In order to minimize DMSO content in the drug preparation, apocynin was 
dissolved in 10 μL of DMSO. This solution was then mixed with 9990 μL of saline resulting 
in a 0.1% DMSO mixture. 
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2.2.5. Ebselen preparation and administration 
Mice were treated with ebselen (5 mg/kg; Sigma-Aldrich, Sydney, Australia) or vehicle (5% 
CM-Cellulose in PBS) via oral gavage 5 days per week throughout the 56 day period. 
2.3. Sample collection 
On day 56 mice were killed by an anaesthetic overdose using pentobarbitone ( mg/kg) 
prepared in sterile saline. Blood was collected from the abdominal vena cava, transferred into 
a Microvette® collection tube coated with lithium heparin (Sarstedt, Germany), and spun at 
10,000 x g rpm for 5 min to separate the plasma. Plasma was stored at -80 °C for later 
analysis. Bronchoalveolar lavage fluid (BALF) was collected from each mouse by flushing 
with a 400ml aliquot of PBS, followed by three 300 μL aliquots of PBS, as previously 
described [208]. Thymus, spleen, kidney, were removed and weighed. The lungs, the left side 
hind limb skeletal muscles (tibialis anterior (TA), soleus, plantaris, gastrocnemius), testicular 
white adipose tissue (WAT) and retroperitoneal WAT were removed, weighed, snap-frozen 
and stored at -80 °C for subsequent analysis. The right side hind limb skeletal muscles were 
removed, weighed, embedded in OCT and frozen in melting isopentane, and stored at -80 °C 
for subsequent analysis. The liver was also removed and weighed, with the largest lobe snap-
frozen and stored at -80 °C for subsequent analysis. 
2.4. Measures of lung inflammation 
Viable cells in the BALF were counted using the fluorophores ethidium bromide and acridine 
orange (AO/EB), on a Nikon Eclipse E600. Cytospins were prepared using 100 μL of BALF 
at 400 x g rpm for 10 min using a Cytospin 3 (Shandon, UK). Cytospin preparations were 
stained with DiffQuik (Dade Baxter, Australia), and 500 cells per slide were counted and 
differentiated into macrophages, neutrophils and lymphocytes using standard morphological 
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criteria. BALF was centrifuged and the supernatant was stored at -80 °C for subsequent 
analysis. 
2.5. Measures of systemic inflammation and oxidative stress 
The protein concentrations of mouse CRP and 8-isoprostane in serum were determined using 
commercially available ELISA kits. RayBiotech (GA, USA) ELISA kits were used to 
measure Mouse CRP. OxiSelect™ 8-iso-Prostaglandin F2α ELISA kits were used to measure 
8-isoprostane (Cell Biolabs, Inc., CA, USA). Measurements were made according to 
manufacturer’s specifications.  
MDA in mouse serum was measured as marker as of systemic oxidative stress. The 
concentration of MDA was measured using an OxiSelect™ TBARS Assay Kit (Cell Biolabs, 
Inc., CA, USA) according to manufacturer’s specifications. 
2.6. Western blotting and oxyblot 
Western Blot 
2.6.1. Tissue homogenization 
Tissue was ground via mortar and pestle and 20 mg was resuspended with 500 μL of RIPA 
lysis buffer (containing 1% B-mercaptoethanol and 1% protease inhibitor). The samples were 
homogenized with syringe and 21G needle 10-20 times, and incubated on ice for 30 minutes, 
unexposed to light. The samples were then centrifuged for 10 minutes at 14000 x g rpm, 4°C. 
The supernatant was collected for immediate use or stored at -80°C. 
 
2.6.2. Protein quantification 
Protein concentrations were determined through use of commercially available colorimetric 
bi-cinchonnic acid (BCA) protein kit (Thermo Fisher Scientific, Melbourne, Australia). 
Tissue lysate was diluted in lysis buffer in ranges of ½ up to 1/20, then 200 μL BCA reagent 
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mix (50 parts reagent A to 1 parts reagent B) was added to detect concentration of protein in 
the each sample. Solutions were mixed and incubated at 37°C for up to 30 mins or when 
nearing saturation (whichever occurred first) prior to the determination of absorbance by 
spectrophotometry at 562 nm using a clariostar microplate reader (BMG LabTech, VIC, 
Australia). With each BCA assay, varying dilutions of BSA protein were included to create a 
standard curve between the ranges of 0 μg/mL to 2.0 μg/mL. Once protein concentrations 
were determined, samples were normalised to contain the equal amounts of total protein. 
2.6.3. SDS-PAGE (Sodium dodecyl sulphate-polyacrylamide gel electrophoresis) 
10% Acrylamide gels were made using TGX™ and TGX Stain-Free™ FastCast™ 
Acrylamide Kits and Starter Kits (Bio-Rad, CA, USA). For a single gel, 3 mL of resolver A 
and 3 mL of resolver B solutions were combined as per manufacturer’s specifications. 3μL of 
TEMED and 30 μL of freshly made 10% APS was added to the resolver solution and mixed 
thoroughly. The solution was dispensed into the cassette and filled to 0.5-1 cm below the 
bottom of the teeth on the gel comb. The stacking solution was immediately prepared by 
combing 1 mL of stacker A and 1mL of stacker B as per manufacturer’s specifications. 2 μL 
of TEMED and 10 μL of freshly made 10% APS was added to the stacker solution and mixed 
thoroughly. The solution was dispensed slowly into the cassette (on top of the resolver 
solution). The gel comb was aligned and inserted into the cassette carefully in order to 
prevent the trapping of air under the comb teeth. The gel was allowed to polymerize for 45 
minutes before electrophoresis. 6 μL of each sample supernatant was loaded into a 10% 
acrylamide gel and the gels were run at 200V for 60 minutes in running buffer. 
2.6.4. Immunoblotting 
Following the separation of protein by SDS-PAGE, proteins were then transferred from the 
gels to methanol-activated polyvinylidene fluoride (PVDF) transfer membranes (Bio-Rad 
Laboratories Inc., USA) at 260mA for 7 minutes. Non-specific binding was blocked with 5% 
  47 
skim milk in TBS for 1 hour at a room temperature. The membranes were then incubated in 
the appropriate primary antibodies for 2 hours at the room temperature or overnight at 4°C. 
Membranes were washed with 1x TBST for 4 times (5 minutes each time) to remove any 
unbound antibodies, followed by incubation with an appropriate secondary antibody (1:1000 
dilution in 1x TBST) for 2 hours at the room temperature. The membranes were again 
washed with 1x TBST for 4 times (5 mins each time). The bound antibody was detected 
using a chemiluminescence system with Western Lighting Ultra Solution (Perkin Elmer, 
#NEL113001EA). The membranes were exposed to ChemiDoc (Bio-Rad Laboratories Inc., 
USA) capturing images for a sufficient time. Quantitative densitometry analysis of interested 
bands was performed using Image Lab software (Bio-Rad Laboratories Inc., USA). Relative 
protein expression was normalised by the band intensity of β-actin as an internal control. 
2.6.5. Oxyblot  
The commercially available OxyBlot Protein Oxidation Detection kit (Merck, Massachusetts, 
USA) was utilized for immunoblot detection of carbonyl groups introduced onto proteins by 
oxidative reactions. 5 μL of each supernatant was used, with 2 μL of 4x loading buffer added 
and then was boiled at 90°C for 5 minutes. 10μL of supernatant was transferred into 1.5 mL 
tubes, and 10 μL of 12% SDS was added to each sample. 10 μL of each supernatant-SDS 
mixture was transferred into another 1.5 mL tube to act as a negative control. The sample was 
derivatised by adding 10 μL of 1x 2,4-Dinitrophenylhydrazine (DNPH) solution (diluted in 
ddH20), while adding 10 μL of 1x derivatisation-control solution to the negative control. The 
samples were incubated at RT for 15 minutes. 7.5 ul of Neutralization solution was added to 
each sample. 10 μL of each sample was loaded into a 10% acrylamide gel and the samples 
were subjected to SDS-PAGE electrophoresis as stated in section 2.6.3. The resolved proteins 
were transferred onto a PVDF membrane using a Trans-Blot SD transfer cell (Bio-Rad, CA, 
USA) at 200V for 7 min. After transfer, PVDF membranes were incubated in blocking 
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solution for 1 h at room temperature. The carbonylated proteins were then bound with 
primary antibodies and subsequently a secondary antibody as per manufacturer’s instructions. 
The bound antibody was detected using chemiluminescence as stated in section 2.6.4. 
2.7. RNA extraction and RT-qPCR 
2.7.1. Sample crushing 
Lung samples were crushed to a fine powder in liquid nitrogen with a mortar and pestle, 
transferred to a fresh 2 mL safe lock tube and stored at -80°C. The crushed tissue was added 
to either trizol or RNeasy lysis buffer, depending on the ribonucleic acid (RNA) extraction 
method used, and subsequently homogenised by passing 10-20 times through a 21G needle 
with a 1 mL syringe. Gastrocnemius and tibialis anterior samples were crushed as stated 
above and then homogenised via syringe and needle or disrupted and homogenised using a 
Tissue Lyser (Qiagen, Australia) according to the manufacturer’s instructions. 
2.7.2. RNA Extraction  
Trizol RNA extraction 
15 mg of crushed tissue was homogenized in 500 μL trizol (Qiagen, Australia) via syringe 
and needle. Chloroform (200 μL, VWR, #22711324) was added to each homogenate and the 
mixture was capped securely and vigorously hand inverted for 15 seconds followed by 
incubation at room temperature for 5 mins. The homogenates were subsequently centrifuged 
at 12000 x g rpm for 15 mins at 4°C. The mixture was separated into a lower red, phenol 
chloroform phase containing protein, an interphase containing DNA, and a colourless upper 
aqueous phase containing RNA. Only the RNA-containing upper aqueous phase was 
transferred to a set of fresh micro-centrifuge tubes, and mixed with 500 μL of isopropanol 
(Sigma-Aldrich, Sydney, Australia, #I9516) before another centrifuge at 12000 x g rpm for 
10 mins at 4°C. The RNA precipitate formed a gel-like pellet on the bottom side of the tube 
after centrifugation. The supernatant was removed and the pellet was washed once with 1mL 
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75% ethanol (Merck, #1.07017.2511). The sample was then mixed by vortexing and 
centrifuged at 7500 x g for 5 mins at 4°C. The supernatant (ethanol) was removed and the 
RNA pellet was air dried. At the end of the procedure, the pellet was dissolved in Ambion® 
DEPC-treated water (Invitrogen, #AM9916, 50 µl for each sample) for RNA concentration 
determination. 
RNeasy Plus kit RNA extraction 
Samples were crushed as per section 2.7.1 and total RNA was extracted from lung and 
skeletal muscle samples using an RNeasy Plus kit (Qiagen, Australia), according to the 
manufacturer’s instructions. Skeletal muscle samples were were subsequently incubated in 
proteinase K (Qiagen, Australia) for 10 min at 55 °C, prior to RNA extraction.  
2.7.3. Measurement of RNA yield 
RNA concentration was quantified by using a NanoDrop Spectrophotometer (Eppendorf 
Thermo Fisher Scientific, Australia) using an absorbance ratio of 260/280 nm (A260/280). 
The NanoDrop Spectrophotometer was initialized using 1.0 μL of DEPC water, which was 
also used as a blank. Each RNA sample (1.0 μL) was loaded onto the sampling platform for 
the measurement of RNA concentration. Total RNA from samples were reverse transcribed 
to cDNA (Applied Biosystems High Capacity RNA-to-cDNA kit, USA) according to kit 
manufacturer’s specifications. 
2.7.4. Quantitative polymerase chain reaction  
qPCR was performed using mouse-specific TaqMan® Gene Expression Assays (Applied 
Biosystems), using either an ABI 7900HT Sequence Detection System or Quantstudio 7 Flex 
Real-Time PCR System (Applied Biosystems). Samples were assayed in triplicate. Fold 
change was determined in comparison to the sham control group, after standardising to 
GAPDH (housekeeping gene), using the established Delta-Delta CT method [209]. 
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2.8. Functional analysis of live animals 
2.8.1. Muscle Function 
Mouse Grip Strength 
Forelimb and total limb grip strength were determined using a grip strength meter (Columbus 
Instruments, Columbus). Each mouse was held by the base of their tail and suspended above 
a grip ring. After 3 seconds, the mouse was gently lowered towards the ring and allowed to 
grasp the ring with its forepaws for forelimb measurement or all paws for total limb 
measurement. The mouse’s body was lowered to a horizontal position, and the animal’s tail 
was pulled until the mouse broke its grasp from the ring. The mean force was measured with 
an electronic pull strain gauge connected directly to the grasping ring. Maximal force 
obtained from five replicates was used as the dependent measure. 
 
In Situ Muscle Function 
Animals were anaesthetised using ketamine/xylazine until pedal pinch reflex was no longer 
present. The foot of the animal was held in position and secured to a metal plate using elastic 
bands. A small skin incision was made at the front of the ankle and skin was blunt dissected 
up to the knee to reveal the tibialis anterior. A gap was made underneath the TA tendon and 
small incisions were made on each side of the tendon fascia until the tendon was released and 
freed all the way down below the ankle joint. A 8-10 cm long piece of suture thread was fed 
under the tendon and a knot was tied on the front of the tendon near the myotendinous 
junction. Another knot was tied on the underside of the tendon. This was repeated a few mm 
distal to the first thread with a second piece of 8-10cm long suture thread. The TA tendon 
was cut as distally as possible and folded over the knotted threads. The threads of the lower 
knot were placed so they pointed towards the knee. The threads of the upper knot were then 
used to tie a knot in front of the tendon and threads of the lower knot, encompassing them in 
a tight bundle. A reverse knot was then tied to secure the tendon and thread bundle. The 
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threads from the lower knot were then cut off. A scalpel blade was run along the edge of the 
tibia, releasing the muscle from the fascia and freed off the bone until just below the knee. A 
hole was made behind the patellar tendon. 
 
The mouse was transferred to the heated platform of the Aurora system (1300A: 3-in-1 
Whole Animal System – Mouse, Aurora Scientific, Canada) and secured using the foot 
clamp. The upper leg was secured by passing a needle behind the patellar tendon and into the 
heated platform. The remaining threads attached to the TA were used to tie a knot through the 
hole in the force transducer arm, securing the TA to the force transducer. The two fine 
electrodes were inserted into the belly of the TA muscle and the muscle was periodically 
bathed in warm saline through out the testing. 
 
2.8.2. Transthoracic Echocardiographic Analysis of Ventricular Size and Function  
Male WKY rats (300-350g) were anesthetized with 2.5% isofluorane, spontaneously 
ventilated and placed on a heated pad in the semi-left lateral position with upright tilt, 
suitable for echocardiographic examination. Pulse rate, oxygen saturation and temperature 
were continuously monitored. After shaving, a sequential examination of the left and right 
ventricles was performed using a Vivid E9 with i13-L (6-14MHz) linear array transducer (GE 
Vingmed Ultrasound AS, Horten, Norway). Each study imaged the parasternal long axis 
(PLAX) and mid-papillary short axis (SAX) views of the left ventricle (LV), and the 
modified Scherrer-Crosby (SC) and aortic right ventricle outflow tract (RVOT)/pulmonary 
artery SAX view of the right ventricle (RV) (see below, Figure 29). LV morphology was 
assessed for interventricular septal (IVS) wall and posterior wall (PW) thickness, LV end-
diastolic chamber dimension (LVEDD), LV end-systolic chamber dimension (LVESD), 
fractional shortening (FS), LV end-diastolic chamber area (LVEDA), LV end-systolic 
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chamber area (LVESA) and fractional area change (FAC). RV chamber width was assessed 
at mid-chamber in the SC view (R1) and RVOT width measured in the aortic SAX view 
(R2). In this view the main pulmonary artery diameter (PAφ) was also measured. RV wall 
area was measured in both SC and RVOT SAX views calculated from the difference between 
traced epicardial and endocardial areas [210].  Right ventricular ejection was measured in the 
aortic SAX view at the proximal MPA (PA diameter) using 2D-Doppler and the waveform 
analyzed for pulmonary artery velocity-time integral (VTI) and time to peak ejection 
(PAAT), Pulmonary artery systolic pressure (PASP) was not assessed (TR jet not examined). 
 
2.8.3. Strain Analysis 
Real-time imaging loops of ventricular motion during the cardiac cycle were recorded for off-
line analysis. The RV was imaged in the adapted SC view and the LV in the mid-ventricular 
SAX view. High frame rates necessitated manual tracing of epicardial and endocardial walls 
for 2D- strain analysis (Echopac, version 2011, GE Healthcare, Sydney, Australia). 
Segmental and global wall motion was then analysed.  
 
2.8.4. Injection of Agarose Gel and Tissue Collection 
Animals were euthanized using inspiratory CO2, the heart immediately excised and injected 
with KCl. To correlate RV chamber size and wall thickness with echocardiographic 
measurement agarose gel (2%, ScientifiX, Australia) was injected into the RV chamber and 
left to fix at room temperature. The gel was suspended in Hank’s Balanced Salt Solution 40 
mM HEPES (sHBSS).  10 minutes following injection, the RV wall was excised from the 
heart, exposing the hardened agarose gel mould of the RV chamber (see below, Figure 30). 
The RV free wall was then freely dissected away from the septal wall and atrio-ventricular 
valves.  Both the agarose gel mould and RV free wall were weighed. 
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2.8.5. Parameters measured using TTE: 
Left Ventricle (LV) Dimension Parasternal Long Axis (PLAX): 
• LV Internal Diastole Diameter (LVIDD) 
• LV Internal Systole Diameter (LVISD) 
• Posterior Wall Thickness (PWϕ) 
• Interventricular Septum Thickness (IVSϕ) 
LV Dimension Parasternal Short Axis (PSAX) 
• LV End Diastolic Area (LVEDA) 
• LV End Systolic Area (LVESA) 
Right Ventricle (RV) Aortic Valve (AoV) 
• RV Out flow tract (RVOT) Proximal Distance (RVOT prox ϕ) 
• RVOT distal distance (RVOT distal ϕ) 
• Pulmonary Artery diameter (PAϕ) 
• RVOT Epithelial Area (RVOT Epi) 
• RVOT Endothelial Area (RVOT Endo) 
RV Sheer-Crosby (SC) 
• RV Epithelial Area (RV Epi) 
• RV Endothelial Area (RV Endo) 
• RV Distance (RV4) 
Echocardiographic measurements in this study included: 
• Fractional Shortening (FS) = LVIDD-LVISD/LVIDD 
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• Fractional Area Change (FAC) = LVEDA-LVESA/LVEDA 
• LV volume/Stroke volume (SV) = based on geometric truncated ellipsoid 
model[211] 
• RV Free Wall Area = Epicardial area – endocardial area 
• RVOT Free Wall Area = Epicardial area – endocardial area 
• RV ejection stroke volume RVESV = PA area * VTI * HR , where PA area is the 
cross-sectional area of the main pulmonary artery, VTI is the area beneath the PA 
pulsed-wave velocity waveform or velocity-time integral and HR is heart rate. 
2.9. In vitro cell culture studies 
2.9.1. C2C12 mouse skeletal muscle cells 
To explore and assess the mechanisms underlying the effects of cigarette smoke and ROS on 
skeletal muscle, C2C12 mouse skeletal muscle cells were cultured. This cell line was chosen 
as it is well established in existing literature for in vitro studies of skeletal muscle. 
All cell culture experiments were conducted according to the Standard Operating Procedures 
for Physical Containment Level 2 (PC2) Laboratory area (Module B, Module D, Building 
223, RMIT University, Melbourne, Australia) using established facilities including Class II 
Biohazard Safety cabinets and CO2 incubators. 
 
2.9.2. C2C12 storage and handling 
C2C12 murine myoblasts were obtained from ATCC (Manassas, VA, USA) and stored in 2 
mL cryovials (Corning, Melbourne, Australia) at -80°C freezer (short-term storage) or in 
liquid nitrogen (long-term storage). When required, the cryovials were quickly defrosted at 
37°C in a water bath with a constant and moderate agitation until fully thawed. Vials were 
immediately disinfected with 80% (v/v) ethanol and opened in an UV-disinfected cell culture 
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hood (EuroClone, Pero, Italy) before the thawed cells were slowly pipetted into a sterile 15 
mL tube (Falcon, Melbourne, Australia) containing 9 mL pre-warmed growth medium and 
transferred into a T75 culture flask (Corning, Melbourne, Australia). Cells were observed 
under the microscope and cell viability was assessed using standard morphological criteria. 
The flask was then placed in an incubator at 37°C in 5% CO2. After overnight incubation, the 
cells were re-examined and assessed for viability. 
 
2.9.3. General cell culture procedures 
C2C12 myoblasts were grown in vitro in growth media, which consists of Dulbecco’s 
Modified Eagle Medium (DMEM) with 4.5 mmol (per 500 mL) glucose, glutamine, sodium 
pyruvate and supplemented with 10% fetal calf serum and 1% penicillin and streptomycin. 
The cells were grown in a T75 flask and passaged at 1/10 when cells were nearing or at 100% 
confluency.  
Splitting C2C12 cells 
Media was removed from the flask and discarded. Cells were rinsed with 10 mL of sterile 
PBS, which was then discarded. 2 mL of trypsin + EDTA was added and the flask incubated 
in a 5% CO2 incubator at 37°C for 5 minutes or until cells no longer adhered to the flask. 8 
mL of DMEM was added to neutralize the trypsin and resulting in a total volume of 1 0mL.  
1 mL of this mixture was added to another flask containing 15 mL of DMEM, resulting in a 
1/10 passage. The remaining 9 mL of the mixture was used for plate preparations or 
discarded.  Flasks containing C2C12 myoblasts were discarded at passage number 20.  
 
Differentiation of myoblasts to myotubes 
C2C12 cells undergo a myoblast to myotube conversion as they progress from rapidly diving 
to a confluent and contact inhibited state. This conversion can be induced at confluency 
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through the use of low-serum media. The C2C12 cells were seeded into a cell culture plate in 
growth media and allowed to reach 90-100% confluency. The post-confluent cells were 
washed with PBS and the media was changed to differentiation media which consists of 
which consists of Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 mmol (per 500 mL) 
glucose, glutamine, sodium pyruvate supplemented with 2% horse serum and 1% penicillin 
and streptomycin. 
 
Freezing down cells for long-term storage 
A T75 flask containing adherent cells was first washed in 1x PBS to remove all content of 
growth medium. This was subsequently removed and 2 mL of 1x trypsin-EDTA solution 
(ThermoFisher, Australia) added for 1 min. A firm tap to the side of the flask successively 
detached the cells and the enzymatic action of trypsin-EDTA was stopped with the further 
addition of 8 mL of growth medium. This cell suspension was centrifuged at 100 x g rpm for 
5 mins. After removal of the supernatant, the remaining cell pellet was re-suspended in 0.5 
mL of DMEM / 20% FBS / 10% DMSO / 1% Penicillin and Streptomycin to re-suspend 
cells, and then 1 mL aliquots were prepared in each cryovial. Cells were counted using a 
haemocytometer to determine the number added per vial. Cryovials were then transferred to a 
Nalgene® cryo 1°C freezing container (Thermo Fisher Scientific, Australia) filled with 100% 
isopropanol (Sigma-Aldrich, Sydney, Australia, #I9516), and stored overnight at -80°C. The 
following day, the vials were placed in liquid nitrogen for long-term storage. 
 
Counting of cell number 
Cells were counted using a haemocytometer, adding 10 μL of cells suspension between a 
glass coverslip and the surface of a haemocytometer marked as depicted below. Cells were 
viewed using microscope (10x or 20x magnification) and the cell numbers in each area were 
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then calculated (Area 1~4). To find the mean number of cells per Area (4 x 16 corner 
squares), the sum of Areas 1-4 was divided by 4, and this value was then multiplied by 104 
(μL to mL) to provide an estimate for the number of cells per mL. 
 
2.9.4. Cigarette smoke extract preparation 
The gas phase extract of cigarette smoke (CSE) was prepared by bubbling 1 cigarette 
(Winfield Red, ≤16 mg of tar, ≤1.2 mg of nicotine, and ≤15 mg of carbon monoxide; Philip 
Morris, Melbourne, Australia,) through the required media for desired cell culture assays. The 
cigarettes were manually pumped (as shown in the schematic below) at a rate of 5 
mL/second. Only a single cigarette was combusted per 25 mL of media. The extract was then 
sterile filtered for use in cell culture. 
 
2.9.5. Treatment of C2C12 Cells 
Hydrogen peroxide  
C2C12 cells were seeded on a 96 well plate and when differentiated, were treated with 
hydrogen peroxide (30%; Chem-Supply, SA, AUS) at 10, 30, 100, 300, 1000 and 3000 μM 
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and incubated for 1, 3, 6 and 24 hours before viability was measured using both MTS and 
MTT assays. 
Cigarette smoke extract 
C2C12 cells were seeded on a 96 well plate and when differentiated, were treated with CSE 
at 2.5, 5, 10 and 20% CSE solutions prepared as stated previously. The cells were incubated 
for 24, 48 and 72 hours before viability was measured using an MTS assay. 
 
2.9.6. Cell Viability Assays 
To assess the viability of cells following exposure to CSE and H2O2, multiple cell viability 
and cytotoxicity assays were performed. The MTT assay was initially performed but the 
process was found to be too time consuming at the longer time points stated previously. The 
MTS assay was used for the majority of the cell viability assays as it was more efficient, 
easier to perform, and provided results of the same accuracy as the MTT assay. 
Culturing cells for assays 
C2C12 cells were seeded at 10,000 cells per well on a 96-plate, allowed to reach confluency. 
As per section 2.9.3, the growth media was removed and differentiation media was added, in 
order to differentiate the C2C12 myoblasts to myotubes. The myotubes were then treated 
with compounds of interest and incubated as stated previously. Once treatment was complete, 
existing media was removed from each well, cells were washed with PBS and 100 μL of 
differentiation media was added to each well. 
 
2.9.7. MTT Assay 
Vybrant® MTT Cell Proliferation Assay Kit (Thermofisher Scientific, Melbourne, Australia) 
provides a simple method for determination of cell number using standard microplate 
absorbance readers.  The MTT assay involves the conversion of the water soluble MTT (3-
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(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to an insoluble formazan. The 
formazan is then solubilized, and the concentration determined by optical density. 
 
Preparation of solutions 
As per manufacturer’s specifications, a 12 mM MTT stock solution was prepared by adding 1 
mL of sterile PBS to one 5 mg vial of MTT (Component A). This was then mixed by 
vortexing until dissolved. Any undissolved particulate material was removed by filtration if 
required.  Once prepared, the MTT solution could be stored for four weeks at 4°C protected 
from light. Each 5 mg vial of MTT provided sufficient reagent for 100 tests, using 10 μL of 
the stock solution per well. 10 mL of 0.01 M HCl was added to one tube containing 1 g of 
SDS (Component B).  The solution was mixed gently by inversion until the SDS dissolved. 
Once prepared, the solution was used promptly. Each tube makes sufficient solution for 100 
tests, using 100 μL per well.  
Labeling of cells using normal MTT protocol 
After fresh differentiated media was added to each well (as stated in 2.9.5) 10 µL of the 12 
mM MTT stock solution was added to each well. A negative control of 10 µL of the MTT 
stock solution added to a well only containing 100 µL of differentiation media. The plate was 
incubated at 37°C for 2-4 hours depending on the density of the wells. At densities of 
>100,000 per well, incubation time was reduced to 2 hours. 100 µL of the SDS-HCl solution 
was added to each well and mixed thoroughly using the pipette. The Microplate was 
incubated at 37°C for another 4 hours in a humidified chamber. Longer incubations decreased 
the sensitivity of the assay. Each sample was mixed again using a pipette and absorbance 
measured at 570 nm. 
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Labeling of cells using quick MTT protocol 
Due to the lengthy incubation times in the standard MTT protocol, a quick protocol was 
performed according to the manufacturer’s specifications. After labeling the cells with MTT 
(as described previously) all but 25 µL of medium was removed from the wells. 50 µL of 
DMSO was added to each well and mixed thoroughly using a pipette.  The microplate was 
incubated at 37°C for 10 minutes.  Each sample was mixed again and absorbance was 
measured at 540nm (instead of 570nm as stated previously). 
 
2.9.8. MTS Assay 
The commercially available CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, Sydney, Australia) is a tetrazolium-based colorimetric assay for the determination 
of the number of viable cells in proliferation, cytotoxicity or chemosensitivity assays.  
C2C12 cells were seeded at 10,000 cells per well on a 96-plate, allowed to reach confluency 
and differentiated. The myotubes were then treated with compounds of interest and incubated 
as stated previously. Once treatment was complete, existing media was removed from each 
well, cells were washed with PBS, and 100 μL of differentiation media was added to each 
well. As per manufacturer’s protocol, 20 μL of the MTS assay solution was added to each 
well and the plate was then incubated at 37°C in 5% CO2 until desired saturation level was 
reached, usually ranging between  30 minutes to 2 hours. Absorbance was then measured at 
490 nm using a Clariostar 96-well plate reader (BMG Labtech, VIC, Australia). 
 
2.9.9. Extracellular flux assays 
To assess the effects of CSE and H2O2 on cell respiration, extracellular flux assays were 
performed using a Seahorse XFe24 Analyzer (Agilent Technologies, CA, USA). The analyzer 
can be used to measure the oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) of live cells in a 24-well plate format. Respectively, these rates are key 
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indicators of mitochondrial respiration and glycolysis, providing a complete metabolic profile 
of cellular metabolic function in cultured cells, islets, and ex vivo samples. 
 
Culturing of Cells for XF Assay 
Cells were seeded at 10,000 cells per well onto a XFe24 microplate (Agilent Technologies, 
CA, USA), leaving 4 empty wells (A1, B4, C3 and D6) as per manufacturer’s specifications. 
The cells were allowed to reach confluency and the growth media was removed and 
differentiation media was added. When differentiated into myotubes, the cells were treated 
with CSE and H2O2  as described previously. 
 
Analyzer Preparation on the Day Prior to Assay 
Per manufacturer’s specifications, the analyzer was turned on and warmed overnight 
(minimum of 5 hours). The sensor cartridge was hydrated in XF Calibrant at 37°C in a non-
CO2 incubator overnight. The experiment template was designed on the XF software on the 
computer connected to the Seahorse XFe24 Analyzer. 
 
Preparation of XF Media 
The XF Media was prepared on the day of the assay. 100 mL of XF Base Medium was 
warmed to 37°C. 0.45 g of glucose (25mM), 1.0 mL of sodium pyruvate (1.0 mM) and 
1.0mL of L-glutamine (4 mM) was added to the XF Base Medium. The pH was adjusted to 
7.4 using NaOH in small volumes. The medium was sterilized using a 0.2 μm filter and kept 
at 37°C until required for use. 
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2.9.10. Treatment of Cells for XF Assay 
H2O2  
Based on the results acquired from the cell viability assays, cells were treated with 0, 10, 30, 
100 and 300 μM concentrations of H2O2 for 1 hour prior to assay (4 wells per concentration). 
The medium in the wells was removed and replaced with 525 μL of the warmed XF Assay 
medium prepared previously. The microplate was then placed into a non-CO2 incubator for 
an hour prior to the Mito Stress Test Assay. 
 
CSE 
Based on the results acquired from the cell viability assays, cells were treated with 0, 2.5, 5, 
10 and 20% concentrations of CSE for 1 hour prior to assay (4 wells per concentration). The 
medium in the wells was removed and replaced with 525 μL of the warmed XF Assay 
medium prepared previously. The microplate was then placed into a non-CO2 incubator for 
an hour prior to the Mito Stress Test Assay. 
 
2.9.11. Seahorse Mito Stress Test 
The Seahorse XF Cell Mito Stress Test (Agilent, CA, USA) provides a complete 
mitochondrial respiratory profile. The test allows for the determination of: basal respiration, 
ATP production, proton leak, maximal respiration, and reserve capacity of the cell. The 
standard protocol described below, was followed as per the manufacturer’s instructions.   
 
Preparation of Assay Compounds 
Compounds were prepared on the day of the assay and discarded after assay. The foil pouch 
was removed from the XF Cell Mito Stress Test Kit box. Each pouch contained enough 
reagents (Oligomycin, FCCP, and Rotenone/Antimycin A) for one complete microplate. The 
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compounds were allowed to warm up to room temperature in the sealed pouch for 15 
minutes. The contents of each tube were resuspended with the prepared XF Assay Medium as 
follows:  
Oligomycin (100 μM): 630 μL Assay Medium 
FCCP (100 μM): 720 μL Assay Medium 
Rotenone/AA (50 μM): 540 μL Assay Medium 
 
The 3mL solutions of the resuspended compounds were prepared and loaded into the XFe24 
ports as follows: 
(Oligomycin): Final well concentration of 1.0 μM 
300 μL stock solution in 2700 μL Assay Media 
  Loaded 56 μL into port A 
 (FCCP): Final well concentration of 1.0 μM 
300 μL stock solution in 2700 μL Assay Media 
  Loaded 62 μL into port B 
 (Rotenone/AA): Final well concentration of 0.5 μM 
300 μL stock solution in 2700 μL Assay Media 
  Loaded 75 μL into port C 
 
Running the XF Cell Mito Stress Test 
After the Microplate was incubated for 1 hour and compounds loaded into ports, the hydrated 
sensor cartridge was calibrated in the XFe24 Analyzer. When calibrated, the hydration plate 
was removed and the Microplate inserted into the machine. The test was then run according 
to the experimental template designed according to manufacturer’s specifications. 
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2.10. Statistics 
As data were normally distributed, they are presented as grouped data expressed as means ± 
SE; n represents the number of mice. Student’s T test was used to assess significance where 
only two data sets were present. Multivariate analysis was performed via one- or two-way 
ANOVA followed by Bonferroni post hoc test for multiple comparisons, where appropriate. 
All statistical analyses were performed using GraphPad Prism for Windows and Mac, 
versions 6.0-8.1 (GraphPad Software, CA, USA). In all cases, probability levels less than 
0.05 (P < 0.05) were taken to indicate statistical significance. 
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Chapter 3: The effect of ebselen in an 
8-week cigarette smoke exposure in 
vivo model of COPD
  66 
3. Introduction 
 
In this chapter, the effect that treatment with ebselen had on lung inflammation and skeletal 
muscle wasting in an 8-week smoke exposure model of COPD was explored and all the 
experimental results are presented and examined in detail. Due to insufficient animal samples, 
the smoke exposure portion of the study was replicated, however this was completed at 
another animal facility. We determined that the data sets could not be combined due to 
variability between the animal facilities (refer to Chapter 6). As both data sets are included in 
the results section, the first study will be referred to as Study A, and the second referred to as 
Study B for the purpose of this chapter. 
COPD is characterized by persistent airflow limitation and lung inflammation 
resulting in a progressive decline in lung function [12]. In addition to the pulmonary 
manifestation of COPD, many systemic manifestations occur in the form of comorbid 
diseases, such as skeletal muscle wasting [13-15]. Skeletal muscle wasting occurs in 
approximately 20 to 40% of all COPD patients [17, 111, 112] and is multifactorial in nature. 
Such factors include inflammation and oxidative stress and these factors can initiate or 
enhance atrophy in peripheral muscles of patients with COPD [112]. Chronic oxidative stress 
not only contributes to muscle wasting, but it is also associated with dysfunction in both 
respiratory and peripheral skeletal muscle. 
There are currently no effective drug treatments for skeletal muscle wasting in COPD.  
Pharmacological treatments that have been explored include, anabolic steroids, growth 
hormone, other anabolic compounds, bioactive nutrients (e.g. ghrelin, creatine) and 
antioxidants [212-214].  Most of these treatments have shown little to modest benefits when 
treating skeletal muscle wasting and weakness in COPD [215-217]. Therefore, new treatments 
are needed, as limiting muscle wasting in COPD will lead to improved quality of life and 
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increased survivability of patients.  Because of its role in the pathogenesis of comorbid 
skeletal muscle wasting, targeting oxidative stress may be able to slow the progression or 
onset of the disease, giving patients an improved quality of life while managing their other 
symptoms. 
As described in chapter 1, glutathione peroxidases (GPxs) are a family of enzymes that 
catalyze the reduction of H2O2, as well as several other hydroperoxides (such as DNA 
peroxides and lipid peroxides), into relatively harmless water and alcohols [204, 218]. The 
ability of Gpx enzymes to eliminate H2O2 is well established and studies have shown that 
Gpx-1 plays a protective role against oxidative stress [204, 219]. Ebselen (2-phenyl-1,2-
benzisoselenazol-3(2H)-one) is a non-toxic seleno-organic drug that has been 
comprehensively researched for over three decades [220]. It is now under active investigation 
for the treatment of various conditions ranging from diabetes to hearing loss [221, 222]. A 
substantial part of the pharmacological profile of ebselen appears to be due to its action as an 
antioxidant with a unique mode of action [220]. Traditional thiol antioxidants such as N-
acetyl-l-cysteine, act as scavengers of free radicals and thus prevent lipid peroxidation and 
prevent the secondary reactions in the ROS and RNS cascades triggered by them [198, 223]. 
In contrast, ebselen is a poor radical scavenger, but is an effective scavenger of organic 
hydroperoxides, particularly lipid hydroperoxides [224]. Ebselen has also been shown to 
inhibit a number of enzymes involved in inflammation such as lipoxygenases, nitric-oxide 
synthases, NADPH oxidase, protein kinase C, and H+/K+-ATPase [225-228]. Additionally, 
ebselen has been shown to suppress inflammation in a variety of experimental animal models 
making the compound a key candidate for the treatment of chronic inflammatory and 
oxidative conditions such as COPD and its comorbidities [229, 230]. 
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The aim of this study was to investigate whether the Gpx mimetic ebselen protects 
against cigarette smoke-induced lung inflammation and skeletal muscle wasting in an 
established subchronic preclinical model of COPD.  
3.1. Materials and Methods 
3.1.1. Animals 
Eight-week old male Balb/c mice were obtained from the Animal Resource Centre Pty. Ltd. 
(Perth, WA) and housed at 20°C in sterile micro-isolator cages under a 12:12h light dark 
cycle. Mice were given ad libitum access to food and water. Experimental protocols and 
procedures were approved by the Animal Ethics Committee of the University of Melbourne 
(AEC 1413348), and the RMIT Animal Ethics Committee (AEC 1521). Given that my 
supervisor Prof Ross Vlahos moved to RMIT University during my PhD candidature, Study 
A was performed at The University of Melbourne whereas Study B was performed at RMIT 
University  
 
3.1.2. Cigarette Smoke Exposure 
Mice were exposed to the smoke produced by 3 cigarettes (Winfield Red; Philip Morris, 
Melbourne, Australia,), 2 times a day, 5 days per week over a 56-day period as described in 
section 2.2.3. 
 
3.1.3. Ebselen Administration 
Mice were treated with ebselen (10 mg/kg; Sigma-Aldrich, Sydney, Australia) or vehicle (5% 
CM-Cellulose in PBS) via oral gavage 1 hour prior to their first cigarette smoke exposure of 
the day. Further details on the experimental design can be found in section 2.1.2.3. 
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3.1.4. Body Weight and Food Consumption 
Body weight was measured 3 times each week (Monday, Wednesday, Friday) at 
approximately the same time each weighing day. Food consumption was calculated by 
measuring the amount of food remaining in cages every 24 hours and dividing that by the 
number of mice in the cages. 
 
3.1.5. Muscle Function 
The force-frequency relationship of the tibialis anterior muscle was measured in situ using the 
1300A: 3-in-1 Whole Animal System – Mouse (Aurora Scientific, Canada) and further details 
can be found in section 2.8.1.2. 
 
3.1.6. Blood, BALF and Tissue Collection 
On day 56 mice were killed by an overdose of anaesthetic (sodium pentobarbitone, 200 mg/kg 
prepared in sterile saline), blood collected from the abdominal vena cava, transferred into a 
Microvette® collection tube coated with lithium heparin (Sarstedt, Germany), and centrifuged 
at 10,000 x g rpm for 5 min to separate the plasma. Plasma was stored at -80 °C for later 
analysis. Bronchoalveolar lavage fluid (BALF) was collected from each mouse by flushing 
lungs with a 400 μL aliquot of PBS, followed by three 300 μL aliquots of PBS. The thymus, 
spleen, and kidneys were removed and weighed. The lungs, the left side hind limb skeletal 
muscles (tibialis anterior, soleus, plantaris, gastrocnemius), testicular white adipose tissue 
(WAT) and retroperitoneal WAT were also removed, weighed, snap-frozen in liquid nitrogen 
and stored at -80 °C for subsequent analysis. The right side hind limb skeletal muscles (tibialis 
anterior, soleus, plantaris, gastrocnemius) were removed, weighed, embedded in OCT and 
frozen in melting isopentane, and stored at -80 °C for subsequent analysis. The liver was also 
removed and weighed, with the largest lobe snap-frozen and stored at -80 °C for subsequent 
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analysis.  The total number of viable cells, macrophages, neutrophils and lymphocytes in the 
BALF was determined as described in secton 2.2.4. 
 
3.1.7. Quantitative RT-qPCR 
In the lungs, the mRNA expression of the following inflammatory cytokines, proteins and 
enzymes was measured: MMP-9, MMP-12, GM-CSF, G-CSF, TNF-α, CXCL9, IL-6, IL-23, 
IL-17, IL-1β, MCP-1, and MIP-2α. In the tibialis anterior and gastrocnemius muscles, the 
mRNA expression of atrogin-1, MuRF-1, IGF-1eA, IGF-1eB, myostatin, IL-6, NOX-2, 
PPARGC1A, and NFE2L2 were measured. GAPDH was used as the reference gene against 
all genes measured and all measurements were made using commercially available, validated 
Taqman primer/probes. In order to measure as many genes as possible while rationing 
collected samples, preliminary analysis used pooled samples from each animal in each group. 
As the samples were pooled, only trends could be observed and statistical significance could 
not be determined. Refer to section 2.7 for RNA extraction and RT-qPCR protocol 
information. 
 
3.1.8. ELISAs and TBARS 
The protein concentrations of IL-6, IGF-1, CRP and 8-isoprostane were determined in serum 
using commercially available ELISA kits and measured according to manufacturer’s 
instructions. Further details can be found in section 2.5. 
The concentration of MDA was measured using an OxiSelect™ TBARS Assay Kit (Cell 
Biolabs, Inc., CA, USA) according to manufacturer’s instructions. 
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3.1.9. Oxyblot 
Protein carbonylation, a marker of oxidative stress, was measured in muscle tissue using an 
Oxyblot Protein Oxidation Detection kit (Merck, Massachusetts, USA). β-actin was used as 
the reference protein. For further details, refer to sections 2.6.1 and 2.6.2 respectively. 
 
3.1.10. Statistical Analyses 
As data were normally distributed, they are presented as grouped data expressed as mean ± 
SEM; n represents the number of mice. Student’s t test was used to assess significance where 
only two data sets were present. Multivariate analysis was performed via one- or two-way 
ANOVA followed by Bonferroni post hoc test for multiple comparisons, where appropriate. 
All statistical analyses were performed using GraphPad Prism for Windows and Mac (version 
6.0-8.1). In all cases, probability levels less than 0.05 (P < 0.05) were taken to indicate 
statistical significance.  
 
3.2. Ebselen Study A 
 
3.2.1. Assessment of BALF inflammation 
As a measure of local inflammation in the lungs, BALF was collected and total cells were 
counted. A differential cell count was then performed to determine the number of 
macrophages and neutrophils. Cigarette smoke exposure (6 cigarettes/day, 5 days/week for 8 
weeks) significantly increased the total, macrophage and neutrophil number in BALF. 
However, smoke-exposed mice treated with ebselen had a significant reduction in total cells 
and neutrophils compared with vehicle treated smoke-exposed mice. Following the 56-day 
exposure period, the number of total cells in the BALF was 2.36x105 ± 2.45x104, 1.93x105 ± 
1.62x104, 8.24x105±5.05x104, and 6.55x105±4.93x104 cells/mL for the sham + vehicle, sham 
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+ ebselen, smoke + vehicle, and smoke + ebselen respectively (Figure 7A). The number of 
macrophage cells was 2.33x105 ± 2.41x104, 1.93x105±1.61 x104, 5.79x105 ± 6.20x104, and 
5.26x105 ± 3.94x104 cells/mL (Figure 7B), whilst the number of neutrophils was 
2.82x103±88.4, 363±159, 2.43x105±4.84x104, and 1.29x105±1.42x104 cells/mL for the sham 
+ vehicle, sham + ebselen, smoke + vehicle, and smoke + ebselen respectively (Figure 7C).  
 
 
Figure 7. The effect of ebselen (10mg kg-1) administration on BALF cellularity in mice 
exposed to air (sham) or after cigarette smoke (smoke) exposure. 
BALF cellularity is shown as (A) the total number of cells, (B) macrophages, (C) neutrophils. 
Data are expressed as mean ± SEM for n=10 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
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3.2.2. Assessment of cytokine and chemokine mRNA expression in lungs 
Lung tissue was pooled, and RNA extracted. The expression of matrix metalloprotease 9 
(MMP-9), MMP-12, granulocyte macrophage colony stimulating factor (GM-CSF), tumour 
growth factor beta (TGF-β), tumour necrosis factor alpha (TNF-α), C-X-C motif chemokine 
10 (CXCL10), interleukin-6 (IL-6), IL-23, IL-17, IL-1β, monocyte chemoattractant protein 1 
(MCP-1), and macrophage inflammatory protein 2-alpha (MIP-2α) was measured via qRT-
PCR (Figure 8). 
Cigarette smoke exposure elevated GM-CSF, MIP-2α, IL-1β, MCP-1, TNF-α, TGF-β, 
MMP12, IL-23, IL-17A and IL-6 mRNA expression. Additionally, smoke exposure reduced 
MMP9 expression. Treatment with ebselen reduced in smoke-induced GM-CSF, MIP-2α, 
MCP-1, TNF-α, TGF-β, MMP12, IL-23, IL-17A and IL-6 expression (all the above excluding 
IL-1β). mRNA expression of CXCL10 was not affected by cigarette smoke exposure. Due to 
the pooling of samples, statistical analysis could not be performed for this data. 
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Figure 8. The effect ebselen (10mg kg-1) administration on pooled lung tissue mRNA 
expression of inflammatory cytokines and chemokines in mice exposed to air (sham) or 
cigarette smoke (smoke) exposure  
Data are expressed as pooled value from n=10 mice per treatment group. As the samples were 
pooled, this data could not be statistically analysed. 
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3.2.3. Impact of smoke exposure on total body weight and food consumption  
Mouse body weight was measured each day and food consumption was measured Monday, 
Wednesday and Friday, with both measurements conducted at approximately the same time 
per day. Smoke-exposed mice, regardless of treatment, experienced reduced growth compared 
to their sham counterparts. Surprisingly, smoke-exposed mice treated with ebselen 
experienced a reduced rate of growth over the vehicle treated group, however this difference 
was minimal by day 56 (Figure 9A). This is reflected in the final percentage change shown in 
Figure 9B, which shows that smoke exposure caused a significant reduction in body weight 
and that the smoke + ebselen group had no improvement in total body weight over the smoke 
+ vehicle group on day 56. 
At the end of the 56 exposure period, the average body weights of the mice increased 
by 16.2±1.1%, 17.7±1.0%, 0.380±1.1%, and -1.14±1.2% in the sham + vehicle, sham + 
ebselen, smoke + vehicle, and smoke + ebselen groups respectively to 24.34±0.50g, 
25.2±0.63g, 21.2±0.50g *, and 20.7±0.39g*#. (Table 2 and Figure 9A).  
Food intake was measured to determine if ebselen had an impact on nicotine-induced 
reductions in appetite [231]. As expected, both smoke-exposed groups experienced a 
significant reduction in food intake compared to their sham counterparts (Figure 9C). In 
addition, ebselen did not impact daily food intake. The average daily food intake of the 
animals was 3.54±0.06g, 3.57±0.05g, 3.12±0.02g, and 3.14±0.02g for the sham + vehicle, 
sham + ebselen, smoke + vehicle, and smoke + ebselen groups respectively. 
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Figure 9. The effect of ebselen (10mg kg-1) administration on total body weight and food 
consumption in mice after smoke exposure. 
(A) Body weight was recorded daily for each group over the 56-day period. (B) Final 
percentage weight change on day 56. (C) Food intake was calculated by measuring the 
amount of food remaining in the cages and dividing the difference between days by the 
number of mice in the cage. Data are expressed as mean ± SEM for n=10 mice per treatment 
group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess statistical 
significance. *P<0.05 vs Sham + Vehicle 
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13.7% (Table 2). Cigarette smoke exposure significantly reduced heart weight, which was not 
improved by treatment with ebselen. Specifically, compared to the sham + vehicle control, the 
smoke + vehicle mice heart weight decreased by 16.2% and the smoke + ebselen group by 
10.9%. This was in contrast to the expected effect of smoke exposure causing an increase in 
cardiac mass. This is concordant with the decrease in heart mass observed in the apocynin 
study (refer to Chapter 4). Due to the poor outcomes of the cardiac pilot analysis outlined in 
Chapter 4, I did not assess cardiac changes in this study and sought to instead develop a model 
of cardiac dysfunction using cigarette smoke exposure (refer to Chapter 5). 
 
Skeletal muscle and WAT wet weight 
In general, cigarette smoke exposure significantly decreased the weights of the tibialis 
anterior, gastrocnemius, and both WAT (Table 2). There was no significant weight loss 
observed in the plantaris and soleus muscles, however the reduction in soleus weight 
approached statistical significance (P<0.06). Smoke exposure significantly reduced the 
weights of the tibialis anterior and gastrocnemius by 9.6% and 9.7% respectively in the smoke 
+ vehicle mice, and 10.14% and 8.9% in the smoke + ebselen mice. Additionally, smoke-
exposure significantly reduced the weight of the testicular WAT and retroperitoneal WAT by 
36.7% and 47.5% respectively in the smoke + vehicle mice and 41.2% and 51.1% in the 
smoke + ebselen mice. Treatment with ebselen did not protect mice from this smoke-induced 
reduction in skeletal muscle and WAT weight.  
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Sham Cigarette Smoke 
Tissue Vehicle Ebselen Vehicle Ebselen 
Body Weight (g) 24.3 ± 0.50 25.2 ± 0.63* 21.2 ± 0.50* 20.7 ± 0.39* 
Tibialis anterior (mg) 55.9 ± 2.3 54.9 ± 1.5 50.5 ± 0.9 * 50.2 ± 1.1* 
Soleus (mg) 8.40 ± 0.3 8.80 ± 0.4 7.90 ± 0.3  9.10 ± 0.1 
Gastrocnemius (mg) 136 ± 2.5 130 ± 4.5 123 ± 2.2 * 124 ± 2.6 * 
Plantaris (mg) 17.3 ± 0.6 17.6 ± 0.4 15.8 ± 0.6  16.7 ± 1.6  
Testicular WAT (mg) 724 ± 56 833 ± 60.7 459 ± 39 * 426 ± 37 * 
Retroperitoneal WAT (mg) 129 ± 12.1 150 ± 10.5 67.8 ± 7.3 * 63.2 ± 5.1 * 
Lung (mg) 253 ± 7.0 240 ± 4.2 281 ± 9.6 * 288 ± 6.1 * 
Heart(mg) 130 ± 3.1 126 ± 3.0 109 ± 9.0 * 116 ± 2.8 * 
 
Table 2. The effect of ebselen (10 mg kg-1) administration on lung, heart, skeletal muscle 
weights, and WAT weights in mice after cigarette smoke exposure. 
Data are expressed as mean ± SEM for n=10 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
Sham + Vehicle 
 
 
 
3.2.5. Assessment of hind limb and total limb muscle function 
On day 53, mouse grip strength collected as a measurement of skeletal muscle dysfunction 
following smoke exposure. In general, smoke exposure caused a reduction in grip strength in 
both the forelimb and total limb data sets. Additionally, treatment with ebselen did not 
improve either of the outcomes. Specifically, forelimb grip strength was 0.186 ± 0.006 N, 
0.188 ± 0.006 N, 0.153 ± 0.003 N, and 0.160 ±0.007 N (Figure 10A) and total limb grip 
strength was 0.266 ± 0.011 N, 0.274 ± 0.012 N, 0.246±0.006 N, and 0.249 ± 0.007 N for the 
sham + vehicle, sham + ebselen, smoke + vehicle, and smoke + ebselen respectively (Figure 
10B). When normalised to body weight, the reduction in grip strength was not significant 
(Figure 10C and 10D), indicating that the observed loss in grip strength is proportional to the 
total body weight loss in the animals. In hindsight, a more accurate measurement of 
normalisation could have been the use of total body length (nose to tail) or tibia length.  
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Additionally, the changes observed in the raw data may also be a reflection of operator bias as 
the technique is highly dependent on the researcher. Therefore, to collect specific muscle 
measurements in the studies that followed, the use of the grip strength meter was 
discontinued, and muscle function instead measured in situ using a force transducer.  
  
 
Figure 10. The effect of ebselen (10mg kg-1) administration on forelimb and total limb 
grip strength in mice after cigarette smoke exposure. 
(A) Forelimb (unadjusted), (B) total limb (unadjusted), (C) forelimb normalised to body 
weight, and (D) total limb normalised to body weight. Data are expressed as mean ± SEM for 
n=10 mice per treatment group. Two-way ANOVA with Bonferroni post-hoc test was 
performed to assess statistical significance. *P<0.05 vs Sham + Vehicle 
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3.3. Ebselen Study B 
3.3.1. Assessment of BALF inflammation 
In the second study, cigarette smoke exposure (6 cigarettes/day, 5 days/week for 8 weeks) 
significantly increased the total, macrophage and neutrophil number in BALF (Figure 11). 
However, smoke exposed mice treated with ebselen had a significant reduction in neutrophils 
of 51.7% when compared to the smoke + vehicle mice (Figure 11C). As previously observed, 
ebselen did not significantly reduce the number of macrophages in the BALF (Figure 11B). 
Following the 56-day exposure period, the number of total cells in the BALF was 1.57x105 ± 
1.34 x104, 1,18x105 ± 1.24x104, 6.98x105 ± 4.71x104, and 6.42x105 ± 3.82 x104 cells/mL for 
the sham + vehicle, sham + ebselen, smoke + vehicle, and smoke + ebselen respectively 
(Figure 11A). The number of macrophage cells was 1.57x105 ± 1.52x104, 1.16x105 ± 
1.21x104, 4.52x105 ± 3.16x104, and 5.07x105 ± 2.67x104 cells/mL (Figure 11B), whilst the 
number of neutrophils was 4.29x103 ± 1.07x103, 168 ± 2.14x103, 2.76x105 ± 1.03x104, and 
1.33x105 ± 1.92 x104 cells/mL for the sham + vehicle, sham + ebselen, smoke + vehicle, and 
smoke + ebselen respectively (Figure 11C).  
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Figure 11. The effect of ebselen (10mg kg-1) administration on BALF cellularity in mice 
after smoke exposure. 
BALF cellularity is shown as (A) the total number of cells, (B) macrophages, (C) neutrophils. 
Data are expressed as mean ± SEM for n=12 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
 
 
3.3.2. Impact of smoke exposure on total body weight and food intake 
As with Study A, mouse body weight was measured each day and food consumption was 
measured Monday, Wednesday and Friday, with both measurements conducted at 
approximately the same time per day. Smoke-exposed mice, regardless of treatment, 
experienced reduced growth compared to their sham counterparts. As seen in Figure 12A, 
smoke-exposed mice treated with ebselen experienced a slightly improved rate of growth 
over the 56 day period compared to the vehicle treated group. However, when examining the 
final percentage change shown in Figure 12B, there was no significant improvement in total 
body weight as a result of treatment with ebselen. At the end of the 56 day exposure period, 
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the average body weights of the mice increased by 11.4 ± 1.0%, 13.6 ± 0.9%, 2.99 ± 1.3%, 
and 5.21 ± 1.1% in the sham + vehicle, sham + ebselen, smoke + vehicle, and smoke + 
ebselen groups respectively to 24.3 ± 0.50g, 25.2 ± 0.63g, 21.2 ± 0.50g *, and 20.7 ± 0.39g*# 
(Figure 12 and Table 3).  
Both smoke-exposed groups experienced a significant reduction in food intake 
compared to their sham counterparts over the 8-week period (Figure 12C). In addition, 
ebselen had no effect on food intake in either the sham or smoke-exposed animals. The 
average daily food intake of the animals was 2.66 ± 0.10g, 2.75 ± 0.10g, 2.45 ± 0.09g, and 
2.53 ± 0.08g for the sham + vehicle, sham + ebselen, smoke + vehicle, and smoke + ebselen 
groups respectively. 
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Figure 12 The effect of ebselen (10mg kg-1) administration on total body weight and food 
consumption in mice after smoke exposure. 
(A) Body weight was recorded daily for each group over the 56-day period. (B) Final 
percentage weight change on day 56. (C) Food intake was calculated by measuring the 
amount of food remaining in the cages and dividing the difference between days by the 
number of mice in the cage. Data are expressed as mean ± SEM for n=12 mice per treatment 
group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess statistical 
significance. *P<0.05 vs Sham + Vehicle 
 
 
3.3.3. Impact of cigarette smoke exposure on organ and skeletal muscle weight 
Lungs 
In this study, only the lungs, hind limb skeletal muscles, and WAT were collected. Smoke-
exposure caused a significant increase in lung weight, which was not reduced by treatment 
with ebselen. Specifically, compared to the sham + vehicle control, the smoke + vehicle mice 
lung weight increased by 15.0% and the smoke + ebselen group by 13.5% (Table 3).  
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Skeletal Muscle 
In this study, muscle wasting was observed in the gastrocnemius, plantaris and both RWAT 
and TWAT. Specifically, cigarette smoke exposure significantly reduced the weights of the 
gastrocnemius and plantaris by 7%, and 8.3% respectively (Table 3). In contrast to previous 
studies, significant muscle wasting was not observed in the tibialis anterior and soleus 
muscles. Treatment with ebselen had no effect on the significant wasting observed in the 
gastrocnemius but appears to have had a protective effect on the plantaris (Table 3). The tibias 
of the animals were collected and their length measured. The lengths of the TA and 
gastrocnemius were normalised to the tibia length, however this did not affect the statistical 
significance of the muscle wasting observed due to cigarette smoke exposure. This indicates 
that the wasting observed was not proportional to the observed reduction in total body weight 
of the cigarette smoke-exposed mice. 
 
White adipose tissue 
Smoke exposure significantly reduced the weight of the testicular WAT and retroperitoneal 
WAT by 39.2% and 43.3% respectively (Table 3). As with Study A, treatment with ebselen 
did not protect mice from this cigarette smoke-induced reduction WAT. Both RWAT and 
TWAT were collected from this study, however, due to time constraints they were not 
analysed. 
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Sham Cigarette Smoke 
Tissue Vehicle Ebselen Vehicle Ebselen 
Body Weight (g) 24.0 ± 0.28 24.4 ± 0.29* 21.9 ± 0.34* 22.7 ± 0.34* 
Tibialis anterior (mg) 58.4 ± 1.0 54.5 ± 2.4 54.3 ± 0.9  55.4 ± 1.1 
Soleus (mg) 10.3 ± 0.4 9.20 ± 0.4 9.60 ± 0.2 9.30 ± 0.5 
Gastrocnemius (mg) 147 ± 1.6 144 ± 2.6 137 ± 1.6 * 136 ± 2.6 * 
Plantaris (mg) 19.0 ± 0.3 18.6 ± 0.5 17.4 ± 0.3 * 17.6 ± 0.4 
Testicular WAT (mg) 509 ± 27 477 ± 35 310 ± 23 * 322 ± 18 * 
Retroperitoneal WAT (mg) 82.7 ± 7.2 76.8 ± 7.4 46.9 ± 11.4 * 43.7 ± 3.3 * 
Lung (mg) 266 ± 3.3 258 ± 5.9 306 ± 5.3 * 302 ± 9.1 * 
 
Table 3. The effect of ebselen (10 mg kg-1) administration on lung, skeletal muscle 
weights, and WAT weights in mice after cigarette smoke exposure. 
Data are expressed as mean ± SEM for n=12 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
Sham + Vehicle 
 
 
3.3.4. Assessment of tibialis anterior muscle function in situ 
 
Neither forelimb nor total grip strength was measured in this study. The maximum force-
frequency, rate of contraction, force generated at 120 Hz, and the specific force at 120 Hz 
were measured using a force transducer in situ.  
 
Force Frequency 
As seen in Figure 13A, the frequency-dependent gain in contractile force was observed in the 
mice, with the peak occurring at approximately 100-120 Hz for the sham + vehicle control 
group. Following smoke exposure, there were no alterations to the force-frequency 
relationship in terms of the peak threshold. This indicates that there is no observed muscle 
impairment in terms of contractility in this study. Surprisingly, the smoke + ebselen treated 
mice showed the greatest force generated at all frequencies above 30Hz and this is reflected in 
both the rate of contraction (Figure 13C) and maximum force at 120Hz (Figure 13B). 
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Rate of Contraction 
As seen in Figure 13B, the frequency dependent gain in the maximum rate of contraction was 
observed in all groups. As with the force-frequency (Figure 13A), smoke exposure did not 
alter the frequency dependent gain. Surprisingly, the sham + vehicle showed a lower 
maximum rate of contraction at all frequencies compared to every other treatment group. In 
addition, the smoke + ebselen group showed a trend of increased maximum rates of 
contraction at all frequencies above 30 Hz, which may be a reflection of the increased force 
generated at all frequencies as seen in Figure 13A. 
 
Max Force at 120Hz, Specific Force at 120Hz, and Absolute Max Force 
In this study, peak force generation occurred at 100-120 Hz for all groups. The maximum 
force at 120Hz did not significantly differ between the 4 groups, regardless of exposure or 
treatment (Figure 13C). Surprisingly, there was a slight trend for the smoke-exposed groups 
to have increased force generation at 120 Hz. Specifically, maximum force at 120 Hz was 
721 ± 28.6 mN, 692 ± 25.0 mN, 772 ± 31.8 mN, and 829 ± 36.8 mN for the sham + vehicle, 
sham + ebselen, smoke + vehicle, and smoke + ebselen groups respectively.  
The maximum force at 120Hz was normalised using the Lo, the optimised 100 Hz 
twitch test length of each TA muscle, which provided the specific force at 120Hz. Specific 
force was 186 ± 9.5 mN, 187 ± 8.5 mN, 187 ± 8.8 mN, and 189 ± 10.8 mN respectively. As 
with the maximum force, the specific force did not significantly differ between the 4 groups, 
regardless of exposure or treatment (Figure 13D). In addition, the trend observed in the 
maximum force (Figure 13C) was ameliorated once the data was normalised. The same result 
is seen in Figure 13E where there is no difference in the absolute maximum force generated 
was observed regardless of frequency. Absolute maximum force was 735 ± 35.1 mN for the 
sham + vehicle group and 787 ± 26.7 mN for the smoke + vehicle group. 
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Figure 13. Effect of ebselen (10mg kg-1) administration on tibialis anterior contractile 
function in mice after cigarette smoke exposure. 
(A) Maximum force-frequency relationship, (B) maximum rate of contraction, (C) maximum 
force generated at 120Hz, (D) specific force generated at 120Hz, and (E) maximum absolute 
force. Data are expressed as mean ± SEM for n=6-12 mice per treatment group. Two-way 
ANOVA with Bonferroni post-hoc test was performed to assess statistical significance in A-
D. Student’s t-test was performed to assess statistical significance in E. 
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3.3.5. Assessment of mRNA expression in skeletal muscle tissue  
Tibialis anterior 
In this study, there was no observed wasting in the tibialis anterior muscle. To determine 
possible causes of the lack of wasting even though there was an abundance of lung 
inflammation, we measured the mRNA expression of Atrogin-1, MuRF-1, IGF-1 (eA and eB 
isoforms), myostatin, IL-6, Gpx-1, Ppargc1a and Nfe2l2 in the gastrocnemius via qRT-PCR. 
Surprisingly, there were no significant differences in expression of any of the genes measured 
as a result of either cigarette smoke exposure or treatment with ebselen (Table 4). 
 
 
Sham Cigarette Smoke 
Gene Vehicle Ebselen Vehicle Ebselen 
Atrogin-1 1.00 ± 0.14 1.12 ± 0.15 1.12 ± 0.17 1.20 ± 0.11 
MuRF-1 1.00 ± 0.12 0.83 ± 0.12 0.80 ± 0.09 0.96 ± 0.16 
IGF-1eA 1.00 ± 0.16 0.94 ± 0.15 1.18 ± 0.10 1.09 ± 0.13 
IGF-1eB 1.00 ± 0.14 1.01 ± 0.18 1.19 ± 0.16 1.09 ± 0.09 
Myostatin 1.00 ± 0.17 0.70 ± 0.07 0.86 ± 0.06 0.91 ± 0.10 
IL-6 1.00 ± 0.20 0.79 ± 0.08 1.00 ± 0.12 0.80 ± 0.03 
Gpx-1 1.00 ± 0.17 0.97 ± 0.16 1.26 ± 0.29 0.92 ± 0.10 
PPARGC1A 1.00 ± 0.13 1.17 ± 0.27 1.00 ± 0.11 0.98 ± 0.13 
Nfe2l2 1.00 ± 0.06 1.30 ± 0.28 1.13 ± 0.10 1.10 ± 0.10 
 
Table 4 The effect of ebselen (10mg kg-1) administration on tibialis anterior tissue mRNA 
expression of Atrogin-1, MuRF-1, IGF-1, myostatin, IL-6, Gpx-1, Ppargc1a and Nfe2l2 
in mice after cigarette smoke exposure.  
Data are expressed as mean ± SEM for n=9-12 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. 
 
 
Gastrocnemius 
In this study, there was significant wasting of the gastrocnemius as a result of cigarette smoke 
exposure. Although significant improvements in gastrocnemius mass were not observed 
following treatment with ebselen, significant wasting was still observed in these tissues 
which warranted analysis to help elucidate the mechanism by which this wasting occurred. 
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The mRNA expression of Atrogin-1, muscle RING-finger protein-1 (MuRF-1), insulin-like 
growth factor (IGF-1eA and eB isoforms), myostatin, IL-6, Gpx-1, Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PPARGC1A) and Nuclear factor, erythroid 2 
like 2 (Nfe2l2) in the gastrocnemius was measured via qRT-PCR. As with the tibialis 
anterior, there were no observed changes to mRNA expression in the gastrocnemius (Table 
5). 
 
 
Sham Cigarette Smoke 
Gene Vehicle Ebselen Vehicle Ebselen 
Atrogin-1 1.00 ± 0.12 1.07 ± 0.18 1.36 ± 0.33 1.11 ± 0.15 
MuRF-1 1.00 ± 0.17 0.91 ± 0.06 0.97 ± 0.12 0.91 ± 0.07 
IGF-1eA 1.00 ± 0.10 1.00 ± 0.11 1.09 ± 0.20 1.06 ± 0.15 
IGF-1eB 1.00 ± 0.14 1.06 ± 0.10 0.99 ± 0.12 1.20 ± 0.20 
Myostatin 1.00 ± 0.09 1.13 ± 0.06 1.17 ± 0.10 1.15 ± 0.09 
IL-6 1.00 ± 0.10 1.17 ± 0.18 1.1 ± 0.12 0.99 ± 0.08 
Gpx-1 1.00 ± 0.05 1.01 ± 0.08 1.08 ± 0.08 1.09 ± 0.10 
PPARGC1A 1.00 ± 0.08 1.00 ± 0.08 0.95 ± 0.08 1.02 ± 0.09 
Nfe2l2 1.00 ± 0.04 0.97 ± 0.04 0.95 ± 0.06 1.01 ± 0.05 
 
Table 5. The effect of ebselen (10 mg kg-1) administration on gastrocnemius tissue 
mRNA expression of Atrogin-1, MuRF-1, IGF-1, myostatin, IL-6, Gpx-1, PPARGC1A 
and Nfe2l2 in mice after smoke exposure.  
Data are expressed as mean ± SEM for n=9-12 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance.  
 
 
3.3.6. Markers of systemic inflammation and oxidative stress 
C-reactive protein 
C-reactive protein (CRP) is an acute phase protein that is commonly used as a marker of 
systemic inflammation. CRP is produced in the liver and is measured in serum. In humans, 
CRP levels can be elevated because of chronic inflammatory conditions such as arthiritis, 
cancer, and COPD, or as a result of acute conditions such as infections, burns and trauma 
[232, 233]. 
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In this study, cigarette smoke exposure caused a significant increase in serum CRP levels but 
this was not improved by treatment with ebselen. Compared to the sham + vehicle group, 
there was an increase of 31.8% in the smoke + vehicle group and 27.9% in the smoke + 
ebselen group (Figure 14A). Specifically, CRP was 2.55x103 ± 148 ng/mL, 3.21x103 ± 240 
ng/mL, 3.37x103 ± 171 ng/mL*, and 3.27x103 ± 147 ng/mL* for the sham + vehicle, sham + 
ebselen, smoke + vehicle, and smoke + ebselen groups respectively. 
 
TBARS (Malondialdehyde) 
As ROS and RNS have extremely short half-lives, they are difficult to measure directly. 
Consequently, the products of oxidative damage were measured as surrogates of ROS and 
RNS levels. One type of product of oxidative stress that can be detected in serum is 
thiobarbituric acid reactive substances (TBARS). A commonly measured TBARS is 
malondialdehyde (MDA), which is formed as a by-product of lipid peroxidation. The TBARS 
assay uses thiobarbituric acid as a reagent to measure the concentration of MDA and 
measures the MDA generated from lipid hydroperoxides by the hydrolytic conditions of the 
reaction. 
In this study, cigarette smoke exposure had no impact on serum MDA levels and, 
subsequently, neither did treatment with ebselen (Figure 14B). Specifically, MDA was 
measured as 20.8 ± 0.57 ng/mL, 21.8 ± 1.29 ng/mL, 19.8 ± 1.06 ng/mL*, and 20.8 ± 0.91 
ng/mL* for the sham + vehicle, sham + ebselen, smoke + vehicle, and smoke + ebselen 
groups respectively. 
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Figure 14 The effect of ebselen (10mg kg-1) administration on markers of systemic 
inflammation and systemic oxidative stress in mice after cigarette smoke exposure. 
(A) Levels of C-reactive protein (CRP), and (B) Malondialdehyde (MDA). Data are 
expressed as mean +- SEM for n=7-8 mice per treatment group. Two-way ANOVA with 
Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs Sham + 
Vehicle 
 
 
3.3.7. Assessment of oxidative stress in gastrocnemius tissue 
As with previous studies, protein was extracted from gastrocnemius tissues and protein 
carbonylation was measured using an oxyblot chemiluminescence assay as a marker of 
oxidative stress. Gastrocnemius tissue was used as all the tibialis anterior tissue had been 
consumed for gene expression analysis. Compared to the sham + vehicle treated group, 
cigarette smoke exposure caused a significant increase in protein carbonylation which was 
unaltered by treatment with ebselen (Figure 15A and 15B). This is consistent with the 
observed changes to gastrocnemius mass where ebselen had no effect on tissue mass. 
Specifically, protein carbonylation densitometry of the gastrocnemius tissue was measured to 
be 3.14x106±5.8x105Int, 9.14x106±2.16x106Int, 2.85x107±4.0x106Int*, and 3.78x107±4.6 
x106Int* for the sham + vehicle, sham + ebselen, smoke + vehicle, and smoke + ebselen 
groups respectively after normalisation to β-actin (Figure 15B). 
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Figure 15. The effect of ebselen (10 mg kg-1) administration on protein carbonylation in 
gastrocnemius tissue in mice after smoke exposure.  
(A) Representative oxyblot showing differences in smearing between treatment groups: Sham 
+ Vehicle (SV), Sham + Ebselen (SE), Cigarette Smoke + Vehicle (CSV) and Cigarette 
Smoke + Ebselen (CSE). (B) Densitometry analysis of oxyblots normalised to β-actin. Data 
are expressed as mean ± SEM for n=3-4 mice per treatment group. Two-way ANOVA with 
Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs Sham + 
Vehicle 
 
 
Due to time constraints, the muscle samples that were collected for histological examination 
could not be examined. Additionally, the gene expression of the lung samples was not 
assessed due to the focus of the experiments on the skeletal muscle aspects of the study. This 
should be conducted in the future to explore the anti-inflammatory effects of ebselen in the 
lung in further detail. 
3.4. Discussion  
The principal objective of these studies was to investigate whether reducing levels of H2O2 
with the Gpx-1 mimetic ebselen protects against cigarette smoke-induced lung inflammation 
and skeletal muscle wasting in an established animal model of COPD.  
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This study showed that mice exposed to sub-chronic cigarette smoke have enhanced BALF 
inflammation whereas treatment with ebselen attenuated this increase in inflammation 
(Figure 7 and 11). As seen in previous studies [207], smoke exposed mice, regardless of 
treatment, had a significant increase in total cells, macrophages and neutrophils in the BALF. 
In both study A and B, smoke exposed mice treated with ebselen experienced a significant 
reduction in neutrophil numbers of approximately 50-55% but the treatment did not impact 
macrophage numbers. This reduction in neutrophils is similar in magnitude to that seen in 
acute smoke exposure studies. Animals exposed to cigarette smoke, inoculated with influenza 
A virus and treated with 10 mg/kg of ebselen per day for 7 days experienced a 50% decrease 
in neutrophil counts in BALF [229]. It should be noted that a slight but significant reduction 
in macrophages and overall total cell counts in BALF was observed in an acute smoke 
exposure model as a result of ebselen treatment and this was not observed in Study B. The 
similarity between the BALF cell counts of the vehicle treated and ebselen treated sham mice 
indicates that reducing H2O2 with ebselen had no effect on BALF cellularity in the sham-
exposed mice in both studies. Due to ebselen’s mechanism of action, we believe that the 
observed anti-inflammatory effects are a result of reduced ROS leading to reduced 
inflammation as hypothesised in Chapter 1. The significant increase in lung mass observed in 
all smoke exposure groups can be attributed to increased inflammation and pulmonary 
oedema (Table 2 and 3). It has been shown previously that 8 weeks of smoke exposure does 
not induce changes in airspace in BALB/c mice [234] which typically takes a much longer 
period of time (6 months) or through the use of a nose-cone smoke exposure model [235, 
236], therefore, airspace enlargement as a model of emphysema was not determined in the 
current study.  
Consistent with previous studies conducted by our group, cigarette smoke exposure 
increased mRNA expression of a number of inflammatory cytokines and chemokines in the 
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lungs of the mice (Figure 8). It should be noted that lung mRNA expression was not assessed 
in Study B due to time limitations. The pro-inflammatory cytokines TGF-β, IL-1β and IL-6 
are known drivers of pathology in chronic inflammatory diseases and the concentration of 
these cytokines is elevated in the serum and lungs of COPD patients [237, 238]. In this 
model, smoke exposure caused an increase in expression of these pro-inflammatory 
cytokines, which was attenuated by treatment with ebselen. This indicates that the increased 
reduction of hydrogen peroxide Gpx-1 mimetic ebselen may have therapeutic benefit for the 
treatment of pulmonary manifestations of COPD. 
MCP-1 and CXCL-10 are important monocyte recruitment factors responsible for 
macrophage accumulation [239, 240]. These chemoattractants are increased in the lungs of 
patients with both chronic and acute lung inflammation and increased expression of these 
genes has been observed in various respiratory conditions, including COPD [238, 241, 242]. 
The increase in MCP-1 and CXCL-10 gene expression in lung tissue of smoke-exposed 
vehicle treated mice most likely explains the very large increase in BALF macrophage 
numbers (Figure 8B and 8E). While there was an increase in the expression of both MCP-1 
and CXCL10 in the lungs as a result of smoke exposure, treatment with ebselen only reduced 
expression of MCP-1. As there was no significant reduction in macrophage numbers in 
BALF as a result of treatment with ebselen, even though MCP-1 expression was reduced, 
indicates that CXCL10 may be playing a greater role in macrophage chemoattraction in this 
model.  
 MIP-2α is a chemokine, secreted by macrophages, which acts as a 
polymorphonuclear leukocyte chemoattractant, and IL-17A is a cytokine involved in 
activating neutrophil-mobilizing factors such as IL-8 and GM-CSF and hence sustaining the 
accumulation and activity of neutrophils locally in the lungs [243]. The increase in expression 
of MIP-2α, IL-17A and, subsequently, GM-CSF may all be contributing to the increase in 
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neutrophils observed in the BALF of the smoke exposed animals (Figure 8A, 8C and 8K). 
Additionally, treatment with ebselen caused a marked reduction in both the expression of 
these genes and the number of neutrophils in BALF, further emphasizing that MIP-2α, IL-
17A and GM-CSF are driving neutrophil accumulation in this smoke model. Another 
potential explanation of the high macrophage counts and decreased neutrophil counts is that 
the macrophages may be clearing the neutrophils in the lungs via efferocytosis, however, 
further experiments are required to determine the exact mechanism of this phenomenon.  
The expression of MMP9, was also increased by smoke exposure but was not reduced 
by treatment with ebselen (Figure 8H). The MMP family of enzymes are involved in the 
breakdown of extracellular matrix in normal physiological processes but are also implicated 
in pathological processes, such as in inflammatory diseases [244]. It should be noted that 
MMP9 in particular appears to be a regulatory factor in neutrophil migration in addition to its 
proteolytic functions [245]. While this combination of neutrophil chemoattraction and 
extracellular degradation makes MMP9 a potential key driver of lung inflammation, it does 
not appear to be a key driver of disease in this model. 
In addition to pulmonary inflammation that is characteristic of the disease, COPD 
patients also have elevated levels of various biomarkers indicating the presence of systemic 
inflammation [246, 247].  Systemic inflammation is associated with an accelerated decline in 
lung function [248] and is also a driver of systemic oxidative stress, which in turn further 
perpetuates systemic inflammation [102]. This vicious cycle leads to systemic manifestations 
of disease in the form of comorbidities, such as peripheral skeletal muscle wasting [112]. 
Serum concentration of CRP, an acute phase protein that is reported to be elevated in COPD 
patients, was measured as a marker of systemic inflammation in this model. As expected, 
serum CRP levels were elevated in response to smoke exposure, however, treatment with 
ebselen had no effect (Figure 14A). This is in contrast to the reduced BALF cellularity 
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observed in the treatment animals. This indicates that although lung inflammation is 
hypothesized to spillover into systemic circulation in COPD [249], this phenomenon may not 
be a key driver of systemic inflammation in this model and, subsequently, not a key driver of 
systemic manifestations of disease either. This indicates that the observed systemic 
inflammation is likely originating outside of the lungs. This is consistent with the hypothesis 
that systemic inflammation in COPD is not necessarily related to local pulmonary 
inflammation but instead originates from a parallel inflammatory response in other tissues, 
such as adipose tissue [250, 251]. It should be noted that significant systemic oxidative stress, 
as measured by MDA concentration in serum, was not observed in response to either smoke 
exposure and, therefore, the impact of ebselen on systemic oxidative stress could not be 
determined in this study (Figure 14B). This mild systemic response to smoke exposure was 
further emphasized by the modest impact that smoke exposure had on skeletal muscle mass. 
Both acute and chronic smoke exposure is known to reduce total body mass in animal 
models [252, 253]. This smoke-induced reduction in body weight is mostly caused by a 
reduction in adipose tissue; however, reduced muscle tissue mass also contributes to this 
decrease. As expected, the smoke exposed animals experienced a significant reduction in 
total body weight compared to their sham exposed counterparts (Figure 9A and 9B). Ebselen 
did not have a significant effect against smoke induced weight loss. Additionally, smoke 
exposure caused a significant reduction in adipose tissue mass and this also was not improved 
by treatment with ebselen (Tables 2 and 3). This indicates that the beneficial effect that 
ebselen demonstrated in the lungs may not extend to systemic pathologies.  
While the appetite suppressing effect of cigarette smoke is well established [254] and 
may possibly account for the reduction in body weight and skeletal muscle mass, it has been 
previously shown by using long-term pair-feeding that cigarette smoke exposure causes a 
greater reduction in body weight compared to equivalent food restriction alone (smoke 
  97 
exposure protocols of 1 and 3 months) [147, 207]. In the present study, the smoke-exposed 
animals had a suppressed appetite that was unaffected by treatment with ebselen (Figure 9C). 
Additionally, ebselen did not impact the appetite of sham-exposed animals, indicating that 
any alterations to pathology and physiology of the animals cannot be attributed to increased 
food intake/caloric surplus in the treatment groups.  
Although overall body mass was reduced due to smoke exposure, lung mass was 
significantly increased as expected. Surprisingly, cigarette smoke caused a significant 
reduction in heart mass that was not improved by ebselen (Tables 2 and 3). This is in contrast 
to the hypertrophy of cardiac tissue widely observed in the hearts and vasculature of COPD 
patients that arises from cardiovascular manifestations of disease [255, 256]. Potential 
mechanisms driving this reduction in heart mass were explored and are described in chapter 
4.  
Peripheral skeletal muscle wasting is highly prevalent in COPD and is associated with 
reduced quality of life, decline in lung function and increased mortality [112, 257]. Increased 
inflammation and oxidative stress both contribute to the onset and development of skeletal 
muscle wasting [212, 258]. The targeting of oxidant-dependent mechanisms that overlap 
between COPD and comorbid muscle wasting should be able to reduce oxidative stress and 
subsequently reduce perpetuation of inflammation, resulting in improved pulmonary 
symptoms and increased muscle mass and function. It has been reported that smoke exposure 
is known to cause a reduction in muscle mass of hind limb muscles in mice [207, 259]. In this 
study, smoke exposure caused a significant reduction in mass of the larger hind limb muscles, 
specifically the tibialis anterior and the gastrocnemius (Tables 2 and 3). It should be noted 
that TA wasting was only observed in study A. Although previously reported [259-261], 
wasting of the smaller gastrocnemius complex muscles (the soleus and plantaris) was not 
observed in this model. While the lack of sensitivity of the scales used in this study may have 
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hindered the ability to measure slight reductions in mass of the soleus and plantaris, it is more 
likely that the response to smoke was too mild to promote significant wasting in these tissues. 
Treatment with ebselen did not protect against smoke induced muscle wasting even though 
lung pathology was significantly improved. These results are concordant with the changes 
observed in body weight, white adipose tissue, systemic inflammation and systemic oxidative 
stress. This further indicates that the pulmonary response to cigarette smoke exposure was not 
driving the systemic pathologies observed in this model. 
Skeletal muscle dysfunction commonly accompanies skeletal muscle wasting in 
COPD [262]. Occasionally, this dysfunction can be disproportional to the muscle mass loss; 
however this is only observed in patients chronically treated with glucocorticosteroids [112]. 
Furthermore, muscle dysfunction in COPD is also associated with a significantly poorer 
prognosis and increased mortality [263]. Despite the fact that COPD patients experience 
skeletal muscle dysfunction in both respiratory and peripheral muscle groups, the latter are 
generally affected with greater severity [264, 265]. In patients, muscle function is commonly 
measured by quadriceps strength and endurance since the upper limb muscles are frequently 
spared from severe wasting [18, 120, 266-268]. Due to anatomical differences, muscle 
function in mouse models is usually measured via whole limb function (grip strength testing) 
or individual hind limb muscle contractility [269, 270]. In Study A, both total limb and 
forelimb grip strength was assessed by means of a commercially available automatic grip 
strength meter. Cigarette smoke caused a significant decrease in both total limb and forelimb 
grip strength that was unaffected by ebselen (Figure 10A and 10B). When normalized to 
body weight, this reduction is no longer observed, indicating that the dysfunction is 
proportional to total body mass (Figure 10C and 10D). This is in accordance with the 
proportional loss in quadriceps muscle mass and function observed in COPD patients [271]. 
Due to the greater capacity for human error when assessing function using grip strength 
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meters, isolated whole muscle contractility was used to assess TA muscle function in Study 
B. In contrast to the grip strength results from Study A, no significant reduction in muscle 
contractility, endurance or force generation was observed in response to smoke exposure in 
Study B, although there was a trend towards altered contractile function (Figure 13A and 
13C). This insignificant response was unsurprising, as the TA muscle did not experience a 
signification reduction in mass. Because significant muscle dysfunction was not observed via 
either assessment, the effect that ebselen has on muscle dysfunction could not be determined. 
The finely balanced processes that regulate muscle mass homeostasis can be 
distinguished into atrophy-related (protein degradation) and hypertrophy-related (protein 
synthesis) pathways. In skeletal muscle wasting, there is an imbalance between these 
pathways that shifts the homeostatic balance in favor of protein degradation [272]. This 
imbalance arises from increased atrophy signaling, decreased hypertrophy signaling, or a 
combination of the two. The ubiquitin-proteasome system is one of the major atrophy-related 
pathways in skeletal muscle and is widely studied in cachexia, sarcopenia and comorbid 
skeletal muscle wasting [273]. Atrogin-1 and MuRF-1 are E3 ubiquitin ligases that are key 
regulators of ubiquitin-mediated protein degradation in skeletal muscle [274, 275]. Increased 
transcription of these ligases results in downstream increases in protein degradation and 
drives atrophy of the muscle if chronically elevated. This is evident in biopsies taken from the 
quadriceps of COPD patients [276, 277]. In this study, smoke exposure had no significant 
effects on Atrogin-1 or MuRF-1 mRNA expression in the tibialis anterior and gastrocnemius 
muscles (Table 4 and 5). Additionally, smoke exposure had no effect on mRNA levels of 
other proteins involved in atrophy or hypertrophy related pathways, specifically myostatin 
and IGF-1. This indicates that the reduction in muscle mass was not driven by the 
characteristic alterations to protein homeostasis signaling pathways observed in COPD 
patients.  
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Additionally, the expression of IL-6 was measured as an indicator of local skeletal 
muscle inflammation and was also found to be unaffected by smoke exposure. This indicates 
that while there was a significant increase in pulmonary inflammation in the smoke exposed 
mice, the significant reduction in skeletal muscle mass was not being driven by a similar local 
inflammatory response in the muscles. In addition to reduced muscle mass, metabolic 
alterations in muscle such as reduced oxidative enzyme activity and reduced mitochondrial 
function are known contributors to skeletal muscle weakness and fatigue in COPD [278-280]. 
The mRNA expression of Nfe2l2 and PARGC1A, which regulate mitochondrial function and 
mitochondrial biogenesis respectively [281, 282], was measured to assess mitochondrial 
impairment following smoke exposure and no significant alterations to mRNA expression 
were found. This was expected as muscle function was not impaired in response to smoke 
exposure. Lastly, while the mRNA expression of other glutathione-related enzymes is known 
to acutely increase following exposure to cigarette smoke, Gpx-1 expression does not 
increase [283, 284]. This phenomenon was also observed in this study, as Gpx-1 expression 
was unchanged in the gastrocnemius of the smoke exposed animals. 
While there is no strong relationship between muscle oxidative stress and local 
inflammation in patients with COPD [101, 285], 8 weeks of smoke exposure induced a 
significant increase in skeletal muscle oxidative stress in this model as measured by protein 
carbonylation in the gastrocnemius (Figure 15A and 15B). These oxidative alterations were 
not accompanied by a marked increase in local inflammation (as measured by IL-6 mRNA 
expression), which echoes what is seen in COPD. Evidence of strong oxidative stress is 
consistently found in peripheral muscles even if levels of local and systemic levels of 
inflammatory mediators are relatively low in these patients [101, 286, 287]. While 
inflammation and oxidative stress both initiate the proteolysis cascade, increased oxidative 
stress is also known to impair contractility in peripheral skeletal muscles [288, 289]. 
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Although muscle contractility was unaffected in this study, there was a significant increase in 
protein carbonylation following smoke exposure, which was unaffected by treatment with 
ebselen (Figure 15B). This indicates that while ebselen was able to improve pulmonary 
inflammation, it was ineffective in preventing oxidative damage in skeletal muscle.  
In summary, the findings of this study identified mimicking GPX-1 activity, via 
treatment with ebselen, to be an effective therapy for pulmonary inflammation in this model 
of COPD. Ebselen successfully reduced smoke-induced increases in lung inflammation, lung 
inflammatory cytokine and chemokine mRNA expression. The therapeutic impact of ebselen 
on systemic manifestations of disease was not determined in this study. Ebselen had no effect 
on smoke-induced skeletal muscle and WAT wasting, expression of muscle growth signaling 
pathways, muscle contractility and function. This study shows that while smoke exposure 
induced the pulmonary and some of the systemic alterations characteristic of COPD, ebselen 
was only able to effectively treat the pulmonary manifestations of disease in this model. 
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Chapter 4: The effect of apocynin in an 
8-week CS-exposure in vivo model of 
COPD 
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4. Introduction  
 
In this chapter, the effect that treatment with apocynin had on lung inflammation and skeletal 
muscle wasting in an 8-week smoke exposure model of COPD is explored and all the 
experimental results are presented and examined in detail. Due to insufficient animal 
samples, the smoke exposure portion of the study was replicated, however this was 
completed at another animal facility. We determined that the data sets could not be combined 
due to variability between the animal facilities (refer to Chapter 6). As this study was 
replicated, the first study will be referred to as Study A, and the second referred to as Study B 
for the purpose of this thesis. 
COPD is characterized by persistent airflow limitation and lung inflammation 
resulting in a progressive decline in lung function [12]. In addition to the pulmonary 
manifestation of COPD, many systemic manifestations occur in the form of comorbid 
diseases, such as skeletal muscle wasting [13-15]. Skeletal muscle wasting occurs in 
approximately 20 to 40% of all COPD patients [17, 111, 112] and is multifactorial in nature. 
Such factors include inflammation and oxidative stress and these factors can initiate or 
enhance negative alterations in peripheral muscles of patients with COPD [112]. Chronic 
oxidative stress not only contributes to muscle wasting, but it is also associated with 
dysfunction in both respiratory and peripheral skeletal muscle. 
Aside from exercise therapy, there are currently no effective treatments for skeletal 
muscle wasting in COPD.  Pharmacological treatments that have been explored include, 
anabolic steroids, growth hormone, other anabolic compounds, bioactive nutrients (e.g. 
ghrelin, creatine) and antioxidants [212-214].  Most of these treatments have only shown little 
to modest benefits when treating skeletal muscle wasting and weakness in COPD [215-217]. 
Therefore, new treatments are needed, as limiting muscle wasting in COPD will lead to 
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improved quality of life and increased survivability of patients.  Because of its role in the 
pathogenesis of comorbid skeletal muscle wasting, targeting oxidative stress may be able to 
slow the progression or onset of the disease, giving patients an improved quality of life while 
managing their other symptoms. 
 
As described in chapter 1, nicotinamide adenine dinucleotide phosphate oxidase, or NADPH 
oxidase (NOX) -1 and -2 are the primary generators of O2•- and are responsible for the 
initiation of the ROS cascade. NOX-2 is a unique target in the sense that inhibiting the 
activity of the enzyme would not only reduce the generation of a single oxidant species but 
also reduce the generation of all other ROS and RNS. NOX-2 is an enzyme complex, 
consisting of p47phox and p67phox subunits, membrane-bound cytochrome b558, p22phox, 
and a small G protein ‘rac’ [290, 291]. Following the assembly of the subunits, the enzyme 
activates and generates superoxide via the one-electron reduction of molecular oxygen [292]. 
It is well established that increased NOX-2 activity leads to oxidative damage and can 
contribute to the development oxidative stress under inflammatory conditions [293-295] 
Apocynin, also known as acetovanillone, is an organic compound that inhibits the release of 
O2- by NOX. Apocynin blocks the migration of the p47phox subunit to the membrane, 
preventing the assembly of the functional NOX complex, which then leaves the enzyme in an 
inactive state . Apocynin administered locally by nebulization has been shown to be safe and 
reduces ROS concentrations in healthy subjects and mild asthmatics [296, 297]. Apocynin 
has been shown to suppress inflammation in several pre-clinical animal models and 
clinically, COPD patients treated with apocynin experienced a reduction in H2O2 and NO2- in 
their exhaled breath concentrate compared to placebo control [201, 298]. Although not 
widely studied in chronic inflammatory conditions, apocynin’s anti-inflammatory and 
antioxidant effects make it a key candidate for the treatment of COPD and its comorbidities. 
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The aim of this study was to investigate whether the NOX-2 inhibitor apocynin 
protects against cigarette smoke-induced lung inflammation and skeletal muscle wasting in 
an established subchronic preclinical model of COPD.  
4.1. Materials and Methods 
4.1.1. Animals 
Eight-week old male Balb/c mice were obtained from the Animal Resource Centre Pty. Ltd. 
(Perth, WA) and housed at 20°C in sterile micro-isolator cages under a 12:12h light dark 
cycle. Mice were given ad libitum access to food and water. Experimental protocols and 
procedures were approved by the Animal Ethics Committee of the University of Melbourne 
(AEC 1112185, 1413348), and the RMIT Animal Ethics Committee (AEC 1521). 
 
4.1.2. Cigarette Smoke Exposure 
Mice were exposed to the smoke produced by 3 cigarettes (Winfield Red; Philip Morris, 
Melbourne, Australia), 2 times a day, 5 days per week over a 56-day period as described in 
section 2.2.3. 
 
4.1.3. Apocynin Administration 
Mice were treated with apocynin (5 mg/kg; Sigma-Aldrich, Sydney, Australia) or vehicle 
(0.1% DMSO in Saline) via intraperitoneal (i.p) injection 1 hour prior to their first cigarette 
smoke exposure of the day. Further details on the experimental design and how apocynin was 
prepared can be found in sections 2.2.2 and 2.2.4. 
 
4.1.4. Body Weight and Food Consumption 
Body weight was measured 3 times each week (Monday, Wednesday, Friday) at 
approximately the same time each weighing day. Food consumption was calculated by 
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measuring the amount of food remaining in cages every 24 hours and dividing that by the 
number of mice in the cages. 
 
4.1.5. Muscle Function 
The force-frequency relationship of the tibialis anterior muscle was measured in situ using 
the 1300A: 3-in-1 Whole Animal System – Mouse (Aurora Scientific, Canada). Frequencies 
ranging from 10Hz to 250Hz were used and further details can be found in section 2.8.1. 
 
4.1.6. Blood, BALF and Tissue Collection 
On day 56 mice were killed by an overdose of anaesthetic (pentobarbitone, 200mg/kg 
prepared in sterile saline), blood collected from the abdominal vena cava, transferred into a 
Microvette® collection tube coated with lithium heparin (Sarstedt, Germany), and 
centrifuged at 10,000 x g rpm for 5 min to separate the plasma. Plasma was stored at -80 °C 
for later analysis. Bronchoalveolar lavage fluid (BALF) was collected from each mouse by 
flushing with a 400 µL aliquot of PBS, followed by three 300 µL aliquots of PBS as 
described in section 2.3. The thymus, spleen, and kidneys were removed and weighed. The 
lungs, the left side hind limb skeletal muscles (tibialis anterior, soleus, plantaris, 
gastrocnemius), testicular white adipose tissue (WAT) and retroperitoneal WAT were also 
removed, weighed, snap-frozen in liquid nitrogen and stored at -80 °C for subsequent 
analysis. The right side hind limb skeletal muscles (tibialis anterior, soleus, plantaris, 
gastrocnemius) were removed, weighed, embedded in OCT and frozen in melting isopentane, 
and stored at -80 °C for subsequent analysis. The liver was also removed and weighed, with 
the largest lobe snap-frozen and stored at -80 °C for subsequent analysis.  The total number 
of viable cells, macrophages, neutrophils and lymphocytes in the BALF was determined as 
described in section 2.4. 
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4.1.7. Quantitative RT-qPCR 
In the lungs, the mRNA expression of the following inflammatory cytokines, proteins and 
enzymes was measured: MMP-9, MMP-12, GM-CSF, G-CSF, TNF-α, CXCL9, IL-6, IL-23, 
IL-17, IL-1β, MCP-1, and MIP-2α. In the tibialis anterior and gastrocnemius muscles, the 
mRNA expression of atrogin-1, MuRF-1, IGF-1eA, IGF-1eB, myostatin, IL-6, NOX-2, 
PPARGC1A, and NFE2L2 were measured. For the in vitro C2C12 mouse skeletal muscle 
cells, IL-6 and TNF-α were measured. GAPDH was used as the reference gene against all 
genes measured and all measurements were made using commercially available, validated 
Taqman primer/probes. In order to measure as many genes as possible while rationing 
collected samples, preliminary analysis used pooled samples from each animal in each group. 
As the samples were pooled, only trends could be observed and statistical significance could 
not be determined. Refer to section 2.7 for RNA extraction and RT-qPCR protocol 
information. 
 
4.1.1. ELISAs and TBARS 
The protein concentrations of IL-6, IGF-1, Mouse CRP and 8-isoprostane in serum were 
determined using commercially available ELISA kits and measured according to 
manufacturer’s instructions and as detailed in section 2.5. The concentration of MDA was 
measured using an OxiSelect™ TBARS Assay Kit (Cell Biolabs, Inc., CA, USA) according 
to manufacturer’s instructions. 
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4.1.2. Oxyblot 
Protein carbonylation, a marker of oxidative stress, was measured in muscle tissue using an 
Oxyblot Protein Oxidation Detection kit (Merck, Massachusetts, USA). β-actin was used as 
the reference protein. For further details, refer to sections 2.6.1 and 2.6.2 respectively. 
 
4.1.3. C2C12 Mouse Skeletal Muscle Cells 
The C2C12 cell line is a subclone (produced by H. Blau, et al. [299]) of the mouse myoblast 
cell line established by D. Yaffe and O. Saxel [300].  This cell line differentiates rapidly, 
forming contractile myotubes and producing characteristic muscle proteins. Initial pilot 
studies to highlight the direct impact of cigarette smoke and, more specifically, oxidative 
stress were conducted using this cell line.  
C2C12 myoblasts were cultured in growth media, which consists of Dulbecco’s Modified 
Eagle Medium (DMEM) with 4.5mmol glucose, glutamine, sodium pyruvate and 
supplemented with 10% fetal calf serum and 1% penicillin and streptomycin. Seeded 
myoblasts were differentiated to myotubes using DMEM with 4.5mmol glucose, glutamine, 
sodium pyruvate supplemented with 2% horse serum and 1% penicillin and streptomycin and 
as described in section 2.9.3. 
 
4.1.4. H2O2 and Cigarette Smoke Extract Exposure 
Please refer to sections 2.9.4 and 2.9.5 for relevant protocols. 
 
4.1.5. Cell Viability  
C2C12 cell viability following H2O2 exposure was measured using commercially available 
MTT and MTS cell viability assays. Further details can be found in section 2.9.7 and 2.9.8. 
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4.1.6. Mitochondrial Stress Test 
Following H2O2 exposure, C2C12 basal respiration, ATP production, proton leak, maximal 
respiration, and reserve capacity was measured using the ‘Seahorse’ XF Mito Stress Test Kit 
(Agilent, CA, USA) according to manufacturer’s specifications. Further details can be found 
in section 2.9.9. 
4.1.7. Statistical Analyses 
As data were normally distributed, they are presented as grouped data expressed as mean ± 
SEM; n represents the number of mice. Student’s t test was used to assess significance where 
only two data sets were present. Multivariate analysis was performed via one- or two-way 
ANOVA followed by Bonferroni post hoc test for multiple comparisons, where appropriate. 
All statistical analyses were performed using GraphPad Prism for Windows and Mac (version 
6.0-8.1). In all cases, probability levels less than 0.05 (P < 0.05) were taken to indicate 
statistical significance. 
4.2. Apocynin Study A 
4.2.1. Assessment of BALF inflammation 
As a measure of local inflammation in the lungs, BALF was collected and total cells were 
counted. A differential cell count was then performed to determine the number of 
macrophages and neutrophils. Cigarette smoke exposure (6 cigarettes/day, 5 days/week for 8 
weeks) significantly increased the total, macrophage and neutrophil number in BALF (Figure 
16) as observed in Chapter 3. However, smoke-exposed mice treated with apocynin had a 
significant reduction in total cells, macrophages and neutrophils compared with vehicle 
treated smoke-exposed mice. Following the 56-day cigarette smoke exposure period, the 
number of total cells in the BALF was 2.48x105 ± 2.45x104, 2.74x105 ± 1.92 x104, 9.11x105 ± 
6.72x104, and 6.53x105 ± 4.62x104 cells/mL for the sham + vehicle, sham + apocynin, smoke 
+ vehicle, and smoke + apocynin respectively (Figure 16A). The number of macrophage cells 
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was 2.48x105 ± 2.46x104, 2.74x105 ± 1.92x104, 6.51x105 ± 4.96x1054, and 5.24x105 ± 4.23x104 
cells/mL (Figure 16B), whilst the number of neutrophils was 861 ± 50.6, 296 ± 15.4, 256x105 
± 2.55x104, and 1.28x105±8.99x103 cells/mL for the sham + vehicle, sham + apocynin, smoke 
+ vehicle, and smoke + apocynin respectively (Figure 16C). 
 
 
Figure 16. The effect of  apocynin (5 mg kg-1) administration on BALF cellularity in 
mice exposed to air (sham) or  cigarette smoke (Smoke). 
BALF cellularity is shown as (A) the total number of cells, (B) macrophages, and (C) 
neutrophils. Data are expressed as mean ± SEM for n=8 mice per treatment group. Two-way 
ANOVA with Bonferroni post-hoc test was performed to assess statistical significance. 
*P<0.05 vs Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
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4.2.2. Assessment of cytokine mRNA expression in lungs 
To measure the mRNA expression of inflammatory cytokines and chemokines, lung tissue 
was pooled and RNA was extracted. Specifically, RT-qPCR was used to measure the 
expression of macrophage chemoattractants CXCL10, and MCP-1, and neutrophil 
chemokines MIP-2α, and IL-17A. Cigarette smoke exposure elevated the mRNA expression 
of CXCL10, MCP-1, MIP-2α, and IL-17A in the lung tissue in the vehicle-treated mice. 
However, treatment with apocynin caused a reduction in cigarette smoke-induced increases in 
mRNA expression of CXCL10 and MCP-1 but not MIP-2α and IL-17A. With regards to 
CXCL10 mRNA expression, compared to the sham + vehicle groups, there was a fold-change 
of 0.8, 1.6, and 0.7 in the sham + apocynin, smoke + vehicle, and smoke + apocynin groups 
respectively (Figure 17A). For MCP-1, there was a fold-change of 0.4, 5.1, and 1.8 in the 
sham + apocynin, smoke + vehicle, and smoke + apocynin groups respectively (Figure 17B). 
For MIP-2α, there was a fold-change of 0.3, 2.2, and 3.3 in the sham + apocynin, smoke + 
vehicle, and smoke + apocynin groups respectively (Figure 17C). For IL-17A, there was a 
fold-change of 0.3, 6.4, and 7.5 in the sham + apocynin, smoke + vehicle, and smoke + 
apocynin groups respectively (Figure 17D). It was interesting to note that apocynin treatment 
of sham-exposed mice also resulted in a reduction in CXCL10, MCP-1, MIP-2α and IL-17A 
(Figure 17 A-D).  Due to the pooling of samples, statistical analysis could not be performed 
for this data.   
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Figure 17. The effect of apocynin (5 mg kg-1) on pooled whole lung tissue mRNA 
expression of cytokines and chemokines in mice exposed to air (sham) or cigarette smoke 
(smoke).   
Data are expressed as mean, n=8 mice per treatment group. As the samples were pooled, this 
data could not be statistically analysed. 
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4.2.3. Impact of smoke exposure on total body weight and food consumption  
To determine the impact of smoke exposure on weight loss and growth, mouse body weight 
was measured each day and food consumption was measured on Monday, Wednesday and 
Friday, with both measurements conducted at approximately the same time per day. Smoke-
exposed mice, regardless of treatment, experienced reduced growth compared to their sham 
counterparts. However, smoke-exposed mice treated with apocynin experienced an improved 
rate of growth over the vehicle treated group. Figure 18A shows the steady increase in body 
weights of the mice over the 56-day period. At the end of the 56 day exposure period, the 
average body weights of the mice increased by 14.0 ± 1.3%, 13.6 ± 1.2%, -0.01 ± 1.5%, and 
4.58 ± 1.7% in the sham + vehicle, sham + apocynin, smoke + vehicle, and smoke + 
apocynin groups respectively to 25.2 ± 0.49g, 25.2 ± 0.58g, 22.3 ± 0.63g, and 23.0 ± 0.53g 
(Table 6 and Figure 18B). This is reflected in the final percentage change shown in Figure 
18B, which shows that the smoke + apocynin mice had a 32.6% improvement in total body 
weight over the smoke + vehicle group on day 56 (when compared to the sham + vehicle). 
Food intake was measured to determine if apocynin had an impact on nicotine-
induced reductions in appetite. As expected, both smoke-exposed groups experienced a 
significant reduction in food intake compared to their sham counterparts (Figure 18C). In 
addition, apocynin did not impact daily food intake. The average daily food intake of the 
animals was 3.71 ± 0.08 g, 3.56 ± 0.07 g, 3.08 ± 0.08 g, and 2.86 ± 0.07 g for the sham + 
vehicle, sham + apocynin, smoke + vehicle, and smoke + apocynin groups respectively. 
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Figure 18. The effect of apocynin administration (5 mg kg-1) on total body weight and 
food consumption in mice after cigarette smoke exposure. 
(A) Body weight was recorded daily for each group over the 56-day period. (B) Final 
percentage weight change on day 56. (C) Food intake was calculated by measuring the 
amount of food remaining in the cages and dividing the difference between days by the 
number of mice in the cage. Data are expressed as mean ± SEM for n=8 mice per treatment 
group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess statistical 
significance. *P<0.05 vs Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
 
 
4.2.4. Impact of smoke on organ, skeletal muscle and adipose tissue mass  
To measure the impact of cigarette smoke on skeletal muscle mass, the tibialis anterior, 
gastrocnemius, plantaris, and soleus were extracted and weighed (Table 6). Cigarette smoke 
exposure caused a significant reduction in mass of the tibialis anterior and soleus muscles by 
8.2 and 7.7% respectively, with apocynin treatment protecting against these changes. 
Specifically, tibialis anterior mass was 51.2 ± 1.2 mg, 51.8 ± 1.1 mg, 47.0 ± 1.0 mg*, and 
48.6 ± 0.99 mg in the sham + vehicle, sham + apocynin, smoke + vehicle, and smoke + 
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apocynin groups respectively. Soleus mass was 7.32 ± 0.77 mg, 7.66 ± 0.87 mg, 6.76 ± 
0.80*, and 7.16 ± 0.65 mg in the sham + vehicle, sham + apocynin, smoke + vehicle, and 
smoke + apocynin groups respectively. Surprisingly, the masses of the gastrocnemius and 
plantaris muscles were not affected by either smoke exposure or apocynin treatment. 
Specifically, gastrocnemius mass was 123 ± 3.4 mg, 124 ± 2.4 mg, 116 ± 2.6 mg, and 119 ± 
2.5 mg, and plantaris mass was 15.8 ± 0.5 mg, 16.2 ± 0.4 mg, 15.3 ± 0.3 mg, and 15.0 ± 0.4 
mg in the sham + vehicle, sham + apocynin, smoke + vehicle, and smoke + apocynin groups 
respectively. Additionally, muscle weight was not normalised to tibia length in this study. 
To determine the extent that fat loss contributed to the smoke-induced total body 
weight loss, testicular and retroperitoneal WAT were extracted and weighed (Table 1). 
Cigarette smoke caused a significant reduction in the testicular WAT and retroperitoneal 
WAT by 29.6% and 37.9% respectively, and treatment with apocynin protected against these 
changes. Specifically, testicular WAT mass was 596 ± 52 mg, 534 ± 66 mg, 420 ± 46 mg*, 
and 513.9 ± 41mg, and retroperitoneal WAT mass was 106.5 ± 8.0mg, 100.9±15mg, 66.15 ± 
7.2 mg*, and 89.0 ± 10# mg in the sham + vehicle, sham + apocynin, smoke + vehicle, and 
smoke + apocynin groups respectively. Unfortunately, the WAT samples were not collected 
so no further analysis was conducted using these samples. 
To measure potential inflammation and oedema in organs, the weights of the lungs, 
heart, kidney, liver, and spleen were measured (Table 6). Smoke-exposure caused a 
significant increase in lung weight, which was not reduced by treatment with apocynin. 
Compared to the sham + vehicle control, the smoke + vehicle mice lung weight increased by 
23.7% and the smoke + apocynin group by 30.0%. Specifically, the lung weights were 228 ± 
8.0 mg, 247 ± 6.3 mg, 282 ± 17.9 mg, and 296 ± 16.0 mg in the sham + vehicle, sham + 
apocynin, smoke + vehicle, and smoke + apocynin groups respectively. 
 
  116 
Smoke-exposure significantly reduced heart weight, which was not improved by treatment 
with apocynin. Compared to the sham + vehicle control, the smoke + vehicle mice heart 
weight decreased by 8.9% and the smoke + apocynin group by 8.2%. This is in contrast to the 
expected effect of smoke-exposure causing an increase in cardiac mass. Specifically, the 
heart weights were 126 ± 3.1 mg, 127 ± 3.1 mg, 115 ± 4.6 mg, and 115 ± 3.8 mg in the sham 
+ vehicle, sham + apocynin, smoke + vehicle, and smoke + apocynin groups respectively. 
Additionally, smoke-exposure significantly reduced spleen weight, however, the significant 
reduction was not observed in the apocynin treated mice. Compared to the sham + vehicle 
control, the smoke + vehicle mice spleen weight decreased by 21.38% and the smoke + 
apocynin group by 16.2%. Specifically, the spleen weights were 88.8 ±3.2mg, 95.7 ± 2.1mg, 
69.8 ± 6.6 mg, and 74.4 ± 2.0 mg in the sham + vehicle, sham + apocynin, smoke + vehicle, 
and smoke + apocynin groups respectively. Spleen tissue was not collected so further 
analysis could not be conducted. 
In general, neither smoke-exposure nor treatment with apocynin had an effect on liver 
and kidney weights in this model. Specifically, the liver weights were 1.31103 ± 78.1 mg, 
1.10x103 ± 39.8 mg, 1.08x103 ± 37.0 mg, and 983 ± 41.0 mg, and the kidney weights were 
369 ± 12.4 mg, 372 ± 8.0 mg, 350 ± 14.1 mg, and 341 ± 15.7 mg in the sham + vehicle, sham 
+ apocynin, smoke + vehicle, and smoke + apocynin groups respectively. 
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Tissue SV SA CSV CSA 
Body Weight (g) 25.2 ± 0.49 25.2 ± 0.58 22.3 ± 0.63 * 230 ± 0.53 *# 
Tibialis anterior (mg) 51.2 ± 1.2 51.8 ± 1.1 47.0 ± 1.0 * 48.6 ± 0.99 
Soleus (mg) 7.32 ± 0.77 7.66 ± 0.87 6.76 ± 0.80 * 7.16 ± 0.65 
Gastrocnemius (mg) 123 ± 3.4 124 ± 2.4 116 ± 2.6  119 ± 2.5 
Plantaris (mg) 15.8 ± 0.5 16.2 ± 0.4 15.3 ± 0.3 15.0 ± 0.4 
Testicular WAT (mg) 596 ± 52 533 ± 66 420 ± 46 * 514 ± 41 
Retroperitoneal WAT (mg) 107 ± 8.0 101 ± 15 66.2 ± 7.2 * 89.0 ± 10 # 
Lung (mg) 228 ± 8.0 247 ± 6.3 282 ± 17.9 * 296 ± 16.0 * 
Heart(mg) 126 ± 3.1 127 ± 3.1 114.6 ± 4.6 * 115.4 ± 3.8 * 
Spleen (mg) 88.8 ± 3.2 95.68 ± 2.1 69.8 ± 6.6 * 74.4 ± 2.0 
Liver (mg) 1.31x103 ± 78 1.10x103 ± 40 1.08x103 ± 37 983 ± 41 
Kidney(mg) 369 ± 12.4 372 ± 8.0 350 ± 14.1  341 ± 15.7 
 
Table 6. The effect of apocynin (5 mg kg-1) administration on lung, heart, kidney, liver, 
spleen, skeletal muscle weights, and WAT weights in mice after smoke exposure.  
Sham + vehicle (SV), sham + apocynin (SA), cigarette smoke + vehicle (CSV), and cigarette 
smoke + apocynin (CSA) data are expressed as mean ± SEM for n=8 mice per treatment 
group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess statistical 
significance. *P<0.05 vs Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
 
 
4.2.5. Assessment of mRNA expression in tibialis anterior 
Tibialis anterior tissue was pooled and RNA was extracted. The expression of MuRF-1, 
atrogin-1, IGF-1b, and myostatin was measured via qRT-PCR. Smoke exposure caused a 
reduction in atrogin-1 mRNA expression but surprisingly, had no effect on MuRF-1 mRNA 
expression in the tibialis anterior muscle in either treatment group (Figure 19A and 19B). 
Cigarette smoke caused a reduction in IGF-1 and an increase in myostatin mRNA expression 
(Figure 19C and 19D). The mice treated with apocynin did not experience these cigarette 
smoke-induced changes in IGF-1 and myostatin mRNA expression. Specifically, with regards 
to atrogin-1 mRNA expression, there was a fold-change of 1.1, 0.7, and 0.7 in the sham + 
apocynin, smoke + vehicle, and smoke + apocynin groups respectively compared to the sham 
+ vehicle groups (Figure 19A). For MuRF-1, there was a fold-change of 1.4, 1.1, and 1.2 in 
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the sham + apocynin, smoke + vehicle, and smoke + apocynin groups respectively (Figure 
19B). For IGF-1b, there was a fold-change of 1.2, 0.5, and 1.0 in the sham + apocynin, smoke 
+ vehicle, and smoke + apocynin groups respectively (Figure 19C). For Myostatin, there was 
a fold-change of 0.9, 1.4, and 1.1 in the sham + apocynin, smoke + vehicle, and smoke + 
apocynin groups respectively (Figure 19D). This indicates that in this model, the skeletal 
muscle wasting observed was likely a result of a reduction in protein synthesis rather than an 
increase in protein degradation as demonstrated by the changes seen in expression of IGF-1 
and Myostatin, which are implicated in muscle growth homeostatis pathways. Due to the 
pooling of samples, statistical analysis could not be performed for this data. 
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Figure 19. The effect of apocynin (5 mg kg-1) administration on pooled tibialis anterior 
tissue mRNA expression of MuRF-1, atrogin-1, myostatin, IGF-1 and IL-6 in mice after 
smoke exposure. 
Data are expressed as mean for n=8 mice per treatment group. As the samples were pooled, 
this data could not be statistically analysed. 
 
 
4.2.6. Assessment of mRNA expression in heart tissue 
Due to the significant reduction in heart mass, we measured the expression of 4 genes known 
to contribute to various cardiovascular disorders, natriuretic peptide A (NPPA), myosin-1 
(Myh1), tumour necrosis factor alpha (TNFα) and interleukin 1 alpha (IL-1α). There were no 
significant changes in expression in any of the genes, however there was a trend for IL-1α to 
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increase with smoke exposure. Specifically, with regards to NPPA mRNA expression, 
compared to the sham + vehicle groups, there was a fold-change of 1.10, 1.07, and 0.97 in the 
sham + apocynin, smoke + vehicle, and smoke + apocynin groups respectively (Figure 20A). 
For Myh-1, there was a fold-change of 1.40, 1.08, and 1.62 in the sham + apocynin, smoke + 
vehicle, and smoke + apocynin groups respectively (Figure 20B). For TNF-α , there was a 
fold-change of 1.17, 1.44, and 1.29 in the sham + apocynin, smoke + vehicle, and smoke + 
apocynin groups respectively (Figure 20C). For IL-1α, there was a fold-change of 1.16, 1.75, 
and 1.93 in the sham + apocynin, smoke + vehicle, and smoke + apocynin groups 
respectively (Figure 20D). As differences observed did not reach significance in any of the 
data sets, it can be assumed that 8-weeks was likely not a long enough time for significant 
cardiovascular modifications to occur. This indicates that the reduction in heart mass 
observed in Table 1 may have just been a result of overall body mass reduction in the 
animals. Further analysis using more sensitive techniques may be required to observed and 
examine any cardiovascular modifications occurring in this model. Due to this, I sought to 
establish a mouse model for cardiac dysfunction following cigarette smoke exposure (refer to 
Chapter 5). 
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Figure 20. The effect of apocynin (5mg kg-1) administration on heart tissue mRNA 
expression of NPPA, Myh1, TNF-α, and IL-1α in mice after smoke exposure. 
Data are expressed as mean ± SEM for n=8 mice per treatment group.  
 
 
Due to insufficient sample volume and time constraints, ELISAs to measure systemic 
inflammation and systemic oxidative stress in this model could not be performed in Study A 
and muscle samples that were collected for histological examination could not be assessed. 
The collected tissues were preserved for future histological assessment. Lastly, functional 
testing of skeletal muscle in the mice was not available at this time. Following this 
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preliminary apocynin study, we replicated the same model with an increased sample size of 
n=12 to increase the statistical power of the study and increase the number of assays 
performed. Due to its efficacy in treating lung inflammation and protecting against skeletal 
muscle wasting, we hypothesised that the results observed with apocynin treatment would be 
reproduced. 
4.3. Apocynin Study B 
4.3.1. Assessment of BALF inflammation 
In Study B, cigarette smoke exposure (6 cigarettes/day, 5 days/week for 8 weeks) 
significantly increased the total, macrophage and neutrophil number in BALF. However, in 
contrast to the first apocynin study (Figure 16), apocynin did not reduce cigarette smoke-
induced increases in BALF total cells and macrophages (Figure 21A and 21B).  However, 
smoke-exposed mice treated with apocynin had a significant reduction in neutrophils 
compared with vehicle treated smoke-exposed mice (Figure 21C) which is consistent with 
that observed in the first apocynin study (Figure 16C). Following the 56-day smoke exposure 
period, the number of total cells in the BALF was 1.61x105 ± 1.41x104, 1.74x105 ± 3.76x104, 
5.37x105 ± 5.91x104, and 5.49x105 ± 4.76x104 cells/mL for the sham + vehicle, sham + 
apocynin, smoke + vehicle, and smoke + apocynin respectively (Figure 21A). The number of 
macrophage cells was 1.58x105 ± 1.38x105, 1.79x105 ± 4.14x104, 4.42x105 ± 5.62x104, and 
5.06x105 ± 5.10x104 cells/mL (Figure 21B), whilst the number of neutrophils was 2.57x103 ± 
613, 1.96x103 ± 638, 9.38x104 ± 1.81x104, and 4.13x104 ± 1.13x104 cells/mL for the sham + 
vehicle, sham + apocynin, smoke + vehicle, and smoke + apocynin respectively (Figure 21C). 
Surprisingly the number of neutrophils across all groups was higher than those observed in 
the first apocynin study (A). There was approximately a 3-fold difference in the sham groups 
and a 2-fold difference in the smoke groups. This may be due to differences in air quality at 
the different animal facilities these studies were conducted in (Study A performed at The 
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University of Melbourne whereas Study B was performed at RMIT University given that my 
supervisor Prof Ross Vlahos moved to RMIT University during my PhD candidature). Lung 
PCR was not performed again in this repeat study due to time constraints. 
 
 
Figure 21. The effect of apocynin (5 mg kg-1) administration on BALF cellularity in mice 
after smoke exposure. 
Balf cellularity is shown as (A) the total number of cells, (B) macrophages, (C) neutrophils. Data are 
expressed as mean ± SEM for n=12 mice per treatment group. Two-way ANOVA with Bonferroni 
post-hoc test was performed to assess statistical significance. *P<0.05 vs Sham + Vehicle, #P<0.05 vs 
Smoke + Vehicle. 
 
 
4.3.2. Impact of smoke exposure on total body weight and food intake 
In Study B, mouse body weight was measured each day and food consumption was measured 
Monday, Wednesday and Friday, with both measurements conducted at approximately the 
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same time per day. Smoke-exposed mice, regardless of treatment, experienced reduced 
growth compared to their sham counterparts. As seen in Figure 22A, which shows the 
average weekly weight of the animals, smoke-exposed mice treated with apocynin 
experienced a slightly improved rate of growth over the 56-day period compared to the 
vehicle treated group. However, unlike in study A when examining the final percentage 
change shown in Figure 22B, we see that there was no significant improvement in total body 
weight in the apocynin treated group. On day 56, the final increase in total bodyweight 
percentage was 16.1±0.8%, 14.4±1.1%, 1.97±1.7%, and 3.47±1.1% for the sham + vehicle, 
sham + apocynin, smoke + vehicle, and smoke + apocynin groups respectively (Figure 22B). 
Both smoke-exposed groups experienced a significant reduction in food intake 
compared to their sham counterparts over the 8-week period (Figure 22C). In addition, 
apocynin did not impact food intake. Food intake was 2.84±0.19, 2.83±0.19, 2.33±0.17, and 
2.25±0.15 g/mouse/day for the sham + vehicle, sham + apocynin, smoke + vehicle, and 
smoke + apocynin groups respectively. 
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Figure 22. The effect of apocynin (5 mg kg-1) administration on total body weight and 
food consumption in mice after smoke exposure. 
(A) Body weight was recorded daily for each group over the 56-day period. (B) Final percentage 
weight change on day 56. (C) Food intake was calculated by measuring the amount of food remaining 
in the cages and dividing the difference between days by the number of mice in the cage. Data are 
expressed as mean ± SEM for n=12 mice per treatment group. Two-way ANOVA with Bonferroni 
post-hoc test was performed to assess statistical significance. *P<0.05 vs Sham + Vehicle 
 
 
4.3.3. Impact of smoke exposure on organ and skeletal muscle weights  
Lungs 
In this second study, the focus of the study was narrowed and we only collected the lungs, 
hind limb skeletal muscles, and WAT (Table 7). Lung weight was 282 ± 5.3 mg, 281 ± 6.6 
mg, 305 ± 7.9 mg, and 300 ± 6.3 mg for the sham + vehicle, sham + apocynin, smoke + 
vehicle, and smoke + apocynin groups respectively. Smoke-exposure caused a significant 
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increase in lung weight, which was not reduced by treatment with apocynin. Compared to the 
sham + vehicle control, the smoke + vehicle, mean lung mass increased by 8.0% and the 
smoke + apocynin group by 6.3%. These values are considerably smaller than values 
acquired from the first study, which may be a reflection of the reduced inflammation across 
all groups in study 2. 
 
Skeletal Muscle 
In the second study, greater levels of wasting was observed as smoke exposure significantly 
decreased the weights of all 4 hind limb skeletal muscles and in both TWAT and RWAT 
(Table 6). Respectively for the sham + vehicle, sham + apocynin, smoke + vehicle, and 
smoke + apocynin groups, muscle weights are as follows: Tibialis anterior: 60.5 ± 0.9 mg, 
60.3 ± 1.3 mg, 54.0 ± 1.0 mg*, and 56.6 ± 1.6 mg. Soleus: 10.3 ± 0.3 mg, 10.2 ± 0.3 mg, 8.9 
± 0.3mg*, and 9.9 ± 0.4 mg. Plantaris: 19.1 ± 0.3 mg, 19.4 ± 0.5 mg, 16.1 ± 0.4 mg*, and 
16.9 ± 0.5 mg*. Gastrocnemius: 149 ± 2.1 mg, 148 ± 2.2 mg, 131 ± 2.4 mg*, and 137 ± 2.2 
mg*. Smoke-exposure significantly reduced the mean weight of the tibialis anterior, soleus, 
plantaris and gastrocnemius by 10.8%, 14.6%, 15.7%, and 12.2% respectively. Significant 
muscle wasting was not observed in the tibialis anterior and soleus muscles of the mice 
treated with apocynin, however, significant wasting was still observed in the plantaris and 
gastrocnemius. The tibias of the animals were collected and the length measured. The lengths 
of the TA and gastrocnemius were normalised to the tibia length, however this did not affect 
the statistical significance of the muscle wasting observed as a result of smoke-exposure. This 
indicates that the wasting observed was not proportional to the observed reduction in total 
body weight of the smoke-exposed mice. 
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White adipose tissue 
With regards to adipose tissue mass, testicular WAT weights were 639 ± 37 mg, 529 ± 35 
mg, 444 ± 57 mg*, and 381 ± 29 mg* and for retroperitoneal WAT, weights were 99.4 ± 5.3 
mg, 74.5 ± 7.2 mg, 64.3 ± 9.3 mg*, and 54.6 ±4.4 mg* respectively for the sham + vehicle, 
sham + apocynin, smoke + vehicle, and smoke + apocynin groups. Smoke-exposure 
significantly reduced the weight of the testicular WAT and retroperitoneal WAT by 30.6% 
and 35.4% respectively. Unlike the first study, treatment with apocynin did not protect mice 
from this smoke-induced reduction WAT.  
 
Tissue SV SA CSV CSA 
Body Weight (g) 27.3 ± 0.39 26.8 ± 0.48 23.6 ± 0.66 * 23.7 ± 0.27 * 
Tibialis anterior (mg) 60.5 ± 0.9 60.3 ± 1.3 54.0 ± 1.0 * 56.6 ± 1.6 
Soleus (mg) 10.4 ± 0.3 10.2 ± 0.3 8.9 ± 0.3 * 9.9 ± 0.4 
Gastrocnemius (mg) 149 ± 2.1 148 ± 2.2 131 ± 2.4 * 137 ± 2.2 * 
Plantaris (mg) 19.1 ± 0.3 19.4 ± 0.5 16.1 ± 0.4 * 16.9 ± 0.5 * 
Testicular WAT (mg) 639 ± 37 529 ± 35 444 ± 57 * 381 ± 29 * 
Retroperitoneal WAT (mg) 99.4 ± 5.3 74.5 ± 7.2 64.3 ± 9.3 * 54.6 ± 4.4 * 
Lung (mg) 282 ± 5.3 281 ± 6.6 305 ± 7.9 * 300 ± 6.2 * 
 
Table 7. The effect of apocynin (5 mg kg-1) administration on lung, heart, skeletal 
muscle, and WAT weights in mice after smoke exposure. 
Data are expressed as mean ± SEM for n=12 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
Sham + Vehicle 
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4.3.4. Assessment of tibialis anterior muscle function in situ 
In the second apocynin study, the maximum force-frequency, rate of contraction, force 
generated at 120Hz, and the specific force at 120Hz were measured in situ using the 1300A: 
3-in-1 Whole Animal System – Mouse force transducer apparatus as described in the 
Methods section (section 4.1.5) of this Chapter and the methods section in the General 
Methods Chapter (section 2.8.1).  
 
Force Frequency 
The frequency-dependent gain in contractility is an intrinsic property of both skeletal and 
cardiac muscle in mammals. As frequency increases, maximum force generated also 
increases until it reaches the peak threshold of possible force generation. In healthy mice, this 
peak occurs at approximately 120 Hz. As seen in Chapter 3 (Figure 9A), the frequency-
dependent gain in contractile force was observed in the mice, with the peak occurring at 120 
Hz for the sham + vehicle control group (Figure 23A). Following smoke exposure, the force-
frequency relationship is altered, trending towards lower force generation across all 
frequencies. Additionally, the peak threshold is shifted in the smoke + vehicle animals, now 
occurring at 150Hz. This indicates that the function of the muscle may be impaired, which 
could be due to impaired mitochondrial function or the result of a shift in fibre type from type 
I (slow twitch) muscle fibres to type II (fast twitch) muscles known to occur in COPD [114]. 
We did not observed these trends in the mice treated with apocynin indicating that apocynin 
may have a protective effect against the contractile dysfunction in this model. 
 
Rate of Contraction 
As with the force-frequency relationship, there is also an intrinsic frequency-dependent gain 
in the rate of contraction of cardiac and skeletal muscle in mammals. As frequency increases, 
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the rate of contraction increases. In accordance with Figure 23A, the frequency dependent 
gain in the maximum rate of contraction was observed in all groups. Compared to vehicle 
treated groups, there was an observed trend showing that smoke exposure caused a reduction 
in maximum rate of contraction at all frequencies. Treatment with apocynin improved the 
maximum rate of contraction across all frequencies when compared to the smoke + vehicle 
group (Figure 23C). Specifically, at the initial and peak force-frequencies, there was a 14.5% 
improvement at 10 Hz, and a 13.8% improvement at 120 Hz with apocynin treatment. Once 
again, this data suggests that apocynin had a protective effect against contractile dysfunction 
in this model. 
 
Max Force at 120Hz, Specific Force at 120Hz, and Absolute Max Force 
Peak force generation occurred at 120Hz for all groups excluding the smoke + vehicle group. 
The maximum force at 120Hz did not significantly differ between the 4 groups, regardless of 
exposure or treatment (Figure 23B). Specifically, maximum force at 120Hz was 692 ± 74.7 
mN, 632 ± 58.2 mN, 508 ± 74.1 mN, and 643 ± 31.7mN for the sham + vehicle, sham + 
apocynin, smoke + vehicle, and smoke + apocynin groups respectively. The smoke + vehicle 
group appears to have reduced force generation at 120 Hz, which corresponds to the observed 
shift in max force from 120 Hz to 150 Hz for this treatment group as seen in Figure 23A. The 
maximum force at 120 Hz was normalised using the Lo, which provided the specific force at 
120 Hz.  
Specific force was 161 ± 20.7 mN, 154 ± 12.5 mN, 141.2 ± 19.2 mN, and 160 ± 11.7 
mN respectively (Figure 23D). As with the maximum force, the specific force did not 
significantly differ between the 4 groups, regardless of exposure or treatment. However, the 
same trend of reduced maximum force was observed in the smoke + vehicle group which also 
had reduced specific force generation at 120 Hz. To account for the discrepancy in the force-
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frequency relationship of the smoke + vehicle group with the other groups, we examined the 
absolute maximum force generated regardless of frequency in the sham + vehicle and smoke 
+ vehicle groups (Figure 23E).  
Absolute maximum force was 669 ± 75.0 mN for the sham + vehicle group and 571 ± 
79.8 mN for the smoke + vehicle group. Like the previous data, there is also an observed 
trend for reduced absolute maximum contractile force in the smoke-exposed mice. 
Although not significant, this data shows a clear trend for impaired maximum 
contractile function because of smoke exposure that approaches significance. An increased 
sample size (n=20+) could offset the variance in contractile function observed. 
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Figure 23. The effect of apocynin (5mg kg-1) administration on tibialis anterior 
contractile function in mice after smoke exposure. 
(A) Maximum force-frequency relationship, (B) maximum rate of contraction, (C) maximum force 
generated at 120Hz, (D) specific force generated at 120Hz, and (E) maximum absolute force. Data are 
expressed as mean ± SEM for n=10-12 mice per treatment group.  
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4.3.5. Assessment of mRNA expression in skeletal muscle tissue  
Tibialis anterior 
In this study, the tibialis anterior and soleus muscles were protected against cigarette smoke-
induced muscle wasting. Unlike study A the tibialis anterior tissues of this study were not 
pooled so statistical analysis could be performed. Additionally, due to difficulties in acquiring 
a sufficient RNA yield from soleus skeletal muscle tissues, the expression of mRNA in the 
soleus was not analysed. 
The mRNA expression of atrogin-1, MuRF-1, IGF-1eA, IGF-1eB, myostatin, IL-6, 
NOX-2, PPARGC1A, and NFE2L2 was measured in both the tibialis anterior and 
gastrocnemius skeletal muscles. Refer to Table 8 for specific mRNA expression fold-change. 
In contrast to Study A, there were no alterations to the mRNA expression of any gene 
measured – specifically there were no alterations in IGF-1b or myostatin mRNA expression. 
As apocynin had a beneficial effect and acts via the inhibition of NOX-2 formation, the 
mechanism behind these beneficial effects is unclear as there is no clear driver of the 
observed wasting based on these results. It is possible that NOX-2 activity is increased, 
inflammatory cell infiltration into the muscle may be occurring, or ROS is being generated by 
another source (e.g. mitochondria) as a result of smoke exposure. Flow cytometry or 
immunohistochemistry should be performed in future studies to determine if there is 
inflammatory cell infiltration in the skeletal muscle of the animals as a result of this smoke-
exposure model. 
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Sham Cigarette Smoke 
Gene Vehicle Apocynin Vehicle Apocynin 
Atrogin-1 1.00 ± 0.21 1.10 ± 0.23 1.03 ± 0.15 1.02 ± 0.15 
MuRF-1 1.00 ± 0.15 0.99 ± 0.20 0.91 ± 0.20 0.95 ± 0.22 
IGF-1eA 1.00 ± 0.14 1.09 ± 0.30 0.96 ± 0.30 0.97 ± 0.20 
IGF-1eB 1.00 ± 0.11 1.12 ± 0.14 1.14 ± 0.14 0.95 ± 0.11 
Myostatin 1.00 ± 0.12 1.01 ± 0.15 0.96 ± 0.15 0.97 ± 0.09 
IL-6 1.00 ± 0.16 0.75 ± 0.09 0.64 ± 0.09 0.99 ± 0.22 
NOX-2 1.00 ± 0.16 0.88 ± 0.12 0.86 ± 0.08 0.87 ± 0.11 
Ppargc1a 1.00 ± 0.11 1.24 ± 0.18 1.34 ± 0.26 1.03 ± 0.11 
Nfe2l2 1.00 ± 0.14 1.10 ± 0.14 1.07 ± 0.11 1.09 ± 0.16 
 
Table 8. The effect of apocynin (5 mg kg-1) administration on tibialis anterior tissue 
mRNA expression of atrogin-1, MuRF-1, IGF-1eA, IGF-1eB, myostatin, IL-6, NOX-2, 
PPARGC1A, and NFE2L2 in mice after cigarette smoke exposure. 
Data are expressed as mean ± SEM for n=3-11 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance.  
 
 
Gastrocnemius 
In this study, there was significant wasting of the gastrocnemius due to cigarette smoke 
exposure. Although significant improvements in gastrocnemius mass were not observed 
following treatment with apocynin, significant wasting was still observed in these tissues 
which warranted analysis to help elucidate the mechanism by which this wasting occurred.  
Unlike study A, which only explored mRNA expression in the tibialis anterior, the mRNA 
expression of atrogin-1, MuRF-1, IGF-1eA, IGF-1eB, myostatin, IL-6, NOX-2, PPARGC1A, 
and NFE2L2 was also measured via qRT-PCR. Refer to Table 9 for specific mRNA 
expression fold-change. As with the tibialis anterior tissue, there were no significant 
alterations to the mRNA expression of any gene measured. As these observations were in 
concordance with the skeletal muscle mRNA expression data in Chapter 3, it is likely that the 
wasting observed in this smoke exposure model is primarily driven by direct muscle damage 
rather than alterations to the protein homeostasis pathway. 
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Sham Cigarette Smoke 
Gene Vehicle Apocynin Vehicle Apocynin 
Atrogin-1 1.00 ± 0.14 1.08 ± 0.18 0.91 ± 0.12 0.91± 0.12 
MuRF-1 1.00 ± 0.14 0.90 ± 0.12 0.87 ± 0.12 0.91 ± 0.11 
IGF-1eA 1.00 ± 0.18 1.12 ± 0.15 0.84 ± 0.08 0.95 ± 0.14 
IGF-1eB 1.00 ± 0.10 1.29 ± 0.16 1.08 ± 0.08 1.17 ± 0.16 
Myostatin 1.00 ± 0.25 0.78 ± 0.11 0.86 ± 0.09 0.98 ± 0.21 
IL-6 1.00 ± 0.13 0.94 ± 0.12 0.88 ± 0.13 1.09 ± 0.17 
NOX-2 1.00 ± 0.21 1.05 ± 0.17 0.85 ± 0.11 0.96 ± 0.12 
Ppargc1a 1.00 ± 0.21 0.87 ± 0.11 0.85 ± 0.07 1.10 ± 0.24 
Nfe2l2 1.00 ± 0.15 1.04 ± 0.15 0.90 ± 0.06 1.02 ± 0.13 
 
Table 9. The effect of apocynin (5 mg kg-1) administration on gastrocnemius tissue 
mRNA expression of atrogin-1, MuRF-1, IGF-1eA, IGF-1eB, myostatin, IL-6, NOX-2, 
PPARGC1A, and NFE2L2 in mice after cigarette smoke exposure.  
Data are expressed as mean ± SEM for n=6-11 mice per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
 
 
4.3.6. Markers of systemic inflammation and oxidative stress 
C-reactive protein 
C-reactive protein was measured as a marker of systemic inflammation. In this study, CRP 
was 3.17x103 ± 247 ng/mL, 3 75x103 ± 169 ng/mL, 4.43x103 ± 349 ng/mL*, and 5.68 ± 356 
ng/mL*# for sham + vehicle, sham + apocynin, smoke + vehicle, and smoke + apocynin 
groups respectively (Figure 24A). Smoke exposure caused significant increases in serum 
CRP levels, which was not improved by treatment with apocynin but rather worsened with 
treatment. Specifically, compared to the sham + vehicle group, there was an increase of 
34.0% in the smoke + vehicle group and an even greater 90% increase in the smoke + 
apocynin group.  This result was unexpected, and it is possible that the combination of 
cigarette smoke and inhibition of NOX-2 by apocynin had a negative effect on systemic 
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regulation of CRP. Additionally, to our knowledge, no other published studies have shown 
this phenomenon. 
TBARS (MDA) 
Malondialdehyde (MDA) was measured as a marker of systemic oxidative stress. In this 
study, smoke exposure caused a significant increase in MDA concentration in the serum of 
both treatment groups. MDA concentration was 49.0 ± 3.7 ng/mL, 43.7 ± 3.4 ng/mL, 59.6 ± 
5.9 ng/mL, and 68.1 ± 8.7 ng/mL for the sham + vehicle, sham + apocynin, smoke + vehicle, 
and smoke + apocynin groups respectively (Figure 24B).  
 
8-isoprostane  
Isoprostanes are a family of eicosanoids produced by the random oxidation of tissue 
phospholipids by ROS. They are detected in plasma and urine under normal conditions and 
are elevated by oxidative stress. 8-Isoprostane has been proposed as a marker of antioxidant 
deficiency and oxidative stress. Additionally, elevated levels of 8-isoprostane have been 
found in heavy smokers. 
Although the serum concentration of MDA was elevated with cigarette smoke 
exposure, the concentration of 8-isoprostane was unchanged, (Figure 24C) which was 
unexpected as both are markers of oxidative stress. This result may be due to the degradation 
of the serum samples due to the high number of freeze-thaw cycles undergone by the samples 
by the time the 8-isoprostane ELISA was performed.  
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Figure 24. The effect of apocynin (5 mg kg-1) administration on markers of systemic 
inflammation and systemic oxidative stress in mice after cigarette smoke exposure. 
(A) Levels of C-reactive protein (CRP), (B) malondialdehyde (MDA) and (C) 8-isoprostane 
in serum. Data are expressed as mean ± SEM for n=7-8 mice per treatment group. Two-way 
ANOVA with Bonferroni post-hoc test was performed to assess statistical significance. 
*P<0.05 vs Sham + Vehicle, #P<0.05 vs Smoke + Vehicle. 
 
 
4.3.7. Assessment of oxidative stress in gastrocnemius tissue 
As with study A, protein was extracted from gastrocnemius tissues and protein carbonylation 
was measured using an oxyblot chemiluminescence assay as a marker of oxidative stress. 
Gastrocnemius tissue was used as all the tibialis anterior tissue had been consumed for gene 
expression analysis. Protein carbonylation was then quantified and normalised to β-actin. 
Figure 25A shows a representative lane for each treatment group and it was apparent from 
0
2000
4000
6000
8000
C
R
P 
in
 S
er
um
 (n
g/
m
l)
C-reactive Protein
Vehicle
Apocynin
*
*
#
Sham Smoke
0
200
400
600
8-
is
op
ro
st
an
e 
in
 S
er
um
 (p
g/
m
l)
8-Isoprostane
Sham Smoke
0
20
40
60
80
M
D
A 
in
 S
er
um
 (n
g/
m
l)
MDA
*
*
Sham Smoke
A B
C
  137 
this alone that cigarette smoke caused a drastic increase in protein carbonylation in the tissue 
sample. Cigarette smoke caused a significant increase in protein carbonylation compared to 
the sham vehicle group. Specifically, protein carbonylation densitometry of the 
gastrocnemius tissue was measured to be 7.80x106 ± 6.3x105 Int, 7.67x106 ± 6.16x105 Int, 
1.82x107 ± 2.1x106 Int*, and 1.25x107 ± 2.4x106 Int* for sham + vehicle, sham + apocynin, 
smoke + vehicle, and smoke + apocynin groups respectively after normalisation to β-actin 
(Figure 25B). Treatment with apocynin did not result in a significant reduction in smoke-
induced protein carbonylation however it trended towards significance (P=0.09). Due to time 
constraints, the mouse skeletal muscle samples that were collected for histological 
examination were not examined. 
  
 
Figure 25. The effect of apocynin (5 mg kg-1) administration on protein carbonylation in 
gastrocnemius tissue from mice after smoke exposure. 
(A) Representative oxyblot showing differences in smearing between treatment groups. (B) 
Densitometry analysis of oxyblots normalised to β-actin. Data are expressed as mean ± SEM 
for n=3-4 mice per treatment group. Two-way ANOVA with Bonferroni post-hoc test was 
performed to assess statistical significance. *P<0.05 vs Sham + Vehicle 
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4.4. C2C12 In Vitro pilot studies 
The following pilot studies were conducted to explore the mechanisms that may be driving 
the changes in skeletal muscle mass and function seen in vivo because of increase oxidative 
stress. The C2C12 cell line is a sub-clone (produced by H. Blau, et al [299]) of the mouse 
myoblast cell line established by D. Yaffe and O. Saxel [300].  This cell line differentiates 
rapidly, forming contractile myotubes and producing characteristic muscle proteins. Initial 
pilot studies to highlight the direct impact of cigarette smoke and, more specifically, 
oxidative stress were conducted using this cell line. 
 
4.4.1. Impact of H2O2 on C2C12 skeletal muscle cell viability 
As seen in Figure 12, exposure to supra-physiological concentrations of H2O2 caused a 
significant reduction in C2C12 cell viability at both 1 and 3-hour time points. Exposure to 
concentrations ranging from 30 μM to 100 μM resulted in an approximate 75% reduction in 
cell viability. Specifically, at 1-hour H2O2 stimulation, absorbance reading was 1.18 ± 0.4 
AU, 1.17 ± 0.4 AU, 0.630 ± 0.6 AU, 0.570 ± 0.3 AU, and 0.300 ± 0.2 AU for 0, 10, 30, 100, 
and 300 μM concentrations of H2O2 respectively (Figure 26). Concentrations of H2O2 greater 
than 100 μM resulted in complete cell death. Based on this data, there was a clear shift in cell 
viability that occurred between 10 μM and 30 μM; thus, future studies used 10-30µM 
concentrations of H2O2 for C2C12 stimulation. 
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Figure 26. The effect of increasing H2O2 concentrations on C2C12 cell viability at 1 and 3 
hours post treatment. 
Data are expressed as mean ± SEM for n=3 samples per treatment group. Two-way ANOVA 
with Bonferroni post-hoc test was performed to assess statistical significance. *P<0.05 vs 
control 
 
 
4.4.2. Impact of H2O2 on mRNA expression in C2C12 cells 
C2C12 cells were lysed, pooled and RNA was extracted. The expression of TNF-α and IL-6 
was measured via qRT-PCR. An approximate 3-fold increase in mRNA expression of both 
genes was observed following stimulation with 10 μM H2O2 (Figure 27). Due to the pooling 
of samples, statistical analysis could not be performed for this data, however, these 
experimental parameters have since been explored by Mastronardo et al. (unpublished) who 
showed the same observed increase in mRNA expression of both TNF-α and IL-6 with 
statistical significance. This indicates that small increases in oxidative stress are sufficient to 
induce acute changes in skeletal muscle mRNA expression of inflammatory cytokines. 
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Figure 27. The effect of 10 μM of H2O2 on C2C12 TNF-α and IL-6 mRNA expression 1 
hour post treatment. 
Data are expressed as mean for n=3 pooled samples per treatment group. Due to pooling, 
statistical analyses could not be performed on this data. 
 
 
4.4.3. Impact of H2O2 on mitochondrial respiration in C2C12 cells 
As mitochondria are an important source of intracellular ROS, an extracellular flux 
mitochondrial stress test was performed to determine the effect of supraphysiological 
concentrations of H2O2 on mitochondrial function. Impaired mitochondrial function can result 
in impaired muscle function and increased intracellular oxidant generation. Specifically, basal 
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respiration, and mitochondrial reserve capacity were measured in C2C12 mouse skeletal 
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eliminated. This data indicates that oxidative stress indiscriminately impaired mitochondrial 
respiration along all processes of the electron transport chain. Although the observed trends 
show impaired mitochondrial function, the small sample size is inadequate to provide well-
defined conclusions and future studies should use a greater sample size. 
The mitochondrial impairment reported above may be one mechanism contributing to 
reduced contractile function observed in mice following chronic cigarette exposure (Figure 9) 
however further exploration is required. Future studies should explore mitochondrial function 
in primary skeletal muscle tissue extracted from mice following a 56-day cigarette smoke 
exposure protocol. 
  
Figure 28. The effect of 10 and 30 μM H2O2 on C2C12 respiration after 1 hour of 
exposure. 
Data are expressed as mean ± SEM for n=2 samples per treatment group. Due to the small 
sample size, statistical analyses could not be performed on this data. 
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4.5. Discussion  
This is the first study to show the successful inhibition of cigarette smoke-induced lung 
inflammation and skeletal muscle wasting due to inhibition of NOX-2 via treatment with 
apocynin, in an established animal model of COPD. This data supports the potential benefits 
of targeting oxidant dependent mechanisms for dual therapy to treat both pulmonary and 
systemic manifestations of COPD. 
Our findings showed that mice exposed to sub-chronic cigarette smoke have enhanced 
BALF inflammation whereas treatment with apocynin attenuated this increase in 
inflammation. As seen in previous studies [207], smoke exposed mice, regardless of 
treatment, had a significant increase in total cells, macrophages and neutrophils in the BALF 
(Figure 16 and 21). In both Study A and B, smoke exposed mice treated with apocynin 
experienced a significant reduction in neutrophil numbers of approximately 50-55% however, 
significant reductions in total cells and macrophages were only observed in Study A (Figure 
16B). This reduction in neutrophils was similar in magnitude to that seen in acute smoke 
exposure studies and that seen in Chapter 3 and is consistent with the 50% decrease in 
neutrophil counts in BALF observed in animals treated with 5mg/kg of apocynin per day for 
7 days following cigarette smoke exposure and inoculation with influenza A virus [229]. It 
should be noted that a slight but significant reduction in macrophages and overall total cell 
counts in BALF was also observed in an acute smoke exposure model as a result of apocynin 
treatment [229] and this was not observed in our findings. The similarity between the BALF 
cell counts in the vehicle treated and apocynin treated sham-exposed mice indicates that 
inhibition of NOX-2 has no effect on BALF cellularity in healthy mice. The significant 
increase in lung mass observed in all smoke exposure groups can be attributed to increased 
inflammation and pulmonary oedema. As per chapter 3, airspace enlargement was not 
determined in this model.  
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Consistent with the observations in Chapter 3, smoke exposure caused an increase in 
expression of several pro-inflammatory cytokines and chemokines in Study A (IL-17A, MIP-
2α, MCP-1, and CXCL-10) and treatment with apocynin reversed some of these smoke 
induced alterations (Figure 17 A-D). It should be noted that lung mRNA expression was not 
assessed in Study B due to time limitations. MCP-1 and CXCL-10 are important monocyte 
recruitment factors responsible for macrophage accumulation [239, 240, 301]. The pooled 
data showed an increase in MCP-1 and CXCL-10 gene expression in lung tissue of smoke-
exposed vehicle treated mice and this increase likely explains the very large infiltration of 
macrophages in the lungs. Additionally, treatment with apocynin reduced expression of both 
genes and may explain the reduction in macrophages in Study A.  
MIP-2α is a chemokine, secreted by macrophages, which acts as a 
polymorphonuclear leukocyte chemoattractant and IL-17A is a cytokine involved in 
activating neutrophil-mobilizing factors such as IL-8 and GM-CSF and hence sustaining the 
accumulation and activity of neutrophils locally in the lungs [243, 302, 303]. The elevation of 
IL-17A and MIP-2α may explain the increase in BALF neutrophil numbers; however, the 
apocynin treated smoke-exposed animals still exhibited elevated expression of these genes. 
This indicates that other factors are driving the significant reduction in BALF neutrophils 
seen in the apocynin treated smoke-exposed mice. Some potential mechanisms driving the 
influx of neutrophils and the subsequent reduction in the apocynin treated mice could be 
other neutrophil chemoattractants that were not measured, and/or the efferocytosis of 
neutrophils by alveolar macrophages. It is known that macrophage efferocytosis is reduced in 
COPD and it is possible that apocynin restored alveolar macrophage phagocytic ability back 
to baseline, promoting clearance of neutrophils [304, 305]. Further experiments need to be 
conducted to determine the exact mechanism. Regardless of mechanism of action, the effect 
of apocynin on BALF cellularity and inflammatory mediator expression indicates that 
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inhibiting NOX-2 may be of great therapeutic benefit for the treatment of pulmonary 
manifestations in COPD. 
In addition to the pulmonary inflammation that is characteristic of the disease, COPD 
patients exhibit chronic systemic inflammation [246, 247].  Systemic inflammation is 
associated with an accelerated decline in lung function [248] and is also a driver of systemic 
oxidative stress, which in turn further perpetuates systemic inflammation [102]. This vicious 
cycle leads to systemic manifestations of disease in the form of comorbidities, such as 
peripheral skeletal muscle wasting [112].  
Serum concentration of CRP, an acute phase protein that is known to have elevated 
levels in COPD patients, was measured as a marker of systemic inflammation in this model. 
As expected, serum CRP levels were elevated in response to smoke exposure, however, 
treatment with apocynin actually caused a further increase in CRP concentration rather than a 
decrease (Figure 24A). This is in contrast to the reduced BALF cellularity observed in the 
treatment animals, which showed an improvement in smoke-induced neutrophilic 
inflammation (Figure 16C and 21C). This suggests that although lung inflammation is 
hypothesized to spillover into systemic circulation in COPD [249], this phenomenon may not 
be a key driver of systemic inflammation in this model and, subsequently, lung inflammation 
is likely not a key driver of systemic manifestations of disease either. This indicates that the 
observed systemic inflammation is likely originating outside of the lungs and is consistent 
with the hypothesis that systemic inflammation in COPD instead originates from a parallel 
inflammatory response in other tissues, such as adipose tissue [250, 251]. In addition to the 
increase in serum CRP, there was also a significant increase in MDA concentration in serum 
following smoke exposure (Figure 24B). An increase in plasma MDA concentration is among 
the most common and consistent alterations experienced in COPD and several studies have 
shown that increases in MDA occur in parallel to increasing severity of disease [306-308]. To 
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our knowledge, this is the first time that the characteristic increase in circulating MDA 
observed in COPD patients has been induced in a cigarette smoke exposure animal model of 
COPD. Inhibition of NOX-2 with apocynin did not attenuate this increased systemic 
oxidative stress indicating that while sufficient for the treatment of pulmonary pathologies, 
the dose used may have been inadequate for the reduction of circulating oxidative stress. 
Alternatively, the systemic oxidative stress may not be NOX-mediated and further 
experiments will be required to determine the exact mechanism and origin. 
Both acute and chronic smoke exposure is known to reduce total body mass in animal 
models [252, 253]. As expected, and as observed in Chapter 3, the smoke exposed animals 
experienced a significant reduction in total body weight compared to their sham exposed 
counterparts (Figure 18 and 22). In Study A, apocynin was able to significantly improve the 
body weights of animals however this observation was not replicated in Study B (Figure 
18B). Additionally, smoke exposure caused a significant reduction in adipose tissue mass and 
apocynin was only able to attenuate this reduction in Study A (Table 6), which explains why 
there was no significant difference in total body weights of smoke-exposed animals in Study 
B (Table 7). These conflicting results between the two apocynin studies make it difficult to 
draw meaningful conclusions regarding the efficacy of apocynin on smoke induced total body 
weight reduction. 
While the appetite suppressing effect of cigarette smoke is well established [254] and 
may possibly account for the reduction in body weight and skeletal muscle masses, it has 
been previously shown by using long-term pair-feeding that cigarette smoke exposure causes 
a greater reduction in body weight compared to equivalent food restriction alone (smoke 
exposure protocols of 1 and 3 months) [147, 207]. In this study, the smoke-exposed animals 
had a suppressed appetite that was unaffected by treatment with apocynin (Figure 18C and 
22C). Additionally, apocynin did not impact the appetite of sham-exposed animals, indicating 
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that any alterations to the disease pathology and/or physiology of the animals cannot be 
attributed to increased food intake/caloric surplus in the treatment groups.  
Although overall body mass was reduced due to smoke exposure, lung mass was 
significantly increased as expected (Table 6 and 7). Surprisingly, cigarette smoke caused a 
significant reduction in heart mass that was not improved by apocynin.  This is in contrast to 
the hypertrophy of cardiac tissue widely observed in the hearts and vasculature of COPD 
patients that arises from cardiovascular manifestations of disease [255, 256]. As there were 
no significant alterations to mRNA expression of factors that may be driving alterations to 
cardiac mass (Figure 20), 8-weeks of smoke exposure is likely insufficient to induce 
significant cardiovascular modifications. This indicates that the significant reduction in heart 
mass may simply be driven by the overall body mass reduction in the animals. Further 
analysis using more sensitive techniques may be required to observe and examine 
modifications cardiovascular morphology and function that may be occurring in this model. 
The design and development of a suitable technique is described in Chapter 5. 
Peripheral skeletal muscle wasting is highly prevalent in COPD and is associated with 
reduced quality of life, decline in lung function and increased mortality [112, 257]. Increased 
inflammation and oxidative stress both contribute to the onset and development of skeletal 
muscle wasting [212, 258]. In this study, smoke exposure caused a significant reduction in 
mass of the hind limb muscles, primarily in the tibialis anterior and the soleus. It should be 
noted that significant wasting was also observed in the gastrocnemius and plantaris muscles 
of smoke-exposed animals in Study B (Table 7). The observed wasting of the smaller 
gastrocnemius complex muscles (the soleus and plantaris) is consistent the reports of others 
[259-261]. This is contrast to our findings from Chapter 3 where smoke exposure did not 
induce wasting in the smaller gastrocnemius muscles (Table 2 and 3). This more severe 
response to smoke-exposure, as shown by the significant increases in systemic oxidative 
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stress, may be magnifying the skeletal muscle alterations in this study (Figure 24B). 
Treatment with apocynin prevented wasting in all hind limb muscles except the 
gastrocnemius (Table 6 and 7). This indicates that while NOX-2 inhibition did not improve 
systemic oxidative stress, it did improve local skeletal muscle alterations induced by smoke 
exposure. These findings highlight the possibility that systemic inflammation and systemic 
oxidative may only be involved in the onset of muscle wasting and they may not be involved 
in the ongoing progression of the comorbidity. This is consistent with the fact that COPD 
patients generally have relatively low concentrations of systemic inflammation and oxidative 
stress biomarkers even when these biomarkers are elevated in skeletal muscle [101, 286, 
287].  While the link is well established, further studies are required to determine the exact 
contribution that systemic inflammation and systemic oxidative stress have in the pathology 
of comorbid skeletal muscle wasting. 
Skeletal muscle dysfunction commonly accompanies skeletal muscle wasting in 
COPD [262]. Whole muscle contractility was used to assess TA muscle function in Study B. 
In contrast to the results observed in Chapter 3, there was a trend to altered skeletal muscle 
function in response to smoke exposure (Figure 23). Specifically, smoke exposure reduced 
TA contractility, endurance and force generation. This was consistent with the significant 
wasting observed in the TA muscle following smoke exposure. Additionally, treatment with 
apocynin was improved contractility and force generation, which was consistent with the 
improvements to TA mass. This echoes the observations seen in COPD patients where 
impaired skeletal muscle function is a reflection of skeletal muscle wasting severity [309, 
310]. This demonstrates that by treating skeletal muscle wasting, we were also able to 
improve the associated skeletal muscle dysfunction via treatment with a single antioxidant 
compound. 
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Current literature has mostly focused on the catabolic mechanisms in skeletal muscle, 
specifically the ubiquitin-proteasome pathway. This pathway is one of the major atrophy-
related pathways in skeletal muscle and is widely studied in cachexia, sarcopenia and 
comorbid skeletal muscle wasting [273]. Atrogin-1 and MuRF-1 are E3 ubiquitin ligases that 
are key regulators of ubiquitin-mediated protein degradation in skeletal muscle [274, 275]. 
Increased transcription of these ligases results in downstream increases in protein degradation 
and drives atrophy of the muscle if chronically elevated. This is evident in biopsies taken 
from the quadriceps of COPD patients [276, 277]. In this study, smoke exposure had no 
significant effects on the mRNA expression of the E3 ligases Atrogin-1 or MuRF-1 in the 
tibialis anterior and gastrocnemius muscles (Figure 19A, 19B, Table 8 and 9). When 
examining the alterations to expression of proteins involved in hypertrophy-related pathway, 
we were presented with inconsistent observations between Study A and Study B. In the 
pooled TA tissue from Study A, we saw a decrease in Insulin-like Growth Factor-1 (IGF-1) 
and an increase in myostatin expression (Figure 19C and 19D). As discussed in Chapter 1, 
IGF-1 initiates the protein synthesis pathway leading to increased muscle growth [311, 312]. 
On the other hand, myostatin acts as part of the atrophy-related process but instead of 
promoting protein degradation, it inhibits AKT in the IGF-1 pathway leading to reduced 
protein synthesis (Refer to Chapter 1, Figure 5) [313]. This indicates that smoke-exposure 
affected both sides and shifted the homeostatic balance towards protein degradation. 
Treatment with apocynin prevented these smoke-induced alterations, which is consistent with 
its ability to prevent wasting in the TA and soleus muscles in this study. This indicates that a 
reduction in muscle protein synthesis, rather than an increase in muscle protein degradation, 
may be the primary driver of the wasting observed in this model. These findings are in 
contrast to what was observed in Study B where smoke exposure had no effect on mRNA of 
other proteins involved in atrophy or hypertrophy related pathways, including myostatin and 
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IGF-1 (Table 8 and 9). This indicates that the reduction in muscle mass in the replicate study 
was not driven by the characteristic alterations to protein homeostasis signalling pathways 
observed in COPD patients. Additionally this data was not generated using pooled tissue 
unlike Study A, and is consistent with the findings from Chapter 3. As such, it is likely that 
the mRNA alterations observed in Study A are not representative of the underlying 
mechanisms of the skeletal muscle wasting induced by this model. While the alterations to 
the muscle homeostatic pathway gene expression were inconsistent, increased oxidative 
stress in the gastrocnemius following smoke exposure was observed in Study B. This will be 
addressed later in this thesis. 
Similar to the observations reported in Chapter 3, there were no alterations to the 
mRNA expression of the inflammatory mediator IL-6 indicating that while there was a 
significant increase in pulmonary inflammation in the smoke exposed mice, the significant 
reduction in skeletal muscle mass was not being driven by a similar local inflammatory 
response in the muscles. Additionally, mitochondrial Nfe2l2 and PARGC1A expression was 
also unaltered indicating that the impaired muscle function in response to smoke-exposure is 
driven by reductions in muscle mass rather than altered mitochondrial function. Lastly, NOX-
2 expression was unaffected following smoke-exposure. This indicates that skeletal muscle 
NOX-2 levels are not increased in response to cigarette smoke; however, this does not 
necessarily mean NOX-2 activity is unaltered. Superoxide generation in skeletal muscle may 
have increased, however, further assessments are required to determine this. Treatment with 
apocynin did not affect NOX-2 expression and this was expected as apocynin acts by 
inhibiting the assembly of NOX subunits rather than altering mRNA expression or 
transcription of the proteins [314]. 
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While there is no strong relationship between muscle oxidative stress and local inflammation 
in patients with COPD [101, 285], 8 weeks of smoke exposure induced a significant increase 
in skeletal muscle oxidative stress in this model as measured by protein carbonylation in the 
gastrocnemius (Figure 25). Similar to the observations in Chapter 3, these oxidative 
alterations were not accompanied by a marked increase in local inflammation (as measured 
by IL-6 mRNA expression), which echoes what is seen in COPD. There was a significant 
increase in protein carbonylation following smoke exposure, which was reduced by treatment 
with apocynin (Figure 25B). This implies that unlike ebselen, treatment with apocynin was 
able to improve pulmonary inflammation and also prevent oxidative damage in the skeletal 
muscles of the animals. As with Chapter 3, this data indicates that oxidative stress a key 
driver of muscle wasting in this model and that targeting oxidative stress was able to 
significantly improve both pulmonary and skeletal muscle manifestations of disease. 
In addition to the in vivo model of disease, we sought to establish an in vitro model of 
oxidative stress-induced skeletal muscle wasting that could be used to identify the specific 
mechanisms driving the alterations to skeletal muscle in COPD. This pilot study was 
conducted to determine the appropriate concentrations of H2O2 required to alter skeletal 
muscle morphology, create a pro-inflammatory environment, and induce impaired function in 
the C2C12 mouse skeletal muscle cell line. Published studies exploring the effects of 
oxidative stress on this cell line have generally used high concentrations of H2O2 with acute 
exposure times [315-317]. As we required alterations to morphology, mRNA expression and 
mitochondrial function, acute exposure was likely sufficient to only alter mRNA expression 
and mitochondrial function but not cell morphology. As such, the effect of various exposure 
times and stimuli concentrations was explored to determine the appropriate conditions. 
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Concentrations of H2O2 greater than 100µM resulted in complete cell death regardless of 
length of exposure (Figure 26). Additionally, there was a clear shift in cell viability that 
occurred between 10µM and 30µM and at both 1 hour and 3 hours of exposure. Thus, a 
concentration range of 10-30µM and 1 hour of exposure was determined to be sufficient to 
explore the impact of H2O2 on mRNA expression and mitochondrial function without 
significant impact to cell viability. Preliminary microscopic analysis showed no distinct signs 
of cell degradation or cell debris indicating these conditions were suitable for assessing 
alterations in morphology. In pooled samples, these conditions were able to cause increased 
expression of both IL-6 and TNF-α, pro-inflammatory cytokines that are known to be 
increased locally and systemically in COPD (Figure 27). This indicates that small increases in 
oxidative stress are sufficient to induce acute changes in skeletal muscle mRNA expression 
of inflammatory cytokines. Additionally, H2O2 exposure indiscriminately impaired 
mitochondrial respiration along all processes of the electron transport chain (Figure 28). 
These results validate the use of this in vitro model for assessing the specific effects of 
oxidative stress in skeletal muscle, the mechanisms involved in protein synthesis and 
degradation, and the impact of antioxidant treatment on these mechanisms. Due to time 
limitations, we were unable to conduct further experiments for this thesis using this model; 
however, this model has been successfully used in other studies conducted by our group 
(Mastronardo et al, unpublished). 
In summary, we have shown that inhibition of NOX-2, via treatment with apocynin, is 
an effective therapy for both pulmonary and skeletal muscle manifestations of smoke 
exposure in this model of COPD. Apocynin successfully reduced smoke-induced increases 
lung inflammation, lung inflammatory cytokine and chemokine mRNA expression, and lung 
mass. Apocynin also reduced smoke-induced skeletal muscle and WAT wasting, improved 
muscle contractility and function, and reduced oxidative damage to muscle tissue. This pre-
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clinical study presents a strong case for the viability of treating both COPD and its associated 
comorbidities with a single antioxidant compound.   
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Chapter 5: Evaluation of right heart 
function in a rat model using modified 
echocardiographic views 
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5. Introduction 
 
This chapter was published in PLOS One (2017) with the same title, “Evaluation of right 
heart function in a rat model using modified echocardiographic views”. The full publication 
can be found in the appendices. The manuscript was slightly modified to match the format of 
this thesis. Following the observed cardiovascular alterations in chapters 3 and 4, I sought to 
explore cardiovascular manifestations of COPD in greater detail. Upon review, we 
determined that current rodent imaging techniques were not suitable to provide detailed 
observation and analysis of cardiac morphology and function when compared to techniques 
performed in human patients. The aim of this study was to adapt the Scherrer-Crosbie (SC) 
short axis (SAX) view to transthoracic examination in the rat, and compare right ventricle 
(RV) assessment at the mid-ventricular SAX level, with the aortic SAX view of the right 
ventricular outflow tract (RVOT). Additionally, the suitability of the modified SC view for 
2D-strain analysis was investigated. 
 
Animal models provide valuable insight into the pathophysiology of chronic lung disease, 
and enable assessment of potential therapeutics for conditions such as chronic obstructive 
pulmonary disease (COPD) [318, 319]. Animal exposure to chronic hypoxia, monocrotaline 
injury or pulmonary trunk banding, have contributed greatly to understanding the relationship 
between lung injury and progressive dysfunction of the right ventricle (RV) [320]. In many 
studies echocardiography plays a major role in assessing RV function and the efficacy of 
therapeutic intervention. Transthoracic views of the RV include the short-axis (SAX) mid-
ventricular and aortic RV outflow views (RVOT), and the long-axis (LAX) apical 4-chamber 
view. Recent advances in ultrasound technology, including 2D speckle tracking or strain, 
have seen these modalities now being applied to clinical practice[321]. However the 
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application of 2D-Strain in small animals is emerging, and has been recently reported for left 
ventricular assessment [322]. A limitation of transthoracic imaging in small animals is the 
effect of anatomical artifact from the thoracic cage or liver on image quality. Suboptimal 
imaging limits RV assessment with standard views, and can prevent the application of 
advanced analysis including 2D-strain imaging.  
In an alternative approach, Scherrer-Crosbie et al developed a transoesophageal technique in 
mice, where the right ventricular wall and chamber were evaluated in the mid-ventricular 
SAX view [210]. Significantly, echocardiographic findings were validated with ultrasound 
flow-measurement and magnetic resonance imaging (MRI). This modified RV approach is 
relevant to current clinical guidelines, which advocate the use of a RV-focused view over the 
standard four-chamber view. Optimal RV assessment occurs when imaging allows 
visualization of most or entire RV free wall [323]. 
In this study we aimed to adapt the Scherrer-Crosbie SAX (SC) view to transthoracic 
examination in the rat, and compare RV assessment at the mid-ventricular SAX level, with 
the aortic SAX view of the right ventricular outflow tract (RVOT). The RVOT view is a 
valuable window for assessing Doppler-derived RV ejection. In addition I plan to investigate 
whether the modified SC view is suitable for 2D-strain analysis.  
 
5.1. Methods 
Studies were conducted in accordance with National Health and Medical Research Council of 
Australia guidelines, and approved by the University of Melbourne Animal Ethics Committee 
(Ethics No. 1212675). All animals were acquired from the Animal Resource Center, Perth, 
Australia. 
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5.1.1. Echocardiographic Analysis of Ventricular Size and Function 
Male WKY rats (300-350g) were anesthetized with 2.5% isoflurane, spontaneously ventilated 
and placed on a heated pad in the semi-left lateral position with upright tilt, suitable for 
echocardiographic examination.  Pulse rate, oxygen saturation and temperature were 
continuously monitored. After shaving, a sequential examination of the left and right 
ventricles was performed using a Vivid E9 with i13-L (6-14MHz) linear array transducer (GE 
Vingmed Ultrasound AS, Horten, Norway). Each study imaged the PLAX and mid-papillary 
SAX views of the LV, and the modified Scherrer-Crosby and aortic RVOT/pulmonary artery 
SAX view of the RV (Figure 29). LV morphology was assessed for interventricular septal 
(IVS) wall and posterior wall (PW) thickness, LV end-diastolic chamber dimension 
(LVEDD), LV end-systolic chamber dimension (LVESD), fractional shortening (FS), LV 
end-diastolic chamber area (LVEDA), LV end-systolic chamber area (LVESA) and fractional 
area change (FAC). RV chamber width was assessed at mid-chamber in the SC view (R1) 
and RVOT width measured in the aortic SAX view (R2). In this view the main pulmonary 
artery diameter (PAφ) was also measured. RV wall area was measured in both SC and RVOT 
SAX views calculated from the difference between traced epicardial and endocardial areas 
[210].  Right ventricular ejection was measured in the aortic SAX view at the proximal MPA 
(PA diameter) using 2D-Doppler and the waveform analyzed for pulmonary artery velocity-
time integral (VTI) and time to peak ejection (PAAT), Pulmonary artery systolic pressure 
(PASP) was not assessed (TR jet not examined). 
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Figure 29. Echocardiographic views used to assess cardiac function 
a. Parasternal long-axis (PLAX) view of LV (1. Interventricular septum IVS, 2 End-diastolic 
dimension LVIDD, 3. Posterior wall PWD). b. Mid-ventricular SAX papillary view (1. LV end-
diastolic chamber area LVEDA, 2. IVS, 3. PW). c. Right ventricular focused view SC, modified from 
Scherrer-Crosby[210], (1. R1 mid-chamber dimension, 2. Sub-epicardial chamber area RVepi, 3. Sub-
endocardial chamber area RVendo, 4. IVS). d. Short axis (SAX) right ventricular outflow tract (RVOT) 
view (1. Main pulmonary artery diameter PAΦ, and locus for PWD measurement of ejection velocity 
time integral VTI 2. RVOT dimension R2, 3. Sub-epicardial RVOT chamber area RVOTepi, 4. Sub-
endocardial RVOT chamber area RVOTendo). 
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5.1.2. Echocardiographic calculations 
Fractional Shortening (FS) = LVIDD-LVISD/LVIDD 
Fractional Area Change (FAC) = LVEDA-LVESA/LVEDA 
LV volume/Stroke volume (SV) = based on geometric truncated ellipsoid model[211] 
RV Free Wall Area = Epicardial area – endocardial area 
RVOT Free Wall Area = Epicardial area – endocardial area 
RV ejection stroke volume RVESV = PA area * VTI * HR where PA area is the cross-
sectional area of the main pulmonary artery, VTI is the area beneath the PA pulsed-wave 
velocity waveform or velocity-time integral and HR is heart rate. 
 
5.1.3. Strain Analysis 
Real-time imaging loops of ventricular motion during the cardiac cycle were recorded for off-
line analysis. The RV was imaged in the adapted SC view and the LV in the mid-ventricular 
SAX view. High frame rates necessitated manual tracing of epicardial and endocardial walls 
for 2D- strain analysis (Echopac, version 2011, GE Healthcare). Segmental and global wall 
motion was then analyzed.  
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Figure 30. Example of an agarose gel mold of the right ventricle 
Representative image of an agarose gel mold. The molds were extracted following injection and 
solidification of agarose within the RV chamber. 
 
 
5.1.4. Injection of Agarose Gel and Tissue Collection 
Animals were euthanized using inspiratory CO2, the heart immediately excised and injected 
with KCl. To correlate RV chamber size and wall thickness with echocardiographic 
measurement agarose gel (2%, ScientifiX, Australia) was injected into the RV chamber and 
left to fix at room temperature. The gel was suspended in Hank’s Balanced Salt Solution 40 
mM HEPES (sHBSS).  Following injection (at 10 min) the RV wall was excised from the 
heart, exposing the hardened agarose gel mould of the RV chamber (Figure 30). The RV free 
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wall was then freely dissected away from the septal wall and atrio-ventricular valves.  Both 
the agarose gel mould and RV free wall were weighed. 
 
5.1.5. Statistics and Analysis 
Data are expressed mean (SD). Linear regression was used for correlation between 
echocardiographic findings and agarose gel mass, and RV wall mass at necropsy. P<0.05 was 
taken as significant (Graphpad Prism version 6 was used). 
5.2. Results 
5.2.1. Echocardiographic measurement of ventricle size and function 
Left ventricle 
LVIDD and LVISD were 0.71± 0.09 and 0.36± 0.07cm respectively, and using the 
hemisphere-cylinder model equation[211], end-diastolic chamber volume was estimated as  
0.38 ± 0.09cm3. Fractional shortening was 47.21± 8.67 %, FAC measured as 65%, and 
calculated stroke volume 0.20 ± 0.05 ml, indicating normal systolic function. 
 
Right ventricle 
Due to the geometrical shape of the RV, the SC view imaged a larger proportion of the RV 
chamber than the outflow RVOT view. The SC mid-ventricular dimension (R1) was 0.42± 
0.07cm, the RVOT dimension (R2) was 0.34± 0.06cm, and chamber end-diastolic area 
measurements were 0.36± 0.09 cm2 and 0.28± 0.08cm2 for SC and RVOT views respectively. 
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5.2.2. Correlation with necropsy 
The gel mass was 0.18 ± 0.10g, the RVOT dimension (R2) was 0.34 ± 0.06cm and the mid-
ventricular dimension (R1) was 0.42 ± 0.07cm for SC and RVOT views respectively. Neither 
RVOT nor SC dimensions correlated with agarose gel mass (R=0.098, P =0.41 and R=0.018, 
P=0.73) (Figure 31A). The chamber area was 0.28 ± 0.08 cm2 and 0.38 ± 0.09 cm2. Both 
RVOT and SC chamber areas correlated with gel mass (R=0.72, P =0.02 and R=0.78, 
P=0.03). The RV wall mass was 0.19 ± 0.04g, and the wall area was 0.069 ± 0.017cm2 and 
0.084 ± 0.017cm2 for RVOT and SC views respectively. Neither RVOT nor SC wall area 
correlated with RV wall mass (R=0.004, P =0.84 and R=0.009, P=0.77) (Figure 31C). 
 
RV chamber dimension R1 and R2 had no correlation (p= 0.41 and 0.73 respectively), 
whereas RVOT and SC chamber area did correlate with gel mass, (p=0.002 and 0.03 
respectively, Figure 31B). Echocardiographic RV wall area, 0.08±0.02 and 0.07±0.02 cm2 for 
SC and RVOT views respectively, corresponded to a total RV free wall mass of 0.19±0.04g 
 
Parameter Measurement 
Left end diastolic internal diameter (LVIDD) 0.71± 0.09 
Left end systolic internal diameter (LVISD) 0.36± 0.07cm 
End diastolic chamber volume 0.38 ± 0.09cm3 
Fractional shortening 47.21± 8.67 % 
Fractional area change (FAC) 65% 
Left ventricle stroke volume 0.20 ± 0.05 mL 
SC mid-ventricular dimension (R1) 0.42± 0.07cm 
RVOT dimension (R2) 0.34± 0.06cm 
SC Chamber end-diastolic area 0.36± 0.09 cm2  
RVOT Chamber end-diastolic area 0.28± 0.08cm2 
Table 10. Cardiac measurement of left and right ventricle chamber size and function 
Cardiac measurement of ventricular chamber size and function were within the normal range for our 
laboratory, and consistent with previous reports. Data is expressed as mean ± SD, n=12-18. 
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at necropsy. There was no correlation between wall mass and RV wall area in either view, R 
0.004 and 0.009, p= 0.84 and 0.77 respectively (Figure 3C).  
 
 
Figure 31. Correlation of RV chamber dimensions with gel mass from necropsy findings 
Comparisons between (A) agarose gel mass and right ventricle dimensions, (B) agarose gel 
mass and right ventricle chamber area, and (C) right ventricle wall mass and right ventricle 
wall area. N=8-10. 
 
 
5.2.3. Right Ventricular ejection 
Ejection indices of cardiac output (RV CO and LV CO) 110.6 ± 26.5 mL/min and 70.63 ± 
17.3 mL/min respectively, left-ventricular fractional area change (LV FAC) 73.41 ± 9.3 % 
and Fractional shortening (LV FS) 47.21 ± 8.7 %.  The average RVESV was 0.32±0.08 mL, 
with estimated RV CO 111 ± 26 mL.min-1. These values were consistent with cardiac output 
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ranges measured via echocardiography in existing literature [324]. Cardiac output was higher 
with direct Doppler measurement of RV ejection compared to calculated cardiac output based 
on LV geometrical change (110.61 ± 26.53mL/min and 70.63 ± 17.29mL/min respectively).  
Other indices of LV ejection, FAC and FS, were consistent in measurement (Figure 32).  
 
 
 
 
 
 
 
Figure 32. Assessment of ventricular function 
Right ventricle cardiac output (mL/min), left ventricle cardiac output (mL/min), left ventricle 
fractional area change (%), and left ventricle fractional shortening (%). Data is expressed as mean ± 
SD, n=12-17. 
 
 
5.2.4. 2D-Strain analysis 
Strain analysis was performed in both ventricles.  Strain analysis of left ventricular 
contraction was applied in the SAX view and RV analysis applied in the SC view (Figure 
33). In many animals, poor endocardial border definition of the RV limited strain analysis; 
however, as Figure 33 demonstrates, segmental wall motion analysis was possible in the SC 
modified view. This study has demonstrated 2D-strain analysis of the rodent RV is feasible, 
and also indicates that further investigation is necessary to define normal strain values in 
rodents. 
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Figure 33. Representative 2D-Strain measurement of ventricular contraction 
(A) Mid-papillary SAX view of left ventricle with segmental wall analysis. (B) Similar measurement 
of right ventricular free wall contraction in modified SC view. Segmental deformation during cardiac 
cycle relative to aortic valve closure (AVC). 
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5.3. Discussion 
This study has shown echocardiographic measurement of RV chamber area to correlate with 
RV chamber gel volume in both mid-ventricular SC and RVOT views (Figure 31B). 
Chamber width dimension or RV wall area however, did not correlate with gel volume or 
wall mass at necroscopy in these normal animals (Figure 31C). In pathological states of RV 
dilatation or hypertrophy, it is possible that correlation with echocardigraphic measurement 
may become evident, as changes in dimension and area are more pronounced. The study has 
also demonstrated the mid-ventricular SC view to be suitable for strain analysis, since a large 
area of the RV free wall is easily visualized. Examination with the RVOT view provides 
further valuable imaging of the RV infundibulum and proximal pulmonary artery, and 
enables measurement of RV stroke volume using pulsed-wave Doppler. Analysis of the 
pulmonary spectral velocity waveform also allows measurement of the pulmonary artery 
acceleration time (PAAT), an index of elevated  pulmonary arterial pressure in rodent models 
[325]. Both views are complimentary, and together; provide a focused but comprehensive 
assessment of right ventricular structure and function. A focus of this study was to identify a 
practical approach to RV assessment, particularly when transthoracic imaging is limited in 
small animals.   
Current clinical guidelines advise the use of multiple echocardiographic views, for 
comprehensive assessment of right ventricular function [323]. This relates to the complex RV 
anatomy, involving a pyramidal-shaped chamber, with inlet and outlet portions 
communicating to the right atrium and main pulmonary artery. Unlike the left ventricle, the 
right ventricular wall comprises myofibrils predominantly oriented in a longitudinal 
direction, with circumferential myofibrils present only in the thinner subepicardium [326]. 
Consequently RV contraction is effectively longitudinal with ejection propagating from apex 
towards outflow tract, and rotational deformation being only a minor component of RV 
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contraction [327]. During RV contraction, ventricular length shortens and the base is 
translocated towards the apex.  Analysis of this dynamic ventricular movement is used to 
assess both contractile function and diastolic relaxation. During systole the tricuspid annular 
plane descends towards the apex, which itself remains relatively stationary [328]. Tricuspid 
annular plane systolic excursion (TAPSE) provides an approximation of RV longitudinal 
contractility, and can be measured using M-mode or with pulse-wave tissue Doppler imaging  
(S, E’ and A’ waveforms). With this approach Linqvist et al reported RVOT fractional 
shortening (RVOTFS) to correlate with both RV longitudinal function as measured by 
TAPSE, and pulmonary arterial pressure [329]. TAPSE, however, was not performed in this 
study since this it is appropriately measured using the more expanded apical 4-chamber view. 
2D-strain is a further analysis of cardiac motion based on the tracking of “speckle” 
movement within the myocardial wall during the cardiac cycle. Naturally occurring bright 
speckles within the myocardium act as acoustic markers for tracking, and are generated by 
backscatter signal during ultrasound examination [330]. Analysis is offline and based on 
commercial software algorithms. Strain (ε) is calculated from the relation L - Lo / Lo ,  where L 
is the final length and Lo the initial length of a myocardial wall speckle. Strain measures 
vector movement in relation to myofibril architecture: deformation is negative with 
longitudinal and circumferential strain, and positive for radial strain relating to wall 
thickening. Strain rate is the velocity of deformation, or ε/time between frames.  
The value of LV global longitudinal strain (GLS) is evident in clinical studies, where 
strain deformation has an earlier prognostic value than ejection fraction, particularly in 
predicting major adverse cardiac events [331]. Strain analysis of the RV is similarly reported 
to identify early changes in RV function before maladaptive remodelling becomes evident. In 
patients with pulmonary hypertension for example, longitudinal strain is segmentally 
decreased despite normal global RV function [332]. With respect to animal models the 
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application of 2D-strain is emerging, particularly in the assessment of left ventricular 
function [322, 333, 334]. However the application of RV strain to animal models, is not 
previously reported, but as with clinical studies, has major potential in characterizing RV 
function. This study has demonstrated 2D-strain analysis of the rodent RV is feasible, and 
also indicates that further investigation is necessary to define normal strain values in rodents. 
The use of animal models of disease has direct translational value in assessing the 
efficacy of potential therapeutic agents [319]. In COPD, for example, it is recognized that 
40% of deaths in COPD result directly from associated cardiovascular disease and 
particularly from RH dysfunction [14], [335, 336]. In many patients, mild to moderate 
pulmonary hypertension (PH) is common [337], with mean pulmonary arterial pressure 
(mPAP) between 25 and 30 mmHg [338]. The adaptive response of the right ventricle to 
increased pulmonary pressure includes chamber dilatation, wall hypertrophy and systolic 
dysfunction [339]. The presence of PH in COPD is associated with a poor prognosis and 
reduces survival [340]. In this respect assessment of right ventricular function using 2D-
echocardiography remains an important aspect of clinical management [341].  
A limitation to this study was the variation in image quality between animals.  
Technical accuracy is dependent on anatomical recognition and orientation, which ensures 
standardization of echocardiographic views. Incomplete or oblique views, poor definition of 
endocardial or epicardial borders, as well as Doppler mal-alignment, are all potential sources 
of error. Our experience indicates incomplete imaging to occur in only 1 of the 15 animals. 
However strain analysis was particularly affected by poor border definition and high frame 
rates, and prevented analysis in many animals. With gel injection and RV wall dissection at 
autopsy, potential artifactual error was possible between animals, as well as the failure to 
index measurements to animal body surface area. A further limitation is that CO was not 
validated with ultrasound measurement of PA flow, but our values were consistent with 
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reported values. Transthoracic examination was well tolerated, with hemodynamic stability 
present during anesthesia.  
In summary, we have demonstrated that examination using the modified SC and 
RVOT views has the potential to provide a comprehensive assessment of the RV particularly 
when standard 4C or 2C apical views are often suboptimal. These views enable a large 
section of the RV free wall to be imaged, enabling assessment of dilatation, wall hypertrophy 
and strain analysis. Further examination of the RVOT allows RV morphology, and contractile 
function to be serially assessed. In rodents 2D-strain imaging of the RV is feasible, and with 
appropriate study design has the potential to identify early systolic dysfunction.  
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Chapter 6: General Discussion
  170
6. Major Findings 
 
The present studies examined whether targeting the oxidant-dependent mechanisms that drive 
COPD and its co-morbidities had a positive impact on the pulmonary and extrapulmonary 
manifestations of the disease.  We assessed the effectiveness of two antioxidant therapies that 
act on different levels of the reactive oxygen species cascade via differing mechanisms of 
action. In Chapter 3, we first assessed the efficacy of the Gpx-1 mimetic ebselen, exploring 
the impact of enhanced hydrogen peroxide reduction in an established animal model of 
COPD. In Chapter 4, apocynin was used to reduce superoxide production via inhibition of 
NOX-2 in the same in vivo model of COPD. 
The 8-week cigarette smoke exposure model used in Chapters 3 and 4 was able to 
manifest pulmonary, systemic, and skeletal muscle characteristics of COPD in the form of 
lung inflammation, systemic inflammation, reduced body mass, skeletal muscle oxidative 
damage and skeletal muscle wasting. Although there were differences in the overall 
effectiveness of the two novel antioxidant compounds in this model, both significantly 
improved lung inflammation as measured by BALF cellularity and pro-inflammatory 
cytokine and chemokine expression in lung tissue. Though these findings are in accordance 
with the established anti-inflammatory effects of ebselen and apocynin in acute respiratory 
conditions [229, 298], only the therapeutic effectiveness of apocynin extended to the 
observed skeletal muscle wasting in mice whereas the GPX-1 mimetic ebselen did not 
produce the same anti-wasting effect. While this lack of effect in muscle was surprising, 
apocynin’s superior efficacy compared to ebselen was expected as apocynin acts earlier in the 
ROS cascade. As described in Chapter 1, inhibition of NOX-2 prevents superoxide 
generation and the subsequent formation of all other oxidants in the ROS and RNS cascades, 
whereas mimicking Gpx-1 only inhibits hydrogen peroxide accumulation and hydroxyl 
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radical formation. As most published studies exploring the use of antioxidant therapy in 
cachexic, sarcopenia, and skeletal muscle wasting show little to no benefit [212, 342, 343], 
this was the first study to show the successful inhibition of cigarette smoke-induced lung 
inflammation and skeletal muscle wasting in an established animal model of COPD via 
targeted antioxidant therapy (i.e. inhibition of NOX-2 with apocynin). This proof of concept 
supports the potential benefits of targeting oxidant dependent mechanisms for dual therapy to 
treat both pulmonary and systemic manifestations of COPD. While there are many potential 
targets in oxidative stress pathways, our findings present the use of apocynin to inhibit NOX-
2 as a logical choice for further antioxidant research. It should be noted that the physiological 
functions of several NOX isoforms remain unidentified and potential unpredictable side 
effects of long-term NOX inhibition need to be considered [344, 345]. Therefore, apocynin 
may not necessarily be the best option for clinical trials until its mechanism of action in this 
model is fully characterised in pre-clinical studies. 
Additionally, we developed and validated multiple methodologies to assess the 
contribution of oxidative stress to the development of comorbid skeletal muscle wasting and 
cardiovascular disease. In addition to the in vivo studies in Chapter 4, a pilot study was 
conducted to develop an in vitro model that could be used to identify the specific mechanisms 
driving the oxidative stress-induced alterations to skeletal muscle in COPD. By modifying 
the parameters used in similar studies [315, 346, 347], we successfully determined the 
conditions required to alter skeletal muscle morphology, promote inflammation, and induce 
impaired mitochondrial function in C2C12 myotubes via stimulus with hydrogen peroxide. 
Whilst the use of this in vitro model was not explored further in this thesis, this model was 
extensively used in other studies conducted by our group. 
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As cardiovascular comorbidities of COPD can take at least 6 months to develop in animal 
models of COPD [348], we required a non-invasive technique that could be used to assess the 
development of these manifestations in vivo without terminating the animals so longitudinal 
studies could be performed. In Chapter 5, an innovative method to measure changes in rodent 
cardiac morphology and function was developed, validated and successfully published [349]. 
Whilst we intended to utilize this novel methodology in a chronic smoke exposure protocol 
once validated, no further experiments were conducted due to time constraints. Other known 
comorbidities of COPD were not investigated in this thesis. 
6.1. Limitations 
The largest limitation to this study was the inability to combine the data from both Study A 
and Study B for both Chapters 3 and 4. This resulted in a reduced sample size for all 
parameters explored resulting in decreased statistical power. While the protocols for each 
study were identical in terms of handling, cigarette smoke exposure and treatment, the 
differences between the animal research facilities that each study was conducted in resulted 
in major variables that could not be ignored. The University of Melbourne animal facility 
used in Study A was equipped with a class II biosafety cabinet with a HEPA filter and 
filtered mouse cages that housed up to 12 animals concurrently. The RMIT facility on the 
other hand was equipped with fume cupboards and ventilated microisolation cages that 
housed a maximum of 6 mice.   
A class II biosafety cabinet equipped with a HEPA filter is inadequate for the complete 
ventilation of cigarette smoke, as although they draw smoke away from the animals, only the 
particulate matter in the smoke is filtered and the gases are released back into the room. Fume 
cupboards are more suited for the removal of smoke as they exhaust fumes to an external duct 
and are able to remove much more volatile compounds than cigarette smoke at a much faster 
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rate than biosafety cabinets. This means that the animals in Study A had greater exposure, 
albeit passively, to the gaseous components of cigarette smoke over the 8-week periods.  
In addition to this, the ventilated microisolator cages at the RMIT facility provided the 
animals with superior air quality and reduced cage population/density outside of smoke 
exposure sessions. It has been shown that increased population and cage density results in 
negative outcomes for animals such as reduced body weights and increased mortality [350] 
and while we did not see a clear correlation between cage density and smoke response, the 
combination of these factors may explain the discrepancies in the response of the mice to 
smoke exposure in the four studies described in this thesis. 
In addition to the sample size issue, there was insufficient time to explore all the 
parameters relevant to our study. While we were able to determine the overall therapeutic 
effects of the novel antioxidant compounds and establish a framework for future studies, 
many questions and potential research avenues remain. In ideal circumstances, we would 
have conducted the following experiments: measure lung and serum inflammatory cytokine 
and chemokine levels, measure lung mRNA expression in all studies, measure other markers 
of oxidative stress and ROS generation in the lung and skeletal muscle, and also examine 
alterations to skeletal muscle morphology in mice via immunohistochemistry. Given more 
time, we would conduct the above experiments using the stored tissue collected during the 
four studies outlined in this thesis. These experiments would have provided further 
characterization of both the smoke exposure model and the novel antioxidants explored, and 
may provide further insight on the mechanisms driving the comorbidities of COPD. Lastly, 
we would have also conducted an in vivo study to explore the role of oxidative stress in 
comorbid cardiovascular disease; however, this was not viable due to the length of smoke 
exposure required to induce these changes. 
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Overall, given these limitations, it was still possible to determine that antioxidant therapy is a 
viable therapeutic approach for the treatment of COPD and skeletal muscle wasting in mice. 
The findings of this thesis provide a solid framework for future studies involving the oxidant-
mediated pathways that overlap between COPD and its comorbidities. 
6.2. Future Directions 
While the primary findings of this thesis show clear therapeutic benefit for the use of targeted 
antioxidant therapy in COPD, further studies should be conducted before these compounds 
can be assessed in a clinical setting. To build on our findings, further research should 1) 
further optimise pre-clinical models of COPD and its comorbidities to identify the exact 
contribution of oxidative stress in skeletal muscle and the specific mechanism of action 
apocynin, 2) characterise the pulmonary manifestations in this model and the effect of 
antioxidant therapy in the lungs, and 3) assess the effect of targeting oxidant-dependent 
mechanisms in comorbid cardiovascular disease 
 
6.2.1. Optimisation of in vivo models to identify the exact role of oxidative stress in 
skeletal muscle wasting in COPD and validate NOX-2 inhibition  
Oxidative stress has a well-defined association with COPD and comorbid skeletal muscle 
wasting but the exact role of oxidative stress is still unclear. Currently, most studies explored 
oxidative stress’ ability to promote the activation of the ubiquitin proteasome system, leading 
to increased protein breakdown [275, 351-355]. In contrast to these studies, we did not 
observe these changes in our model as we were unable to produce any alterations to the 
mRNA expression of the E3 ligases involved in the ubiquitin proteasome system in any of the 
smoke exposure studies. However, our data suggests that oxidant generation via NOX-2 is 
involved in the development of skeletal muscle wasting, as the inhibition of NOX-2 by 
apocynin prevented the smoke-induced wasting. The exact mechanism of action of oxidative 
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stress in COPD and comorbid skeletal muscle is still unclear and these mechanisms need to 
be identified and characterised in order to properly validate the use of targeted antioxidant 
therapy. In order to do so, the 8-week smoke exposure protocol needs to be optimised and 
explored further.  
In Chapters 3 and 4, significant alterations to various parameters in the lungs, 
systemically, and in the skeletal muscle were observed, however, the specific alterations were 
inconsistent between the four in vivo studies conducted. Although the smoke-exposure 
methodology is well established [252, 253, 319, 356], these inconsistencies greatly limited 
our ability to interpret the data and suggests that there is room for further optimisation of the 
chronic smoke exposure protocol to improve reproducibility. The key parameters of the 
model that need to be optimised are the length of the protocol and the number of cigarettes 
per day. Acute smoke-exposure protocols generally have animals exposed to cigarette smoke 
over a 4-day period but with 9 cigarettes or more per day rather than 6 cigarettes as per the 
model used in this study [204, 229]. This 50% increase in the number of cigarettes used is 
able to produce a significant inflammatory response in the lungs of mice in a very short 
period of time. Chronic smoke exposure models that aim to induce manifestations of disease 
that take longer to develop, such as cardiovascular alterations, generally require a period of 
exposure ranging from 4 to 6 months rather than the 2 month exposure period of our model 
[357, 358]. As the smoke-induced alterations in this thesis were either inconsistent between 
studies or lacking in severity, an increase in the number of cigarettes and/or a lengthened 
exposure period may be able to provide more consistent and amplified smoke-induced 
alterations. With a more consistent model, we would be able to obtain more reliable results 
and better identify the mechanisms driving comorbid skeletal muscle wasting and the exact 
impact NOX inhibition has on these mechanisms. It should be noted that there are 
opportunity costs that need to be considered when making alterations to the protocol as it is a 
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manual process and a lengthened period of exposure would require increased researcher input 
to conduct the study. Therefore, the optimised model should be able to consistently induce 
significant pulmonary and muscular alterations in the shortest possible time. 
 
6.2.2. Characterisation of the pulmonary manifestations induced by cigarette smoke 
exposure and the effect of targeted antioxidant therapy 
We have previously shown that both ebselen and apocynin have therapeutic benefits in 
respiratory conditions, which is consistent with the observations in this thesis. Yet the 
experiments conducted in this thesis primarily focused on skeletal muscle wasting and 
pulmonary manifestations of disease were only considered briefly. As COPD is first and 
foremost a respiratory condition, a compound that aims to treat pulmonary and systemic 
manifestations of disease needs to have a substantial impact on the pulmonary symptoms of 
COPD. The mouse cigarette smoke exposure model is known to induce the pulmonary 
pathophysiology of COPD such as chronic inflammation, impaired lung function, airspace 
enlargement (emphysema), airway remodeling, goblet cell hyperplasia, mucus secretion, and 
lung vascular angiogenesis [118, 236, 359, 360].  
While it is unfeasible to induce and assess all of the above parameters in a single 
study, the effect that targeting oxidant-dependent mechanisms of COPD has on several 
smoke-induced disease pathophysiologies should be explored. If targeted antioxidant therapy 
successfully attenuates the pulmonary manifestations of COPD, the exact mechanism by 
which oxidative stress contributes to the development of airway restriction in COPD could be 
identified. In addition to this, a successful outcome would present a strong case for these 
compounds to be translated for use in clinical settings for the treatment of both pulmonary 
and systemic manifestations of COPD. 
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Another consideration would be any potential impairment to pathogen response 
and/or clearance as a result of antioxidant therapy, particularly in the context of AECOPD. 
While we do not believe that the initial pathogen response would be impaired, it is possible 
that pathogen clearance may be impacted if oxidant generation is impaired and this will need 
to be explored further using models of AECOPD. 
 
6.2.3. Assessment of targeted antioxidant therapy in animal models of comorbid 
cardiovascular disease 
Chronic inflammation and oxidative stress are also associated with other comorbidities of 
COPD such as cardiovascular disease (CVD), osteoporosis, stroke, and even lung cancer 
[257]. As such, reducing both chronic inflammation and oxidative stress by targeting the 
oxidant-dependent of COPD that overlap with these comorbidities should produce therapeutic 
benefits that echo those found in this thesis.  
Of particular interest to our research group is comorbid cardiovascular disease as it is 
the most frequently occurring comorbidity of COPD with 25-70% of patients presenting with 
pulmonary hypertension [164, 165]. Additionally, 40% of deaths in COPD result directly 
from associated cardiovascular disease and particularly from right heart dysfunction [14, 335, 
336]. As discussed in Chapter 1, persistent low-grade systemic inflammation and increased 
oxidative stress has been associated with the development of comorbid CVD [106] and we 
postulated that targeting oxidative stress with a compound like ebselen or apocynin would be 
of great therapeutic benefit. As we were previously limited by the lack of non-invasive 
techniques to measure cardiovascular morphology and function in a non-terminal manner, we 
have yet to explore this aspect of COPD in our model. 
With the development and validation of our modified echocardiographic methodology 
in Chapter 5, it is now possible to assess ventricular dilatation, wall hypertrophy, strain 
  178 
analysis, ventricle morphology, and contractile function. While the in vivo model may need 
to be optimised to induce cardiovascular manifestations, it is possible that correlation with 
echocardigraphic measurement may become evident as changes in dimension and area are 
more pronounced. As such, any therapeutic effects of antioxidant treatment would also be 
more noticeable when assessed with this technique and the non-terminal nature of the 
technique allows for longitudinal studies to be conducted. This will allow for the 
cardiovascular alterations to be assessed over a long period of time, providing valuable 
insight on the development of these alterations in response to smoke exposure. Therefore, 
targeted antioxidant therapy for the treatment of comorbid cardiovascular manifestations of 
COPD should be explored in preclinical models and assessed using the technique we have 
established in this thesis. 
6.3. Conclusion 
In summary, we conclude that targeting the oxidant-dependent mechanisms that overlap 
between COPD and its associated comorbidities is a viable therapeutic approach for the 
treatment of pulmonary and skeletal muscle manifestations of the disease. This is the first 
study to show that treatment with novel antioxidant compounds is able to reduce both smoke-
induced lung inflammation and skeletal muscle wasting and dysfunction in an in vivo model 
of COPD. We found that the inhibition of NOX-2 with apocynin had greater efficacy than the 
mimicking of Gpx by ebselen, however the reason for this is still unclear. Nevertheless, these 
compounds have shown exciting promise as viable pharmacological options for COPD 
patients who respond poorly to conventional pharmacological therapies and/or pulmonary 
rehabilitation. Additionally, we developed an in vitro model that can be used to further 
explore the contribution of oxidative stress in skeletal muscle wasting and dysfunction.  
Lastly, we also developed and validated a technique to examine alterations to cardiovascular 
morphology and functions in vivo. In summary, this thesis provided further insights into the 
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therapeutic benefits of targeting oxidative stress for the treatment of COPD and its skeletal 
muscle wasting, contributed to the characterization of the novel antioxidants ebselen and 
apocynin and established viable methods for the identification of the mechanisms that drive 
the onset and development of comorbidities of COPD.  
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Appendix 1 
 
Category  Gene  TaqMan assay ID 
Housekeeping gene  GAPDH Mm99999915_g1 
Inflammatory 
cytokines and 
chemokines 
CXCL10 Mm00445235_m1 
G-CSF Mm00438334_m1 
GM-CSF Mm01290062_m1 
IL-17A Mm00439618_m1 
IL-1β Mm00434228_m1 
IL-23 Mm00518984_m1 
IL-6 Mm00446190_m1 
MCP-1 Mm00441242_m1 
MIP-2α Mm00436450_m1 
MMP12 Mm00500554_m1 
MMP9 Mm00442991_m1 
TGF-β Mm01178820_m1 
TNF-α Mm00443258_m1 
Oxidative-stress 
enzymes  
NOX2/CYBB Mm01287743_m1 
Gpx1 Mm00656767_g1 
Atrophic factors  Atrogin-1/FBXO32 Mm00499523_m1 Myostatin  Mm01254559_m1 
Hypertrophic factors IGF1-Ea Mm00439560_m1 IGF1-Eb Mm00439559_m1 
Mitochondrial factors Nfe2l2 Mm00477784_m1 PPARGC1A Mm01208835_m1 
 
Table 11. Taqman assay IDs. 
List of genes and their corresponding Taqman assay identification codes. 
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Chronic obstructive pulmonary disease (COPD) is an incurable global health burden and is characterised by pro-
gressive airﬂow limitation and loss of lung function. In addition to the pulmonary impact of the disease, COPD
patients often develop comorbid diseases such as cardiovascular disease, skeletal muscle wasting, lung cancer
and osteoporosis. One key feature of COPD, yet often underappreciated, is the contribution of oxidative stress
in the onset and development of the disease. Patients experience an increased burden of oxidative stress due
to the combined effects of excess reactive oxygen species (ROS) and nitrogen species (RNS) generation, antiox-
idant depletion and reduced antioxidant enzyme activity. Currently, there is a lack of effective treatments for
COPD, and an even greater lack of research regarding interventions that treat both COPD and its comorbidities.
Due to the involvement of oxidative stress in the pathogenesis of COPD and many of its comorbidities, a unique
therapeutic opportunity arises where the treatment of a multitude of diseases may be possible with only one
therapeutic target. In this review, oxidative stress and the roles of ROS/RNS in the context of COPD and comorbid
cardiovascular disease, skeletal musclewasting, lung cancer, and osteoporosis are discussed and the potential for
therapeutic beneﬁt of anti-oxidative treatment in these conditions is outlined. Because of the unique interplay
between oxidative stress and these diseases, oxidative stress represents a novel target for the treatment of
COPD and its comorbidities.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Appendix 2
1. Introduction
An increased burden of oxidative stress is an important feature of the
pathogenesis of chronic obstructive pulmonary disease (COPD) and its
associated comorbid diseases (comorbidities). Current forms of therapy
for COPD are largely ineffective and the development of effective treat-
ments for COPD has been severely hampered as the mechanisms and
mediators that drive the induction and progression of chronic inﬂamma-
tion, emphysema, altered lung function, defective lung immunity and
many extrapulmonary comorbidities are still poorly understood. What
is known is that four primary mechanisms have been implicated in the
pathophysiological alterations observed in COPD: oxidative stress; in-
ﬂammation; protease–antiprotease imbalance; and apoptosis (Barnes,
2013, 2014; Hillas, Nikolakopoulou, Hussain, & Vassilakopoulos, 2013).
Althoughmostly underappreciated, oxidative stress has been recognized
as a central component in the pathogenesis of COPD as it can trigger and
further potentiate the other three mechanisms. In this review we focus
on the role of oxidative stress in the pathogenesis of COPD and its comor-
bidities. Given its pivotal role in the onset and development of COPD, ox-
idative stress may be a novel target for the treatment of COPD and its
comorbidities.
1.1. Chronic obstructive pulmonary disease overview
COPD represents an increasing global burden, afﬂicting over 600
million people and corresponding to approximately 5% of all deaths
globally (Koul, 2013). It is currently the third leading cause of death
(Lozano et al., 2012). It is well known that lower/middle income coun-
tries bear most of the burden of COPDwith almost 90% of COPD-related
deaths worldwide taking place in these countries (Lopez et al., 2006).
Although the incidence rate of COPD is likely to escalate in both devel-
oped and developing countries, COPD poses a heavier burden on the
Asia-Paciﬁc and African regions where smoking is still widespread and
gradually increasing (Chan-Yeung, Ait-Khaled, White, Ip, & Tan, 2004;
Adeloye et al., 2015). Cigarette smoke is inarguably the biggest risk fac-
tor for COPD, with 90% of deaths from COPD directly attributable to
smoking (Tashkin & Murray, 2009). Other risk factors include exposure
to air pollutants and biomass fuels (Song, Christiani, XiaorongWang, &
Ren, 2014). In addition, there is generally a long latency period between
exposure to smoke and clinically-evident disease and as such, there is a
high incidence of COPD in the older population and ex-smokers
(Theander et al., 2014). This latency period generally lasts a number of
years and by the time patients become symptomatic, the damage is al-
ready irreversible.
COPD is characterized by persistent airﬂow limitation and lung
inﬂammation resulting in a progressive decline in lung function
(Angelis et al., 2014). The main symptoms of the disease are chronic
cough (smoker's cough), excessive mucus production and dyspnoea
(particularly during exercise) (Theander et al., 2014). In addition to the
pulmonary manifestation of COPD, many systemic manifestations occur
in the formof comorbid diseases, such as skeletalmusclewasting, cardiac
dysfunction, osteoporosis and lung cancer (Chatila, Thomashow, Minai,
Criner, & Make, 2008; Barnes & Celli, 2009; Patel & Hurst, 2011). These
comorbidities have been associated with increased oxidative stress and
are known to affect, or are strong predictors of, themortality of COPD pa-
tients independent of the decline in lung function (Schols, Slangen,
Volovics, & Wouters, 1998; Marquis et al., 2002; Sin, Anthonisen,
Soriano, & Agusti, 2006; Swallow et al., 2007).
Although COPD is a largely preventable disease; the numbers of di-
agnoses continue to increase resulting in ever increasing medical costs
to patients, communities and governments (Lozano et al., 2012; GOLD,
2015). COPD patients generally have long hospital stays, require long-
term treatments, and in addition to these medical costs, other “costs”
such as an increase in days missed fromwork and limitations to quality
of life, are important consequences of this disease (Rabe, 2007; Vestbo
et al., 2013).
1.2. Acute exacerbations of chronic obstructive pulmonary disease
Patients with COPD often experience episodes of sudden worsening
of symptoms, known as acute exacerbations (AECOPD). The Global ini-
tiative for chronic Obstructive Lung Disease (GOLD) deﬁnes an exacer-
bation as “a change in the patient's baseline dyspnoea, cough, and/or
sputum and beyond normal day-to-day variations, that is acute in
onset and may warrant a change in regular medication in a patient
with underlying COPD”. These exacerbations are considered to be part
of the natural progression and chronicity of the disease and as COPD
progresses, exacerbations become increasingly more frequent (Hurst
& Wedzicha, 2009; Mackay & Hurst, 2013). Exacerbations result in a
dramatic increase in lung inﬂammation and are associated with in-
creased systemic inﬂammation compared to stable disease and as a re-
sult, there is only an increase in oxidative stress markers (Stanojkovic
et al., 2011). This contributes to the worsening of symptoms and it has
been shown that followinghospitalisation for AECOPD, patients have in-
creased mortality rates (Steer, Gibson, & Bourke, 2010).
AECOPD is often triggered by respiratory infections, such as those
caused by the bacteria Streptococcus pneumoniae and Inﬂuenza A virus,
or acute exposure to airborne irritants (Repine, Bast, & Lankhorst,
1997; Mackay & Hurst, 2013). There are also many non-aetiological
risk factors that contribute to the frequency of exacerbations such
as age, frequent past exacerbations and the presence of comorbid
diseases (especially cardiovascular disease) (Laratta & van Eeden,
2014). The rates of exacerbations vary dramatically depending on
the parameters used to deﬁne an exacerbation, however, rates of se-
vere AECOPD measured by hospitalisations occur at an approximate
rate of 0.5 to 3.6/person-year depending on the study cited (de Melo,
Ernst, & Suissa, 2004; Seemungal, Hurst, &Wedzicha, 2009). The out-
comes of AECOPD can vary from the return to near baseline spiro-
metric parameters to respiratory failure and death. Exacerbations
are the largest direct cost for the treatment of COPD due to the length
of hospital stays and the frequency of the exacerbations per patient
(Miravitlles, Murio, Guerrero, Gisbert, & EPOC, 2002; Miravitlles
et al., 2004; Mackay & Hurst, 2013).
2. Oxidative stress in chronic obstructive pulmonary disease
2.1. What is oxidative stress?
Oxidative stress refers to the imbalance between the oxidant and an-
tioxidant levels in favour of a pro-oxidant environment in cells and tis-
sues (Kalyanaraman, 2013). An oxidant is a species that causes or
promotes oxidation and an antioxidant is amolecule that inhibits either
the formation of oxidants or inhibits oxidation itself. Oxidative stress
arises from the inability of innate antioxidant mechanisms to neutralize
oxidants generated endo- or exogenously resulting in an imbalance be-
tween oxidant and antioxidant factors. Consequentially, the oxidants
predominate and chronic oxidative stress occurs, leading to themodiﬁ-
cation of lipids, proteins, and DNA (Rahman, 2005; Biswas, Hwang,
Kirkham, & Rahman, 2013). The harmfulmodiﬁcations caused by oxida-
tive stress are referred to as oxidative damage.
Oxidative stress can result from increased production of oxidants (in
the form of free radicals/reactive oxygen and nitrogen species) or from
diminished antioxidant levels or reduced antioxidant enzyme activity
(Kalyanaraman, 2013). The depletion of dietary antioxidants
(e.g., vitamins E, C, andD,ﬂavonoids and carotenoids) andmicronutrients
(e.g., iron, copper, zinc, selenium) can also contribute to oxidative stress
as they are needed for proper functioning of antioxidant enzymes
(Delles, Xiong, True, Ao, &Dawson, 2014). In chronic inﬂammatory condi-
tions, such as COPD, oxidative stress primarily results from the increased
production of reactive oxygen species (ROS) fromexposure to toxins (e.g.,
cigarette smoke, infection) and continuous activation of endogenous en-
zymes (e.g., NADPH oxidases) (Fig. 1).
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2.1.1. Chronic obstructive pulmonary disease and oxidative stress
The prolonged increase in oxidative stress is a major factor in poten-
tiating both the airway and systemic inﬂammation in COPD and is
known to play a key role in the onset and development of COPD and
its comorbidities (Montuschi et al., 2000; Cavailles et al., 2013;
Kirkham & Barnes, 2013). Direct damage occurs due to the oxidants
found in cigarette smoke and from excessive levels of ROS and reactive
nitrogen species (RNS) produced as a result of both pulmonary and sys-
temic inﬂammation. An increase in ROS production in the airways is
reﬂected by elevated levels of markers of oxidative stress (e.g., superox-
ide and malondialdehyde) in the airspaces, sputum, breath, lungs, and
blood in patients with COPD (Rahman, 2005; Stanojkovic et al., 2011).
These levels of oxidative stress markers are also dramatically increased
during exacerbations of COPD (Antus, Harnasi, Drozdovszky, & Barta,
2014). Due to the nature of the oxidative burden and its consequences
in the progression of COPD, this review is primarily focused on the
role of ROS/RNS in the pathogenesis of COPD and its comorbidities,
and the potential pharmacological targets related to ROS signalling.
2.1.2. Environmentally-derived reactive oxygen species
Eachpuff of cigarette smoke containsmore than 1015–17 oxidant/free
radical molecules and over 4700 highly reactive chemical compounds,
such as aldehydes and quinones, which increases the oxidant burden
in smokers (Church & Pryor, 1985; Nakayama, Church, & Pryor, 1989;
Pryor & Stone, 1993; Rahman, 2005, 2012; Kirkham & Barnes, 2013).
The nature of ROS found within cigarette smoke varies from short-
lived oxidants, such as the superoxide radical (O2•−) and the nitric
oxide radical (NO•), to long-lived organic radicals, such as semiquinones
that can undergo redox cycling within the epithelial lining ﬂuid of
smokers for some considerable period of time (Nakayama et al., 1989;
Valavanidis, Vlachogianni, & Fiotakis, 2009a,2009b). Lung and systemic
formation of protein carbonyls in response to cigarette smoke-derived
lipid peroxides/carbonyls have also been implicated in the pathogenesis
of COPD (Montuschi et al., 2000).
In addition to the release of oxidants, cigarette smoking is also asso-
ciated with an increased amount of myeloperoxidase (MPO) in neutro-
phils, an oxidising factor that forms hypochlorous acid and converts
tyrosine to tyrosyl radical (Bridges, Fu, & Rehm, 1985). Studies have
shown a correlation between the content of MPO in neutrophils and
the degree of pulmonary dysfunction observed in patients (Vaguliene,
Zemaitis, Lavinskiene, Miliauskas, & Sakalauskas, 2013). In addition,
studies suggest that neutrophil MPO-mediated oxidative stress plays a
role in lung inﬂammation (Gernez, Tirouvanziam, & Chanez, 2010). It
is also known that cigarette smoke can cause the activation of alveolar
macrophages, which is observed in the bronchoalveolar lavage ﬂuid
(BALF) from the lungs of smokers and COPD patients but not present
in non-smokers. The activation of macrophages contributes to the en-
dogenous generation of ROS in the respiratory tract (Kirkham,
Spooner, Ffoulkes-Jones, & Calvez, 2003; Barnes, 2004).
2.1.3. Cellular derived reactive oxygen species
Cellular-derived ROS is enzymatically produced by inﬂammatory
and epithelial cells within the lung and/or systemically as part of an
inﬂammatory-immune response towards a pathogen or irritant (Kim
et al., 2013). Production of ROS by phagocytes can be enhanced by oxi-
dants present in cigarette smoke leading to the release of inﬂammatory
mediators (Rahman, 2012). Several sources for ROS production exist
within a cell; however, the primary ROS generator is the enzyme
NADPH oxidase (NOX), which comes in various isoforms: NOX-1,
NOX-2, and NOX-4 (Selemidis, Sobey, Wingler, Schmidt, &
Drummond, 2008; Drummond, Selemidis, Griendling, & Sobey, 2011).
Fig. 1.Overview of oxidative stress in the pathogenesis of COPD. The generation of reactive oxidant species both exogenously and endogenously can lead to the onset and development of
COPD and its comorbidities. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are found in cigarette smoke but in COPD the primary sources of ROS and RNS are from
inﬂammatory cells includingmacrophages, neutrophils and epithelial cells.When activated by inhaled irritants (e.g., cigarette smoke), enzymatic (e.g., NADPH oxidase) generation of ox-
idants leads to the depletion of scavenging antioxidants (e.g., vitamin E), resulting in oxidative stress.
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In humans, NOX-1 and -2 are signiﬁcant ROS-generators which are
made up of an enzyme complex which is present in phagocytic and
non-phagocytic cells including epithelial cells, macrophages, and skele-
tal muscles (Grifﬁth et al., 2009; Barbieri & Sestili, 2012). Although NOX
is found in many cell types, it is latent in neutrophils under normal cir-
cumstances (MacNee&Rahman, 2001). Once activated, neutrophils and
macrophages can generate ROS via the NADPH oxidase system, leading
to further augmentation of oxidative stress in the lungs of smokers and
COPD patients (Fig. 2).
NOX-generated ROS have long been recognized to play key roles in
the pathogenesis of a number of diverse chronic lung disorders that re-
sult in obstructive physiology, in particular asthma, cystic ﬁbrosis, and
emphysema (Grifﬁth et al., 2009). Mice deﬁcient in p47phox or NOX-2
exhibit increased cigarette smoke-induced lung inﬂammation and em-
physema despite decreased ROS production compared with control
mice (Yao et al., 2008). The lung responses in p47phox- and NOX2-null
mice were associated with increased production of pro-inﬂammatory
cytokines and chemokines via a TLR4–NF-kB pathway, indicating that
NOX-2maymediate anti-inﬂammatory functions by restraining TLR4 ac-
tivation (Yao et al., 2008). However, another group reported that
p47phox-null mice have less inﬂammation, IL-6, keratinocyte-derived
chemokine, and monocyte chemoattractant protein-1 in lung-lavage
specimens after cigarette-smoke exposure compared with WT mice
(Gicquel et al., 2008). The differences observed by these groups may be
due to variability in lung compartment sampling, cellular distributions,
and chronicity of cigarette-smoke exposure.
2.1.4. Reactive nitrogen species
Although increased production of ROS is the primary mechanism of
oxidative stress in COPD/chronic lung diseases/acute lung diseases,
there is compelling evidence to suggest that RNS also play a role in
COPD (Ichinose, Sugiura, Yamagata, Koarai, & Shirato, 2000; Ichinose
et al., 2003). Reactive nitrogen species include nitric oxide (NO•), a ni-
trogen free radical, and its derivative species such as peroxynitrite and
nitrogen dioxide (Fig. 3). As with ROS, in addition to generation
endogenously, RNS are present in cigarette smoke and air pollutants
in the form of NO• and has many of the same harmful effects as ROS
(Hasnis, Bar-Shai, Burbea, & Reznick, 2007). Endogenously, NO• is asso-
ciated with a multitude of signalling pathways in mammalian physio-
logical and pathological processes; however, in excess it too causes
Fig. 2. Cellular generation of reactive oxygen and nitrogen species in COPD. Cigarette smoke acts on inﬂammatory cells in the lung (e.g., macrophages, neutrophils, epithelium) where
activation of NADPH oxidase 2 (Nox2) generates superoxide radicals. (O2•−) which can then either react with nitric oxide (NO•) to form the reactive peroxynitrite molecule (ONOO−)
or be rapidly converted to hydrogen peroxide (H2O2) via the enzymatic activity of superoxide dismutase (SOD). In the presence of Fe2+, H2O2 can be converted into the more damaging
hydroxyl radical (•OH) via the Fenton reaction. This reaction causes the oxidation of Fe2+ to Fe3+, and in this oxidation state, the presence of iron can directly generate •OH from O2•−.
These iron reactions have increased importance in COPD as a higher concentration of iron has been reported in the lungs of smokers, thereby increasing the potential ROS burden
(Gloire et al., 2006). The glutathione peroxidase (Gpx) family of enzymes, and catalase (CAT) are responsible for the conversion of H2O2 into harmlesswater and oxygen, which effectively
reduces circulating ROS and thus reduces the oxidative burden (Vlahos & Bozinovski, 2013).
Fig. 3.The reactive nitrogen species cascade. In addition to its ability to cause direct damage,
ONOO− can also reactwith carbon dioxide (CO2) in vivo. The reaction betweenONOO− and
CO2 occurs rapidly under physiological conditions, forming nitrosoperoxycarbonate
(ONOOCO2−). ONOOCO2− homolyzes (the molecule dissociates into 2 free radicals) to form
the carbonate radical (•CO32−) and nitrogen dioxide (•NO2) (Kalyanaraman, 2013). It is
these radicals (•CO32− and •NO2) that are believed to cause peroxynitrite-related cellular
damage. The conjugate acid of peroxynitrite, peroxynitrous acid (HNO3) also homolyzes
into •OH and •NO2 radicals, adding to the oxidative burden caused by peroxynitrite
(Merenyi, Lind, Goldstein, & Czapski, 1998).
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indiscriminate damage to surrounding tissues and can react with O2•−
forming the even more harmful peroxynitrite radical (ONOO−).
2.1.4.1. Nitric oxide. For years, NO• had only been considered as a toxic,
unstable free radical gas that was just a constituent of air pollutant and
cigarette smoke.However, it is nowknown thatNO• can be generated en-
dogenously in several types of cells (Bredt, 1999). This implicated NO• in
various physiological roles and pathways, including host defence, vascu-
lar regulation and neuronal communication (Kalyanaraman, 2013). NO•
has been well characterized in human biology and is perhaps the most
important endogenous vasoprotective molecule in addition to its role in
cardiovascular function (Moncada & Higgs, 2006; Tang & Vanhoutte,
2009; Vanhoutte, Shimokawa, Tang, & Feletou, 2009; Feletou, Kohler, &
Vanhoutte, 2012). NO• inhibits vascular smooth muscle contraction and
growth, platelet aggregation, and leukocyte adhesion to the endothelium,
contributing to vascular homeostasis (Cooke, 2004; Moncada & Higgs,
2006; Tang & Vanhoutte, 2009; Vanhoutte et al., 2009; Feletou et al.,
2012; Triggle et al., 2012). Individuals with hypertension, atherosclerosis
and/or diabetes often show impaired NO• signalling, highlighting the im-
portance of NO•with regards to comorbid cardiovascular disease (Huang,
2009) (see below).
Nitric oxide is generated by phagocytes and is biosynthesized endog-
enously from the amino acid L-arginine, oxygen, and NADPH by various
nitric oxide synthase (NOS) enzymes (Palmer, Ashton, & Moncada,
1988). In addition to its signalling roles, NO• has both pro-oxidant and
antioxidant activities; excessive NO• can cause direct oxidative damage,
however, NO• can also scavenge circulating ROS (Joshi, Ponthier, &
Lancaster, 1999;Wink et al., 2001). More importantly, O2•− can react di-
rectly with endothelium-derived NO• forming the harmful ONOO−
molecule.
2.1.4.2. Peroxynitrite. Peroxynitrite is formed by the reaction between
O2•− and NO• in vivo. The pairing of these 2 radicals results in ONOO−
anion, which is not a free radical but is still a very potent oxidant.
ONOO− is both an oxidising and nitrating agent and can thus damage
a wide array of molecules, including DNA and proteins (Beckman,
1996; Szabo &Ohshima, 1997). The formation of ONOO− is of particular
relevance to the comorbidities of COPD as its formation involves the
consumption of NO•, reducing the bioavailability of NO• for physiologi-
cal processes (see Section 3.2.3).
2.1.5. Depletion of antioxidants
ROS/RNS generated exogenously or endogenously, whether circulat-
ing or in pulmonary vasculature, are scavenged by blood antioxidants
and antioxidant enzymes. Accordingly, the ability to protect against the
deleterious effects of oxidative stress depends greatly on the antioxidant
capacity of the blood and the tissues (Rahman, Morrison, Donaldson, &
MacNee, 1996; Rahal et al., 2014). Studies have shown that in addition
to the increased levels of circulating oxidants, there is also an observed
decrease in systemic antioxidant capacity in smokers and patients with
COPD (Rahman, Swarska, Henry, Stolk, & MacNee, 2000). This is due to
the saturation of lung antioxidants, plasma antioxidants and protein sulf-
hydryls by the excessive amounts of circulating ROS released by neutro-
phils and macrophages (Rahman et al., 2000). The saturation of many of
these antioxidants, such as uric acid, glutathione (GSH), vitamin E, and
ascorbate is also associated with the severity of COPD exacerbations
(Rahman, Skwarska, & MacNee, 1997). Cigarette smoke, the main
aetiological risk factor for COPD, has also been shown to irreversibly
modify glutathione to glutathione conjugates in the airway epithelium
resulting in antioxidant deﬁciency and injurious lung response (van
der Toorn et al., 2007). Cigarette smoking also inhibits the protective ex-
pression of the Nrf2/antioxidant response element pathway in peripher-
al mononuclear cells of smokers, favouring a pro-inﬂammatory state
(Garbin et al., 2009). In addition to the antioxidant saturation, studies
have also shown a decrease in anti-oxidative enzyme function in COPD
patients; speciﬁcally reduced SOD and Gpx activity (Kurys, Kurys,
Kuzniar, & Kieszko, 2001).
There is evidence to suggest that the anti-oxidant enzyme glutathi-
one peroxidase-1 (Gpx-1) may have a role in regulating the inﬂamma-
tory response to cigarette smoke exposure. Elevated levels of H2O2 are
measured in the exhaled breath condensate of COPD patients, particu-
larly during exacerbations (Dekhuijzen et al., 1996). There is upregula-
tion of Gpx-1 gene expression in the lungs of smokers (Bentley,
Emrani, & Cassano, 2008) and depletion of Gpx activity in COPDpatients
and smokers (Santos et al., 2004; Kluchova, Petrasova, Joppa, Dorkova, &
Tkacova, 2007; Vibhuti, Arif, Deepak, Singh, & Qadar Pasha, 2007).With
respect to reduced Gpx activity in COPD patients and smokers, erythro-
cyte Gpx activity was signiﬁcantly lower in patients with severe COPD
compared with patients with moderate COPD and there is a direct rela-
tionship between systemic Gpx activity and FEV1 (Kluchova et al.,
2007). In addition, Gpx activity was decreased in plasma from COPD pa-
tients and oxidative stress correlates with both lung function and body
mass index in COPD (Vibhuti et al., 2007). Moreover, Gpx activity was
decreased in total blood from smokers and ex-smokers (Santos et al.,
2004). However, these studies did not identify the isoform of Gpx that
was involved in reduced activity of Gpx.
2.2. Oxidative modiﬁcations
Oxidative stress causes a wide array of physiological and pathologi-
cal consequences not necessarily limited to just COPD patients. In COPD,
increased oxidative stress can cause cell damage, cell necrosis, apopto-
sis, autophagy, remodelling of extracellular matrix and blood vessels,
endothelial dysfunction, inactivation of antiproteases, premature cellu-
lar senescence, elevated mucus secretion, steroid resistance, unfolded
protein response, cell proliferation, epigenetic changes, and autoimmu-
nity (Rahman, 2005; Rahman & Kinnula, 2012; Kirkham & Barnes,
2013). Oxidativemodiﬁcations of DNA, proteins and lipids all contribute
to the pathophysiology of the disease.
2.2.1. DNA
Unlike the other ROS and RNSwhich do not react with DNA bases or
deoxyribose, the hydroxyl radical and peroxynitrite can react with both
purine (adenine & guanine) and pyrimidine (cytosine & thymine),
forming speciﬁc products (Cooke, Evans, Dizdaroglu, & Lunec, 2003).
This oxidative damage can lead to mutation of DNA bases caused by
AT–GC transition and GC-AT transversion and, if left unrepaired, can re-
sult in changes in protein gene expression (Kalyanaraman, 2013). In ad-
dition to this, ROS/RNS-induced DNA damage also involves single- or
double-stranded DNA breaks and DNA cross-links, DNA damage induc-
ing either arrest or induction of transcription, induction of signal trans-
duction pathways, replication errors, and genomic instability (Naito,
Suematsu, & Yoshikawa, 2011).
2.2.2. Protein
Oxidative modiﬁcations to proteins caused by ROS/RNS include pro-
tein fragmentation, oxidation of amino acids, the formation of car-
bonyls, dityrosine and nitrated and chlorinated tyrosines (Berlett &
Stadtman, 1997; Grimsrud, Xie, Grifﬁn, & Bernlohr, 2008). In COPD
and other inﬂammatory diseases, elevated levels of nitrated, chlorinated
and brominated tyrosines have been detected in the tissues of patients
(Kim, Mofarrahi & Hussain, 2008). These oxidative changes to proteins
can result in various functional consequences, such as inhibition of en-
zymatic and binding activities, increased susceptibility to aggregation
and proteolysis, modiﬁcations in uptake by cells, and altered immuno-
genicity (Shacter, 2000).
2.2.3. Lipids
In the presence of ROS/RNS and oxygen, lipids undergo a chain oxi-
dation reaction leading to peroxidation. This chain reaction is initiated
by oxidants, primarily the hydroxyl radical and leads to the formation
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of lipid peroxide and lipid radicals which can reinitiate the chain reac-
tion. This process continues indeﬁnitely unless terminated by phenolic
antioxidants, also known as chain-breaking antioxidants (e.g., vitamin
E) (Kalyanaraman, 2013) (Fig. 4). This is especially important in comor-
bid cardiovascular disease where the formation of plaques in the arter-
ies is initiated from lipid peroxidation.
2.3. Effects of oxidative stress
ROS and RNS normally play roles in cell signalling and homeostasis;
however, in excess they become increasingly toxic. The ROS and RNS
O2•−, ONOO−, H2O2 and •OH, in addition to their indiscriminate
oxidization of proteins, lipids and DNA (Taraseviciene-Stewart &
Voelkel, 2012), can result in direct lungdamage or induce an assortment
of cellular responses. Additionally, these oxidants also inﬂuence the in-
ﬂammatory responses in the lungs via various pathways such as the ac-
tivation of transcription factor NF-κB, and transcription of pro-
inﬂammatory mediator genes, further potentiating the inﬂammatory
response in COPD (Gloire, Legrand-Poels, & Piette, 2006). This induces
a pro-inﬂammatory state that drives the sustained production of more
ROS, leading to a vicious cycle of oxidative stress and inﬂammation.
The oxidative damage and modiﬁcations caused by ROS are known to
precede the characteristic respiratory changes seen in COPD such as air-
way remodelling and emphysema (Barreiro et al., 2010). Recent studies
have also shown a decrease in glucocorticosteroid receptor expression
as a result of prolonged oxidative stress indicating that in a pro-
oxidant environment, such as in COPD patients, steroid therapy is of
limited therapeutic beneﬁt highlighting the need for new treatments
(van Eeden & Sin, 2013).
2.3.1. Systemic oxidative stress
Even after smoke cessation, systemic oxidative stress still persists in
COPD patients. This is reﬂected by an elevation in circulating ROS and a
depletion of antioxidants. The increased oxidative stress is likely due to
the persistent low grade systemic inﬂammation resulting in the produc-
tion of ROS systemically (Foschino Barbaro, Carpagnano, Spanevello,
Cagnazzo, & Barnes, 2007). This systemic oxidative stress has been im-
plicated in various systemic manifestations of COPD, with many studies
associating this increased burden of oxidative stress with skeletal mus-
cle wasting and cardiovascular disease in COPD (Foschino Barbaro et al.,
2007; Dalal, Shah, Lunacsek, & Hanania, 2011; Zampetaki, Dudek, &
Mayr, 2013). In addition to the links between oxidative stress in COPD
and comorbid diseases, increased extrapulmonary oxidative stress is
also an independent risk factor of many comorbidities such as cardio-
vascular disease, osteoporosis and depressive disorders in patients
without COPD (Sanchez-Rodriguez, Ruiz-Ramos, Correa-Munoz, &
Mendoza-Nunez, 2007; Kawada, 2012; Michel, Pulschen, & Thome,
2012).
2.4. Oxidative stress in comorbidities
of chronic obstructive pulmonary disease
A prominent feature of COPD is the presence of comorbid diseases
(or comorbidities) in patients (Chatila et al., 2008; Patel & Hurst,
2011). These diseases can range frommore “mild” conditions that affect
quality of life such as osteoporosis anddepression, tomore fatal diseases
such as ischaemic heart disease and cancer. COPD-related mortality is
likely underestimated due to these comorbidities as their presence
makes it difﬁcult to determine the precise cause of death. Respiratory
failure is considered to be the major cause of death in advanced COPD;
however, comorbidities such as cardiovascular disease and lung cancer
are also major causes of death. In early/mid stages of COPD, comorbidi-
ties are the leading causes ofmortality (Sin et al., 2006). Comprehensive
studies on the speciﬁc cause of deaths in COPD patients have found that
rather than dying from progressive respiratory failure, many COPD pa-
tients die from a complex web of interconnected comorbidities (van
Eeden& Sin, 2013). For the purpose of this review, comorbidities are de-
ﬁned as the presence of one or more distinct diseases or disorders that
are not directly related to COPD or are not part of the natural history/
progression of the disease (e.g., respiratory infections resulting in
AECOPD). The underlyingmechanisms resulting in these systemicman-
ifestations in COPD are not fully understood; however, they have been
linked to the persistent low-grade systemic inﬂammation and persis-
tent oxidative stress in COPD as discussed earlier.
3. Cardiovascular disease (CVD)
3.1. Cardiovascular disease overview
CVD is a broad term used to describe any disease involving the heart
and/or blood vessels. The presence of CVD is very common in COPD pa-
tients and is the leading cause ofmorbidity andmortality in younger pa-
tients and patients with mild-to-moderate COPD (Sin et al., 2006).
Comorbid CVD can manifest itself in one or more various disorders
such as angina, stroke, arrhythmias, hypertrophy of the heart, andmyo-
cardial infarction, and its presence greatly reduces the survivability of
COPD patients (Dalal et al., 2011).
Fig. 4.Oxidants (•OH) abstract the allylic hydrogen from lipid molecules (LH) forming the
carbon-centred lipid radical. This radical then undergoes molecular rearrangement to
form a more stable form of the carbon-centred radical (L•). In the presence of oxygen, L•
rapidly forms a lipid peroxy radical (LOO•). This new radical can then abstract an allylic hy-
drogen from another lipid molecule generating a new L•. This process can be terminated
by the donation of a hydrogen atom from vitamin E to the LOO• species forming a vitamin
E radical. The vitamin E radical then reacts with another LOO• forming non-radical prod-
ucts and thus terminating the reaction.
65I. Bernardo et al. / Pharmacology & Therapeutics 155 (2015) 60–79
3.1.1. Cardiovascular disease and
chronic obstructive pulmonary disease links
It is well documented that COPD and CVD share many of the same
risk factors, such as smoking, diet, and pre-existing hypertension.
When considering these risk factors it is of signiﬁcance that many, if
not all, contribute to disease progression at least in part via oxidative
stress. Multiple studies have shown links between COPD and classical
cardiovascular risk factors such as family history of coronary heart dis-
ease and diabetes (Sidney et al., 2005; Bursi, Vassallo, Weston, Killian,
& Roger, 2010; Terzano et al., 2010; Ford et al., 2012). Persistent low-
grade systemic inﬂammation is present in both COPD and CVD and ox-
idative stress, which plays a major role in COPD, has also been implicat-
ed in CVD (Zampetaki et al., 2013). This indicates that the systemic
inﬂammation and increased oxidative stress in COPD may lead to the
onset and development of comorbid CVD.
In addition to this, acute inﬂammatory lung conditions, such as bac-
terial/viral infection or acute exposure to airborne irritants, are also as-
sociated with vascular dysfunction (Mills et al., 2005, 2007). Increased
systemic inﬂammation, as a result of these lung conditions, is capable
of destabilizing vulnerable plaques, inducing a prothrombotic state
(Man, Van Eeden & Sin, 2012). COPD patients generally do not tolerate
cardiac injury or intervention as well as healthy individuals. COPD pa-
tients with acute myocardial infarction have a ﬁve-year survival rate
of 46% compared to 68% in those without COPD (Bursi et al., 2010).
3.1.2. Cardiovascular disease and acute
exacerbations of chronic obstructive pulmonary disease
Although many factors have been associated with poor outcomes
fromAECOPD, CVD is becoming increasingly recognized as a strong pre-
dictor of in-hospital mortality. Studies have shown that over 50% of pa-
tients hospitalized for AECOPD have a high prevalence of coexisting
cardiovascular disease (Stefanelli et al., 2013). Comorbid cardiovascular
disease is independently associated with increased risk of AECOPD
(Masunaga et al., 2003). The severity of airway obstruction is a major
predictor of AECOPD, and is also an independent risk factor for cardio-
vascular disease (Roberts et al., 2002; Mannino & Davis, 2006; Steer
et al., 2010; Mannino, 2011). There is also mounting evidence associat-
ing a high frequency of acute CVDwith acute respiratory illness, such as
pneumonia or AECOPD. Studies have shown that in the general popula-
tion, subjects with respiratory tract infections are more likely to experi-
ence a myocardial infarction within 2 weeks of infection (Meier, Jick,
Derby, Vasilakis, & Jick, 1998; Corrales-Medina, Madjid, & Musher,
2010). A retrospective review examining 24 h mortality following
AECOPD hospitalisation found that approximately 60% of deaths that
occurred resulted from cardiovascular causes (Pastor et al., 2013).
3.1.3. Pulmonary hypertension, hypertrophy and heart failure
There are two principal pathological features in the pulmonary vas-
culature common to most forms of pulmonary hypertension: excessive
vasoconstriction and remodelling of the pulmonary arteriolar wall,
which primarily occur by a mechanism of smooth muscle proliferation
within the medial layer (Demarco, Whaley-Connell, Sowers, Habibi, &
Dellsperger, 2010). Because ROSmaypromote vasoconstriction, smooth
muscle cell proliferation, and vascular remodelling, oxidative stress like-
ly plays a critical role in many forms of pulmonary hypertension.
Multiple studies have shown that 25–70% of COPD patients have
pulmonary hypertension, depending on the deﬁnition used (Rasubala,
Yoshikawa, Nagata, Iijima, & Ohishi, 2003; Sekine et al., 2014). In addi-
tion to this, it is estimated that 25% of patients withmoderate-to-severe
COPD develop pulmonary hypertension within 6 years if they have no
hypertension at baseline (Zhai, Yu, Wei, Su, & Christiani, 2014). The
pathological changes implicated in the development of pulmonary hy-
pertension can also be seen in tissue samples of COPD patients who
do not have a diagnosis of pulmonary hypertension (Weitzenblum,
1984; Santos et al., 2002).
A major feature of COPD is emphysema, contributing to airway ob-
struction. The destruction of alveolar walls and enlargement of air-
spaces results in a reduction in gas exchange (van der Toorn et al.,
2007). To compensate for this, blood pressure is increased to facilitate
more pulmonary blood ﬂow leading to pulmonary hypertension. This
results in increased work in the right heart and over time this increased
workload can lead to concentric hypertrophy of the right ventricle (RV)
(Neofytou, Tzortzaki, Chatziantoniou, & Siafakas, 2012). This can lead to
reduced ejection fraction, elevated end diastolic RV pressure, imped-
ance of the right heart and, if left unchecked, can lead to heart failure.
These changes can be detected in COPD patients, especially in end-
stage COPD patients, using transthoracic echocardiography, which al-
lows for the measurement of various parameters in the heart such as
systolic and diastolic wall thickness, and chamber size. Both pulmonary
hypertension and right heart failure are associated with an increase in
morbidity and mortality in COPD patients, independent of the decline
in lung function (Stone, Machan, Mazer, Casserly, & Klinger, 2011).
3.2. Oxidative stress in cardiovascular disease
The presence of oxidative stress in the form of increased ROS/RNS
formation (e.g., O2•−, ONOO−) has been observed both clinically and
in animal models of CVD (Schnabel & Blankenberg, 2007; Afanas'ev,
2011). Although implicated in CVD, the cause–effect relationship of ox-
idative stresswith any of the different cardiovascular diseases has yet to
be established. The increased generation of ROS due to impaired mito-
chondrial reduction ofmolecular oxygen, secretion of ROS by inﬂamma-
tory cells, endothelial dysfunction, auto-oxidation of catecholamines, as
well as exposure to radiation or air pollution can drive the oxidative
stress in cardiac and vascular myocytes (Dhalla, Temsah, & Netticadan,
2000). In addition to the increased oxidant production, depression in
the antioxidant reserve has also been implicated in CVD. These typically
phenolic antioxidants (e.g., vitamin E) act as a protective mechanism in
cardiac and vascular myocytes, and their reduced levels appear to be
due to both the saturation by excess ROS/RNS and/or changes in gene
expression. The harmful effects caused by ROS/RNS in cardiovascular
tissues are mainly due to ability of the oxidant species to drive changes
in subcellular organelles (e.g., mitochondria), reduce NO• bioavailabili-
ty, and induce intracellular Ca2+-overload (Dhalla et al., 2000).
3.2.1. Cardiovascular generation of
reactive oxygen species/reactive nitrogen species
As stated earlier, in addition to phagocytising cells, NOX-dependent
ROS-generation has been observed in numerous non-phagocytising
cells, though at a lower level. In the cardiovascular system these include
vascular smoothmuscle cells (VSMCs), endothelial cells, adventitial and
cardiac ﬁbroblasts and cardiomyocytes (Cave, Grieve, Johar, Zhang, &
Shah, 2005). Normally, these cells continuously generate low levels of
ROS even in the absence of external stimuli, and ROS derived from vas-
cular NOX act as second messengers in VSMC signalling. Over long pe-
riods of time, vascular NOX complexes only produce low levels of
O2•−, with much of it generated intracellularly where it participates in
cell signalling (compared to phagocyte O2•− which is generated extra-
cellularly) (Fisher, 2009). When stimulated however, there is a signiﬁ-
cant increase in NOX-driven ROS production by these cells. It is
important to recognize that both vascular and phagocytic NOX play an
important role in superoxide production as phagocytes can inﬁltrate
cardiovascular tissues and facilitate the functional and structural alter-
ations observed in CVD (Matoba & Egashira, 2011).
3.2.2. Oxidative stress in the pathogenesis of cardiovascular disease
Damage to the endothelium is the initiating step in CVD. This dam-
age can expose endothelial cells, along with the underlying cell layers,
to the deleterious effects of the inﬂammatory process, which can ulti-
mately lead to the formation of atherosclerotic lesions. Cellular oxida-
tive stress caused by excess ROS/RNS production is considered to be
66 I. Bernardo et al. / Pharmacology & Therapeutics 155 (2015) 60–79
intrinsic to atherosclerotic lesion formation (Vogiatzi, Tousoulis, &
Stefanadis, 2009). Exogenous factors contributing to oxidative stress
such as smoking and comorbid diabetes also contribute to vascular ox-
idative stress and are strong risk factors for CVD (Fearon & Faux, 2009).
Cigarette smoke has been associated with the down-regulation of key
exogenous and endogenous antioxidants such as vitamin C (ascorbic
acid), carotene, Gpx and SOD (Tsuchiya et al., 2002; Agnihotri et al.,
2009). This can lead to dysfunction in endothelial cells, monocytes
and VSMCs as well as mitochondrial damage. In addition to this, DNA
damage can be caused by oxidised lipids and this may also contribute
to the dysfunction of endothelial cells, VSMCs, T lymphocytes and mac-
rophages (Madamanchi & Runge, 2007).
Oxidative stress has also been associated with the apoptosis or pro-
grammed cell death of cardio myocytes (Singal, Khaper, Palace, &
Kumar, 1998). The loss of myocytes via apoptosis has been observed
in the infarct regions of myocardium from patients that have suffered
from heart failure or a myocardial infarction (MI) (Krijnen et al.,
2002). Both in vitro studies and in vivo animal model studies found
that apoptosis occurs in response to cardiovascular complications,
such as MI, and chronic pressure overload (Fiorillo et al., 2005). The
common factor in all of these conditions is the generation of oxidative
stress and oxidative stress is known to play a role in the initiation of ap-
optosis (Nagata et al., 2003). Additionally, the apoptosis of myocytes is
inhibited by antioxidants such as vitamin E and SOD, implicating ROS/
RNS in the pathological pathways of CVD (Kumar, Lou, & Singal,
2002). Although studies have implicated a role for ROS/RNS in CVD re-
lated apoptosis, the exact contribution of oxidative stress in the loss of
myocardial function and heart failure remains to be established.
3.2.3. Nitric oxide in cardiovascular disease
The role of nitric oxide NO• in vascular homeostasis and signalling
has been well characterized. As stated earlier, NO• plays a pivotal role
in the maintenance of vascular tone and vasoreactivity. In contrast to
this distinct role in cell physiology, NO• can also contribute to CVD pa-
thology. Under certain conditions eNOS (the endothelial isoform of
the nitric oxide synthase) becomes uncoupled from a NO• to an O2-pro-
ducing state (Montezano & Touyz, 2012). The excess O2 produced can
react with NO• resulting in the formation of excessive ONOO−. This re-
action reduces the bioavailability of NO•, leading to cardiovascular dys-
function and reduced endothelial vasoregulatory capacity (Kolluru, Bir,
& Kevil, 2012). ONOO− has also been shown to promote the uncoupling
of eNOS, propagating the increased ONOO− formation and decreased
NO• bioavailability (Cassuto et al., 2014).
3.3. Current treatments and antioxidant therapies
The current treatments for comorbid CVD are the same treatments
used for CVD independent of COPD, such as β receptor blockers, ACE in-
hibitors, or angiotensin receptor blockers. However, the beneﬁt of these
drugs in COPDpatientswith CVD is conﬂicting. Some studies have found
that these treatmentsmay be detrimental for COPD patients, worsening
the pulmonary symptoms of the disease (Nojiri et al., 2014). However,
others have shown that when given to COPD patients with and without
comorbid COPD, these treatments have shown notable beneﬁts with
regards to airway symptoms (Huang et al., 2013). This may be due to
the fact that both ACE inhibitors and angiotensin receptor blockers
have displayed pleiotropic antioxidant effects in addition to their anti-
hypertensive effects (Munger, 2011). Thus, this presents a unique op-
portunity for dual action therapy using CVD-speciﬁc treatments and
antioxidants, and obviously warrants further research.
CVD and COPD also overlap with regards to their non-
pharmacological management. Cardiovascular modifying factors such
as physical activity and diet modiﬁcation are reported to decrease hos-
pital readmission for COPD (McLachlan, Hambly, Almsherqi, El Oakley,
&McGuire, 2006). The recognition of the importance of oxidative stress
in CVD has led to the fervent use of antioxidants in the treatment and
prevention of the disease, however, the results of prospective, random-
ized clinical trials have been generally disappointing (Myung et al.,
2013; Ye, Li, & Yuan, 2013). In contradiction, studies have shown that
antioxidant therapy is beneﬁcial in non-comorbid hypertension, athero-
sclerosis, ischaemic heart disease, cardiomyopathies and congestive
heart failure (Dhalla et al., 2000). It should be noted that almost all an-
tioxidant clinical studies only explored the effectiveness of traditional
scavenging antioxidants such as vitamin E.
With regards to antioxidant treatments, the protective role of exer-
cise in preventing oxidative stress is noteworthy. Acutely, it is known
that exercise causes oxidative stress (Fisher-Wellman & Bloomer,
2009). However, exercise also leads to longer-term activation and en-
hanced synthesis of antioxidants and antioxidant enzymes (e.g., SOD,
Gpx-1), as well as decreasing oxidant production (Gonzalez, Marquina,
Rondon, Rodriguez-Malaver, & Reyes, 2008). This may explain the links
between prolonged exercise and the beneﬁcial effects to both COPD
and CVD patients, and highlights the potential beneﬁts of targeting oxi-
dative stress in comorbid CVD.
Overall, it appears that targeting oxidative stress with antioxidant
enzyme modifying treatments may have great potential in COPD and
comorbid CVD by providing beneﬁcial effects with regards to both the
pulmonary and cardiovascular aspects.
4. Skeletal muscle wasting
4.1. Skeletal muscle wasting overview
Skeletal muscle wasting, also referred to as cachexia or skeletalmus-
cle atrophy, occurs in approximately 20 to 40% of all COPD patients
(Schols et al., 1998; Congleton, 1999; Maltais et al., 2014). Muscle
wasting is characterized by a marked decrease in skeletal muscle
mass, an increase in proportion of type I muscle ﬁbres in the diaphragm
and type 2muscle ﬁbres in the periphery, and associatedwith low exer-
cise capacity and skeletal muscle weakness. Skeletal muscle wasting in
COPD is a strong predictor of mortality, independent of decline in lung
function (Schols et al., 1998; Marquis et al., 2002; Swallow et al.,
2007). Although present in a large population of patients, the preva-
lence of muscle wasting can only be approximated as there are no sim-
ple techniques to measure muscle mass. Knowing this, the actual
prevalence and extent of muscle wasting in the COPD population are
likely underestimated. This is because all the data is extrapolated from
body weight measurements and lean body mass, an index of muscle
mass, may be reduced despite the preservation of total body weight.
This is further supported by the fact that patients have a proportionally
greater reduction in thigh muscle cross-sectional area compared to re-
duction in bodyweight (Marquis et al., 2002). This indicates that a pref-
erential loss of muscle tissue exists in emaciated patients with COPD
(Kim et al., 2008).
Skeletal muscle wasting, although not a directly fatal condition, re-
duces health-related quality of life and decreases survivability for
COPD patients. The main feature of comorbid skeletal muscle wasting
is a reduction in fat free mass (FFM) and is associated with weaker pe-
ripheral muscles, impaired functional status, as well as poor health-
related quality of life (Debigare, Cote, & Maltais, 2001; Mathur, Brooks,
& Carvalho, 2014). In COPD, the reduction inmusclemass is proportion-
al to that of the reduction in strength indicating that the remaining con-
tractile apparatus may be functionally preserved. However, in patients
chronically treated with glucocorticosteroids, it is possible for the loss
of strength to be disproportional to the reduction in muscle mass.
Deteriorations in FFM have also been described following acute ex-
acerbations. These COPD patients also experience a reduction in exer-
cise capabilities, with skeletal muscle alterations contributing to
limitations in exercise in addition to pulmonary dysfunction (Wust &
Degens, 2007). It should be noted that the strength of the quadriceps
is a key determinant of exercise tolerance in COPD. This is explained
by the inﬂuence that muscle strength has on the perceived leg effort
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required during exercise, which is considered to be the main limiting
symptom in 40–45% of patients with COPD (Debigare & Maltais, 2008).
4.1.1. Mechanisms of skeletal muscle dysfunction
The pathophysiological interaction between COPD and alterations in
skeletalmuscle tissue is poorly understood and represents an important
gap in knowledge of the disease. Skeletal muscle wasting in COPD is
multifactorial in nature with several of these factors likely interacting.
Many factors (e.g., inﬂammation, oxidative stress, and poor nutrition)
can initiate or enhance alterations in skeletal muscle, such as change
in ﬁbre type phenotypic expression and regenerative defects in periph-
eral muscles of patients with COPD (Maltais et al., 2014). In this review,
multiple risk factors will be brieﬂy discussed along with a more in-
depth discussion regarding the role of oxidative stress and ROS.
4.1.1.1. Smoking. Cigarette smoking or exposure to other airborne irri-
tants is unlikely to be the primary mechanism involved in skeletal
muscle wasting in COPD, as seen in several studies where patients and
control subjects were matched for smoking history (Maltais et al.,
2014). Nevertheless, smoking does have some effect on muscle biology
and it may predispose patients to the development of skeletal muscle
dysfunction (De Paepe et al., 2008; Rinaldi et al., 2012). Smoking is
also associated with skeletal muscle weakness in otherwise healthy in-
dividuals (Seymour et al., 2010; Barreiro et al., 2011; vanden Borst et al.,
2011).
4.1.1.2. Disuse. Peripheral (or limb) muscle dysfunction in COPD has
been partly attributed to a reduction in physical activity, or
“deconditioning.” In general, the disuse of muscle can lead to many of
the features and alterations of skeletal muscle in COPD patients: muscle
weakness, muscle atrophy, loss of type I ﬁbres, decreased cross-
sectional area of muscle ﬁbres, reduced oxidative enzyme activity, re-
duced capillary-to-ﬁbre ratio, early lactate release, reduced rate of phos-
phocreatine synthesis after exercise and altered redox status (Booth &
Gollnick, 1983; Coyle, Martin, Bloomﬁeld, Lowry, & Holloszy, 1985;
Larsson & Ansved, 1985; Polkey & Moxham, 2006). In healthy adults
these changes are fully reversible in response to training and increased
exercise; however, full recovery is unusual in COPD patients (Troosters,
Gosselink, & Decramer, 2000; Polkey & Moxham, 2006, 2011; Man,
Kemp, Moxham & Polkey, 2009).
4.1.1.3. Inﬂammation. A low body mass index (BMI) has been linked to
systemic inﬂammation in COPD patients. As seen in Fig. 5, inﬂammation
plays a key role in the activation of protein breakdown in skeletalmuscle.
Inﬂammation results in theproduction of key cytokines, such as IL-8, that
can generate an array of cellular responses. This includes the induction of
the ubiquitin proteasome (UbP) system through the transcriptional ac-
tivities of NF-κB and FOXOs, apoptosis, and macroautophagy, all of
which have been linked to the muscle atrophy (Kandarian & Jackman,
2006). In COPD patients, there is a lack of evidence with regards to in-
ﬂammation in skeletal muscle during stable disease (Gosker et al.,
2003; Montes de Oca et al., 2005); however, increased inﬂammation is
seen during periods of exacerbation (Spruit et al., 2003; Yende et al.,
2006). Because of this, the role of inﬂammation as the key event for the
development of skeletal muscle dysfunction in COPD is still widely
debated.
4.1.1.4. Hypoxia. In humans (Hoppeler et al., 1990) and animals
(Magalhaes et al., 2005) muscle mass decreases under hypoxic condi-
tions. COPD patients that have low arterial O2 and reduced O2 delivery
tend to have lower body mass than those with normal levels of arterial
O2 and sufﬁcient O2 delivery (Semenza, 2009). Hypoxia may be a factor
driving changes in limb muscle tissue as hypoxia can induce down-
stream effects leading to the activation of the UbP system and reduced
myogenesis (Caron, Theriault, Pare, Maltais, & Debigare, 2009).
4.2. Oxidative stress in skeletal muscle wasting
In addition to chronic inﬂammation, hypoxia, cigarette smoke, sepsis
and an increased cost of breathing cause the increased generation of ox-
idants in the lungs (e.g., H2O2, O2•−, MDA) (Rahman, 2005). It is sug-
gested that, in addition to inﬂammatory mediators, these oxidants can
Fig. 5. Regulation of muscle mass relies on various hypertrophy and atrophy signalling pathways. In skeletal muscle wasting, there is an imbalance between these anabolic and catabolic
processes resulting in enhancedmuscle degradation as a result of protein breakdown.Myostatin (a negative regulator ofmusclemass) can inhibitmuscle growth. Inﬂammatorymediators
and ROS can lead to the downstream activation of atrophagy-related genes (e.g., Atrogin-1, MuRF-1) resulting in enhanced protein degradation. Inﬂammation and oxidative stress have
also been implicated in the activation of theubiquitin–proteasome (UbP) system. TheUbP system is theprimarymechanismof theprotein catabolism inmammalian skeletalmuscle. Refer
to Maltais et al. (2014) for an exhaustive overview of the signalling pathways involved.
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spill into circulation, increasing the systemic oxidative stress burden of
COPD patients (Zeng et al., 2013). In in vivo models of skeletal muscle
wasting in COPD, increased oxidative stress has been observed
(Rinaldi et al., 2012). This increase in oxidative stress canmodifymuscle
proteins, reducing their integrity and enhancing their degradation
(Aiken, Kaake, Wang, & Huang, 2011). Direct exposure to oxidative
stress from environmentally-derived oxidants, or indirect exposure via
cellular-derived ROS due to inﬂammation, can induce proteolysis.
Acute bouts of physical exercise and acute exacerbations can also in-
crease the level of oxidative stress (Couillard et al., 2003; Karadag,
Karul, Cildag, Yilmaz, & Ozcan, 2008; Stanojkovic et al., 2011). It is sug-
gested that oxidative stress may acutely affect skeletal muscle function
by inhibiting the activity of the sodium/potassium pump, sarcoplasmic
reticulum function, myosin ATPase and mitochondrial respiration
(Wust &Degens, 2007). In addition to these acute effects, chronic oxida-
tive stress also contributes to muscle wasting and dysfunction in both
respiratory and peripheralmuscles. The increased presence of ROS asso-
ciated with COPD causes an increase in the expression of UbP compo-
nents leading to increased protein breakdown in skeletal muscle
(Fig. 6) (Maltais et al., 2014). There is evidence that COPD patients
with muscle wasting experience a more severe abnormal oxidative
stress response to submaximal and maximal exercises compared to
non-muscle-wasted patients with COPD (Van Helvoort et al., 2006). Al-
though most studies focus on the increased signalling of atrophy path-
ways as the major driving force of comorbid skeletal muscle wasting,
it should be noted that decreases in hypertrophy signalling may also
contribute greatly to thepathology of the disease. Further studies are re-
quired to determine the exact contribution of these various pathways to
the disease.
4.3. Current treatments and antioxidant therapies
There are currently no effective drug treatments for skeletal muscle
wasting in COPD. Pharmacological treatments that have been explored
include anabolic steroids, growth hormone, other growth anabolic com-
pounds and bioactive nutrients (e.g., ghrelin, creatine) and antioxidants.
Most of these treatments have only shown little to modest beneﬁts
when treating skeletal muscle wasting and weakness in COPD. As with
CVD, skeletal muscle wasting and COPD also overlap with regards to
their non-pharmacological management. Currently, the most potent
treatment for limb muscle dysfunction is exercise training, which is al-
ready a key component for the management of COPD (Maltais et al.,
2014). Some treatments such as lifestyle modiﬁcations (diet and exer-
cise) and anabolic steroids have shown improvement in patients; how-
ever, they do not reverse the progression of muscle loss and may only
increase muscle growth without substantial improvements in strength
or endurance (Casaburi et al., 2004; Hansen, Gualano, Bozinovski,
Vlahos, & Anderson, 2006). Therefore, new treatments are needed as
limiting muscle wasting in COPD will lead to improved quality of life
and increased survivability of patients. Because of its role in the patho-
genesis of comorbid skeletal muscle wasting, targeting oxidative stress
may be able to slow the progression or onset of the disease, giving pa-
tients an improved quality of life whilst managing their other symp-
toms. Furthermore, it has been reported that increasing antioxidant
potential can improve muscle performance whilst attenuating muscle
fatigue (Maltais et al., 2014). Further pre-clinical and clinical studies
are required to determine the effectiveness of targeting oxidative stress
in comorbid skeletal muscle wasting.
5. Lung cancer
5.1. Lung cancer overview
Lung cancer is one of the more fatal comorbidities of COPD. It is cur-
rently themost frequently diagnosed cancerworldwide and is the num-
ber one cause of cancer-related deaths in males (Jemal et al., 2011).
Lung cancer accounts for up to 13% of all cancer diagnoses worldwide,
accounting for more than one million deaths per year (Alberg &
Fig. 6. Points of therapeutic intervention in COPD and its comorbidities. Oxidative stress indiscriminately damages a number of tissues and, as such, has been implicated in the onset and
development of multiple diseases regardless of COPD diagnosis. Using novel antioxidant therapies it may be possible to treat COPD, AECOPD and comorbidities of COPD. Inhibiting the
generation of ROS and RNS with pharmacological compounds could reduce lung and systemic inﬂammation, reduce the severity and progression of COPD and comorbidities, improve
the quality of life of patients, and increase their survival.
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Nonemaker, 2008; WHO, 2013). Patients with COPD have a higher risk
of developing lung cancer and due to the presence of comorbid lung
cancer, the survival rate of these COPD patients is drastically low
(Raviv, Hawkins, DeCamp, & Kalhan, 2011). It is estimated that up to
70% of lung cancer patients have co-existing COPD, and one study
found that the most common cause of death among patients with air-
ﬂow obstruction was lung cancer (Lung Health Study Research, 2000).
It is also known that, whilst lung cancer survival in the general popula-
tion is very low, COPD patients with comorbid lung cancer have an even
lower rate of survival. In one study, lung cancer patients without COPD
had a 26% 3 year survival after diagnosis versus 15% in lung cancer pa-
tients with COPD (Kiri, Soriano, Visick, & Fabbri, 2010).
5.1.1. Lung cancer and chronic obstructive pulmonary disease links
It is well established that exposure to airborne irritants, especially
those in cigarette smoke, induces both diseases. Cigarette smoke,
among other airborne irritants, is an independent risk factor of both
COPD and lung cancer with approximately 80% and 90% of cases associ-
ated with cigarette smoking respectively (Fathy, Hamed, Youssif,
Fawzy, & Ashour, 2014). Additionally, almost 1% of COPD patients de-
velop lung cancer yearly, whichmay be associated with genetic suscep-
tibility to particulates found in cigarette smoke (Sekine, Katsura, Koh,
Hiroshima, & Fujisawa, 2012). COPD is also considered to be a risk factor
for lung cancer independent of smoking status. It has also been sug-
gested that even a small reduction in airﬂow signiﬁcantly predicted
lung cancer (Wilson et al., 2008). The Multiple Risk Factor Intervention
Trial reported that a 10% reduction in lung functionwas associatedwith
an almost 3-times greater risk of lung cancer compared to patients
without airﬂow limitations, after adjusting for smoking (Shaten et al.,
1997). It also indicated that the lag time between smoking cessation
and the beneﬁcial effects on lung cancer development may be as long
as 20 years. A separate study found that the presence of COPD increases
the risk of lung cancer by up to 4.5-fold (Wang, 2013). This indicates
that COPD patients have a greater risk of developing lung cancer com-
pared to those with normal pulmonary function regardless of smoker
status. On the other hand, a study looking at the prevalence of COPD
in lung cancer patients, independent of age, sex, or smoking history, de-
termined that the prevalence of pre- or co-existing COPD in recently di-
agnosed lung cancer cases was six-times greater than in smokers
without lung cancer (Young et al., 2009). The study found that approx-
imately 50% of newly diagnosed lung cancer patients had COPD,where-
as this numberwas only 8% in otherwise healthy smokers. This suggests
that impaired lung function may be more important than age or
smoking history as a predictor of lung cancer.
Whilst the association between lung cancer and COPD has always
been of great interest, the details of their various molecular pathways
involved and their clinical correlates have only begun to be established.
Chronic inﬂammation is known to induce both COPD and lung cancer
by means of the release of inﬂammatory mediators and the excess
production of ROS/RNS (Lawless, O'Byrne, & Gray, 2009; Lee, Walser &
Dubinett, 2009; Bozinovski et al., 2015). Inﬂammatory mediators may
promote the growth of bronchoalveolar stem cells, activation of NF-κB
and signal transducer and activation of transcription 3 (STAT3), which
all play crucial roles in the development of lung cancer (Sekine et al.,
2012). Chronic inﬂammation leads to increased ROS production, and in-
creased oxidative stress has also been associated with the development
of lung cancer (Barreiro et al., 2013).
5.2. Oxidative stress in lung cancer
The primary association between oxidative stress and the develop-
ment of lung cancer is the oxidative modiﬁcations to DNA as a result of
ROS/RNS (Cooke et al., 2003; Paz-Elizur et al., 2003). Oxidative damage
to DNA by ROS and RNS has been implicated in carcinogenesis (Cooke
et al., 2003). As stated earlier it is known that oxidant-inducedDNAdam-
age also involves single- or double-stranded DNA breaks and DNA cross-
links, DNAdamage inducing either arrest or inductionof transcription, in-
duction of signal transduction pathways, replication errors, and genomic
instability, all of which have been linked to carcinogenesis (Dawane &
Pandit, 2012). It should be noted that studies have found that excessive
amounts of NO• increase apoptosis in some tumour cells, whereas re-
duced amounts of NO• can increase the vascularity of the tumour and
protect the cells from apoptosis, particularly in lung cancer (Masri, 2010).
Due to the direct damage to DNA and the increased demand for DNA
repair as a result of oxidative stress, more DNA mutations may occur.
One of themost important oxidativemodiﬁcations to DNA is the adduct
of •OH on DNA nucleobases. The 8-hydroxy-2′-deoxyguanosine (8-
OHdG) and/or its tautomeric 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxodG) have been widely studied and proven important mutagenic
adducts to DNA and are therefore key biomarkers of oxidative stress in-
duced carcinogenesis (Valavanidis et al., 2009a,2009b). Mutations of 8-
oxodG involve a GC→AT transversion which can modify protein tran-
scription as stated earlier in the review. In addition to this, ROS and
RNS may initiate carcinogenesis by attacking DNA nucleobases causing
changes in oncogenes and tumour suppressor genes (Valavanidis,
Vlachogianni, Fiotakis, & Loridas, 2013). Studies found that •OHcan gen-
erate various DNA phenotypes with various metastatic potentials
(Malins, Polissar, & Gunselman, 1996; Valavanidis et al., 2013). It is sug-
gested that these different phenotypes likely contribute to the diverse
physiological properties and heterogeneity characteristic of metastatic
cell population (Malins et al., 1996).
In addition to direct damage to DNA, ROS and RNS can indirectly
damage DNA via oxidative modiﬁcations to lipids. This occurs when
ROS and/or RNS react with cellular membrane phospholipids generating
lipoperoxide radicals (LOO•) and toxic aldehydes (malondialdehyde,
MDA). This results inmembranepermeability andmicrocirculation alter-
ation and also causes the activation of nuclear factors leading to other
pro-inﬂammatory agents (Valavanidis et al., 2013). MDA is a naturally
occurring by-product of lipid peroxidation and is a known mutagenic
and carcinogenic compound. MDA reacts with DNA to formmultiple ad-
ductswithmutagenic potential (Marnett, 2000). Additionally, MDA itself
has also been shown to be carcinogenic (Marnett & Tuttle, 1980).
As with patients with COPD and comorbid lung cancer, patients
without co-existingCOPDalso experience an increase in systemic oxida-
tive stress and inﬂammation (Barreiro et al., 2013). These processes can
cause the activation of NF-κB,which has been associatedwith the devel-
opment of comorbid lung cancer (Chen, Li, Bai, & Lin, 2011). NF-κB acti-
vation and the subsequent actions of inﬂammatory-related genes may
play a central role in both COPD and lung cancer. Activation of NF-κB in-
creases the release of inﬂammatory mediators that can induce COPD,
whilst also inhibiting apoptosis, inducing proliferation and, accelerating
cancer development (Karin, 2009). The release of these inﬂammatory
mediators can activate STAT3 which is a transcription factor with vari-
ous physiological functions. Continuous activation of the STAT3 signal-
ling pathway can potentiate pulmonary inﬂammation and induce
adenocarcinoma formation in the lung (Takata et al., 2012). Clinically,
activation of STAT3 and its downstream genes serve as biomarkers of
COPD and lung cancer diagnosis and prognosis (Qu et al., 2009).
As stated previously, oxidative stress can stimulate the recruitment
of macrophages and neutrophils which release various cytokines and
chemokines. Released matrix metalloproteinases and ROS promote in-
ﬂammation, induce apoptosis, matrix degradation, and ineffective tis-
sue repair, resulting in enlarged airspaces (emphysema) (Belvisi &
Bottomley, 2003). Bronchoalveolar stem cells may attempt to repair
and replace damaged alveolar cells however, in an inﬂammatory envi-
ronment, they can enhance carcinogenesis (Sekine et al., 2012).
5.3. Current treatments and antioxidant therapies
Treatment for lung cancer, regardless of co-existing COPD, depends
on the type and severity of the cancer with the main treatments being
surgery, chemotherapy and radiotherapy in varying combinations
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(Byers & Rudin, 2015). It is thought that chemotherapy may have sup-
pressive effects against oxidative stress in patients that respond well
to the treatment, compared to non-responders (Gupta et al., 2010).
This phenomenonmay be at least partially responsible for the improved
survival among responders.
As with COPD, the most effective lung cancer prevention measure is
smoking cessation. Because of the long lag time between smoke cessa-
tion and beneﬁcial effects with regards to lung cancer development,
new treatments for comorbid lung cancer should be primarily focused
on prevention and early detection. Early detection, prevention and in-
tervention are critical for both COPD and lung cancer as both diseases
have high mortality rates and incur severe economic burdens world-
wide. Due to the strong associations and interactions between lung can-
cer and COPD, novel therapies for the prevention of developing
comorbid lung cancer should focus on targeting pathways implicated
in both diseases. Inﬂammation and oxidative stress go hand-in-hand
in the onset and development of both of these diseases and are there-
fore key candidates for preventative therapy of comorbid COPD. More
research is required to determine the exact contribution of oxidative
stress to the pathology of lung cancer and the effectiveness of antioxi-
dant compounds in the disease.
6. Osteoporosis
6.1. Osteoporosis overview
Osteoporosis is a progressive, metabolic bone disease that is charac-
terized by a decrease in bonemass and density which leads to a deterio-
ration in bone strength and an increased risk of fracture (Kanis et al.,
2013). Patientswith osteoporosis experience reduced bonemineral den-
sity (BMD) and deterioration of bone microarchitecture (Kanis, 2002).
Additionally, patients experience alterations to the amount and variety
of proteins in bone as a result of the disease (Donoso, Pino, Seitz, Osses,
& Rodriguez, 2015). Osteoporosis presents no actual symptoms; howev-
er the major consequence of osteoporosis is the increased risk of bone
fractures as a result of the bone alterations. The key difference between
normal bone fractures and osteoporotic fractures is that osteoporotic
fractures occur in scenarios where healthy individuals would not nor-
mally break a bone. Therefore, these fractures are often regarded as fra-
gility fractures. Generally, these fragility fractures occur in the vertebral
column, ribs, hips and wrists (Adachi et al., 2003; Leslie et al., 2014).
As bone is a dynamic tissue, it continuously renews itself throughout
life and this is accomplished via bone remodelling. This process is car-
ried out by a functional and anatomic structure known as the basicmul-
ticellular unit. This structure requires the coordinated action of three
major types of bone cells: osteoclasts, osteoblasts and osteocytes
(Feng & McDonald, 2011). The interactions between these cells and
multiple molecular mediators, including hormones, growth factors,
and cytokines, drive the remodelling process (Mundy, 1993). Bone re-
modelling follows a time sequence that lasts approximately six months
in humans and during this process, osteoclasts eliminate old and/or
damaged bone which is then replaced by new bone formed by osteo-
blasts. Osteocytes are relatively inert cells, however, they are primarily
responsible for themolecular synthesis andmodiﬁcation, and transduc-
tion of signals (akin to the nervous system) necessary to sustain me-
chanical loads (Compton & Lee, 2014). In order to prevent signiﬁcant
alterations to bone mass and/or mechanical strength following after
each remodelling cycle, the process of bone formation and bone resorp-
tion is tightly regulated and maintained in healthy bone (Feng &
McDonald, 2011). Any disturbance in the remodelling process can lead
to the development of metabolic bone diseases. Oxidative stress is
known to affect the remodelling process by altering the functions of
both osteoclasts and osteoblasts and, as such, is associated with the
pathogenesis of osteoporosis. Due to the overlap in risk factors of
COPD and osteoporosis, patients with COPD have an increased inci-
dence of osteoporosis (Jorgensen et al., 2007).
6.1.1. Osteoporosis and chronic obstructive pulmonary disease links
In COPD, patient health and treatment is primarily focused on the
level of lung function and ability of oxygenation. Because of this, osteopo-
rosis often goes undiagnosed in COPD even though COPD patients are at
a higher risk of developing the disease. Osteoporosis, however,may be as
equally debilitating as COPD, and can further contribute to the impaired
respiratory function if the patient experiences vertebral compressions
and loss of height as a result of bone degradation (Silverman, 1992;
Yang et al., 2007; Masala et al., 2014). It is not clear why COPD patients
often develop osteoporosis, but many of the risk factors for osteoporosis
overlap with or are also associated with COPD. These risk factors include
smoking, chronic inactivity, reduced weight, medication taken, poor nu-
trition, low antioxidant status and oxidative stress (Cielen, Maes, &
Gayan-Ramirez, 2014). At amolecular level, the pathophysiology under-
lying the development of comorbid osteoporosis is largely unknown;
however, the risk factors and causes of the disease have been well
established.
Chronic treatment with glucocorticosteroids (GCS) is one of the
more obvious causes of osteoporosis in COPD patients (Canalis, 2005).
Although the use of GCS in the treatment of COPD is controversial due
to their limited effectiveness and major side effects, they are still pre-
scribed to patients with severe COPD and patients particularly prone
to exacerbations. Most studies conclude that a beneﬁcial effect from
GCS is only observed when administered to the most severely affected
patients with tendency to exacerbate (Falk, Minai, & Mosenifar, 2008;
Leuppi et al., 2013; Price, Yawn, Brusselle, & Rossi, 2013). The treatment
with GCS for airway impairment is associated with an increased occur-
rence of fractures (De Vries et al., 2007). The incidence of fractures, as a
result of osteoporosis, contributes to the overall disability andmortality
of patients with COPD, whilst adding to the economic burden of the
disease. The increased incidence of osteoporosis is also seen in patients
that are treated with GCs chronically due to other chronic diseases
(McDonough, Curtis, & Saag, 2008). Although GCS use is a risk factor
for the development of comorbid osteoporosis, it does not entirely ac-
count for the low bone mass and high prevalence of osteoporosis in
COPD patients. In addition to chronic GCS use, inﬂammation has also
been determined to be a major risk factor of comorbid osteoporosis.
Systemic inﬂammation as a consequence of COPD has been linked to
the development of a myriad of comorbidities, including osteoporosis.
One study showed that the increased arterial stiffness due to the sever-
ity of airway obstruction experienced by COPD patients is related to os-
teoporosis and various markers of systemic inﬂammation (Sabit et al.,
2007). One such inﬂammatory marker is interleukin (IL)-6; a cytokine
which may also contribute to the increased risk of other comorbidities.
In addition to its pro-inﬂammatory effects, IL-6 is involved in regulation
of bone turnover and has been implicated in osteoporosis development
(Ishimi et al., 1990). Another study suggested that COPD is associated
with increased insulin resistance (another metabolic disorder) and
that this is associatedwith elevation of the proinﬂammatorymarker tu-
mour necrosis factor (TNF)-α receptor expression (Hotamisligil, 1999;
Nieto-Vazquez et al., 2008). TNF-α is a documented stimulator of oste-
oclastic bone resorption andhas been implicated in postmenopausal os-
teoporosis (Boyce et al., 2005). In one study examining patients
awaiting pulmonary transplantation, of which 56% were COPD patients,
there was a positive correlation between TNF-α receptor expression
and bone turnover (Forli et al., 2008). Increased levels of the bone re-
sorption marker 1-CTP were proportional to increased levels of TNF-α
receptor II. This suggests a strong correlation between COPD induced in-
ﬂammation and increased bone loss.
As stated earlier, inﬂammation in COPD is also implicated in skeletal
muscle wasting leading to signiﬁcant reductions in FFM. The increased
enzyme catalytic activity in muscle wasting is also associated with
bone loss. Signiﬁcant changes in enzyme function, such as increased ac-
tivity of alkaline phosphatase (ALP), have been identiﬁed in sera collect-
ed from osteoporosis patients (Leung, Fung, Sher, Li, & Lee, 1993). These
changes have also been associated with increased bone metabolism,
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and altered bone rearrangement in COPD (Jorgensen & Schwarz, 2008).
MMP activity (primarily MMP-9 and MMP-12), which is implicated in
parenchyma destruction, has also been linked to the development of os-
teoporosis in COPD patients (Bolton et al., 2009).
6.2. Oxidative stress in osteoporosis
In addition to inﬂammation, there have been a multitude of studies
implicating oxidative stress with an increased rate of bone loss, thus
making oxidative stress a risk factor for osteoporosis (Varanasi, Francis,
Berger, Papiha, & Datta, 1999; Chavan, More, Mulgund, Saxena, &
Sontakke, 2007; Stanojkovic et al., 2013; Cervellati et al., 2014). It is sug-
gested that ageing and the consequential increase in ROS are responsible
for bone loss (Almeida & O'Brien, 2013). Increased oxidative stress is as-
sociated with alterations in the activity and function of both osteoblast
and osteoclast cells; the two major bone cells involved in the pathogen-
esis of osteoporosis.
6.2.1. Osteoblasts
The role of oxidative stress in osteoblasts has only been researched
extensively in the past decade. As stated earlier, osteoblasts are respon-
sible for replacing old or damaged bone with new bone. Studies found
that osteoblasts can be induced to produce intracellular ROS (O2•−
and H2O2) and the production of which can cause a decrease in ALP
which can cause cell death, and this effect is partially inhibited by scav-
enging antioxidants (Darden, Ries, Wolf, Rodriguiz, & Key, 1996; Onyia
et al., 1999). In high concentrations, ROS can damage osteoblast cells,
preventing the normal growth and development of bone, and has
been shown to induce osteoblast cell death (Lee, Lim, Lee & Yang,
2006). Additionally, H2O2 can modulate the activity of intracellular cal-
cium in osteoblasts by increasing the amount of Ca2+ released from in-
tracellular Ca2+ stores (Nam, Jung, Yoo, Ahn, & Suh, 2002).
6.2.2. Osteoclasts
Whilst still notwell understood, the differentmechanisms and path-
ways involved in the differentiation of osteoclasts and their ability to re-
sorb bone are beginning to be elucidated. It is well known that ROS is
involved in this process, but the extent of its contribution is still to be
determined. Superoxide has been detected intracellularly in osteoclasts
and at the osteoclast–bone interface, suggesting a contribution from su-
peroxide in bone resorption (Key, Wolf, Gundberg, & Ries, 1994). It is
known that osteoclastic superoxide is produced by NOX (Darden et al.,
1996). H2O2 produced by endothelial cells associated with osteoclasts
and the H2O2 produced by osteoclasts have been shown to increase os-
teoclastic activity and bone resorption, which may contribute to the in-
creased breakdown of bone in osteoporosis (Bax et al., 1992). H2O2 has
also been implicated in various other osteoclast functions such as oste-
oclast motility, differentiation of osteoclast precursors and the regula-
tion of osteoclast formation (Steinbeck, Kim, Trudeau, Hauschka, &
Karnovsky, 1998). The reaction of H2O2 with tartrate-resistant acid
phosphatase found on the surface of osteoclasts is responsible for the
degradation of collagen and other proteins (Bull, Murray, Thomas,
Fraser, & Nelson, 2002). Additionally, antioxidants play a role in osteo-
clast activity. Osteoclasts innately possess the antioxidant enzyme
SOD in the plasma membrane (Steinbeck, Appel, Verhoeven, &
Karnovsky, 1994). Studies found that after treating osteoclast cells
with antioxidant enzymes such as SOD and catalase, ROS production is
inhibited indicating that antioxidant therapy may be beneﬁcial for pa-
tients with osteoporosis (Lee, Kim & Jang, 2014).
6.3. Current treatments and antioxidant therapies
In addition to diet supplementation with calcium and vitamin D,
there is also awide range of pharmaceuticals available for the treatment
of osteoporosis. The current anti-resorptive treatments prescribed to os-
teoporosis patients include a number of bisphosphonates which inhibit
bone resorption (MacLean et al., 2008). These vary by way of adminis-
tration and are taken orally either daily, weekly, monthly or intermit-
tently. Many other drugs are available such as, but not limited to,
calcitonin and strontium renalate, both of which increase bone forma-
tion by stimulating osteoblasts, whilst reducing bone resorption via
inhibiting the activity of osteoclasts. Emerging research has shown ben-
eﬁcial effects of anabolic treatments in osteoporosis (Neer et al., 2001).
Currently, the only available pure anabolic drugs are parathyroid hor-
mone mimetics. The use of fully human monoclonal antibodies has
also been approved for osteoporosis and a number of drugs are being
tested clinically for osteoporotic treatment and prevention (Lewiecki,
2011; Padhi, Jang, Stouch, Fang, & Posvar, 2011). However, unsurpris-
ingly, there is a lack of interventional studies regarding the treatment
of osteoporosis in patients with COPD.
Antioxidant treatment for osteoporosis has proven to be quite effec-
tive. The beneﬁcial effects of antioxidants with regards to bone health
and osteoporosis have also been demonstrated epidemiologically and
through clinical intervention (Rao, 2013). Bearing in mind the possible
adverse effects of hormonal therapy and the increasing reports regard-
ing the side effects of bisphosphonates in the management of osteopo-
rosis, there is a high demand for complementary and/or alternative
medicine for the prevention and treatment of osteoporosis. This is espe-
cially true for COPD patients who are inherently at a greater risk of de-
veloping the disease. Due to the damaging effects of ROS on bone
growth and regulation, targeting oxidative stress in COPD patients
may prove to be beneﬁcial for both COPD and osteoporosis.
7. Novel antioxidant approaches for the
treatment of chronic obstructive pulmonary disease
Besides never smoking, smoke cessation is the only effectivemethod
for preventing the onset and progression of COPD. The progression
of airway inﬂammation, increased oxidative stress, and protease
burden even months/years after cessation, and non-responsiveness to
glucocorticosteroids have been documented as therapeutic challenges
for the treatment of COPD (Kalyanaraman, 2013). Because of this,
there is a lack of effective treatments for COPD and its comorbidities.
As stated throughout this review, tissue injury and inﬂammation as a
result of oxidative stress are common to COPD and many of its comor-
bidities. A common theme throughout this review is the similarity and
interplay between the pathological mechanisms of each condition and
it is this similarity that provides a unique therapeutic opportunity
(Fig. 6). Treatment with antioxidants may be able to progressively pre-
vent and treat multiple diseases by suppressing the generation of ROS/
RNS, neutralizing oxidants or both. Due to the overwhelming evidence
implicating oxidative stress in the pathogenesis of COPD and its comor-
bidities, it is only logical to consider antioxidant intervention in this
patient population. It is important that such interventions not only neu-
tralize the excessive ROS and RNS generated, inhibit peroxidation of
lipids, and the subsequent inﬂammatory response, but to also identify
the source of these oxidants and inhibit their generation (Selemidis
et al., 2008). Due to the imbalance in oxidants and antioxidants,
this can be achieved by two approaches: increasing the endogenous
antioxidant enzyme activity via enzyme modulators/mimetics, or by
replenishing the depleted non-enzymatic defences through dietary or
pharmacological means.
It should be noted that typical radical scavenging treatments, such as
vitamin E and other dietary antioxidants, have shown minimal im-
provements in either COPD or the comorbidities outlined in this review.
This may be due to the dose, route of administration or the speciﬁc an-
tioxidant given and thus more research is required to determine the
efﬁcacy of these compoundswith certainty. In addition, traditional anti-
oxidants act in a “sacriﬁcialmanner,” due to the fact that once they have
scavenged a radical, they are essentially consumed.
Undoubtedly, themost damaging of all the ROS/RNS are the hydrox-
yl radical and peroxynitrite. These species are extremely reactive and
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indiscriminate to the point that they basically react with the ﬁrst sub-
strate they come into contact with. Knowing this, the most effective
form of protection would be to prevent their generation in the ﬁrst
place and this cannot be performed by traditional antioxidants (scaven-
gers). Therefore, a pharmacological approach which inhibits the pro-
duction of oxidant species is required. In addition to this, it may also
prove beneﬁcial to use combination therapy and treat patients with
the pharmacological enzymatic antioxidants (e.g., NOX inhibitors)
whilst also supplementing themwith dietary antioxidants (e.g., vitamin
E supplements).
7.1. Novel antioxidants
As shown on the ROS cascade (Fig. 2), there are 3 key enzymes that
can be targeted in order to reduce oxidative stress; NOX, SOD, and Gpx/
Cat. These enzymes can either be inhibited to reduce their activity (e.g.,
NOX inhibitor— apocynin) or ampliﬁed/mimicked to increase their ac-
tivity (e.g., Gpx mimetics — ebselen). Outlined below are just some of
the enzymatic compounds that may be of therapeutic beneﬁt to COPD
patients (also see Table 1).
7.1.1. NADPH oxidase inhibitors
As stated earlier, NOX-1 and -2 are the primary generators of O2•−
and are responsible for the initiation of the ROS cascade (Fig. 2). NOX
is a unique target in the sense that inhibiting the activity of the enzyme
would not only reduce the generation of a single oxidant species but
also reduce the generation of all other ROS and RNS. Inhibiting NOX
would reduce O2•− production which would result in less available
O2•− for the generation of H2O2 and ONOO−, subsequently reducing
•OH generation and increasing •NO bioavailability as a result.
7.1.1.1. Current studies. There are several NOX inhibitors currently being
studied, however the most common is apocynin, which is a NOX inhib-
itor that preferentially blocks NOX-2 at low doses. It inhibits NOX
by preventing the assembly of the NOX enzyme subunits, resulting in
the reduced formation of NOX complexes (Selemidis et al., 2008;
Drummond et al., 2011). We have shown that apocynin reduces
cigarette smoke-induced lung inﬂammation in mice (Bernardo et al.,
unpublished observations). Additionally, the inhibition of NOX-2 activ-
ity ameliorates inﬂuenza A virus-induced lung inﬂammation, indicating
that pharmacologically targeting NOX-2 may also have therapeutic po-
tential in seasonal and possibly pandemic inﬂuenza infection (Vlahos
et al., 2011; Vlahos, Stambas, & Selemidis, 2012). Because of this, the
possible therapeutic utility of NOX-2 inhibitors may extend to AECOPD.
Clinically, COPD patients treated with apocynin had reduced H2O2 and
NO2− in their exhaled breath concentrate compared to placebo control
(Stefanska et al., 2012).
7.1.2. Superoxide dismutase mimetics
There are 3 human isoforms of SOD (1, 2, and 3), each of which can
transform O2•− to H2O2. SOD3 (or extracellular SOD) is located in the
extracellular matrix, the junctions of airway epithelial cells, the surface
of airway smooth muscle, and the lining of blood vessels of the lung
(Kinnula & Crapo, 2003). It should be noted that smokers and COPD pa-
tients have increased sputum levels of SOD3 as an adaptive response to
the increased oxidative burden (Regan et al., 2011). Additionally, poly-
morphisms in the SOD3 gene have been associated with emphysema
but not COPD susceptibility (Sorheim et al., 2010). It is possible to en-
hance the conversion of O2•− to H2O2 by introducing SOD mimetics.
Thiswould result in the same effects caused by NOX inhibition: reduced
O2•−, increasedNO bioavailability, however, itwould also increase H2O2
generated. Although there is increased H2O2 generation, the newest
class of SOD mimetics (salen complexes — “salens”) have also shown
Catalase like activity, enhancing the neutralization of H2O2 in cells and
decomposing ONOO− (Sharpe, Ollosson, Stewart, & Clark, 2002). Addi-
tionally, it has been suggested that SODmimetics may be beneﬁcial for
the treatment of cancer in combination with traditional cancer thera-
pies (Thomas & Shariﬁ, 2012).
7.1.2.1. Current studies. Since the administration of exogenous SODs
themselves has often proven to be problematic, a variety of innovative
approaches are currently being explored, one of these being SOD mi-
metics. Multiple classes of SOD mimetics have been developed and
each class has generally been effective in animal models of COPD. Ad-
ministration of the SOD mimetic M40419 in rats treated with VEFG re-
ceptor blockers signiﬁcantly decreased markers of oxidative stress in
the lungs and prevented the development of emphysema (Tuder et al.,
2003). In cigarette smoke-exposed rats, treatmentwith the SODmimet-
ic AEOL 10150 was found to signiﬁcantly reduce BALF inﬂammation
(Smith et al., 2002). It is known that the acute loss of SOD3 in adult
mice causes death,whereas overexpression of SOD3 in animals exposed
to hyperoxia reduces mortality (Folz, Abushamaa, & Suliman, 1999;
Gongora et al., 2008). Additionally, administration of SOD mimetic sig-
niﬁcantly attenuated the elastase-induced emphysema in both wild-
type and SOD3 knockout mice (Yao et al., 2010). This study found that
SOD3 protected against oxidative fragmentation of extracellular matrix
(ECM), resulting in the mitigation of lung inﬂammatory response and
emphysema. Knowing this, it is possible that SOD3 may be more effec-
tive than other SOD isoforms for the management of COPD. Therefore,
the development of pharmacological mimetics to replenish and aug-
ment SOD3 in the lung may have a therapeutic potential for the treat-
ment of COPD/emphysema (Rahman, 2012).
7.1.3. Glutathione peroxidase mimetics
The Gpx family of enzymes, along with catalase, are responsible for
the termination of the ROS cascade. There are 8 known isoforms of
Gpx (1 to 8) but the most abundant isoform is Gpx-1, which is found
in the cytoplasm of almost all mammalian cells and whose preferred
substrate is H2O2 (Vlahos & Bozinovski, 2013). The main function of
Gpx is the reduction of H2O2 to H2O and O2; however, Gpx is also
known to reduce lipid peroxides to their corresponding alcohols. Addi-
tionally, it has been reported that Gpx-2 is a major cigarette smoke-
inducible isoform found in the lung (Singh et al., 2006). As with SOD,
Table 1
Various antioxidant compounds that have been studied in the context of COPD and/or its
comorbidities. Pre-clinical and clinical tests are investigating, or have investigated, the ef-
fectiveness of intervention with various small-molecular weight antioxidant compounds
that target oxidant generation, or quench inﬂammation/cigarette smoke-derived oxidants
and aldehydes. Refer to Rahman andMacNee (2012) for an in-depth analysis of these var-
ious compounds.
Antioxidant compounds Examples
Thiol compounds N-acetyl-L-cysteine (NAC)
Glutathione esters
Fudosteine
Thioredoxin
Inducers of glutathione biosynthesis
Nrf2 activators CDDO-imidazolide
Sulforaphane
NOX, SOD, Gpx
Mimetics Salen compounds
Metaloporphyrins
Ebselen
Inhibitors Apocynin
Lipid peroxidation/protein carbonylation
inhibitors/blockers
Lazaroids/tirilazad
Edaravone
Other antioxidants/enzymes and oxidant
scavengers
Nitrone spin traps
Peroxynitrite decomposition catalysts
Porphyrins
Polyphenols, natural products, and dietary
agents
Polyphenols/ﬂavonoids/natural
compounds
(Apocynin, vitamin D, vitamin E,
omega-3-fatty acid)
Source of the data: Rahman and MacNee (2012).
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it is possible to increase the reduction of H2O2 by introducing Gpx (or
catalase) mimetics. This would result in the termination of the ROS cas-
cade by increasing conversion of H2O2 to H2O and O2, and subsequently
reduced levels of •OH and decreased levels of lipid peroxides.
7.1.3.1. Current studies. There is currently a limited amount of studies
exploring the effectiveness of Gpx mimetics in COPD. When exposed to
cigarette smoke, Gpx-1 knockout mice exhibited increased BALF neutro-
phils, macrophages, proteolytic burden, whole lung IL-17A, and MIP1
mRNA compared withWTmice (Duong et al., 2010). When treated pro-
phylactically with the Gpx-1 mimetic ebselen, the cigarette smoke-
induced increases in BALFmacrophages, neutrophils, proteolytic burden,
and macrophage and neutrophil chemotactic factor gene expression
were all inhibited in both theWTandknockoutmice. In addition, ebselen
inhibited established BALF inﬂammationwhen administered therapeuti-
cally, suggesting that Gpx-1 mimetics may have therapeutic utility in
inﬂammatory lung diseases where cigarette smoke plays a role such as
COPD (Vlahos & Bozinovski, 2013). In addition, we have shown that
ebselen caused a reduction in inﬂuenza A virus-induced lung inﬂamma-
tion in mice, suggesting that targeting Gpx-1 may be of therapeutic ben-
eﬁt for AECOPD (Yatmaz et al., 2013).
Ebselen has also been shown to be protective in vivo in disease situ-
ations hallmarked by oxidative stress such as diabetes-associated
atherosclerosis and cerebral ischaemia–reperfusion injury (Wong,
Bozinovski, Hertzog, Hickey, & Crack, 2008). Additionally, ebselen has
been used in clinical trials of acute ischaemic stroke and was found to
improve the outcome of patients when administered within 24 h of
stroke (Yamaguchi et al., 1998).
7.1.4. Nuclear factor erythroid 2-related factor 2 activators
In addition to the 3 enzymes in the ROS cascade, the DNA binding
protein nuclear factor erythroid 2-related factor 2 (Nrf2) presents a po-
tential target for reducing oxidative stress in COPD (Boutten, Goven,
Artaud-Macari, Boczkowski, & Bonay, 2011). Nrf2 is found in the cyto-
plasm of many mammalian cells and is responsible for the regulation
of various antioxidants and cytoprotective genes, acting as a “master
switch” for these genes. In response to oxidative stress, Nrf2 translocates
to the nucleus and binds to the antioxidant response element (ARE) of
target genes, along with other binding factors and cofactors, resulting
in the induction of stress response genes (Rahman, 2012). COPD patients
have decreased levels of Nrf2 in the lungs, and may be linked to the re-
duced antioxidant capacity observed in patients (Nguyen, Nioi, &
Pickett, 2009). In addition, Nrf2 may also help improve the clearance of
bacteria by alveolar macrophages, which is particularly relevant to the
prevention and treatment of AECOPD (Harvey et al., 2011).
7.1.4.1. Current studies. It is known that Nrf2 signalling is impaired in
several chronic diseases, including COPD, cancer, and neurodegenera-
tive diseases (Boutten et al., 2011; Bauer, Hill, & Alexander, 2013). The
levels of Nrf2 protein are decreased in lungs of patients with COPD
and one study found that Nrf2-dependent antioxidants was negatively
associated with severity of COPD, suggesting that therapy directed to-
wards enhancing Nrf2-regulated antioxidants may be a novel strategy
for attenuating the effects of oxidative stress in the pathogenesis of
COPD (Malhotra et al., 2008). Studies have shown increased susceptibil-
ity of Nrf2 knockoutmice to CS- or elastase-induced pulmonary emphy-
sema (Rangasamy et al., 2004; Iizuka et al., 2005; Ishii et al., 2005).
ComparedwithWT littermates, theNrf2 knockouts exhibitedmore pro-
nounced inﬂammation and neutrophilic elastase activity in the BALF,
enhanced alveolar expression of oxidative stress markers, increased
numbers of apoptotic endothelial and alveolar type II epithelial cells,
and decreased antioxidant and antiprotease gene expression in alveolar
macrophages. Nrf2 deﬁciency also results in impaired alveolar type II
cell growth and enhanced sensitivity to oxidants, thereby contributing
to abnormal lung injury and repair (Boutten et al., 2011). Treatment
with the Nrf2 activator CDDO-imidazolide was found to attenuate
cigarette smoke-induced emphysema and cardiac dysfunction in mice
(Sussan et al., 2009). Nrf2 appears to protect against pulmonary
hyperoxia/bleomycin injury and ovalbumin challenge in mice, presum-
ably by upregulating the transcription of lung antioxidant defence en-
zymes. It was also found that treatment with Nrf2 activators may be
able to restore glucocorticosteroid sensitivity in COPD patients
(Malhotra et al., 2011). A clinical trial of theNrf2 activators sulforaphane
is currently in progress in patients with COPD (Barnes, 2013).
Activation of Nrf2 has also been observed to have anticancer effects.
Several studies have found that Nrf2-activating compounds can prevent
or suppress cancer in mouse models (Sporn & Liby, 2012).
8. Concluding remarks
COPD is amajor incurable global health burden and is the 4th largest
cause of death in the world. Exacerbations are a common occurrence in
COPD patients and contribute mainly to morbidity, death and health-
related quality of life. Comorbid diseases, in particular cardiovascular
disease and skeletal muscle wasting, are also common in COPD and po-
tentiate the morbidity of COPD, leading to increased hospitalisations,
mortality and healthcare costs. Current treatments have limited efﬁcacy
and fail to modify the factors that initiate and drive the long-term pro-
gression of COPD, its exacerbations and its co-morbidities. In addition,
no pharmacological treatment has been shown to reduce the risk of
death in COPD in prospective clinical trials. It is now evident that in-
creased oxidative stress within the local lung microenvironment is a
major driving mechanism in the pathophysiology of COPD and that it
may directly inﬂuence peripheral organ (e.g., heart, skeletal muscle,
brain, bone) behaviour in a ‘COPD-speciﬁcmanner’. Therefore, targeting
oxidant-dependentmechanisms that drive COPD and its co-morbidities
may have great therapeutic potential.
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Abstract
Echocardiography plays a major role in assessing cardiac function in animal models. We
investigated use of a modified parasternal mid right-ventricular (MRV) and right ventricle
(RV) outflow (RVOT) view, in assessing RV size and function, and the suitability of ad-
vanced 2D-strain analysis. 15 WKY rats were examined using transthoracic echocardiogra-
phy. The left heart was assessed using standard short and long axis views. For the right
ventricle a MRV and RVOT view were used to measure RV chamber and free wall area. 2D-
strain analysis was applied to both ventricles using off-line analysis. RV chamber volume
was determined by injection of 2% agarose gel, and RV free wall dissected and weighed.
Echocardiography measurement was correlated with necropsy findings. The RV mid-ven-
tricular dimension (R1) was 0.42±0.07cm and the right ventricular outflow tract dimension
(R2) was 0.34±0.06cm, chamber end-diastolic area measurements were 0.38±0.09cm2 and
0.29±0.08cm2 for MRV and RVOT views respectively. RVOT and MRV chamber area corre-
lated with gel mass. Doppler RV stroke volume was 0.32±0.08ml, cardiac output (CO) 110
±27 ml.min-1 and RV free wall contractility assessed using 2D-strain analysis was demon-
strated. We have shown that modified MRV and RVOT views can provide detailed assess-
ment of the RV in rodents, with 2D-strain analysis of the RV free wall potentially feasible.
Introduction
Animal models provide valuable insight into the pathophysiology of chronic lung disease, and
enable assessment of potential therapeutics for conditions such as chronic obstructive pulmo-
nary disease (COPD) [1–3]. Animal exposure to chronic hypoxia, monocrotaline injury or
pulmonary trunk banding, have contributed greatly to understanding the relationship between
lung injury and progressive dysfunction of the right ventricle (RV) [4]. In many studies echo-
cardiography plays a major role in assessing RV function and the efficacy of therapeutic
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Appendix 
intervention. Transthoracic views of the RV include the short-axis (SAX) mid-ventricular and
aortic RV outflow views (RVOT), and the long-axis (LAX) apical 4-chamber view. Recent
advances in ultrasound technology, including 2D speckle tracking or strain, have seen these
modalities now being applied to clinical practice [5]. However the application of 2D-Strain in
small animals is emerging, and has been recently reported for left ventricular assessment [6]. A
limitation of transthoracic imaging in small animals is the effect of anatomical artifact from
the thoracic cage or liver on image quality. Suboptimal imaging limits RV assessment with
standard views, and can prevent the application of advanced analysis including 2D-strain
imaging.
In an alternative approach, Scherrer-Crosbie et al developed a transoesophageal technique
in mice, where the right ventricular wall and chamber were evaluated in the mid-right ventric-
ular SAX view [7]. Significantly, echocardiographic findings were validated with ultrasound
flow-measurement and magnetic resonance imaging (MRI). This modified RV approach is rel-
evant to current clinical guidelines, which advocate the use of a RV-focused view over the stan-
dard four-chamber view. Optimal RV assessment occurs when imaging allows visualization of
most or entire RV free wall [8].
In this study we aim to adapt the Scherrer-Crosbie mid-right ventricular (MRV) view to
transthoracic examination in the rat, and compare RV assessment at the mid-ventricular SAX
level, with the aortic SAX view of the right ventricular outflow tract (RVOT). The rat was the
rodent of choice as it has a bigger heart than the mouse and it would therefore be easier to
measure and detect small changes in size, structure and function. The RVOT view is a valuable
window for assessing Doppler-derived RV ejection. In addition we plan to investigate whether
the modified MRV view is suitable for 2D-strain analysis.
Methods
Studies were conducted in accordance with National Health and Medical Research Council of
Australia guidelines, and approved by the University of Melbourne Animal Ethics Committee
(Ethics No. 1212675). All animals were acquired from the Animal Resource Center, Perth,
Australia.
Echocardiographic analysis of ventricular size and function
Fifteen male WKY rats (300-350g) were anesthetized with 2.5% isoflurane, spontaneously ven-
tilated and placed on a heated pad in the semi-left lateral position with upright tilt, suitable for
echocardiographic examination. Pulse rate, oxygen saturation and temperature were continu-
ously monitored. After shaving, a sequential examination of the left and right ventricles was
performed using a Vivid E9 with i13-L (6-14MHz) linear array transducer (GE Vingmed
Ultrasound AS, Horten, Norway). Each study imaged the parasternal long axis (PLAX) and
mid-papillary SAX views of the left ventricle (LV), and the modified MRV and aortic RVOT/
pulmonary artery SAX view of the RV (Fig 1). LV morphology was assessed for interventricu-
lar septal (IVS) wall and posterior wall (PW) thickness, LV internal-diastolic dimension
(LVIDD), LV internal-systolic dimension (LVISD), fractional shortening (FS), LV end-dia-
stolic chamber area (LVEDA), LV end-systolic chamber area (LVESA) and fractional area
change (FAC). RV chamber width was assessed at mid-chamber in the MRV view (R1) and
RVOT width measured in the aortic SAX view (R2). In this view the main pulmonary artery
diameter (PAf) was also measured. RV wall area was measured in both MRV and RVOT SAX
views calculated from the difference between traced epicardial and endocardial areas [7]. Right
ventricular ejection was measured in the aortic SAX view at the proximal main pulmonary
artery (PA diameter) using 2D-Doppler and the waveform analyzed for pulmonary artery
Right heart function using modified echocardiographic views
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Fig 1. Echocardiographic views used to assess cardiac function. a. Parasternal long-axis (PLAX) view
of LV (1. Interventricular septum IVS, 2 End-diastolic dimension LVIDD, 3. Posterior wall dimension PWD). b.
Mid-ventricular SAX papillary view (1. LV end-diastolic chamber area LVEDA, 2. IVS, 3. PW). c. Mid-right
ventricular (MRV) view, modified from Scherrer-Crosby[7], (1. R1 mid-chamber dimension, 2. Sub-epicardial
chamber area RVepi, 3. Sub-endocardial chamber area RVendo, 4. IVS). d. Short axis (SAX) right ventricular
outflow tract (RVOT) view (1. Main pulmonary artery diameter PAΦ, and locus for PWD measurement of
Right heart function using modified echocardiographic views
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velocity-time integral (VTI) and time to peak ejection (PAAT). Pulmonary artery systolic pres-
sure (PASP) was not assessed since analysis of tricuspid regurgitation jet was not performed.
Echocardiographic measurements in this study included:
Fractional Shortening (FS) = LVIDD-LVISD/LVIDD
Fractional Area Change (FAC) = LVEDA-LVESA/LVEDA
LV volume/Stroke volume (SV) = based on geometric truncated ellipsoid model[9]
RV Free Wall Area = Epicardial area–endocardial area
RVOT Free Wall Area = Epicardial area–endocardial area
RV ejection stroke volume RVESV = PA area. VTI. HR, where PA area is the cross-sec-
tional area of the main pulmonary artery, VTI is the area beneath the PA pulsed-wave velocity
waveform or velocity-time integral and HR is heart rate.
Strain analysis
Real-time imaging loops of ventricular motion during the cardiac cycle were recorded for off-
line analysis. The RV was imaged in the adapted MRV view and the LV in the mid-ventricular
SAX view. High frame rates necessitated manual tracing of epicardial and endocardial walls
for 2D-strain analysis (Echopac, version 2011, GE Healthcare). Segmental and global wall
motion was then analyzed.
Injection of agarose gel and tissue collection
Animals were euthanized using inspiratory CO2, the heart immediately excised and injected
with KCl. To correlate RV chamber size and wall thickness with echocardiographic measure-
ment agarose gel (2%, ScientifiX, Australia) was injected (using a 1ml syringe and 21G needle)
into the RV chamber (the needle was inserted into the RV where the RV meets the apex of the
heart and the gel expelled into the RV until the RV was completed saturated to the point of
expansion and gel spill over outside of the heart. This occurred in 100% of animals) and left to
fix at room temperature. The gel was suspended in Hank’s Balanced Salt Solution 40 mM
HEPES (sHBSS). Following injection (at 10 min) the RV wall was excised from the heart,
exposing the hardened agarose gel mould of the RV chamber (Fig 2). The RV free wall was
then freely dissected away from the septal wall and atrio-ventricular valves. Both the agarose
gel mould and RV free wall were weighed.
Statistics and analysis
Data are expressed mean ± standard deviation (SD). Linear regression was used for correlation
between echocardiographic findings and agarose gel mass, and RV wall mass at necropsy.
P<0.05 was taken as significant (Graphpad Prism version 6 was used).
Results
Echocardiography was performed in 15 animals, and autopsy performed in 14 due to poor
image quality in one animal. Animals were of similar age with mean body weight 332 ± 22 g,
and heart rate 347 ± 23 bpm. Cardiac measurement of ventricular chamber size and function
were within the normal range for our laboratory, and consistent with previous reports [10].
Left ventricle: LVIDD and LVISD were 0.72± 0.09 and 0.37± 0.07cm respectively, and
using the hemisphere-cylinder model equation [9], end-diastolic chamber volume was
ejection velocity time integral VTI 2. RVOT dimension R2, 3. Sub-epicardial RVOT chamber area RVOTepi, 4.
Sub-endocardial RVOT chamber area RVOTendo).
https://doi.org/10.1371/journal.pone.0187345.g001
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estimated as 0.39 ± 0.08cm3. Fractional shortening was 48.25± 8.90%, FACmeasured as 72%,
and calculated stroke volume 0.20 ± 0.05 ml, indicating normal systolic function.
Right ventricle: due to the geometrical shape of the RV, the MRV view imaged a larger pro-
portion of the RV chamber than the outflow RVOT view. The MRV chamber dimension (R1)
was 0.42± 0.07cm, the RVOT dimension (R2) was 0.34± 0.06cm, and chamber end-diastolic
area measurements were 0.38± 0.09 cm2 and 0.29± 0.08cm2 for MRV and RVOT views
respectively.
Fig 2. Example of an agarose gel mold of the right ventricle. The molds were extracted following injection and solidification of
agarose within the RV chamber.
https://doi.org/10.1371/journal.pone.0187345.g002
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Correlation with necropsy: RV chamber dimension R1 and R2 had no correlation (p = 0.41
and 0.73 respectively), whereas RVOT and MRV chamber area did correlate with gel mass
(p = 0.002 and 0.03 respectively, Fig 3). Echocardiographic RV wall area, 0.08±0.02 and 0.07
±0.01 cm2 for MRV and RVOT views respectively, corresponded to a total RV free wall mass
of 0.19±0.04g at necropsy. There was no correlation between wall mass and RV wall area in
either view, R 0.004 and 0.009, p = 0.84 and 0.77 respectively (Fig 3).
Right Ventricular Ejection. The average RVESV was 0.32±0.08 ml, with estimated RV CO
110 ± 27 ml/min. These values were consistent with cardiac output ranges measured via echo-
cardiography in existing literature [11]. Cardiac output was higher with direct Doppler mea-
surement of RV ejection compared to calculated cardiac output based on LV geometrical
change (110 ± 27 ml/min and 70.63 ± 17.29ml/min respectively). Other indices of LV ejection,
FAC (72.61 ± 7.92%) and FS (48.25 ± 8.90%), were consistent in measurement (Fig 4).
2D-Strain analysis. Strain analysis was performed in both ventricles. Strain analysis of left
ventricular contraction was applied in the SAX view and RV analysis applied in the MRV view
(Fig 5). In many rats poor endocardial border definition of the RV limited strain analysis;
Fig 3. Correlation of RV chamber dimensions with gel mass from necropsy findings. The gel mass was 0.18 ± 0.10g,
the RVOT dimension (R2) was 0.34 ± 0.06cm and the mid-ventricular dimension (R1) was 0.42 ± 0.07cm for SC and RVOT
views respectively. Neither RVOT nor MRV dimensions correlated with agarose gel mass (R = 0.098, P = 0.41 and
R = 0.018, P = 0.73). The chamber area was 0.29 ± 0.08 cm2 and 0.38 ± 0.09 cm2. Both RVOT and MRV chamber areas
correlated with gel mass (R = 0.72, P = 0.02 and R = 0.78, P = 0.03). The RV wall mass was 0.19 ± 0.04g, and the wall area
was 0.069 ± 0.017cm2 and 0.084 ± 0.017cm2 for RVOT and MRV views respectively. Neither RVOT nor SC wall area
correlated with RV wall mass (R = 0.004, P = 0.84 and R = 0.009, P = 0.77).
https://doi.org/10.1371/journal.pone.0187345.g003
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however, as Fig 5 demonstrates, segmental wall motion analysis was possible in the modified
MRV view.
Discussion
This study has shown echocardiographic measurement of RV chamber area to correlate with
RV chamber gel volume in both MRV and RVOT views. Chamber width dimension or RV
wall area however, did not correlate with gel volume or wall mass at necroscopy in these nor-
mal animals. In pathological states of RV dilatation or hypertrophy, it is possible that correla-
tion with echocardiographic measurement may become evident, as changes in dimension and
area are more pronounced. The study has also demonstrated the MRV view to be suitable for
strain analysis, since a large area of the RV free wall is easily visualized. Examination with the
RVOT view provides further valuable imaging of the RV infundibulum and proximal pulmo-
nary artery, and enables measurement of RV stroke volume using pulsed-wave Doppler. Our
data showed stroke volume to be greater (and likely more accurate) with RVOT Doppler mea-
surement, compared to LV measurement based on geometric estimation alone. Further the
RVOT view enables analysis of the pulmonary spectral velocity waveform, with measurement
of the pulmonary artery acceleration time (PAAT), an index of elevated pulmonary arterial
pressure in rodent models [12]. Both views are complimentary, and together, provide a
focused but comprehensive assessment of right ventricular structure and function. A focus of
this study was to identify a practical approach to RV assessment, particularly when transtho-
racic imaging is limited in small animals.
Current clinical guidelines advise the use of multiple echocardiographic views, for compre-
hensive assessment of right ventricular function [8]. This relates to the complex RV anatomy,
involving a pyramidal-shaped chamber, with inlet and outlet portions communicating to the
right atrium and main pulmonary artery. Unlike the left ventricle, the right ventricular wall
comprises myofibrils predominantly oriented in a longitudinal direction, with circumferential
myofibrils present only in the thinner subepicardium [13]. Consequently RV contraction is
effectively longitudinal with ejection propagating from apex towards outflow tract, and
Fig 4. Ventricular function. Ejection indices of cardiac output (RV CO and LV CO), left-ventricular fractional
area change (LV FAC) and Fractional shortening (LV FS).
https://doi.org/10.1371/journal.pone.0187345.g004
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Fig 5. 2D-Strain measurement of ventricular contraction. a. Mid-papillary SAX view of left ventricle with segmental wall
analysis. b. Similar measurement of right ventricular free wall contraction in MRV view. A rapid HR necessitated manual
gating of aortic valve opening and closure (AVC) for segmental deformation measurement during the cardiac cycle.
https://doi.org/10.1371/journal.pone.0187345.g005
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rotational deformation being only a minor component of RV contraction [14]. During RV
contraction, ventricular length shortens and the base is translocated towards the apex. Analysis
of this dynamic ventricular movement is used to assess both contractile function and diastolic
relaxation. During systole the tricuspid annular plane descends towards the apex, which itself
remains relatively stationary [15]. Tricuspid annular plane systolic excursion (TAPSE) pro-
vides an approximation of RV longitudinal contractility, and can be measured using M-mode
or with pulse-wave tissue Doppler imaging (S, E’ and A’ waveforms). With this approach Linq-
vist at al reported RVOT fractional shortening (RVOTFS) to correlate with both RV longitudi-
nal function as measured by TAPSE, and pulmonary arterial pressure [16]. TAPSE, however,
was not performed in this study since this it is appropriately measured using the more
expanded apical 4-chamber view.
2D-strain is a further analysis of cardiac motion based on the tracking of “speckle” move-
ment within the myocardial wall during the cardiac cycle. Naturally occurring bright speckles
within the myocardium act as acoustic markers for tracking, and are generated by backscatter
signal during ultrasound examination [15]. Analysis is offline and based on commercial soft-
ware algorithms. Strain (ε) is calculated from the relation L—Lo / Lo, where L is the final length
and Lo the initial length of a myocardial wall speckle. Strain measures vector movement in
relation to myofibril architecture: deformation is negative with longitudinal and circumferen-
tial strain, and positive for radial strain relating to wall thickening. Strain rate is the velocity of
deformation, or ε/time between frames.
The value of LV global longitudinal strain (GLS) is evident in clinical studies, where strain
deformation has an earlier prognostic value than ejection fraction, particularly in predicting
major adverse cardiac events [17]. Strain analysis of the RV is similarly reported to identify
early changes in RV function before maladaptive remodelling becomes evident. In patients
with pulmonary hypertension for example, longitudinal strain is segmentally decreased despite
normal global RV function [18]. With respect to animal models the application of 2D-strain is
emerging, particularly in the assessment of left ventricular function [6, 19, 20]. However, the
application of RV strain to animal models is not previously reported, but as with clinical stud-
ies, has major potential in characterizing RV function. This study has demonstrated 2D-strain
analysis of the rodent RV is feasible. However, we are aware that limitations do exist. Firstly,
strain analysis was suboptimal in many animals due to poor endocardial border definition and
may be specific to our current ultrasound technology. Secondly, the MRV represents a “hybrid
SAX” view with measurement of circumferential, radial (or longitudinal) wall deformation
components being dependant on RV myofibril orientation, relative to the ultrasound beam.
Further investigation of strain analysis using the MRV view is required to define normal values
in rodents.
The use of animal models of disease has direct translational value in assessing the efficacy of
potential therapeutic agents [3]. In COPD, for example, it is recognized that 40% of deaths in
COPD result directly from associated cardiovascular disease and particularly from right heart
(RH) dysfunction [21–24]. In many patients, mild to moderate pulmonary hypertension (PH)
is common [25], with mean pulmonary arterial pressure (mPAP) between 25 and 30 mmHg
[26]. The adaptive response of the right ventricle to increased pulmonary pressure includes
chamber dilatation, wall hypertrophy and systolic dysfunction [27]. The presence of PH in
COPD is associated with a poor prognosis and reduces survival [28]. In this respect assessment
of right ventricular function using 2D-echocardiography remains an important aspect of clini-
cal management [29].
A limitation to this study was the variation in image quality between animals. Technical
accuracy is dependent on anatomical recognition and orientation, which ensures standardiza-
tion of echocardiographic views. Incomplete or oblique views, poor definition of endocardial
Right heart function using modified echocardiographic views
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or epicardial borders, as well as Doppler mal-alignment, are all potential sources of error. Our
experience indicates incomplete imaging to occur in only 1 of the 15 animals. However strain
analysis was particularly affected by poor border definition and high frame rates, and pre-
vented analysis in many animals. With respect to gel injection and RV wall dissection at
autopsy, a potential error was the failure to index measurements to animal body surface area.
A further limitation in methodology is that CO was not validated with ultrasound measure-
ment of PA flow. However our values were consistent with reported values. Transthoracic
examination was well tolerated, with hemodynamic stability throughout anesthesia.
In summary, we have demonstrated that examination using the MRV and RVOT views has
the potential to provide a comprehensive assessment of the RV particularly when standard 4C
or 2C apical views are often suboptimal. These views enable a large section of the RV free wall
to be imaged, enabling assessment of dilatation, wall hypertrophy and strain analysis. Further
examination of the RVOT allows RV morphology, and contractile function to be serially
assessed. In rodents 2D-strain imaging of the RV is feasible, and with appropriate study design
has the potential to identify early systolic dysfunction.
Supporting information
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2.     PROJECT SUMMARY
BACKGROUND, AIMS AND OUTLINE
2.1 Provide a brief discussion of the background of the project and describe the progress of the project to
date.
Chronic obstructive pulmonary disease (COPD) is a lung disease that afflicts millions of people worldwide and 
there is currently no effective therapy to treat people with this debilitating disease. Patients with COPD are also 
prone to respiratory infections (commonly called acute exacerbations of COPD - AECOPD) that cause an 
accelerated decline in lung function, hospitalisation and even death. These respiratory infections consist of 
bacteria and viruses that get into the lungs of people with COPD. People with COPD find it extremely difficult to 
fight off these respiratory infections. We have developed mouse models of COPD that replicate the features of 
human disease (AEEC #s 02084, 02085, 05097, 05107, 06199, 0810912). These models involve exposing mice 
to low concentrations of the bacterial wall component lipopolysaccharide (LPS) shown to be involved in 
exacerbations of COPD (to replicate the features of acute lung inflammation), low concentrations of cigarette 
smoke (to replicate the features of human COPD) and a mouse-adapted version of the influenza virus which is 
involved in acute exacerbations of human COPD (to replicate the features of acute exacerbations of COPD). 
Thus, we will be using three models to mimic acute lung inflammation (LPS), COPD (cigarette smoke) and acute 
exacerbations of COPD (Influenza). We have shown that LPS, low concentrations of cigarette smoke and 
Influenza cause inflammatory cells to enter the lungs. The influx of inflammatory cells and other cell types in the 
lungs release growth factors which cause even more inflammatory cells to enter the lungs leading to mucus 
secretion and blockage of the airways. In addition, we have discovered that these inflammatory cells release 
substances (called proteases) that cause irreversible destruction of the lungs.
2.2 State the aims of the project.
The aim of this project is to use the mouse models of lung inflammation, COPD and AECOPD to determine the 
processes responsible for the development of COPD and thus develop novel therapies to treat COPD. In 
particular, we will block the production and actions of various mediators we believe contribute to the development 
of acute lung inflammation, COPD and acute exacerbations of COPD, discovered from our previous work. This 
will be achieved using possible therapeutic agents dosed via one of the following routes: oral gavage, 
intraperitoneal injection, intravenous injection or intranasal administration to block the actions of previously 
identified mediators of the disease process. The role of certain proteins identified by our previous work as having 
a role in the development of disease will be assessed by using neutralising antibodies, compounds which inhibit 
the production of factors (siRNAs) and small molecular weight compounds which inhibit the actions of factors 
produced in excess by the inflammatory cells in response to LPS, cigarette smoke and Influenza. The role of 
certain genes identified by our previous work as having a role in the development of disease will be assessed 
using mice that lack these genes. Identifying and treating the cause of COPD, and its exacerbations, will lead to a
reduction in the severity of COPD.
2.3 Briefly outline what will happen to the animals to be used in the amended protocols. It is important to
note that this section is a summary only. Expanded detail of procedures on animals is required in the
Project Description.
To date we have developed mouse models of COPD and AECOPD (AEEC # 02084, 02085, 05097, 05107, 
06199, 0810912). We have shown that these models replicate the relevant aspects of human COPD. Specifically, 
LPS, cigarette smoke and Influenza cause inflammatory cells (macrophages, neutrophils, lymphocytes) to enter 
the lungs, an increase in various factors (cytokines and chemokines) being released from cells in the lung which 
attract even more inflammatory cells to enter the lungs, an increase in lung destroying substances (proteases), an
increase in cells which secrete (goblet cells), muscle wasting and emphysema (destruction of lung tissue). We 
now wish to further explore the role of molecules and/or signal transduction pathways involved in the development
of COPD and AECOPD.
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Experiment 1: Acute lung inflammation will be induced in some mice by intranasal exposure to LPS. The 
inflammation will cause an influx of inflammatory cells to the lung over a period between 3-72 hours. Mice will be 
administered with agents during the experiment within the timeframe of -24 and 72 hours of the experiment and 
killed at 3, 24 or 72 hours. The role of certain genes identified by our previous work as having a role in the 
development of acute lung inflammation will be assessed using mice that lack these genes. Thus, gene deficient 
mice will be treated with LPS intranasally and killed at 3, 24 or 72 hours.
Experiment 2: COPD will be induced in another set of mice by inhalation of low concentrations of cigarette smoke 
for a period of between 1 and 185 days simulating COPD. Briefly, mice will be placed in an 18 litre Perspex 
chamber where cigarette smoke will be forced into as in previous AEC application (#02085, 05097, 0810912). 
Mice will be administered with agents during the experiment at various times between days -7 and 185. 
Gene-deficient mice will also be exposed to cigarette smoke for a period of between 1 and 185 days, but will not 
be treated with any agents. Mice will then be killed and the lungs evaluated for inflammation and emphysema.
Experiment 3: COPD-like exacerbations will be induced in a set of smoke-exposed mice (as described in 
Experiment 2) followed by infection with Influenza (smoke and influenza virus will not run concurrently). The viral 
infection will not exceed 10 days post cigarette smoke exposure as we know from past experience that the 
infection has resolved by 10 days post infection. Drug administration will occur between days -7 and 185. Mice will
then be killed and the lungs evaluated for inflammation and emphysema. Gene-deficient mice will not be used in 
these experiments.
Previous experiments have shown that there is minimal observable discomfort to the animal with these 
procedures and there are no complications associated with the procedures (AEEC #s 00176, 02084, 02085, 
05097, 05107, 06199, 0810912). However, in the event the animals show signs of distress they will be euthanized
by an overdose of anaesthetic (see attached Intervention Criteria Sheet).
Mice will be treated with one of the following agents which block the actions of specific molecules; 
immuno-modulatory test agents, antibodies or small molecular weight compounds that block the actions of 
specific molecules to determine if the severity of the disease can be reduced. The routes of administration include
intraperitoneal injection, intravenous injection, subcutaneous injection and intranasal administration. At the 
conclusion of the experimental protocol, the animals will be killed by an overdose of anaesthetic. The lungs will be
washed (bronchoalveolar lavage) for total cell number and then removed and examined for inflammatory 
changes. Biochemical indices of inflammation will also be measured in fluid obtained from the lungs. In addition, 
gene deficient mice will be exposed to LPS and cigarette smoke and the inflammatory response (or lack thereof) 
monitored.
JUSTIFICATION FOR THE USE OF ANIMALS
2.4 Explain the significance and the potential benefit of the proposed project.
The studies outlined in this proposal will contribute significantly to our understanding of the mechanisms 
underlying COPD and exacerbations of COPD (a sudden worsening of the condition usually in response to lung 
infections such as bacteria (LPS) or virus (Influenza).  The potential benefit of the proposed project is that it may 
identify therapeutic targets to treat people with this debilitating disease.
2.5 Will the degree of pain or distress experienced by animals be the same as outlined in the original project.
The potential impact to animals will be mild.  We have previously shown that treatment with LPS or exposure to 
low doses of cigarette smoke and influenza cause mild lung inflammation and minimal distress to the animal. This
study induces a mild lung inflammation that, in general, correlates with GOLD standard 1, which is the lowest 
level of the four levels of disease severity of COPD. Based on our extensive previous experience, these mice do 
not show behavioral or neurological levels of distress (Chen, H, Am. J. Respir. Crit. Care Med., 2006) and mice 
that have been exposed to cigarette smoke for up to 6 months in one study (Hansen et al Proceedings of 
American Thoracic Society, 2005) do not show excessive weight loss or loss of appetite, and do not show signs of
distress or display avoidance behavior. If anything, mice smoked for longer periods of time appear calm and quiet 
during the smoke exposure and return to normal eating/drinking behavior immediately after exposure. A 
monitoring checklist (see attachment), will be used to ensure comprehensive and regular monitoring of the 
animals, and any animals that show signs of distress (as outlined in the monitoring and intervention checklists) 
will be euthanized immediately by an overdose of anesthetic. At the conclusion of the experiments animals will be 
killed by an overdose of anesthetic.  Our staff is highly experienced in these procedures.
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2.6 Does this project duplicate work that has been carried out previously? If so, please explain why it is
necessary to duplicate the work.
No
2.7 Have any of the animals been the subject of a previous research or teaching activity? If yes, provide AEC
Register Number/s of the other project/s, describe what was done to the animals previously, and justify
their use in this project.
No
REPLACEMENT
3.     ALTERNATIVES
3.1 Have alternatives that totally or partially replace the use of animals been incorporated into this project? If
no, identify potential alternatives and explain why they are unsuitable for use in this project. If yes,
please describe what alternatives are to be used in this project.
No - The complex inflammation that triggers COPD reactions cannot be modeled using computers, nor can cell 
culture techniques address questions involving integrated pathophysiology.  The experiments proposed in this 
application cannot be ethically performed in humans.  The genes and proteins that regulate inflammation in the 
mouse are highly conserved in humans making the findings we obtain directly relevant to understanding human 
disease.  Other members of the laboratory (Drs Steven Bozinovski and Rosa Gualano) have cell culture systems 
where certain cells known to be involved in COPD (eg epithelial and macrophages) are exposed to cigarette 
smoke extract.  These studies have provided us with valuable information but are limited as they cannot replicate 
in vivo biology and only deals with the water-soluble components of cigarette smoke.  Please note that we have 
designed our experiments so as to limit the number of animals used whilst obtaining maximum information.
REDUCTION
4.     ANIMALS REQUESTED
APPROVED NUMBER  OF ANIMALS
Type/Species Breed/Strain Sex Age Total 
Number
Source
 Mouse BALB/c M/F 7 weeks 2268 Other - Animal Resources Centre 
- Western Australia  
 Mouse (Genetically 
Modified)
uPA deficient M/F 7 weeks 240 RMH Medicine Animal Facility  
 Mouse (Genetically 
Modified)
tPA deficient M/F 7 weeks 240 RMH Medicine Animal Facility  
 Mouse (Genetically 
Modified)
Gpx-1 deficient M/F 7 weeks 240 Biological Research Facility  
 Mouse (Genetically 
Modified)
IL-23 deficient M/F 7 weeks 240 Other - Ludwig Institute For 
Cancer Research  
 Mouse (Genetically 
Modified)
MyD88 deficient M/F 7 weeks 240 Bio21 Institute Animal Facility  
 Mouse (Genetically 
Modified)
NOX-4 deficient M/F 7 weeks 240 Other - Monash University  
 Mouse (Genetically 
Modified)
NOX-1 deficient M/F 7 weeks 240 Other - Monash University  
 Mouse (Genetically 
Modified)
IL-17 deficient M/F 7 weeks 240 Other - Monash Institute of 
Medical Research  
 Mouse (Genetically NOX-2 deficient M/F 7 weeks 240 Other - Monash University  
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Type/Species Breed/Strain Sex Age Total 
Number
Source
Modified)
AMENDED NUMBER OF ANIMALS REQUESTED 
Type/Species Breed/Strain Sex Age Total 
Number
Source
 Mouse BALB/c M/F 7 weeks 2268 Other - Animal Resources Centre 
- Western Australia  
 Mouse (Genetically 
Modified)
uPA deficient M/F 7 weeks 240 RMH Medicine Animal Facility  
 Mouse (Genetically 
Modified)
tPA deficient M/F 7 weeks 240 RMH Medicine Animal Facility  
 Mouse (Genetically 
Modified)
Gpx-1 deficient M/F 7 weeks 240 Biological Research Facility  
 Mouse (Genetically 
Modified)
IL-23 deficient M/F 7 weeks 240 Other - Ludwig Institute For 
Cancer Research  
 Mouse (Genetically 
Modified)
MyD88 deficient M/F 7 weeks 240 Bio21 Institute Animal Facility  
 Mouse (Genetically 
Modified)
NOX-4 deficient M/F 7 weeks 240 Other - Monash University  
 Mouse (Genetically 
Modified)
NOX-1 deficient M/F 7 weeks 240 Other - Monash University  
 Mouse (Genetically 
Modified)
IL-17 deficient M/F 7 weeks 240 Other - Monash Institute of 
Medical Research  
 Mouse (Genetically 
Modified)
NOX-2 deficient M/F 7 weeks 240 Other - Monash University  
NOTE: refer to section 6.2 for details of genetically modified and/or cloned animals
5.     JUSTIFICATION FOR NUMBER OF ANIMALS REQUESTED
5.1 Provide an explanation for the number of animals being requested. This explanation should be based on
statistical analysis and/or other considerations in the experimental design (e.g., multiple time points,
quantity of tissue required). Where appropriate, present the numbers in table form.
The group size of 12 per group (8 [biochemistry] + 4 [histology]) has been based on power calculations to ensure 
a maximum likelihood of detecting real differences in parameters between control and treated mice based on 
historical variances in our laboratory for similar protocols (AEEC # 02084, 02085, 05097, 05107, 06199, 
0810912).  The experiments have been designed to extract the maximum information from as few mice as 
possible.  While the animal numbers listed in the attached document (Animals Requested_AEC#1112185.doc) 
seem large, each experiment has been designed to produce definitive outcomes preventing possible repeats of 
experiments.
5.2 To reduce animal use, would the animals or their tissues be suitable for use in another project at the end
of your experiment/s? Identify the suitable project, if known.
No - We have designed the experiments in order to gain the maximum amount of information about the underlying
mechanisms of COPD and potential therapeutic benefits of inhibiting the mediators we have discovered from our 
previous studies to be involved in acute lung inflammation, COPD and AECOPD. Therefore most of the tissues 
from the animals will be collected for subsequent analysis. In addition, many of the animals used will have been
treated with compounds or will be from genetically-modified mice and will be unsuitable for additional 
experimentation.
REFINEMENT
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6.     USE OF ANIMALS
6.1 Justify your choice of animal (species/strain/sex/age).
The genes and proteins that regulate inflammation in the mouse are highly conserved in humans making the 
findings we obtain directly relevant to understanding human disease. In addition, gene modification technology in 
the mouse will be used in this application to extend the information gained from the microarray studies in the 
same species. Moreover, mice are commonly used for these types of experiments due to the accessibility of the
mouse genome, ready availability of commercial antibodies and other immunological reagents and the 
investigators have extensive experience in this species. Balb/c mice (7 weeks of age) were chosen for this series 
of experiments as the models being utilized in this study were developed in these mice. We also would like to 
conduct experiments on the various knockout mice as we have learned that removing the genes listed in the 
application will potentially prevent inflammation and COPD compared to the WT counterparts.
6.2 Genetic Modification or Cloning of Animals.
This project does involve the use or production of genetically modified animals. Summary details as given are 
listed at the end of this application.
This project does not involve the use or production of cloned animals.
6.3 Transport
6.3.1 Will animals need to be transported from the source location/s to the location where they will be
held for this project?
Yes - For those animals that are not bred in the BRF, they will be transported from the source location (eg
ARC, Monash Institute of Medical Research, Monash University, Ludwig Institute for Cancer Research) in 
transport boxes with sufficient access to food and water.  The animals will be weight matched into groups 
and allowed to acclimatise in their micro-isolator cages for a period of a week before experimentation 
starts.
6.3.2 Where will procedures be performed? If animals need to be transported from where they are
housed to where the procedures are carried out, provide details of transport and acclimatisation
procedures.
Cigarette smoke exposure, LPS, influenza and drug administrations will be performed in the BRF.  
Animals will then be transported to our laboratory (N804, Level 8 of the Medical Building, North Wing) in 
transport boxes via the goods and services lift.  Mice will then be killed and the lungs assessed for 
inflammation, COPD and AECOPD as described in the application.
6.4 Location & Housing
6.4.1 Where will animals be housed?
Type/Species Breed/Strain Housing
 Mouse BALB/c Biological Research Facility  
 Mouse (Genetically Modified) uPA deficient Biological Research Facility  
 Mouse (Genetically Modified) tPA deficient Biological Research Facility  
 Mouse (Genetically Modified) Gpx-1 deficient Biological Research Facility  
 Mouse (Genetically Modified) IL-23 deficient Biological Research Facility  
 Mouse (Genetically Modified) MyD88 deficient Biological Research Facility  
 Mouse (Genetically Modified) NOX-4 deficient Biological Research Facility  
 Mouse (Genetically Modified) NOX-1 deficient Biological Research Facility  
 Mouse (Genetically Modified) IL-17 deficient Biological Research Facility  
 Mouse (Genetically Modified) NOX-2 deficient Biological Research Facility  
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6.4.2 Will any animals be housed outdoors? If, contrary to the needs of the species, no shelter is
provided, justify the lack of shelter.
No
6.4.3 What type of housing will be used? Describe any special housing requirements.
Mice will be housed in sterile micro-isolator cages in order to protect our mice from infection.  These 
protect our mice from infection and while it is well established that the influenza virus strain to be used in 
this study is not contagious, it will further reduce the already remote risk of infection to other animals in the
BRF.
6.4.4 Will any animals be housed individually? If yes, explain why, for how long and how the impact of
social isolation will be minimised.
No
7.     PROJECT DESCRIPTION
Once animals are obtained from the relevant source (eg ARC) they will be acclimatised to their new location for 1 week, 
after which animals will be subjected to one intervention to produce either acute lung inflammation, COPD and AECOPD. 
These interventions include LPS (acute lung inflammation), cigarette smoke exposure alone (COPD) and cigarette smoke 
exposure + Influenza infection (AECOPD).
Mice exposed to LPS, cigarette smoke, or smoke and Influenza will be treated with agents that block the actions of 
mediators that cause inflammation. The agents to be used will depend on the mediator we wish to block and its reported 
mode of action. Our previous studies (AEEC# 00176, 02085, 05097, 05107, 06199, 0810912) have shown that the 
mediators found in increased amounts in smoke-exposed lung compared to control (sham) can be blocked by using (i) 
small molecular weight compounds, (ii) neutralising antibodies, or iii) siRNAs. These agents will inhibit the action that a 
variety of inflammatory, COPD and AECOPD associated mediators have on the initial and prolonged disease state that 
may aid in some relief in disease. Thus we should see an inhibition of cigarette smoke-, LPS-, and cigarette smoke + 
Influenza-induced inflammation and associated consequential disease factors such as weight loss and muscle wasting. 
Depending on the experimental model and property of the mediator in question agents will be administered in a variety of 
ways including oral gavage, intraperitoneal injection, subcutaneous injection, intravenous injection or intranasally.
Each individual animal will receive one form of test agent by one route of administration only. Depending on the route or 
administration each animal will not receive more than 1 oral gavage, 2 intraperitoneal injections, 1 intranasal 
administration, 1 intravenous administration or 1 subcutaneous injection in a 24 hour period. Due to the nature of the 
agents we cannot state the exact time intervals between each procedure since many of the test agents have different 
pharmacokinetic profiles (the time period that the drug works).
Oral gavage: Compounds will be administered once by oral gavage in a dose range between 0.2-200 mg/kg. Animals will 
be restrained and a gavage tube will be used to push the head slightly upward and back to straighten the oesophagus. 
The tube will be positioned to the right or left of the mouth and inserted slowly while watching for the swallowing reflex. 
The tube will pass freely into the oesophagus, without being forced. When the desired length of insertion is achieved, the 
compound solution will be injected (no needle is required, volume used will be 100-200 μl per treatment). Mice will then be
observed after the procedure for any signs of distress. 
Intraperitoneal injections will be administered to conscious mice using a 27 gauge needle on a 1 ml syringe. The volume 
of compound will be no more than 300 µl.
Subcutaneous injection: Mice will be flattened slightly against a smooth stable surface and the skin around the shoulders 
will be lightly pinched. A small volume (maximum 200µl) of drug using a 27 gauge needle will be injected just under the 
pinched skin.
Intranasal administration ensures a concentrated dose of agent directly into the lung. Mice will be lightly anaesthetized 
with the inhalation anaesthetic methoxyflurane as described below and a small amount (50 µl) of solution containing (i) 
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small molecular weight compounds or (ii) neutralising antibodies or iii) siRNAs will be applied to the nostrils once per day 
of treatment (up to 14 days).
Intravenous administration: A final group of animals will be treated via intravascular, tail vein injections. Mice will be 
restrained (without sedation), using a purpose-built mouse restrainer and a small volume (50 μl) of compound will be 
injected, using a 30 gauge needle, into the mouse tail vein, once per day of treatment (up to 14 days).
Please note that all of these procedures will only be performed by experienced investigators.
The dose of agent to be used will be obtained from the literature or provided by pharmaceutical companies and will be 
used in the range known to be safe and well tolerated by mice. In designing small molecular weight compounds, each 
company has performed detailed pharmacokinetic analyses which will allow us to use effective doses at blood and target 
tissue. Since they are developmental compounds they have undergone rigorous acute (single rising dose) and 1 week 
protocols (sub-chronic dosing). In addition we know that the drugs are very well tolerated. Some of the companies have 
also developed a range of monoclonal neutralising antibodies that are safe over wide dose ranges. Monoclonal antibodies
are used for larger molecular weight mediators where small molecular weight compounds do not work or have not been 
identified. The class and mode of action of the types of drugs to be used include: (i) chemokine receptor antagonists 
which block white blood cell recruitment to the lungs; (ii) PI3-kinase inhibitors which prevent inflammatory cell activation; 
(iii) colony stimulating factor blockers which prevent inflammatory cell signalling; (iiii) protease inhibitors which prevent the 
actions of proteases which "eat away" the lung tissue; (iv) Monoclonal antibodies will be used to neutralise the actions of 
macrophage growth factors (eg GM-CSF, G-CSF), mediators which sustain neutrophilic inflammation (IL-17, IL-23), 
mediators which cause small airways fibrosis and inflammation (eg connective tissue growth factor) and the serine 
proteases uPA and tPA which cause tissue destruction; macrophage inflammatory protein-2 (MIP-2, involved in neutrophil
recruitment), monocyte chemotactic protein-1 (MCP-1; involved in macrophage recruitment and activation) and tumour 
necrosis factor-α (TNF-α; many effects including weight loss).
Some mice will be treated with neutralising antibodies, small molecular weight compounds and siRNAs. These agents will 
inhibit the production (siRNAs) and action (small molecular weight inhibitors, neutralising antibodies) of macrophage 
growth factors and activity of kinases all of which we have found from microarray and proteomic experiments to be 
up-regulated by cigarette smoke and LPS. Thus we should see an inhibition of cigarette smoke and LPS-induced 
inflammation. These agents will be administered intranasally to ensure direct delivery into the lung.
Experiment 1: Lipopolysaccharide-induced inflammation
Lipolysaccharide (LPS) will be used to trigger mild lung inflammation. Bacteria have been shown to be involved in human 
exacerbations of COPD. LPS is a bacterial cell wall component that induces inflammation in the lung, we propose to treat 
animals with LPS following cigarette smoke exposure to model AECOPD. Mice will be lightly anaesthetized by the 
inhalation anesthetic methoxyflurane by placing them in a small plastic tub (about 0.5 litre) where around 1 ml of 
methoxyflurane is placed on a wad of cotton wool and then 5 layers of gauze are placed on top to prevent direct contact 
with the anesthetic. The mouse is put into the tub and a timer started, it takes around 2 minutes for anesthesia to develop,
as assessed by loss of the “righting reflex” when the tub is gently rocked. The mouse is treated with LPS by gently 
pipeting 50 µl of LPS (10 µg LPS, diluted in saline) onto the nostrils using a 0-200 µl pippette. Anaesthetizing the animals 
allows the experimenter to treat the animal quickly and effectively as they are immobilised and as mice are obligate nose 
breathers the saline containing LPS will be distributed uniformly throughout the lung. We have routinely used 
methoxyflurane for the last 15 years for this reason.  In addition, there are studies showing that inhaled isoflurane inhibits 
LPS-induced lung inflammation in mice (Marcias et al 2010  Inhaled Isoflurane In Mice Ameliorates LPS- and 
Ventilator-Induced Lung Injury; Reutershan et al. 2006 Protective Effects of Isoflurane Pretreatment in Endotoxin-induced 
Lung Injury) and we have recently found that inhaled isoflurane inhibits cigarette smoke-induced lung inflammation.  For 
these reasons, inhaled isoflurane cannot be used in our experiments.  Animals are then placed in a recovery box for 
approximately 5 minutes and make a full recovery. Animals will be killed by an overdose of the anaesthetic (a mixture of 
ketamine 240 mg/kg and xylazine 40 mg/kg) between 3 and 72 hours after LPS administration because we have shown 
that there is significant accumulation of macrophages (a critical cell involved in exacerbations of COPD) within these time 
points. Death will be ensured by opening of the chest cavity.  We have previously shown (AEEC #00176) that 10 μg LPS 
administered intranasally causes mild inflammation with minimal observable discomfort to the animal. However, in the 
event the animals show signs of distress (animals will be monitored daily using attached monitoring and intervention 
checklists) such as loss of body weight (more then 10% over a 24 hour period), lethargy, piloerection, hunched 
appearance, loss of appetite and loss of grooming, they will be immediately killed by an overdose (intraperitoneal 
injection) of anaesthetic (a mixture of ketamine 240 mg/kg and xylazine 40 mg/kg). Death will be ensured by opening of 
the chest cavity.  Similar experiments will also be performed in genetically modified mice to determine the importance of 
defects of certain genes in the development of COPD.
Cigarette smoke exposure protocols (4 days)
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Mice are put into an 18 litre plastic container connected to a 3-way tap where cigarette smoke will be pumped. A cigarette 
is connected to the tap (using a pipette tip) along with a 60 ml syringe, which is then used to push smoke from the lit 
cigarette into the chamber. It takes ~3 min to smoke 1 cigarette using a constant rate of 10 sec to draw up the syringe 
barrel. The box lid is left on for another 12 min and then removed for 5 min of fresh air. This is done 3 times in succession 
3 times per day, ie the maximum smoke exposure is 9 cigarettes per day over at least an 8 hour period. Assay for 
carboxyhaemoglobin in blood has shown that smoke inhalation in mice is similar to mild human smoking, and histology 
has shown that we are not causing acute lung injury. Over a 14 day smoke protocol, mice lose around 7% of their body 
weight but there is no reduction in activity and weight is rapidly regained once smoking stops. 4 days of smoke produces 
many features of COPD, including an increase in numbers of key types of white blood cells in the lung and increased lung
protease activity. Previous experiments (AEEC#s 02084, 02085, 05097, 05107, 06199, 0810912) have shown this to be 
observably painless and causing minimal observable discomfort to the animal. However, in the event the animals show 
signs of distress (animals will be monitored daily using attached monitoring and intervention checklists) such as loss of 
body weight (more than 10% over a 24 h period), lethargy, piloerection, hunched appearance, loss of appetite and loss of 
grooming, they will be immediately killed by an overdose (intraperitoneal injection) of anesthetic (a mixture of ketamine 
240 mg/kg and xylazine 40 mg/kg). A 1 ml syringe with a 27 gauge needle will be used for this injection. Death will be 
ensured by opening of the chest cavity.  Each experiment will have a matched (exposure period) sham smoked group of 
animals that will be placed in the perspex chamber but not exposed to cigarette smoke. Similar experiments will also be 
performed in genetically modified mice to determine the importance of defects of certain genes in the development of 
COPD.
Cigarette smoke exposure (6 month protocol)
Most of the smoking protocols will involve the 4 day protocol, which produces many features of COPD, but for some 
purposes we use longer term models (6 months, 5 days per week) so that the full COPD symptom profile is observed in 
the mice, including a decrease in muscle weight and damage to alveoli ie emphysema (see below). For this model we 
propose to expose mice to cigarette smoke in the same fashion as the 4 day smoke protocol, however rather than 
exposing mice to 9 cigarettes per day we propose 6 cigarettes per day as follows: It takes approximately 3 min to smoke 1
cigarette using a constant rate of 10 sec to draw up the syringe barrel. The box lid is left on for another 12 min and then 
removed for 5 min of fresh air. This is completed twice in succession 3 times per day, ie the maximum smoke exposure is 
6 cigarettes per day over at least an 8 hour period. We and others have shown that long-term smoking of mice is required 
to see damage to alveoli (the small sacs in the lung where gas exchange takes place) which is the other pathological 
feature of COPD. Data from long-term smoking protocols (6 cigarettes/day, 5d/week for 4 weeks or 6 months) show that 
mice do not lose weight but gain less weight than no-smoke control mice. Previous experiments (AEEC #02085, 0810912)
have shown this to be painless and non-noxious and there is minimal discomfort to the animal. However, in the event the 
animals show signs of distress (animals will be monitored daily using attached monitoring and intervention checklists) 
such as loss of body weight (more than 10% over a 24 hour period), lethargy, piloerection, hunched appearance, loss of 
appetite and loss of grooming, they will be immediately killed by an overdose (intraperitoneal injection) of anaesthetic (a 
mixture of ketamine 240 mg/kg and xylazine 40 mg/kg). A 1 ml syringe with a 27 gauge needle will be used for this 
injection. Death will be ensured by opening of the chest cavity. Each experiment will have a matched (exposure period) 
sham smoked group of animals that will be placed in the Perspex chamber but not exposed to cigarette smoke. Similar 
experiments will also be performed in genetically modified mice to determine the importance of defects of certain genes in
the development of COPD.
Cigarette smoke exposure and virus infection protocol
In some experiments, after exposure to 4 days of cigarette smoke exposure (same protocol as above), the 
mouse-adapted influenza A strains Mem71 (H3N1 - low pathogenicity) and HKx31 (H3N2 - intermediate pathogenicity) 
will be used to exacerbate the underlying smoke-induced inflammation. Mice are placed in a ~0.5L plastic tub where 
around 1mL of methoxyflurane is put on a wad of cotton wool and then 5 layers of gauze are placed on top, so that the 
mice does not directly contact the anesthetic (mild irritant). The mouse is then put into the tub and a timer started, it takes 
around 2 min for anesthesia to develop, as assessed by loss of the "righting reflex" when the tub is gently rocked. The 
mouse is then infected with Influenza by gently pipetting 50 μl of Influenza (Mem 71 dose is 31,000 plaque forming units 
diluted in cell culture medium; HKx31 is 1x104 plaque forming units diluted in cell culture medium) onto the nose. Infection
of influenza is allowed to replicate within the animal before peak numbers occur approximately 3-4 days after infection. 
Such influenza infection in normal mice causes mild to moderate airway inflammation but no overt disease. We have done
influenza infection of mice that were smoke exposed and while inflammation was increased in comparison to smoke alone
or virus alone mice, there was no apparent increase in observable illness (AEC# 02084, 05107, 0810912). Genetically 
modified mice will not be used in these experiments.
Animal monitoring
Mice will be monitored daily for signs of illness such as loss of body weight (more than 10% in a 24 hour period), lethargy, 
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ruffled fur, hunched appearance, panting, loss of appetite (as seen by monitoring food intake), isolation from the group 
and loss of grooming (ie criteria set out in attached monitoring and intervention checklists). Weights will be recorded daily 
in all experiments except for the 6 month smoke studies in which weights will be recorded on Monday, Wednesday, 
Friday. Mice will be observed daily during the experimental protocol to ensure that no overt lung responses, respiratory 
distress or discomfort are elicited by LPS treatment, cigarette smoke exposure to virus infection. If an adversely severe 
reaction occurred the mice would show reduced mobility, panting and piloerection - in such circumstances they would be 
immediately killed by anesthetic overdose (a mixture of ketamine 240 mg/kg and xylazine 40 mg/kg). Death will be 
ensured by opening of the chest cavity.
Euthanasia of mice
At the end of the experimental protocol, mice will be killed by an intraperitoneal anaesthetic overdose (a mixture of 
ketamine 240 mg/kg and xylazine 40 mg/kg) administered via a 27 gauge needle and subjected to the procedures 
described below. Death will be ensured by opening of the chest cavity.
Procedures after the animals have been killed:
1.  Blood samples will be taken from the inferior vena cava of each animal and analysed to determine signs of cellular 
inflammation.
2.  The diaphragm is opened, lungs lavaged (method to obtain fluid from the lungs to determine level of inflammation) with
PBS (400 µl, followed by 3 times 300 µl aliquots) via the trachea.
3. The chest cavity is opened and lungs removed and examined for inflammatory changes using (i) Cellular inflammation 
(principally lavage); (ii) RNA extraction for gene profiling using gene microarrays/QPCR and (iii) histology and 
immunohistochemistry. These procedures cannot be concurrently performed in the same animal and the experiments 
have been designed to extract the maximum information from as few mice as possible.
4. Organs such as the liver, kidney, fat pads, muscles, heart, spleen, brain and ilium will be dissected and weight to 
examine non-specific effects of test compounds.
8.     PERSONNEL
PROJECT SUPERVISOR
Name Vlahos, A/Prof Ross
Qualifications PhD, University of Melbourne, Bachelors Degree (Honours), University of Melbourne
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
more than
20
No   
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Oral gavage more than
20
No   
 Mouse Subcutaneous 
injection
more than
20
No   
 Mouse Intravenous 
administration of 
agents
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
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OTHER INVESTIGATOR
 Name Seow, Mr Huei
Qualifications Bachelors Degree (Honours), University of Melbourne, Bachelors Degree, University of Melbourne
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
more than
20
No   
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
 Name Bozinovski, A/Prof Steven
Qualifications PhD, University of Melbourne, Bachelors Degree (Honours), La Trobe University
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Mouse Expose mice to 
cigarette smoke
more than
20
No   
 Name Anthony, Dr Desiree
Qualifications Bachelors Degree (Honours), Deakin University, PhD, University of Melbourne
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Dr Ross Vlahos More than 20  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
 Name Donovan, Chantal
Qualifications Ms Chantal Donovan completed her BSc (Hons) in the Department of Pharmacology in 2011.  She
is now in the second year of her PhD in Dr Jane Bourke's laboratory. We now wish to collaborate 
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to examine the effects of cigarette smoke exposure on mouse large and small airways 
contractility.
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intranasal 
administration of 
agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Name Yatmaz, Mr Selcuk
Qualifications Bachelors Degree (Honours), University of Melbourne, Bachelors Degree, University of Melbourne
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
more than
20
No   
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Oral gavage more than
20
No   
 Mouse Subcutaneous 
injection
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
 Name Oostwoud, Ms Leanne
Qualifications Bachelor of Pharmacy (University of Groningen, Netherlands)
Leanne will now come to my lab for 6 months (2 December 2013 to 2 July 2014)  to conduct her 
master of research project as part of her studies.
Department Organisation Name not found
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intranasal 
administration of 
agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Oral gavage 0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Subcutaneous 
injection
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Anaesthesia overdose 0 Yes Mr Huei Jiunn More than 20 times  
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via intraperitoneal 
injection
Seow
 Mouse Intraperitoneal 
injection of agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Name Hansen, Dr Michelle
Qualifications PhD, University of Melbourne
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
more than
20
No   
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Name Passey, Dr Samantha
Qualifications PhD, University of Bristol, Bachelors Degree, University of Bristol
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
more than
20
No   
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
more than
20
No   
 Mouse Intranasal 
administration of 
agents
more than
20
No   
 Mouse Oral gavage 0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
more than
20
No   
 Mouse Intraperitoneal 
injection of agents
more than
20
No   
 Name Khau, Dr Thippadey
Qualifications PhD, University of Melbourne, Bachelors Degree (Honours), University of Melbourne, Bachelors 
Degree, University of Melbourne
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intranasal 
administration of 
agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Oral gavage 0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
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 Mouse Intraperitoneal 
injection of agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Name Austin, Victoria Margaret Blaire
Qualifications Bachelor of Science
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intranasal 
administration of 
agents
0 Yes Mr Huei Jiunn 
Seow
More than 2o times  
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intraperitoneal 
injection of agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Name Bernardo, Ivan
Qualifications Bachelor of Science
Department Pharmacology And Therapeutics
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intranasal 
administration of 
agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Oral gavage 0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intraperitoneal 
injection of agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Name Ngo, Mr Hoai Buu
Qualifications Bachelor of Science
Department Organisation Name not found
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Mouse Expose mice to 
cigarette smoke
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Methoxyflurane 
anaesthesia for 
intranasal treatment
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Intranasal 
administration of 
agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse Anaesthesia overdose 
via intraperitoneal 
injection
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
 Mouse (Genetically 
Modified)
Intraperitoneal 
injection of agents
0 Yes Mr Huei Jiunn 
Seow
More than 20 times  
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ANIMAL FACILITY MANAGER
 Name Kesar, Ms Marica
Qualifications Applied Diploma, Victoria College
Department School Of Biomedical Sciences
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 
9.     MONITORING
9.1 Day-to-day monitoring during the project.
Who will monitor the animals on weekdays?
A/Prof Ross Vlahos, Mr Huei Seow
Who will monitor the animals after hours (incl. Weekends and holidays)?
A/Prof Ross Vlahos, Mr Huei Seow
9.2 Day-to-day monitoring during the project: What specific signs will be monitored and how frequently?
Attach a copy of the monitoring checklist you will use to record these observations.
Once the animals arrive from the source (eg ARC) the experimental procedures will begin after one week as 
animals require sufficient time to acclimatise to their new environment. During this acclimatisation period, animals 
are monitored twice by the investigators and daily by the Biological Research Facility staff. As animals have not 
undergone any experimental procedures at this time there should be no signs of distress; however we will monitor
to determine if animals are fighting, and whether each animal looks to be in good condition.
9.3 Monitoring during and after procedures/interventions: What specific signs will be monitored and how
frequently? Attach a copy of the monitoring checklist you will use to record these observations.
During the procedures animals will be monitored daily for overt signs of distress including piloerection, decreased 
interaction with peers, loss of appetite (assessed by changes in body weight) using the attached monitoring 
checklist. In addition, body weight will be monitored every Monday, Wednesday and Friday in the 6 month studies.
9.4 What clinical, behavioural or other signs will be used to indicate that intervention is needed to alleviate an
animal's pain or suffering? What action will be taken if these indicators are reached?
Signs of distress are detailed in the attached intervention checklist and include including piloerection, decreased 
interaction with peers, loss of appetite (assessed by changes in body weight).  Determination of whether an 
animal will be euthanized based on clinical and behavioral signs will be made by an experienced investigator and 
will depend on the severity of the symptom.  Mice who display 1 or more of the "severe" signs on the attached 
Intervention Criteria Checklist or have any obvious signs of pain will be euthanized immediately with an overdose 
of anesthetic (a mixture of ketamine 240 mg/kg and xylazine 40 mg/kg) administered via a 27 gauge needle.  
Death will also be ensured by opening of the chest cavity.
9.5 Who is responsible for the management of emergencies?
A/Prof Ross Vlahos, Mr Huei Seow
10.     FATE OF ANIMALS
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10.1 What will be the maximum period of time that an individual animal or group of animals will be used in this
project?
Majority of animals will be kept for up to 2 weeks.  However, in long-term cigarette smoke exposure protocols, 
mice may be kept for up to 7 months.
10.2 What will happen to the animals at the completion of the project?
Animals will be brought down to our laboratory [N804, Level 8 of the Medical Building, North Wing] in transport 
boxes via the service lift.  Animals will then be killed by an anesthetic overdose [0.35 ml intraperitoneal, a mixture 
of ketamine [240 mg/kg] and xylazine [40 mg/kg], blood taken via the inferior vena cava, the diaphragm opened 
and the lungs lavaged and removed for further analysis.
10.3 If the animals are to be killed, how will this be done and by whom? Include information about agents,
dose rates, method and route of administration and experience of personnel.
Animals are to be killed by an anesthetic overdose [0.35 ml], a mixture of ketamine [240 mg/kg] and xylazine [40 
mg/kg] administered into the intraperitoneal cavity using a 27 gauge syringe.  Only an experienced investigator 
will be allowed to administer this agent to the animal.  Each of the investigators listed on this ethics application 
has an experience level above 20 times. Death will also be ensured by opening of the chest cavity.
10.4 What will be the method of disposal of dead animals?
Animals will be placed in black plastic bags and left in the biological hazard freezer in the BRF on the 9th floor.  
The bodies will then be disposed of by the BRF [incinerated by an approved company].
11.     ADDITIONAL DETAILS
11.1 Risk Management
11.1.1 Does the research involve procedures or agents that might pose a health risk to other animals
and/or personnel? If Yes, please explain the risk and describe what precautions will be taken.
Yes - We have developed a mouse model of influenza-induced COPD exacerbation, by infecting mice 
with the mouse-adapted Influenza A virus strains Mem71 [H3N1] and HKx31 [H3N2].  These viruses are 
of low [Mem71] and intermediate [HKx31] virulence.  Mice will be lightly anesthetized by the inhalation of 
methoxyflurane by placing them in a small plastic tub [about 0.5 litre] where around 1 ml of 
methoxyflurane is placed on a wad of cotton wool and then 5 layers of gauze are placed on top to prevent
direct contact with the anesthetic.  The mouse is put into the tub and a timer started, it takes around 2 
minutes for anesthesia to develop, as assessed by loss of the - righting reflex - when the tub is gently 
rocked.  Anesthetizing the animals allows the experimenter to treat the animal quickly and effectively as 
they are immobilized and as mice are obligate nose breathers the saline containing influenza virus will be 
distributed uniformly throughout the lung.  Animals are then placed in a recovery box for approximately 5 
minutes and make a full recovery.  The influenza viruses are not lethal at these doses of infection.  These 
viruses, whilst from human origin, has been extensively laboratory adapted so that they are no longer 
pathogenic to humans. Although it is well established that these mouse-adapted Influenza A virus strain is
not contagious, mice will be housed in sterile micro-isolator cages in order to protect our mice from 
infection and to further reduce the very remote risk of infection to other animals in the BRF.  In addition, 
the procedure will be performed in a safety cabinet and the person performing the procedure will wear a 
mask/hood which has fresh air pumped through it to protect the investigator from breathing in 
methoxyflurane.
11.1.2 Is the acquisition, holding, or use of the animals subject to any permit, law or regulation of the
State or Commonwealth (e.g., OGTR, protected native or imported)? If yes, please specify permit
numbers.
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Yes - IL-17 KO mice = PC1 - N06/08; Gpx-1 KO mice = NLRD PC1, IBC Ref 2008/058; MyD88 KO mice 
= NLRD PC1, IBC Ref # 2008/058; NOX-1, NOX-2 and NOX-4 KO mice = E89/04; tPA and uPA KO mice 
= 577/2002.  IL-23 KO mice have not yet been generated by our collaborator at the Ludwig Institute for 
Cancer Research but once they have approval I will supply the committee with the OGTR permit number.
These experiments will commence in early 2013.
11.2 Glossary of Scientific Terms
Scientific Term Lay Description
 Chronic Obstructive Pulmonary Disease 
(COPD)
A disease also known as emphysema in which there is chronic lung
inflammation and damage resulting in shortness of breath. People 
with emphysema rely on oxygen therapy in the final years of their 
life. There is no cure nor effective treatment for this disease.  
 Acute Exacerbations of Chronic 
Obstructive Pulmonary Disease (AECOPD)
People with Chronic Obstructive Pulmonary Disease often 
experience rapid declines in health often caused by lung infections. 
The rapid decline in lung function consists of high levels of lung 
inflammation, extreme shortness of breath and sometimes death.  
 Reactive Oxygen Species (ROS) Substances released from cells of the lung and white blood cells 
which cause lung inflammation and lung damage.  
 NADPH oxidase-1 (NOX-1) An enzyme responsible for the generation of Reactive Oxygen 
Species  
 NADPH oxidase-2 (NOX-2) An enzyme responsible for the generation of Reactive Oxygen 
Species  
 NADPH oxidase-4 (NOX-4) An enzyme responsible for the generation of Reactive Oxygen 
Species  
 Lipoloysachharide (LPS) A bacterial wall component which causes Acute Exacerbations of 
Chronic Obstructive Pulmonary Disease  
 Gpx-1 An enzyme that converts the toxic hydrogen peroxide to non-toxic 
water and oxygen  
 IL-17 A cytokine produced by white blood cells within the body  
 uPA A protein produced by white blood cells which breaks down blood 
clots  
 IL-23 A cytokine present in white blood cells within the body  
 tPA A protein present in white blood cells which breaks down blood 
clots  
 Cytokine Protein produced and released by individual cells for the purpose of
transmitting distinct messages to the cell  
11.3 Attachments
The following attachments should accompany this application:
Category Description Attached 
Via Themis
Hard Copy
Only
 Miscellaneous Cover letter addressing requested changes Yes No  
 Monitoring checklist 
proforma
Monitoring Checklist Yes No  
 Miscellaneous Intervention Criteria Yes No  
 Miscellaneous Animals Requested Yes No  
11.4 Funding and Contracts
11.4.1 Identify the principal source of funding for this project (internal/external/commercial or private).
External funding agency
11.4.2 Is this project Commercial in Confidence?
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No
11.4.3 Is this project covered by a research contract?
Yes
12.     GENETIC MODIFICATION OR CLONING OF ANIMALS
12.1 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) NOX-2 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.1.1 Describe the function/s of the gene/s that have been/will be modified.
The NOX-2 gene encodes for a protein that is highly expressed in professional phagocytes such as 
neutrophils and macrophages that generate large amounts of superoxide as part of their armoury of 
bactericidal mechanisms. Although NOX-2 containing oxidases intentionally generate Reactive Oxygen 
Species for functions related to innate immunity and signal transduction, we believe that NOX-2 is 
up-regulated in COPD and other lung inflammatory conditions, which is responsible for generating 
unusually higher levels of Reactive Oxygen Species that ultimately damage the lung.
12.1.2 Explain the relevance of the modification to the project.
Our microarray and proteomic studies have shown that a number of oxidative stress molecules are 
involved in the pathogenesis of Chronic Obstructive Pulmonary Disease. We believe that NADPH oxidase
(NOX), the enzyme responsible for generation of lung destroying Reactive Oxygen Species (ROS), may 
be a novel therapeutic target for COPD and Acute Exacerbations of COPD, as it is upstream of other 
anti-oxidants (eg superoxide dismutase). The NOX-2 gene gene encodes for a protein that is highly 
expressed in cells of the lung and blood (neutrophils and macrophages). We propose that mice
deficient in NOX-2 may be protected from cigarette smoke and LPS-induced lung injury because these 
mice are incapable of producing lung destroying Reactive Oxygen Species in response to LPS and 
cigarette smoke. Thus, we now wish to explore whether animals deficient in NOX-2 are protected from
cigarette smoke and LPS-induced lung inflammation.
12.1.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.1.4 What will be the fate of animals that are not of the appropriate genotype?
NOX-2 deficient mice will be sent to us by our collaborator Dr Stavros Selemidis. The genotyping of all 
animals sent to us is done by researchers at Monash University before we receive them. Thus, the 
genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
12.1.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been characterized. The animal has no behavioral, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
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12.1.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.1.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.2 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) IL-17 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.2.1 Describe the function/s of the gene/s that have been/will be modified.
Interleukin-17 (IL-17) is a cytokine produced at local sites (in particular immune cells called T cells) within 
the body.
12.2.2 Explain the relevance of the modification to the project.
The ability to alter the genome of the mouse gives the researchers an insight into the importance of the 
gene, in this case, the role of IL-17 in the effect of COPD and AECOPD.
12.2.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.2.4 What will be the fate of animals that are not of the appropriate genotype?
IL-17 deficient mice will be sent to us by our collaborator A/Prof Brendan Jenkins. The genotyping of all 
animals sent to us is done by researchers at Monash Institute for Medical Research before we receive 
them. Thus, the genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
12.2.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been characterised. The animal has no behavioural, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
IL-17 deficient mice have a normal physical appearance and breed normally. These mice only display 
impaired immune responses if subjected to certain experimental challenges (eg lung asthma models) 
(Nakae et al. 2002. Antigen-Specific T Cell Sensitization Is Impaired in IL-17-Deficient Mice, Causing 
Suppression of Allergic Cellular and Humoral Responses Immunity 17: 375-387).
12.2.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
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No
Breeding (completion of this section is required only if animals are bred in-house):
12.2.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.3 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) NOX-1 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.3.1 Describe the function/s of the gene/s that have been/will be modified.
The NADPH oxidase (NOX)-1 gene encodes for a protein that is highly expressed in epithelial cells in the 
lung and other tissues such as the colon and vasculature. NOX-1 is the major component of an enzyme 
complex that generates toxic Reactive Oxygen Species (such as superoxide) in response to invading 
pathogens and cigarette smoke. We believe that NOX-1 is up-regulated in COPD and other lung 
inflammatory conditions, which is responsible for generating Reactive Oxygen Species that damage the 
lung.
12.3.2 Explain the relevance of the modification to the project.
Our microarray and proteomic studies have shown that a number of oxidative stress molecules are 
involved in the pathogenesis of Chronic Obstructive Pulmonary Disease. We believe that NOX, the 
enzyme responsible for generation of lung destroying Reactive Oxygen Species (ROS), may be a novel
therapeutic target for COPD and Acute Exacerbations of COPD, as it is upstream of other anti-oxidants 
(eg superoxide dismutase). The NOX-1 gene encodes for a protein that is highly expressed in epithelial 
cells in the lung. We propose that mice deficient in NOX-1 may be protected from cigarette smoke and 
LPS-induced lung injury because these mice are incapable of producing lung destroying Reactive Oxygen
Species in response to LPS and cigarette smoke. Thus, we now wish to explore whether animals deficient
in NOX-1 are protected from cigarette smoke and LPS-induced lung inflammation. In all of our proposed 
experiments we will use mice at 6-8 weeks of age, an age where baseline phenotypes would unlikely 
severely impact on the well-being of the animals.
12.3.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.3.4 What will be the fate of animals that are not of the appropriate genotype?
NOX-1 deficient mice will be sent to us by our collaborator Dr Stavros Selemidis. The genotyping of all 
animals sent to us is done by researchers at Monash University before we receive them. Thus, the 
genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
12.3.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
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Yes - The phenotype of this strain of animal has been characterised. The animal has no behavioural, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
12.3.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.3.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.4 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) NOX-4 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.4.1 Describe the function/s of the gene/s that have been/will be modified.
The NOX-4 gene encodes for a protein that is highly expressed in epithelial and endothelial cells in the 
lung. NOX-4 is homologous to NOX-1 and NOX-2 and is an important component of an enzyme complex 
that generates toxic Reactive Oxygen Species such as hydrogen peroxide in those cells. Whilst NOX-4 
expression is generally low, we believe it is up-regulated in COPD and other lung inflammatory conditions 
and responsible for generating reactive oxygen species that damage the lung.
12.4.2 Explain the relevance of the modification to the project.
Our microarray and proteomic studies have shown that a number of oxidative stress molecules are 
involved in the pathogenesis of Chronic Obstructive Pulmonary Disease. We now believe that NADPH 
oxidase (NOX), the enzyme responsible for generation of lung destroying Reactive Oxygen Species 
(ROS), may be a novel therapeutic target for COPD and Acute Exacerbations of COPD, as it is upstream 
of other anti-oxidants (eg superoxide dismutase). The NOX-4 gene encodes for a protein that is highly 
expressed in epithelial and endothelial cells in the lung. We propose that mice deficient in NOX-4 may be 
protected from cigarette smoke and LPS-induced lung injury because these mice are incapable of 
producing lung destroying Reactive Oxygen Species in response to LPS and cigarette smoke. Thus, we 
now wish to explore whether animals deficient in NOX-4 are protected from cigarette smoke and 
LPS-induced lung inflammation.
12.4.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.4.4 What will be the fate of animals that are not of the appropriate genotype?
NOX-4 deficient mice will be sent to us by our collaborator Dr Stavros Selemidis. The genotyping of all 
animals sent to us is done by researchers at Monash University before we receive them. Thus, the 
genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
12.4.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
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modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been characterised. The animal has no behavioural, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
12.4.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.4.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.5 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) MyD88 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.5.1 Describe the function/s of the gene/s that have been/will be modified.
MyD88 ia an adaptor protein involved in the control of innate immunity. The Myd88 gene encodes for a 
protein that is highly expressed in various organs and cell types such as the lung and macrophages. 
MyD88 is a major component of the TLR receptor complex that coordinates the hosts defence responses 
to invading pathogens and other noxious airborne insults. We believe that MyD88 controls inflammatory 
processes in COPD and other lung inflammatory conditions, which contribute to lung tissue damage.
12.5.2 Explain the relevance of the modification to the project.
The ability to alter the genome of the mouse gives the researchers an insight into the importance of the 
gene, in this case, the role of MyD88 in the pathology or protection of COPD. Our preliminary studies 
have shown that a number of inflammatory molecules are involved in the pathogenesis of Chronic 
Obstructive Pulmonary Disease, and that these events are associated with activation of the master 
transcription factor Nuclear Factor kappa B (NFkB). However, it is not clear how NFkB-mediated 
inflammation in COPD and Acute Exacerbations of COPD (AECOPD) typically triggered by infectious 
pathogens are controlled. The TLR receptor pathway is primarily responsible for recognition of various 
airborne respiratory pathogens and other endogenous stress ligands that initiate the early host defence 
response. There are at least 11 TLR family members that utilise MyD88 as an adaptor molecule to initiate 
intracellular signalling cascades responsible for induction of various inflammatory mediators. Since 
MyD88 is a common and central adaptor for all TLR family members with the exception of TLR3, MyD88 
may be an alternative (and perhaps better) therapeutic target for COPD and AECOPD. Particularly, the 
role of TLRs in COPD and AECOPD is currently not well defined and the use of this single genetic 
modification will provide insight into the entire TLR family. By selectively targeting the MyD88 gene we 
can elucidate whether TLR signalling contributes to the inflammatory mechanisms driving COPD and 
whether targeting MyD88 would be a better therapeutic strategy. We propose that mice deficient in 
MyD88 may be protected from cigarette smoke and LPS-induced lung injury because these mice are 
incapable of producing lung destroying inflammatory mediators such as cytokines, chemokines and 
reactive oxygen species in response to LPS and cigarette smoke. Thus, we now wish to explore whether 
animals deficient in MyD88 are protected from cigarette smoke and LPS-induced lung inflammation.
12.5.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
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No
12.5.4 What will be the fate of animals that are not of the appropriate genotype?
MyD88 deficient mice will be given to us by our collaborator Dr Peter Crack. The genotyping of all animals
given to us is done by researchers at The University of Melbourne before we receive them. Thus, the 
genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
12.5.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been well characterised. The MyD88 knockout mice 
demonstrate increased apoptosis after lung injury. They also display abnormal immune physiology, 
decreased inflammatory response, abnormal response to infection and abnormal cytokine secretion. The 
animal has no reproductive and developmental features that affect its health, welfare, breeding or 
lifespan.
12.5.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.5.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.6 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) IL-23 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.6.1 Describe the function/s of the gene/s that have been/will be modified.
Interleukin-23 is a cytokine produced by immune cells within the body.
12.6.2 Explain the relevance of the modification to the project.
The ability to alter the genome of the mouse gives the researchers an insight into the importance of the 
gene, in this case, the role of IL-23 in the effect of COPD and AECOPD.
12.6.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.6.4 What will be the fate of animals that are not of the appropriate genotype?
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IL-23 deficient mice will be sent to us by our collaborator A/Prof Matthias Ernst. The genotyping of all 
animals sent to us is done by researchers at Ludwig Institute for Cancer Research before we receive 
them. Thus, the genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
12.6.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been characterised. The animal has no behavioural, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
12.6.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.6.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.7 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) Gpx-1 deficient C57BL/6
Genotype (if applicable for cloned animals):
12.7.1 Describe the function/s of the gene/s that have been/will be modified.
Glutathione peroxidase-1 (Gpx-1) is an endogenous anti-oxidant enzyme that catalyses the potentially 
toxic hydrogen peroxide to water and oxygen. The mice that lack Gpx-1 are under oxidative stress owing 
to a reduced capacity to clear hydrogen peroxide.
12.7.2 Explain the relevance of the modification to the project.
The ability to alter the genome of the mouse gives the researchers an insight into the importance of the 
gene, in this case, the role of Gpx-1 in the effect of COPD and AECOPD.
12.7.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.7.4 What will be the fate of animals that are not of the appropriate genotype?
Gpx-1 deficient mice will be given to us by our collaborator Dr Peter Crack. The genotyping of all animals 
sent to us is done by researchers at The University of Melbourne before we receive them. Thus, the 
genotype of all animals sent to us is already known by the time we receive them.
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Phenotype:
12.7.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The mice that lack Gpx-1 are under oxidative stress owing to a reduced capacity to clear hydrogen 
peroxide. It has been reported Gpx-1 deficient mice demonstrated increased inflammation and cell death 
following a cold-induced brain injury or cerebral ischemia. At 8 months of age Gpx-1 deficient mice weigh 
20 % less than wild-type controls but no differences were detected in liver, kidney or heart tissue weights 
compared to wild-type controls. Gpx-1 deficient mice have no known histopathological or developmental 
abnormality - they are healthy and fertile (longest reported study up to 15 months of age) consistent with a
limited role for gpx-1 during normal development and under physiological conditions (Ho et al, 1997; 
Cheng et al 1997; de Haan et al 1998).
12.7.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.7.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.8 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) tPA deficient C57BL/6
Genotype (if applicable for cloned animals):
12.8.1 Describe the function/s of the gene/s that have been/will be modified.
Tissue type-plasminogen activator (t-PA) is involved in fibrin breakdown. Fibrin is formed as a clot at the 
end of the coagulation pathway.
12.8.2 Explain the relevance of the modification to the project.
The ability to alter the genome of the mouse gives the researchers an insight into the importance of the 
gene, in this case, the role of tPA in the effect of COPD and AECOPD.
12.8.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.8.4 What will be the fate of animals that are not of the appropriate genotype?
tPA deficient mice will be sent to us by our collaborator Prof John Hamilton. The genotyping of all animals
sent to us is done by researchers at The University of Melbourne (Department of Medicine) before we 
receive them. Thus, the genotype of all animals sent to us is already known by the time we receive them.
Phenotype:
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12.8.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been characterised. The animal has no behavioural, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
12.8.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.8.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
12.9 Type/Species Breed/Strain Background Strain
Mouse (Genetically Modified) uPA deficient C57BL/6
Genotype (if applicable for cloned animals):
12.9.1 Describe the function/s of the gene/s that have been/will be modified.
Urokinase-plasminogen activator (u-PA) is produced by macrophages and is involved in breakdown of 
fibrin and cell migration. Fibrin is formed as a clot at the end of the coagulation pathway.
12.9.2 Explain the relevance of the modification to the project.
The ability to alter the genome of the mouse gives the researchers an insight into the importance of the 
gene, in this case, the role of uPA in the effect of COPD and AECOPD.
12.9.3 Will tissue be collected to use for genotyping? If yes, describe how and when.
No
12.9.4 What will be the fate of animals that are not of the appropriate genotype?
uPA deficient mice will be sent to us by our collaborator Prof John Hamilton. The genotyping of all 
animals sent to us is done by researchers at The University of Melbourne (Department of Medicine) 
before we receive them. Thus, the genotype of all animals sent to us is already known by the time we
receive them.
Phenotype:
12.9.5 Is the phenotype of this strain well characterized? If yes, briefly describe the known behavioural,
physiological, reproductive and developmental features of the strain and identify whether the
modification/s will affect the health, welfare, breeding or lifespan of the animals. If no, briefly
describe the potential or anticipated behavioural, physiological, reproductive and developmental
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features of the strain and identify whether the modification/s will affect the health, welfare,
breeding or lifespan of the animals.
Yes - The phenotype of this strain of animal has been characterised. The animal has no behavioural, 
physiological, reproductive and developmental features that affect its health, welfare, breeding or lifespan.
12.9.6 Does the strain require special husbandry? If yes, describe the particular requirements for care.
No
Breeding (completion of this section is required only if animals are bred in-house):
12.9.7 Describe, or attach Standard Operating Procedures that describe the breeding program (e.g.,
heterozygous, homozygous, back-crossing) that will be used to produce the genetically modified
or cloned animals to be used in the project.
13.     AUTHORISATIONS
The Research Office has verified that the following nominated personnel have signed off on this project
application online through THEMIS on the given date/s:
 Project Supervisor Vlahos, A/Prof Ross 06 March 2014  
 Investigator Hansen, Dr Michelle 07 March 2014  
 Investigator Bozinovski, A/Prof Steven 07 March 2014  
 Investigator Anthony, Dr Desiree 12 March 2014  
 Investigator Seow, Mr Huei 06 March 2014  
 Investigator Khau, Dr Thippadey 06 March 2014  
 Investigator Donovan, Chantal 06 March 2014  
 Investigator Yatmaz, Mr Selcuk 07 March 2014  
 Investigator Passey, Dr Samantha 11 March 2014  
 Investigator Austin, Victoria Margaret Blaire 12 March 2014  
 Investigator Bernardo, Ivan 12 March 2014  
 Animal Facility Manager Kesar, Ms Marica 12 March 2014  
The Project Supervisor has acknowledged that all trainers listed on this application have the relevant expertise
and that they have accepted responsibility to train their nominated researcher/s to be competent in the necessary
procedures.
7/9/2019 Correspondence Sent Message
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Correspondence Sent Message
Content
Sent Message Text
Title: Identification of novel therapeutics for Chronic Obstructive Pulmonary Disease
Ethics ID: 1112185
On behalf of the Anatomy & Neuroscience, Pathology, Pharmacology, and Physiology Animal Ethics Committee, the Chair, in
consultation with the Acting Animal Welfare Office, has approved the request for amendment relating to add new investigators Dr
Michelle Hansen, Dr Samantha Passey, Dr Thippadey Khau, Ms Victoria Austin, Mr Ivan Bernardo and Mr Hoai Buu (Bruce) Ngo to the
above, currently approved project.
You may treat this email as official notification of approval to proceed with the project as amended.
Regards,
Dr Lei Shong Lau
Animal Ethics Officer
Office for Research Ethics and Integrity
Phone: 
Email: 
Copyright (c) 2006, Oracle. All rights reserved.
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GPO Box 2476V 
Melbourne VIC 3001 
Australia 
 
Tel. +61 3 9925 2251 
Fax +61 3 9925 6599 
 
 
8 December 2015 
 
 
 
Associate Professor Ross Vlahos 
School of Health Sciences 
RMIT University 
 
 
 
 
Dear Ross, 
 
AEC 1521: Use of genetically deficient and wild-type mice for the identification of novel 
therapeutics for Chronic Obstructive Pulmonary Disease. 
 
 
I am pleased to advise that this project has been approved by the RMIT University Animal Ethics 
Committee (AEC) for the period from 8 December 2015 until 8 December 2018. An approved version of 
the application is attached.  
 
Animals 
Your application has been approved to use up to n=1848 mice (BALB/c), n=216 mice (C57BL/6 GPX-1 
knockout or wild-type), n=216 mice (C57BL/6 NOX-1 knockout or wild-type), n=216 mice (C57BL/6 
NOX-2 knockout or wild-type), n=216 mice (C57BL/6 NOX-4 knockout or wild-type), and n=216 
mice (C57BL/6 IL-17 knockout or wild-type) over the duration of the project. 
 
Please note that no genetically modified animals may be ordered, or used in this project unless 
appropriate approvals have been obtained from an Institutional Biosafety Committee. 
 
The use of animals in scientific procedures is strictly regulated by the Australian code of practice for the 
care and use of animals for scientific purposes. The above project is conducted under a Scientific 
Procedures and Premises License issued by the Bureau of Animal Welfare. 
  
Responsibilities of investigators 
1. Associate Professor Ross Vlahos 
2. Associate Professor Steven Bozinovski 
3. Dr Samantha Louise Passey 
4. Mr Huei Jiunn Seow 
5. Mr Ivan Bernardo 
6. Mr Selcuk Yatmaz 
7. Ms Victoria Austin 
8. Ms Tricia Murphy 
9. Dr Joo Lee Cham 
10. Ms Emma Colinson 
11. Ms Vikki Smyth 
 
Responsibilities of investigators are described in the Australian code of practice for the care and use of 
animals for scientific purposes (section 3). Investigators have a ‘personal responsibility for all matters 
related to the welfare of animals they use and must act in accordance with all requirements of the code. 
This responsibility begins when an animal is allocated to a project and ends with its fate at the 
completion of the project’ (s.3.1.1). 
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Amendments and extensions 
If you find reason to amend your research method you should advise the AEC and prepare a request for 
minor amendment form. Please note that the AEC may only deal with ‘minor’ amendment requests. 
Major amendments to projects normally require a new project application. 
 
Adverse events or unexpected outcomes 
As the primary investigator you have a significant responsibility to monitor the research and to take 
prompt steps to deal with any unexpected outcomes. You must notify the AEC immediately of any 
serious or unexpected adverse effects on animals, or unforeseen events, which may affect the ethical 
acceptability of your project.  
 
Unwell animals must be immediately reported via the care forms available at the RMIT Animal Facility. In 
the case of any emergency, the Animal Welfare Officer, Dr Rebbecca Wilcox, may be contacted on 0409 
521 234 at any time. In case of any unexpected animal death, the researcher has a responsibility to 
organise an autopsy so as to determine the cause of death. 
 
Investigator guidelines for record keeping 
Investigators are required to adhere to the strict guidelines regarding record keeping for their project. 
Note that records associated with a project ‘should be available for audit by the institution and authorised 
external reviewers’. Failure to maintain proper records may result in a compliance breach of the Code 
and place at risk the researcher’s capacity to carry out research with animals.  
 
Conditions of approval 
The AEC may apply conditions of approval beyond the submission of annual/final reports. Please note 
that no transgenic animals may be ordered, or used in this project unless appropriate approvals have 
been obtained from an Institutional Biosafety Committee. 
 
Reports 
Approval to continue a project is conditional on the submission of annual and final reports. Annual 
reports are requested in December each year, and must be submitted whether or not the project has 
commenced or is inactive. Report forms are available at www1.rmit.edu.au/staff/research/research-
integrity-and-governance/animal-ethics. 
 
Failure to submit reports will mean that a project is no longer approved, and/or that approval will be 
withheld from future projects. 
 
All reports or communication regarding this project are to be forwarded to the research ethics 
coordinator at animalethics@rmit.edu.au 
 
 
On behalf of the AEC I wish you well with your research. 
 
 
 
Dr Brad Hayward 
Research Ethics Coordinator 
On behalf of 
RMIT Animal Ethics Committee 
 
cc:   Ms Tricia Murphy, RAF manager 
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KEY RESPONSIBILITIES
All scientific procedures using animals must be carried out in accordance with the Prevention of Cruelty to Animals Act 1986 Act (the Act), 
associated Regulations and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (the Code).  
These legislative requirements specify that an Animal Ethics Committee (AEC) must verify that the use of animals for research or teaching is justified 
and adheres to the principles of Replacement, Reduction and Refinement. All proposed animal use must be approved by an AEC before 
commencing the project. 
Before completing this application form investigators should be familiar with the following as applicable: 
· The Australian Code of Practice for the Care and use of Animals for Scientific Purposes (the Code). 
· The Code of Practice for the Housing and Care of Laboratory mice, rats, guinea pigs and rabbits (the Housing Code) 
· Part III of the Prevention of Cruelty to Animals Act 1986 and Regulations 2008 (the Act)  
Knowledge of these legal requirements will assist you in completing this application in a satisfactory manner. The above documents can be found at 
www.dpi.vic.gov.au/animalwelfare/
NOTES ON THE COMPLETION OF THIS APPLICATION FORM
Completion Instructions  
  
This is a dynamic form designed to be completed and submitted electronically.  Please do not print this form.  Save a blank copy to your computer 
and open it with the free Adobe Reader software (version 9.0 or later).  If you do not have Adobe Reader installed, or are using an older version, you 
can download the latest free version for Mac and PC from the Adobe website.  Mac Users please note that the default program 'Preview' will not 
display this form correctly - you will need to install Adobe Reader to view and edit this form.   
Insert your answers in the boxes provided below each question. When necessary boxes will expand to accommodate the length of your answer.  A 
response is required for each question.  Write "Not applicable", if necessary.  
Applications must be written in plain English. It should be assumed that assessors have either no scientific knowledge or no knowledge of your 
area of research.  Where scientific language is unavoidable, it must be supported by a suitable lay description or a glossary of terms. It is not
appropriate to include sections from grant applications containing excessive detail of procedures unrelated to the use of animals.  It is 
highly recommended that you ask a colleague and a person with a non-scientific background to read the application before it is submitted.  
Where SOPs are available for a procedure, please refer to the SOP number and title rather than describe the procedure again. 
Submission Instructions  
Complete the form electronically, save it and attach it to an email addressed to the Secretary of the Animal Ethics Committee at animalethics@rmit.
edu.au.  Submission of applications is required by the agenda deadline for each month's Animal Ethics Committee meeting. Please see the animal 
ethics website or contract the Ethics Officer for meeting and submission deadline dates.   
To optimise and expediate the application process it is recommended that you consult with the Animal Welfare Officer on design of projects and 
completion of application forms. The Animal Welfare Officer can be contacted on: awo@rmit.edu.au or 9925 6690/0409 521 234.   
Applicants are reminded that the research may only commence upon receipt of formal written approval from the Animal Ethics Committee. Whilst 
all attempts are made to provide as timely a response as possible, please allow a minimum of 30 working days from the submission of your 
application to receipt of a first written response from the Animal Ethics Committee. Further information can be found on Animal Ethics website at: 
http://www.rmit.edu.au/staff/research/research-integrity-and-governance/animal-ethics, or contact the Ethics Officer at: animalethics@rmit.edu.au.
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APPLICATION FORM 
1.    Project Details
1.1     Project Title
The title of the project should be concise and expressed in lay language. Avoid abbreviations and scientific jargon.
Use of genetically deficient and wild-type mice for the identification of novel therapeutics for Chronic Obstructive Pulmonary 
Disease
1.2     Principal Investigator 
The Principal Investigator has ultimate legal responsibility for the welfare of all animals used
Title & Full Name A/Prof Ross Vlahos
School/Institute School of Health Sciences, Health Innovations Research Institute          Phone 57362
1.3     Duration of Project Approval
Applicants may request approval for a project for up to three (3) years, which is subject to annual review.  If the application is approved, 
you will be advised of the AEC-approved start and end dates on the formal written approval notice.
Proposed project commencement date 30/11/2015        Proposed project conclusion date 30/11/2018
1.4    Indicate the Scientific Procedures Premises/Fieldwork Licence (SPPL/SPFL)
SPPL50 - RMIT Applied Sciences SPPL365 - RMIT Health Sciences✖ SPFL40 - RMIT Life & Physical Sciences
SPPL302 - RDDT for RMIT Drug Discovery Technologies Pty Ltd SPPL49 - RMIT School of Medical Sciences
1.5    Is this project a continuation of a previously approved project?
No✖ Yes
1.6    Project Type 
Diagnosis Product Testing Production of Biological Products
Research✖ Teaching - Undergraduate/Postgraduate Training in Procedural Techniques
Other 
1.7     Use of Genetically Modified Organisms (GMO)
Does this project require approval from RMIT's Institutional Biosafety Committee (IBC)?
No Yes✖
What is the background strain C57BL/6
RMIT University Animal Ethics Committee 
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Have you provided the relevant Animal Facility Manager the 
relevant health profile of the source colony?
No✖ Yes
Briefly describe the function(s) of the gene(s) that have been or 
will be modified?
-The NADPH oxidase (NOX)-1 gene encodes for a 
protein that is highly expressed in epithelial cells in the 
lung and other tissues such as the colon and 
vasculature. NOX-1 is the major component of an 
enzyme complex that generates toxic Reactive Oxygen 
Species (such as superoxide) in response to invading 
pathogens and cigarette smoke. We believe that NOX-1 
is up-regulated in COPD and other lung inflammatory 
conditions and is responsible for generating Reactive 
Oxygen Species that damage the lung. 
 
-The NOX-2 gene encodes for a protein that is highly 
expressed in professional phagocytes such as 
neutrophils and macrophages that generate large 
amounts of superoxide as part of their armoury of 
bactericidal mechanisms. Although NOX-2 containing 
oxidases intentionally generate Reactive Oxygen 
Species for functions related to innate immunity and 
signal transduction, we believe that NOX-2 is up-
regulated in COPD and other lung inflammatory 
conditions, which is responsible for generating 
unusually high levels of Reactive Oxygen Species that 
ultimately damage the lung. 
 
-The NOX-4 gene encodes for a protein that is highly 
expressed in epithelial and endothelial cells in the lung. 
NOX-4 is homologous to NOX-1 and NOX-2 and is an 
important component of an enzyme complex that 
generates toxic Reactive Oxygen Species such as 
hydrogen peroxide in those cells. Whilst NOX-4 
expression is generally low, we believe it is up-regulated 
in COPD and other lung inflammatory conditions and 
responsible for generating reactive oxygen species that 
damage the lung. 
 
-Glutathione peroxidase-1 (Gpx-1) is an endogenous 
anti-oxidant enzyme that catalyses the potentially toxic 
hydrogen peroxide to water and oxygen. The mice that 
lack Gpx-1 have higher levels of oxidative stress owing 
to a reduced capacity to clear hydrogen peroxide. 
 
-Interleukin-17 (IL-17) is a cytokine produced at local 
sites (in particular immune cells called T cells) within the 
body.
-NOX-1: Our microarray and proteomic studies have 
shown that a number of oxidative stress molecules are 
involved in the pathogenesis of Chronic Obstructive 
Pulmonary Disease. We believe that NOX, the 
enzyme responsible for generation of lung destroying 
Reactive Oxygen Species (ROS), may be a novel 
therapeutic target for COPD and Acute Exacerbations of 
COPD, as it is upstream of other anti-oxidants 
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Explain the relevance of this genetic alteration to the project?
(eg superoxide dismutase). The NOX-1 gene encodes for 
a protein that is highly expressed in epithelial 
cells in the lung. We propose that mice deficient in 
NOX-1 may be protected from cigarette smoke-induced 
lung injury because these mice are incapable of 
producing lung destroying Reactive Oxygen Species in 
response to LPS and cigarette smoke. Thus, we now 
wish to explore whether animals deficient 
in NOX-1 are protected from cigarette smoke-induced 
lung inflammation. In all of our proposed 
experiments we will use mice at 7 weeks of age, an age 
where baseline phenotypes would unlikely 
severely impact on the well-being of the animals. 
 
-NOX-2: Our microarray and proteomic studies have 
shown that a number of oxidative stress molecules are 
involved in the pathogenesis of Chronic Obstructive 
Pulmonary Disease. We believe that NADPH oxidase 
(NOX), the enzyme responsible for generation of lung 
destroying Reactive Oxygen Species (ROS), may 
be a novel therapeutic target for COPD and Acute 
Exacerbations of COPD, as it is upstream of other 
anti-oxidants (eg superoxide dismutase). The NOX-2 
gene gene encodes for a protein that is highly 
expressed in cells of the lung and blood (neutrophils 
and macrophages). We propose that mice deficient 
in NOX-2 may be protected from cigarette smoke-
induced lung injury because these mice are 
incapable of producing lung destroying Reactive 
Oxygen Species in response to cigarette 
smoke. Thus, we now wish to explore whether animals 
deficient in NOX-2 are protected from cigarette 
smoke-induced lung inflammation. 
 
-NOX-4: Our microarray and proteomic studies have 
shown that a number of oxidative stress molecules are 
involved in the pathogenesis of COPD. We now believe 
that NADPH oxidase (NOX), the enzyme responsible for 
generation of lung destroying Reactive Oxygen Species 
(ROS), may be a novel therapeutic target for COPD, as it 
is upstream of other anti-oxidants (eg superoxide 
dismutase). The NOX-4 gene encodes for a protein that 
is highly expressed in epithelial and endothelial cells in 
the lung. We propose that mice deficient in NOX-4 may 
be protected from cigarette smoke-induced lung injury 
because these mice are incapable of producing lung 
destroying Reactive Oxygen Species in response to 
cigarette smoke. Thus, we now wish to explore whether 
animals deficient in NOX-4 are protected from cigarette 
smoke-induced lung inflammation. 
 
-Gpx-1: The ability to alter the genome of the mouse 
gives the researchers an insight into the importance of 
the gene, in this case, the role of Gpx-1 in the effect of 
COPD. 
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-IL-17: The ability to alter the genome of the mouse 
gives the researchers an insight into the importance of 
the gene, in this case, the role of IL-17 in the effect of 
COPD.
How much is known about the biological characteristics/phenotype of this strain? (Select an option) 
Well characterised✖ Partially characterised/some information available Unknown
Describe how the animal health, welfare, breeding or lifespan will 
be affected (or the potential effects) by this genetic modification?
-NOX-1: The animal has no behavioural, 
physiological, reproductive and developmental features 
that affect its health, welfare, breeding or lifespan 
(Selemidis S, Seow HJ, Broughton BR, Vinh A, Bozinovski 
S, Sobey CG, Drummond GR, Vlahos R. PLoS 
One. 2013;8(4):e60792). 
 
-NOX-2:  The animal has no behavioral, 
physiological, reproductive and developmental features 
that affect its health, welfare, breeding or lifespan 
(Vlahos et al PLoS Pathogens 2011 Feb 3;7(2):e1001271). 
 
-NOX-4: The animal has no behavioural, 
physiological, reproductive and developmental features 
that affect its health, welfare, breeding or lifespan. 
 
-Gpx-1: The mice that lack Gpx-1 are under oxidative 
stress owing to a reduced capacity to clear hydrogen 
peroxide. It has been reported Gpx-1 deficient mice 
demonstrated increased inflammation and cell death 
following a cold-induced brain injury or cerebral 
ischemia. At 8 months of age Gpx-1 deficient mice 
weigh 20 % less than wild-type controls but no 
differences were detected in liver, kidney or heart tissue 
weights compared to wild-type controls. Gpx-1 
deficient mice have no known histopathological or 
developmental abnormality - they are healthy and 
fertile (longest reported study up to 15 months of age) 
consistent with a limited role for gpx-1 during normal 
development and under physiological conditions (Ho et 
al, 1997; Cheng et al 1997; de Haan et al 1998). 
 
-IL-17: The animal has no behavioural, 
physiological, reproductive and developmental features 
that affect its health, welfare, breeding or lifespan. 
IL-17 deficient mice have a normal physical appearance 
and breed normally. These mice only display 
impaired immune responses if subjected to certain 
experimental challenges (eg lung asthma models) 
(Nakae et al. 2002. Antigen-Specific T Cell Sensitization 
Is Impaired in IL-17-Deficient Mice, Causing 
Suppression of Allergic Cellular and Humoral Responses 
Immunity 17: 375-387).
Describe the breeding program that will be used to produce the 
genetically modified animals.
Does the strain require any special husbandry? No✖ Yes
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1.8     Permits/Licences/Approvals
Are Permits Or Licences Other Than The Scientific Procedures Premises Licence (SPPL) Required (Eg. DSE Wildlife Research Permits, 
Interstate Licences)?
No✖ Yes
2.  Aims and Significance of Project (Code of Practice 2.216 [vi & xi]) 
2.1     General Background Details
Please provide a BRIEF discussion of the background of the project (e.g. is this project part of a larger research programme?) Must be in 
PLAIN ENGLISH. Avoid or DEFINE scientific terms. This section should provide AEC members, particularly external lay or welfare members 
who have no scientific background with a clear idea of the potential benefits and significance of the project.
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that afflicts millions of people worldwide with an 
annual cost of over $800 million in Australia alone. Currently there is no effective therapy to treat people with this debilitating 
disease, which is predicted to become the 3rd leading cause of death worldwide by 2020.   
 
COPD is characterised by increased lung inflammation, leading to an irreversible air flow limitation that causes coughing and 
shortness of breath. The inflammation in the lungs is caused by inhalation of irritants that damage the lungs; the primary cause 
is inhalation of cigarette smoke, either directly through smoking, or via inhalation of secondhand smoke from the air in an 
environment where other people are smoking (i.e. passive smoking). Other irritants that can contribute to COPD are air 
pollution, chemical fumes and dust particles from the environment or workplace.  
 
COPD is a progressive disease, worsening over time and causing damage to the lung structure and enlargement of the airspaces 
(emphysema). In addition to elevated inflammation and immune cells within the lungs, COPD is also associated with a high 
oxidant burden both from the oxidants contained within cigarette smoke and also from oxidative chemicals released from 
activated immune cells.  
 
As the disease progresses, patients with COPD experience a range of debilitating systemic effects including skeletal muscle 
wasting and cardiovascular dysfunction. Skeletal muscle loss (muscle wasting) is experienced by up to 40% of COPD patients 
and is a strong independent risk factor for death, severely reduces the patient's quality of life and increases disease burden and 
the incidence of hospitalisation. Increased lung and systemic inflammation and oxidative stress are thought to be contributing 
factors underlying the skeletal muscle wasting and cardiovascular pathologies seen in COPD patients. Our research aims to 
understand the mechanisms by which inflammation and oxidative stress lead to COPD, muscle wasting and other associated 
pathologies, with the goal of identifying key molecules involved in disease progression that could be targeted through novel 
therapies to help treat COPD patients.  
 
Over a period of 15 years we have developed and established mouse models of COPD that involve exposing mice to low 
concentrations of cigarette smoke (University of Melbourne AEEC #s 02084, 02085, 05097, 05107, 06199, 0810912, 1011596, 
1112185, 1312807, 1312736). We have shown that these models replicate many of the features of human disease including lung 
inflammation, emphysema (air space enlargement) and skeletal muscle wasting. Our previous work has added to the body of 
knowledge about the factors involved in CODP development and progression, and we have identified a number of genes and 
proteins that are likely involved in mediating the effects of COPD and could be potential therapeutic targets for treating this 
debilitating disease. Our current research aims to further investigate the role of oxidative stress and inflammation in COPD and 
its associated comorbidities, and to expand on our recent findings to further develop novel therapies for COPD. 
2.2     Aims
Clearly and concisely describe the aim(s) of the project (preferably in bullet points)
The aims of this project are to: 
- Further understand the role of oxidative stress and chronic inflammation in the development and pathology of COPD both 
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within the lung environment and systemically.  
- Identify genes and proteins that could be targeted therapeutically to prevent, delay or reverse the effects of COPD or its 
comorbidities (muscle wasting and cardiovascular changes) 
- Evaluate the role of genes identified in our previous studies in the pathology of COPD by assessing the effects of cigarette 
smoke exposure in mice genetically deficient in these genes. 
- Evaluate the effectiveness of existing and novel therapeutic agents (eg small molecules and neutralising antibodies) in 
reducing oxidative burden and disease severity using our mouse models of COPD.  
3.  Justification for Animal Use & the three Rs (Code of Practice 2.2.16 [xi])
3.1    Animals to be Used
Please ensure you include ALL animals used, e.g. embryos, neonates, pregnant animals and any expected by-catch in trapping 
projects.  An animal is any live, non-human vertebrate, that is, fish, amphibians, reptiles, birds, and mammals, encompassing 
domestic animals, purpose-bred animals, livestock, wildlife, and also cephalopods such as octopus and squid.  
Species 
(Genetically modified animals - provide details) 
Number of 
Animals (total) 
Source and Permit  
(if required)   
Procedures  
(insert relevant Section 4 numbers)  
Mouse - BALB/c males 1848 Animal Resource Centre - 
Western Australia
Mouse (Genetically Modified) - Gpx-1 deficient 
and Wild-Type males
216 University of Melbourne
Mouse (Genetically Modified) - NOX-1 deficient 
and Wild-Type males
216 Monash University
Mouse (Genetically Modified) - NOX-2 deficient 
and Wild-Type males
216 Monash University
Mouse (Genetically Modified) - NOX-4 deficient 
and Wild-Type males
216 Monash University
Mouse (Genetically Modified) - IL-17 deficient 
and Wild-Type males
216 Hudson Institute of Medical 
Research (formerly Monash 
Institute of Medical Research)
Add row Remove row
Total number of animals to be used for this project: 2,928
3.2     Potential Benefit(s) of the Project (Code of Practice 2.2.16 [v])
What is the potential benefit to humans or animals as per the Code of Practice 1.1 which states that “Scientific and teaching activities 
using animals may be performed only when they are essential
to obtain and establish significant information relevant to the understanding of humans;✖
to obtain and establish significant information relevant to the understanding of animals;
for maintenance and improvement of human health and welfare;✖
for maintenance and improvement of animal health and welfare;
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to obtain and establish significant information relevant to the understanding, maintenance or improvement of the natural 
environment; or
for achievement of educational objectives.”*✖
*mark this box if students are involved with the project
3.3     Referring to the Potential Benefits above, summarise the scientific/environmental and/or educational 
significance and potential benefit(s) of the project (including its relation to previous studies)
The studies outlined in this proposal will contribute significantly to our understanding of the mechanisms underlying COPD, 
with a particular focus on the roles of oxidative stress and chronic inflammation in the progression of both the lung pathology 
and systemic comorbidities (muscle wasting and cardiovascular pathology). This will allow us both to identify key molecules that 
could be targeted therapeutically, and to test the effectiveness of existing and novel pharmacological agents in treating the 
disease in our animal models. 
3.4    Replacement (Code of Practice 2.2.16 [viii])
This section requires you to justify WHY you think you need to use animals in this project.  Are there alternatives to using animals in this 
project? Replacement is defined as the substitution of insentient material for live and conscious higher-order animals.  
  
The Code specifies that techniques that totally or partially replace the use of animals for scientific purposes must be sought and used 
wherever possible. Suitable websites and databases that could be useful include:  
http://altweb.jhsph.edu/resources 
www.nal.usda.gov/awic/alternatives/alternat.htm 
3.4.1  Provide details of the search conducted to find alternatives to the use of animals for this project. Include a list 
of the websites and databases visited (and the dates visited)
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed
3.4.2   Can experiments be conducted on isolated cells, tissues and organs or non-recovery-anaesthetised animals?  
No✖ Yes
Explain why not
The complex inflammation that triggers COPD reactions cannot be modeled using computers, nor can cell culture 
techniques address questions involving integrated pathophysiology. The experiments proposed in this application cannot 
be ethically performed in humans. The genes and proteins that regulate inflammation in the mouse are highly conserved 
in humans making the findings we obtain directly relevant to understanding human disease. Other members of the 
laboratory (A/Prof Steven Bozinovski) have cell culture systems where certain cells known to be involved in COPD (eg 
epithelial and macrophages) are exposed to cigarette smoke extract. These studies have provided us with valuable 
information but are limited as they cannot replicate in vivo biology and only deals with the water-soluble components of 
cigarette smoke. We have designed our experiments so as to limit the number of animals used whilst obtaining maximum 
information.
3.5     Reduction (Code of Practice 2.2.16 [vii])
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Reduction refers to using the minimum number of animals and the most appropriate species/strain/age/sex, whilst obtaining data of 
sufficient volume, precision or statistical significance. Justification must be given for the number of animals used, ensuring that 
research/ teaching activities are not repeated unnecessarily, whilst adequate numbers of animals are used to ensure scientifically sound 
and useful data is obtained. 
3.5.1  What is the basis for selection of the species/strain/sex and age requested?
The genes and proteins that regulate inflammation in the mouse are highly conserved in humans making the findings we 
obtain directly relevant to understanding human disease. In addition, gene modification technology in the mouse will be 
used in this application to extend the information gained from the microarray studies in the same species. Moreover, mice 
are commonly used for these types of experiments due to the accessibility of the mouse genome, ready availability of 
commercial antibodies and other immunological reagents and the investigators have extensive experience in this species. 
Balb/c mice (7 weeks of age) were chosen for this series of experiments as the models being utilized in this study were 
developed in these mice. We have chosen to use male mice for this study due to the hormonal effects causing differences 
in the regulation of bodyweight and muscle mass between males and females. We also would like to conduct experiments 
on the various knockout mice as we have learned that removing the genes listed in the application will potentially prevent 
inflammation and COPD compared to the WT counterparts.
3.5.2  Justify the number of animals requested, in terms of the statistical and/or non-statistical considerations used 
in the study design 
The group size of 12 per group (8 [biochemistry] + 4 [histology]) has been based on power calculations to ensure a 
maximum likelihood of detecting real differences in parameters between control and treated mice based on historical 
variances in our laboratory for similar protocols (University of Melbourne AEEC # 02084, 02085, 05097, 05107, 06199, 
0810912, 1112185, approx. 15 years). The experiments have been designed to extract the maximum information from as 
few mice as possible. While the animal numbers listed in the attached document seem large, each experiment has been 
designed to produce definitive outcomes preventing possible repeats of experiments.
3.5.3  Has a Statistician/Biometrician been consulted about the design of this project?
No✖ Yes
Please explain why this was not considered necessary
Our laboratory has over 15 years experience in performing animal experimentation in accordance to the requirements of 
the animal ethics committee to ensure that the minimal number of mice are used without compromising the 
experimental outcomes. Also see response 3.5.2 above.
3.5.4  Repeated Studies
Does this project duplicate work that has been conducted previously?
No✖ Yes 
3.5.5  Can tissues be shared with/acquired from another project or researcher?
No Yes✖
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Please provide details
Most of the tissues in the mice will be harvested during this project due to the long-term nature of the protocol. The tissues 
will be from mice that have been treated with cigarette smoke and pharmacological agents and so may not be suitable for 
the research purposes of other researchers. However, tissues not required for our experiments will be available any 
students, or researchers who might have need for them, provided they are suitable for those needs.  
3.6     Refinement (Code of Practice 2.2.16 [vii])
Refinement refers to any techniques/modification/design specifications instituted to decrease, minimise and where possible, avoid any 
negative welfare impacts of procedures conducted on animals. 
3.6.1  How has this project been designed to refine animal welfare? Examples include provision of analgesia and project 
design to minimise number procedures conducted on individual animals.
We have chosen the lowest doses of pharmacological agents and minimised the number of doses given to each animal 
(depending on the agent) in order to achieve statistically significant effects. 
3.6.2  If this is a disease/injury model, include a description of how the model works, effects of the progression of the 
disease process and identify humane end-points and previous experience with the model 
Our cigarette smoke exposure protocols model various aspects of COPD in a mouse model. The model works in the same 
way as cigarette smoke exposure causes COPD in humans, through inhalation of cigarette smoke into the lungs. The 
model progresses from a mild lung inflammatory response (from acute exposures to smoke) and progresses to a more 
chronic inflammatory state with damage to the lung structure (emphysema) and associated pathologies including muscle 
wasting arising from long term smoke exposure. We have developed and used this model for the last 15 years and have 
not experienced an adverse side effects or events from the exposure of mice to cigarette smoke for periods of up to 6 
months.  
On arrival into the RAF from the relevant source (eg ARC), mice will be ear-tagged by RAF staff for identification purposes.  We 
will ensure that health reports will be provided to the RMIT Animal Facility prior to animals entering the facility.  Mice will then 
be organised into weight matched groups and acclimatised to their new location for 1 week, after which the experimental 
period will begin.   
 
Treatment with Pharmacological Agents: 
 
This project focuses on reducing inflammation and oxidative stress as a potential therapeutic approach for treating COPD. To 
fulfill this aim,  mice will be treated with agents that have antioxidant functions, block the actions of mediators that cause 
inflammation or regulate oxidative stress and reactive oxygen species production/metabolism. The agents to be used will 
depend on the mediator we wish to block and its reported mode of action. Our previous studies (University of Melbourne AEEC# 
00176, 02085, 05097, 05107, 06199, 0810912, 1011596, 1112185) have shown that the mediators found in increased amounts in 
smoke-exposed lung compared to control (sham) can be blocked by using (i) small molecular weight compounds or (ii) 
neutralising antibodies.  
 
The dose of agent to be used will be obtained from the literature or provided by pharmaceutical companies and will be used in 
the range known to be safe and well tolerated by mice. In designing small molecular weight compounds, each company has 
performed detailed pharmacokinetic analyses which will allow us to use effective doses at blood and target tissue. Since they are 
developmental compounds they have undergone rigorous acute (single rising dose) and 1 week protocols (sub-chronic dosing). 
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In addition we know from previous studies that the drugs are very well tolerated. Some of the companies have also developed a 
range of monoclonal neutralising antibodies that are safe over wide dose ranges. Monoclonal antibodies are used for larger 
molecular weight mediators where small molecular weight compounds do not work or have not been identified.  
 
The class and mode of action of the types of drugs to be used include:  
 
i) Small molecular weight compounds: Apocynin (5mg/kg intraperitoneal injection), Ebselen (10mg/kg oral gavage), Nitroxide 
(30mg/kg IP injection), Milfasartan (30mg/kg IP injection), Nitrosartan (30mg/kg IP injection) 
ii) Neutralising antibodies (eg against GM-CSF, IL-17A): 0.1-5mg/kg, via Intranasal, Intraperitoneal injection, Subcutaneous 
injection or intravenous injection routes.  
 
Depending on the property of the mediator in question the agents will be administered in a variety of ways including oral 
gavage, intraperitoneal injection, subcutaneous injection, intravenous injection or intranasal administration. Each individual 
animal will receive one form of test agent by one route of administration only. Depending on the route of administration each 
animal will not receive more than 1 oral gavage, 2 intraperitoneal injections, 1 intranasal administration, 1 intravenous 
administration or 1 subcutaneous injection in a 24 hour period. Due to the nature of the agents we cannot state the exact time 
intervals between each procedure since many of the test agents have different pharmacokinetic profiles (the time period that 
the drug works). The administration methods to be used are as follows: 
 
Oral gavage: Compounds will be administered once daily by oral gavage in a dose range between 0.2-200 mg/kg. Animals will 
be restrained and a gavage tube will be used to push the head slightly upward and back to straighten the oesophagus. The tube 
will be positioned to the right or left of the mouth and inserted slowly while watching for the swallowing reflex. The tube will 
pass freely into the oesophagus, without being forced. When the desired length of insertion is achieved, the compound solution 
will be dispensed (no needle is required, volume used will be 100-200 μl per treatment). Mice will then be observed after the 
procedure for any signs of distress. While some experiments will use only an acute smoke exposure protocol (4 days), to observe 
the full COPD profile including air space enlargement (emphysema) and muscle wasting we will use longer term models (6 
months, 5 days per week). Therefore, in these instances it is necessary to treat mice by oral gavage daily for the duration of the 6 
month protocol to determine whether cigarette smoke-induced lung damage (i.e. emphysema) and muscle wasting is 
prevented or reduced. 
 
Intraperitoneal (IP) injections:  Injections will be administered to conscious mice using a 27 gauge needle on a 1 ml syringe. The 
volume of compound will be no more than 300 μl. IP injections will be administered using the right hand lower quadrant of the 
abdomen.  
 
Subcutaneous injection: Mice will be flattened slightly against a smooth stable surface and the skin around the shoulders will be 
lightly pinched. A small volume (maximum 200μl) of drug using a 27 gauge needle will be injected just under the pinched skin. 
 
Intranasal administration: This methods ensures a concentrated dose of agent directly into the lung. Mice will be lightly 
anaesthetized with the inhalation anaesthetic methoxyflurane as described below and a small amount (50 μl) of solution 
containing the pharamacological agent will be applied to the nostrils once per day of treatment (up to 14 days). Anaesthetizing 
the animals allows the experimenter to treat the animal quickly and effectively as they are immobilised and as mice are obligate 
nose breathers the treatment agent will be distributed uniformly throughout the lung. We have routinely used methoxyflurane 
for the last 15 years for this reason, and in our experience this procedure is well tolerated by the mice without observed adverse 
effects. In addition, there are studies showing that inhaled isoflurane inhibits LPS-induced lung inflammation in mice (Marcias et 
al 2010 Inhaled Isoflurane In Mice Ameliorates LPS- and Ventilator-Induced Lung Injury; Reutershan et al. 2006 Protective Effects 
of Isoflurane Pretreatment in Endotoxin-induced Lung Injury) and we have recently found that inhaled isoflurane inhibits 
cigarette smoke-induced lung inflammation. For these reasons, inhaled isoflurane cannot be used in our experiments. 
 
Intravenous administration (via tail vein): Mice will be warmed by placing them in a cage under a custom-built heat lamp 
apparatus (owned by the BRF) for a few minutes. Mice will then be removed from the cage and then restrained (without 
sedation), using a purpose-built mouse restrainer and a small volume (50 μl) of compound will be injected, using a 30 gauge 
needle, into the mouse tail vein, once per day of treatment (up to 14 days). The injection site will be rotated so that the top tail 
vein is used one day and the bottom tail vein is used the next day. 
 
Please note that all of these procedures will only be performed by experienced investigators. 
 
Acute Cigarette smoke exposure (4 days): 
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4.  Animal Experience and Impact on Each Individual Animal
4.1     Provide a brief overview of the experimental design and procedures to be performed on animals
 
Mice are put into an 18 litre plastic container connected to a 3-way tap where cigarette smoke will be pumped. A cigarette is 
connected to the tap (using a pipette tip) along with a 60 ml syringe, which is then used to draw smoke from the lit cigarette and 
push it into the chamber. It takes ~3 min to smoke 1 cigarette using a constant rate of 10 sec to draw up the syringe barrel. The 
box lid is left on for another 12 min and then removed for 5 min of fresh air. This is done 3 times in succession 3 times per day, ie 
the maximum smoke exposure is 9 cigarettes per day over at least an 8 hour period. Assay for carboxyhaemoglobin in blood has 
shown that smoke inhalation in mice is similar to mild human smoking, and histology has shown that we are not causing acute 
lung injury. Over a 14 day smoke protocol, mice lose around 7% of their body weight but there is no reduction in activity and 
weight is rapidly regained once smoking stops. 4 days of smoke produces many features of COPD, including an increase in 
numbers of key types of white blood cells in the lung and increased lung protease activity. Each experiment will have a matched 
(exposure period) sham smoked group of animals that will be placed in the perspex chamber but not exposed to cigarette 
smoke. Similar experiments will also be performed in genetically modified mice to determine the importance of defects of 
certain genes in the development of COPD. 
 
In previous studies mice from different experimental groups (drug treated vs untreated) have been exposed to smoke 
simultaneously within the same 18L plastic container, and we have not experienced problems with mice fighting or becoming 
distressed during this period. However, in the event that fighting or other problems do occur during the smoking period, a 
divider will be used to split the smoke box and separate the groups, allowing them to be exposed to the same smoke but 
preventing them from contacting other groups.  
 
Previous experiments (University of Melbourne AEEC#s 02084, 02085, 05097, 05107, 06199, 0810912, 1112185) have shown this 
to be observably painless and causing minimal observable discomfort to the animal. However, in the event the animals show 
signs of distress (animals will be monitored daily using attached monitoring and intervention checklists) such as loss of body 
weight (more than 10% over a 24 h period), changes in respiration, lethargy, piloerection, hunched appearance, loss of appetite 
and loss of grooming, they will be immediately killed by an overdose (intraperitoneal injection) of anesthetic (sodium 
pentobarbitol - 240mg/kg). A 1 ml syringe with a 27 gauge needle will be used for this injection. Death will be ensured by 
opening of the chest cavity.  
 
Chronic Cigarette smoke exposure (6 month protocol): 
 
Whilst the acute 4 day cigarette smoke exposure produces many of the features of COPD, we have shown that longer term 
models (up to 6 months) are required to observe the full COPD symptom profile including air space enlargement (emphysema) 
and skeletal muscle wasting. For this model we propose to expose mice to cigarette smoke in the same fashion as the 4 day 
smoke protocol, however rather than exposing mice to 9 cigarettes per day we propose 6 cigarettes per day (2 in the morning, 2 
at noon, and 2 in the afternoon) – the maximum length of each exposure is 40 minutes. Data from previous long-term smoking 
protocols (6 cigarettes/day, 5d/week for 4 weeks or 6 months) show that mice do not lose weight but gain less weight than no-
smoke control mice. Each experiment will have a matched (exposure period) sham smoked group of animals that will be placed 
in the Perspex chamber but not exposed to cigarette smoke. Similar experiments will also be performed in genetically modified 
mice to determine the importance of defects of certain genes in the development of COPD. 
Previous experiments (University of Melbourne AEEC #02085, 0810912, 1112185) have shown that there is minimal discomfort to 
the animals with long term exposures to cigarette smoke. Animals will be monitored daily using the attached monitoring sheet 
and intervention checklists) and in the event the animals show signs of distress such as loss of body weight (more than 10% over 
a 24 hour period), changes in respiration, lethargy, piloerection, hunched appearance, loss of appetite and loss of grooming, 
they will be immediately killed by an overdose (intraperitoneal injection) of anaesthetic (sodium pentobarbitol - 240mg/kg). A 1 
ml syringe with a 27 gauge needle will be used for this injection. Death will be ensured by opening of the chest cavity.  
 
Pair Feeding: 
 
For the Chronic cigarette smoke exposure protocols (1 and 6 months) it will be important to include a pair-fed control group, 
which will receive the exact amount of food eaten by the relevant experimental group (e.g. smoke-exposed mice) on the 
previous day. This is important as nicotine (contained in cigarette smoke) has been shown to cause a small reduction in food 
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intake, which may impact on the regulation of muscle mass. Exposure to smoke causes a small reduction in food intake which 
we have shown previously (AEC # 02084, 06237) to reduce body weight over the course of 4 month experiment by 
approximately 10%. This small restriction of food does not appear to distress the pair-fed animals. By including pair-fed control 
groups it will be possible to determine the relative contribution of reduced food intake to the observed changes and therefore 
the effect of cigarette smoke exposure itself on changes in muscle mass and pathology. Animals will be monitored daily and in 
the event an animal shows signs of distress they will be immediately killed by an intraperitoneal anaesthetic overdose 
administered via a 27 gauge needle (see below and attached monitoring sheet).  
 
Animal monitoring: 
 
Mice will be monitored daily for signs of illness such as loss of body weight, lethargy, ruffled fur, hunched appearance, panting, 
loss of appetite (as seen by monitoring food intake), isolation from the group and loss of grooming (ie criteria set out in attached 
monitoring and intervention checklists). Weights will be recorded daily in all experiments except for the 6 month smoke studies 
in which weights will be recorded on Monday, Wednesday, Friday. Food intake will also be measured by weighing the food three 
time a week (Monday, Wednesday, Friday). Mice will be observed daily during the experimental protocol to ensure that no overt 
lung responses, respiratory distress or discomfort are elicited by cigarette smoke exposure. If an adversely severe reaction 
occurred the mice would show reduced mobility, panting and piloerection - in such circumstances they would be immediately 
killed by anaesthetic overdose (sodium pentobarbitol - 240mg/kg). Death will be ensured by opening of the chest cavity. 
 
At the conclusion of the experiment: 
  
At the end of the experimental protocol, mice will be killed by an intraperitoneal anaesthetic overdose (sodium pentobarbitol - 
240mg/kg) administered via a 27 gauge needle and subjected to the procedures described below. Death will be ensured by 
opening of the chest cavity. 
Procedures after the animals have been killed: 
1. Blood samples will be taken from the inferior vena cava of each animal and analysed to determine signs of systemic 
inflammation. 
2. The diaphragm is opened, lungs lavaged (method to obtain fluid from the lungs to determine level of inflammation) with PBS 
(400 μl, followed by 3 times 300 μl aliquots) via the trachea. A separate group of animals (n=4 per experimental group) will have 
their lungs inflated with 10% neutral buffered formalin at a pressure of 20cm of mercury for 10 minutes, to fix the lung tissue for 
later histological examination. These two procedures cannot be performed on concurrently on the same animals.  
3. The chest cavity is opened and lungs removed and examined for inflammatory changes using (i) Cellular inflammation
(principally lavage); (ii) RNA extraction for gene profiling using gene microarrays/QPCR and (iii) histology and 
immunohistochemistry. These procedures cannot be concurrently performed in the same animal and the experiments have 
been designed to extract the maximum information from as few mice as possible. 
4. Organs such as the liver, kidney, fat pads, skeletal muscles from the hind limb (gastrocnemius, soleus, tibialis anterior, 
plantaris), heart, spleen, brain and ilium will be dissected, weighed and snap frozen for subsequent analysis. This will include (i) 
RNA extraction for gene profiling, (ii) determination of protein levels and (iii) histology and immunohistochemistry. 
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4.2     Impact on the animals
Do experiments involve (please tick) *ANIMAL USE CATEGORIES*    No          Yes 
A     Immediate euthanasia of animals to obtain tissue for biochemical analysis, or in vitro, cell, tissue 
or organ studies.
✖
B      Experiments under anaesthesia, without recovery (i.e. animals are fully anaesthetised for the 
duration of the experiment, and are killed at its conclusion without recovery from anaesthesia).
✖
C      No anaesthesia, minor procedures used (e.g. injections, blood sampling, antibody raising, minor 
dietary manipulations.)
✖
D      Survival after an intervention which causes minor stress of short duration (eg. following biopsies 
or cannulations).
✖
E      Survival after an intervention which causes major or prolonged stress (eg. major surgery, 
exposure to heat, cold, ionising radiation; administration of toxic drugs; genetic manipulation, 
induction of neoplasia or foetal intervention.) 
✖
F      Experiments under anaesthesia, with recovery. ✖
G     Observation of free roaming animals only ✖
H     Anaesthesia in non-experimental procedures/off protocol procedures (e.g. microchipping for 
identification)
✖
I      Other- please describe: ✖
4.3     Please indicate if the project involves any of the following?
Death as an end point (as defined in the Code) No✖ Yes
Production of monoclonal antibodies by ascites method No✖ Yes
Prolonged restraint or confinement (e.g. CLAMS) No✖ Yes
4.4     What is the maximum period of time that an individual animal or group of animals will be used in this 
project?
6 months
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4.5     Complete the following summary table for ALL procedures to be performed on animals, including killing, 
both from protocol in emergency circumstances
Using the following table, separately identify and specify EACH procedure used in this proposal that may impact an animal's well-being. 
This assessment is a step-by-step description of what will happen each animal. State how adverse effects will be minimised.  List these 
procedures chronologically:
Procedure
Name of procedure Expose mice to cigarette smoke
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-smoke exposure refer to attached 
sheet
up to 6o mins, 3 times daily for 4 
days to 6 months. 
Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
Mice are placed in an 18-liter Perspex chamber in a standard fume hood and exposed to cigarette 
smoke. In cigarette smoke exposure experiments, mice are exposed to cigarette smoke generated 
using 3,6 or 9 cigarettes/day for 4 days up to 6 months. Cigarette smoke is delivered three times per 
day at 8 AM, 12 noon, and 4 PM with 1-3 cigarettes spaced over 1 h, respectively. Sham-exposed mice 
were placed in an 18-liter Perspex chamber but did not receive cigarette smoke.  
What adverse welfare impacts are 
possible? Weight loss, respiratory changes.  
How will adverse impacts be addressed 
and minimised?
Mice will be monitored during and after each smoke session (3 times per day) for signs of distress 
according to the attached intervention criteria sheet. Body weights are monitored throughout the 
study. 
Procedure
Name of procedure Methoxyflurane anaesthesia for intranasal treatment
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-intranasal treatment via 
Methoxyflurane anaesthesia 
refer to attached 
sheet 
5 min Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
Intranasal administration ensures a concentrated dose of agent directly into the lung. Animals will be 
lightly anaesthetised with the inhalation anaesthetic methoxyflurane to induce anaesthesia. A mouse  
will be placed in a 1L air-tight container padded with cotton wool containing 2ml methoxyflurane, 
covered with gauze to prevent the mice coming into direct contact with the anaesthetic agent. The 
mouse is observed until a relaxed breathing is observed and there is a loss of the righting reflex when 
the container is gently tilted. The mouse is then removed from the box for intranasal administration 
and allowed to recover.  This procedure is carried out in a fume hood to avoid release of anaesthetic 
vapours into the room. 
What adverse welfare impacts are 
possible?
This is a routine method well tolerated by the mice - the anaesthesia is light and the mice recover 
within a minute following removal from the anaesthetic chamber. 
How will adverse impacts be addressed 
and minimised?
Mice will be maintained under anaesthesia for the minimum duration and allowed to recover in a well 
ventilated area. Mice will be observed and monitored during their recovery and not returned to their 
home cages until fully recovered. 
Procedure
Name of procedure Intranasal administration of agents
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SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-intranasal treatment via 
Methoxyflurane anaesthesia 
refer to attached 
sheet
5 min Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
Intranasal administration ensures a concentrated dose of agent directly into the lung. Animals will be 
lightly anaesthetised with the inhalation anaesthetic methoxyflurane (see above), in a fume hood.  
Anaesthesia will be confirmed through loss of the "righting reflex" - tested by rocking or tipping the 
contained gently. Once animals are appropriately anaesthetised a 35μl solution containing the agent 
will be applied to the nostrils once per day. Mice will then be allowed to recover until they are active 
before being returned to their home cages. 
What adverse welfare impacts are 
possible? This is a routine procedure well tolerated by the mice. 
How will adverse impacts be addressed 
and minimised?
Mice will be monitored following the procedure to ensure they recover quickly and do not show any 
signs of distress. They will not be returned to their home cages until they are fully recovered and 
moving around normally. 
Procedure
Name of procedure Oral gavage
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-Oral Gavage in Mice refer to attached 
sheet
2 min Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
Compounds will be administered once daily by oral gavage. Mice will be restrained in the hand and a 
round-tip gavage tube (purpose-made) will be used to push the head slightly upward and back to 
straighten the oesophagus. The tube will be positioned to the right or left of the mouth and inserted 
slowly while watching for the swallowing reflex. The tube will pass freely into the oesophagus, 
without being forced. When the desired length of insertion is achieved, the compound solution will 
be instilled (volume used will be no more than 10 mL/kg per dose). Mice will then be observed after 
the procedure for any signs of distress.
What adverse welfare impacts are 
possible? This is a well tolerated and minor procedure
How will adverse impacts be addressed 
and minimised?
Following gavage, mice will be observed after the procedure for any signs of distress and ongoing 
daily monitoring will continue using the attached monitoring sheet.
Procedure
Name of procedure Subcutaneous injection
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-subcutaneous injection of mice refer to attached 
sheet
2 min Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
To ensure a slow-release pharmacokinetic profile some of the test compounds will be 
administered via a subcutaneous injection. Briefly mice will be flattened slightly against a smooth 
stable surface and the skin around the shoulders will be lightly scruffed. Test agent (volume no 
greater than 20ml/kg) will be injected using a 27 gauge needle just under the skin layer.
What adverse welfare impacts are 
possible? Very minor to no distress, possible minor irritation that is not long lasting
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How will adverse impacts be addressed 
and minimised?
The mice will be closely monitored during the short recovery period for signs distress and ongoing 
daily monitoring will continue using the attached monitoring sheet.
Procedure
Name of procedure Intravenous administration of agents
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-intravenous administration in mice refer to attached 
sheet 
5 minutes Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
Mice will be warmed by placing them in a cage under a custom built lamp apparatus for a few 
minutes to cause vasodilation and allow for easier access to tail veins. Mice are then removed from 
the cage and then restrained (without sedation), using a purpose-built mouse restrainer and a small 
volume (50 microlitres) of compound will be injected using a 30 gauge needle, into the mouse tail 
vein. Mice will be treated up to once per day (up to 14 days). 
What adverse welfare impacts are 
possible? Irritation at the injection site. Stress from being restrained. 
How will adverse impacts be addressed 
and minimised?
The injection site will be varied each day (using top tail vein one day, bottom tail vein the next day) to 
minimise irritation from injections. To minimise stress the procedure will only be undertaken by 
experienced, trained investigators and will be conducted as quickly as possible to reduce stress to the 
mice. Mice will be observed following the procedure for signs of distress. 
Procedure
Name of procedure Anaesthesia overdose via intraperitoneal injection
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-Anaesthesia overdose via 
intraperitoneal injection
refer to attached 
sheet 
At end of experiment, duration 2 
min
Vlahos/Bozinovski laboratory (PC2 room)
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
At the conclusion of the experimental protocol, mice will be killed by an intraperitoneal 
anaesthetic overdose of anaesthetic (sodium pentobarbitol 240mg/kg) using a 27 gauge needle 
buffered in PBS). Secondary confirmation of death will be confirmed by performing a thoracotomy. 
What adverse welfare impacts are 
possible?
How will adverse impacts be addressed 
and minimised?
Procedure
Name of procedure Intraperitoneal injection of agents
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
SOP-Intraperitoneal injection of agents 
in mice
refer to attached 
sheet 
2 min, no more than twice in a 
24h period
Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
These injections will be administered to conscious mice in the right lower quadrant of the 
abdomen using a 27 gauge needle on a 1 ml syringe. The volume of compound will be no more than 
300 μL.
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What adverse welfare impacts are 
possible? Very minor to no distress, possible minor abdominal irritation that is not long lasting. 
How will adverse impacts be addressed 
and minimised?
The mice will be closely monitored during the short recovery period for signs of distress and ongoing 
daily monitoring will continue using the attached monitoring sheet.
Procedure
Name of procedure Pair feeding
SOP Reference (if applicable) Number of Animals Timing and Duration of  
procedure
Location where this procedure will be  
conducted
refer to attached 
sheet 
duration of experiment, up to 6 
months
Level 11 PC2 facility
Description  of procedure (if SOP not 
available).  If this is a modified SOP, 
please specify changes
To control for the effects of cigarette smoke and other agents on appetite and food intake, separate 
groups of mice will be pair-fed for the duration of the study, being fed the same amount of food as 
the smoke/treated group ate in the previous 24h. Food intake is monitored by weighing the food. 
What adverse welfare impacts are 
possible?
This procedure is well tolerated and generally involves only a minor restriction on food intake. Some 
weight loss occurs.
How will adverse impacts be addressed 
and minimised?
The mice will be regularly monitored and their bodyweight and condition assessed according to the 
attached monitoring and intervention sheets. We have not experienced any adverse effects of pair 
feeding in previous studies. 
Add procedure Remove procedure
4.6     Fate of Animals
What is the fate of the animals in the project? (Select an option)
Humanely killed.   
Is there an opportunity to provide other investigators with cadavers or 
tissue?
No Yes✖
            Please provide details Most of the tissues are collected for analysis at the end of the experiment, however certain tissues may be available to other researchers if needed. 
Returned to the wild No✖ Yes
Other No✖ Yes
4.7     For wildlife projects please include details of the number of study sites and full address of sites
4.8     Does the project involve the capture or trapping of wildlife?
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Refer to the Code of Practice, Section 5, Prevention of Cruelty to Animals Act 1986 and Prevention of Cruelty to Animals 
Regulations 2008, and include any references to conditions in regards to trapping- Acts and Regulations can be found at: http://
www.dpi.vic.gov.au/agriculture/about-agriculture/legislation-regulation/animal-welfare-legislation/prevention-cruelty-animals-
legislation 
No✖ Yes
5.  Monitoring of Animals
Investigators are responsible for monitoring the welfare of their animals (Code of Practice 2.2.26).  This responsibility begins when an 
animal is allocated to the approved project and end s with the specified fate of the animal at the completion of the project. Unexpected 
incidents that impact on the welfare of any individual animal/group of animals MUST be responded to immediately and reported to the 
AEC via an Adverse Incident Report [need link] 
All personnel identified in this section must be familiar with the criteria for monitoring the welfare of the animals, and maintaining 
monitoring records. Welfare monitoring checklists must be kept together with animals, accessible to all nominated personnel, animal 
facility staff, and the AEC if requested. 
5.1     For Monitoring Purposes, Is This Purely An Observational Study?
No✖ Yes
Describe how animals will be monitored day to day (routine 
monitoring) and by whom
Once the animals arrive from the source (eg ARC) the 
experimental procedures will begin after one week as 
animals require sufficient time to acclimatise to their 
new environment. During this acclimatisation period, 
animals are monitored twice by the investigators and 
daily by the Biological Research Facility staff. As animals 
have not undergone any experimental procedures at 
this time there should be no signs of distress; however 
we will monitor to determine if animals are fighting, and 
whether each animal looks to be in good condition.
During procedures, what specific signs will be monitored and 
how frequently?
During the procedures animals will be monitored daily 
for overt signs of distress including piloerection, 
decreased interaction with peers, loss of appetite 
(assessed by changes in body weight) using the 
attached monitoring checklist. In addition, body weight 
will be monitored every Monday, Wednesday and Friday 
in the 6 month studies.
After procedures, what specific signs will be monitored and how 
frequently?
After the procedures animals will be monitored daily for 
overt signs of distress including piloerection, decreased 
interaction with peers, loss of appetite (assessed by 
changes in body weight) using the attached monitoring 
checklist. In addition, body weight will be monitored 
every Monday, Wednesday and Friday in the 6 month 
studies.
5.2     Responsibility for Monitoring
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WHO will be monitoring the animals under experimentation? 
The responsibility for monitoring animals under experimentation 
lies with the Principal Investigator.
A/Prof Ross Vlahos, A/Prof Steven Bozinovski, Dr Samantha 
Passey, Mr Huei Jiunn Seouw, Mr Ivan Bernardo
WHO will be responsible for emergencies and how will it be 
ensured that nominees can be contacted?
A/Prof Ross Vlahos 
The nominee(s) can be contacted via mobile number or email.
The Animal Facility staff attend the Animal Facility daily. 
WHAT is the longest period the animals under 
experimentation will be left unchecked by the investigators 
(including weekends & Public Holidays)?
48h
Are Animal Facility staff to be asked to take any special 
responsibilities in addition to routine husbandry? 
If yes, staff must be named on the application in the Personal 
Declaration section.
No
What is the maximum time individual animals are to be held 
under experiment? 6 months
What is the maximum time individual animals are to be held 
in the animal facility? 7 months
5.3     Attach a copy of the monitoring checklist and record keeping form(s) you will use to record these 
observations, and label `Section 5.3' 
5.4     Experimental Intervention/Endpoints/Euthanasia criteria
At what point would you intervene to kill or treat the animal to alleviate its pain or suffering? 
Specify in detail what clinical signs, e.g. change in behaviour, loss in body weight, tumour size, changes to normal feeding and 
drinking behaviour etc. you would use in making this decision.
Signs of distress are detailed in the attached intervention checklist and include including piloerection, decreased interaction with 
peers, loss of appetite (assessed by changes in body weight). Determination of whether an animal will be euthanized based on 
clinical and behavioral signs will be made by an experienced investigator and will depend on the severity of the symptom. Mice 
who display 1 or more of the "severe" signs on the attached Intervention Criteria Checklist or have any obvious signs of pain will 
be euthanized immediately with an overdose of anesthetic (sodium pentobarbitol - 240mg/kg) administered via a 27 gauge 
needle. Death will also be ensured by opening of the chest cavity.
Attach a copy of the clinical scoring sheet that will be used to determine intervention and label `Section 5.4'
6.  Chemical & Biological Agents to Be Administered
6.1     Will chemical or biological agents be used/administered in the project? (including the vehicles in which active agents 
are to be delivered).
No Yes✖
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Agent Details
Name of agent Cigarette smoke
Action Cigarette smoke triggers a mild inflammation in the lung and can lead to systemic inflammation
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg)
LD50 (if known)
Route of administration Indirect inhalation 
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
weight loss, appetite supression 
Agent Details
Name of agent Apocynin
Action Inhibitor of the NADPH Oxidase (antioxidant effects)
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg) 5 mg/kg
LD50 (if known) 650 mg/kg (for mouse intraperitoneal injection)
Route of administration Intraperitoneal injection once per day
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
None reported
Agent Details
Name of agent Ebselen
Action Glutathione peroxidase mimetic (antioxidant effects)
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg) 1-10 mg/kg
LD50 (if known) 6810mg/kg (mouse oral LD50)
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Route of administration Oral gavage once per day 
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
None reported
Agent Details
Name of agent Milfasartan
Action Angiotensin II receptor antagonist
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg) 1-30 mg/kg
LD50 (if known)
Route of administration Intraperitoneal injection
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
None reported
Agent Details
Name of agent Nitroxide
Action Antioxidant
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg) 1-30 mg/kg
LD50 (if known)
Route of administration Intraperitoneal injection
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
None reported
Agent Details
Name of agent  Nitrosartan
Action Dual action pharmacophore - antioxidant and angiotensin II receptor antagonist
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Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg) 1-30 mg/kg
LD50 (if known)
Route of administration Intraperitoneal injection
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
None reported
Agent Details
Name of agent Monoclonal antibodies
Action Used to neutralise the actions of macrophage growth factors (eg GM-CSF) or mediators which sustain neutrophilic inflammation (IL-17).
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg) 0.1 to 5mg/kg
LD50 (if known)
Route of administration Intranasal, Intraperitoneal injection, Subcutaneous injection, intravenous injection
Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
No adverse side effects observed based on historical experiences. Vehicle to be used will be 
sterile saline.
Agent Details
Name of agent Methoxyflurane
Action Volatile inhalation anaesthetic agent
Purpose of administration for 
this project (if different from 
action)
Dose rate (mg/kg)
A mouse  will be placed in a 1L air-tight container padded with cotton wool containing 2ml 
methoxyflurane, covered with gauze to prevent the mice coming into direct contact with 
the anaesthetic agent. The mouse is observed until a relaxed breathing is observed and 
there is a loss of the righting reflex when the container is gently tilted. The mouse is then 
removed from the box for intranasal administration and allowed to recover.  This procedure 
is carried out in a fume hood to avoid release of anaesthetic vapours into the room. 
LD50 (if known)
Route of administration Inhalation
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Duration of action
Potential side effects of 
administration or withdrawal 
of the drug
Add agent Remove agent
7.  Source and Housing of Animals
7.1     Is this purely an OBSERVATIONAL study?
No✖ Yes
Where will animals be  
sourced from? (Provide the 
name of the supplier)
Animal Resource Center, Perth; University of Melbourne; Monash University; Hudson 
Institute of Medical Research (formerly Monash Institute of Medical Research).
Where will the animals be 
housed? RMIT Animal Facillity
7.2     Have you consulted with the relevant Animal Facility Manager? 
No Yes✖
7.3     Are the husbandry requirements for the animals described in an existing SOP? 
No Yes✖
Please provide the housing 
SOP code:
RAF SOP1 Animal Users induction 
RAF SOP40 Cage Stacking Policy
*Please discuss the housing requirements with the relevant Animal Facility Manager who will also provide the SOP code.
7.4     Describe how the species-specific behavioural needs of the experimental animals will be met in terms of the 
environmental enrichment that will be provided.
RAF SOP14 Environmental Enrichment
It is recommended that you consult with the relevant animal facility manager for assistance as SOPs for environmental 
enrichment may already have been developed for your species.
8.  Personnel
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Any person proposing to carry out any scientific procedures on animals under this application must be named in this application, 
and sign the following section.  Failure to do so is an offence under the Victorian Prevention of Cruelty to Animals Act 1986.
8.1     List All Personnel Involved In Animal Use in the Project
Personnel Details
Please specify role: Principal Investigator✖ Co-Investigator Other Staff (indicate):
Title/Full Name A/Prof Ross Vlahos       Staff ID
Email   Student ID
Qualifications PhD, University of Melbourne; Bachelor of Science (Honours), University of Melbourne
  Position Associate Professor
Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke Mouse
✖
Methoxyflurane anaesthesia for 
intranasal treatment
Mouse
✖
Intranasal administration of agents Mouse
✖
Oral gavage Mouse
✖
Subcutaneous injection Mouse
✖
Intravenous administration of agents Mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
Mouse
✖
Intraperitoneal injection of agents Mouse
✖
Pair feeding Mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator✖ Other Staff (indicate):
Title/Full Name A/Prof Steven Bozinovski       Staff ID
Email   Student ID
Qualifications PhD, University of Melbourne; Bachelor of Science (Honours), La Trobe University
  Position Associate Professor
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Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke Mouse
✖
Methoxyflurane anaesthesia for 
intranasal treatment
Mouse
✖
Intraperitoneal injection of agents Mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
Mouse
✖
Intranasal administration of agents Mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator✖ Other Staff (indicate): Research Fellow
Title/Full Name Dr Samantha Louise Passey       Staff ID
Email   Student ID
Qualifications PhD Biochemistry, BSc. (Honours) Biochemistry, University of Bristol. 
  Position Research Fellow
Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes No✖ NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
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Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke mouse
✖
Methoxyflurane anaesthesia for 
intranasal administration
mouse
✖
Intraperitoneal injection mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
mouse
✖
Oral gavage mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences, RMIT
Subcutaneous injection mouse
✖
Intravenous administration mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences, RMIT
Pair feeding mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ Research Assistant
Title/Full Name Mr Huei Jiunn Seow       Staff ID
Email   Student ID
Qualifications BSc honours, BBiomedSc   Position Research Assistant
Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes No✖ NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
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Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke mouse
✖
Methoxyflurane anaesthesia for 
intranasal administration
mouse
✖
Intraperitoneal injection mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
mouse
✖
Oral gavage mouse
✖
Subcutaneous injection mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences, RMIT
Intravenous administration mouse
✖
Pair feeding mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ Masters Student
Title/Full Name Mr Ivan Bernardo       Staff ID
Email   Student ID
Qualifications BSc   Position Masters Student
Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes No✖ NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
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Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke mouse
✖
Methoxyflurane anaesthesia for 
intranasal administration
mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences
Intraperitoneal injection mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
mouse
✖
Oral gavage mouse
✖
Subcutaneous injection mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences
Intravenous administration mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences
Pair feeding mouse
✖ Dr Samantha Passey, School of Health 
Sciences
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ Research Assistant
Title/Full Name Mr Selcuk Yatmaz       Staff ID
Email   Student ID
Qualifications BBioMedSc, BSc (honours)   Position Research Assistant
Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
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Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke mouse
✖
Methoxyflurane anaesthesia for 
intranasal administration
mouse
✖
Intraperitoneal injection mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
mouse
✖
Oral gavage mouse
✖
Subcutaneous injection mouse
✖
Intravenous administration mouse
✖
Pair feeding mouse
✖ Dr Samantha Passey, School of Health 
Sciences
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ PhD student
Title/Full Name Miss Victoria Austin       Staff ID
Email   Student ID
Qualifications BBiomed (Honours)   Position PhD student
Department/Institution School of Health Sciences   Scientific Licence* SPPL365
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
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Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Expose mice to cigarette smoke mouse
✖
Methoxyflurane anaesthesia for 
intranasal administration
mouse
✖
Intraperitoneal injection mouse
✖
Anaesthesia overdose via 
intraperitoneal injection
mouse
✖
Oral gavage mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences
Subcutaneous injection mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences
Intravenous administration mouse
✖ A/Prof Ross Vlahos, School of Health 
Sciences
Pair feeding mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ RAF staff
Title/Full Name Tricia Murphy       Staff ID
Email   Student ID
Qualifications   Position Animal Facility Coordinator
Department/Institution RMIT Animal Facility   Scientific Licence*
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Ear-tagging mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ RAF staff
Title/Full Name Joo Lee Cham       Staff ID
Email   Student ID
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Qualifications   Position breeding and quarantine facility officer
Department/Institution RMIT Animal Facility   Scientific Licence*
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Ear-tagging mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ Animal facility assistant
Title/Full Name Emma Collinson       Staff ID
Email   Student ID
Qualifications   Position Animal facility assistant
Department/Institution RMIT Animal Facility   Scientific Licence*
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Ear-tagging Mouse
✖
Add row Remove row
Personnel Details
Please specify role: Principal Investigator Co-Investigator Other Staff (indicate):✖ Animal facility assistant
Title/Full Name Vikki Smyth       Staff ID
Email   Student ID
Qualifications   Position Animal facility assistant
Department/Institution RMIT Animal Facility   Scientific Licence*
Attended RMIT University compulsory information sessions/animal ethics workshop? Yes✖ No NA
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*Non-RMIT collaborators are assumed to be working under the authorisation of their “home” Scientific License, unless the clause below stating otherwise is 
completed by the Scientific Licence Nominee.
List the procedures this person will be doing in this project and their level of experience with this species
Technique/Procedure Species     Level of Experience   (Approx. no. of times 
 procedure performed with this species) 
    None       Limited        High 
    (<5)          (5-20)         (>20)   
If Level of Experience =<20, indicate who 
will provide training and provide details 
below (e.g. will the Animal Welfare Officer 
provide training?)
Ear-tagging mouse
✖
Add row Remove row
Add Personnel Remove Personnel
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DECLARATION
By submitting this application, I, the Principal Investigator declare that:
I have the appropriate qualifications and experience to perform the procedures described in this Application or to ensure that they are 
done correctly;✖
I have read the provisions of Part IV of the Prevention of Cruelty to Animals Act 1986/Regulations 2008, including Amendments, (the Act) and 
the current version of the Australian Code of Practice for the Care and Use ofAnimals for Scientific Purposes (the Code);✖
I understand that scientific/teaching activities involving the use of animals must NOT begin prior to receiving written approval from the 
RMIT University AEC;✖
I accept responsibility for the conduct of the experimental procedures detailed above, in accordance with the requirements of the Act and 
the Code and any other conditions specified by the RMIT University AEC;✖
I understand that I am required to promptly supply annual and final reports as a condition of approval;✖
I further declare that the procedures described in this Application do not constitute unnecessary repetition of work previously carried out 
by other researchers or myself (Section 1.11 of the Code);✖
I declare that all persons engaged in this project have been adequately instructed in, and are competent to perform, procedures they are 
to carry out.  If they are not already skilled in the procedures, I will be responsible for ensuring that they obtain the necessary training, so 
that each procedure on an animal will be carried out in the most appropriate manner;
✖
I declare that all persons engaged in this project have copies / or access to copies of this Application form and any relevant standard 
operating procedures;✖
I acknowledge and declare that I am responsible for ensuring that all regulated approvals, permits and clearances have been obtained 
prior to undertaking any research described in this Application;✖
I have discussed this project with the Animal Facilities Manager who has indicated that the required animals can be maintained in the 
animal facility subject to space availability;✖
I consent for my name and this Application document to be provided to, and kept on file with this AEC;✖
I have ensured that the head of school has sighted this application and that s/he agrees that the required academic expertise and resources 
are available to complete this proposed research. Evidence of this assurance will be retained.✖
1 The application must be submitted electronically by the Chief Investigator from his/her RMIT staff email account.
By submitting this application, we, the Principal Investigator and Co-Investigators, declare that we :
have the appropriate qualifications and experience or will be trained by the person specified to perform the procedures as described in 
this application;✖
have read the above application;✖
have read the provisions of Part III of the Prevention of Cruelty to Animals Act 1986 (including Amendments) and the latest version of the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes;✖
agree to submit to the authority of the Principal Investigator, the Head of Faculty/School /Department and Scientific Licence Nominee 
listed in the section below for the purposes of collaboration on this project;✖
consent for our names and this Application document to be provided to RMIT University AEC and Animal Ethics Office, and kept on file and 
in a confidential database.  We understand that this information may be used in reports made to the University or any government 
department with legal authority to access this information. 
✖
1 The application must be submitted electronically by the Principal Investigator from his/her RMIT staff email account.
2 This evidence may consist of a hard-copy signed document or an email from the co-investigator agreeing to participate as described in the application.
RMIT University Animal Ethics Committee 
Application Form for the Use of Animals for Scientific Purposes in Research & Teaching
Page 35 of 35
RMIT_AEC_ApplicationForm_20130318.v6
CHECKLIST FOR APPLICANTS
Please complete:
Project Title 
Does it describe the work proposed? Yes✖ No
Project Duration
Is the proposed duration stated? Yes✖ No
Safety
Does it describe the work proposed? Yes✖ No
Justification for the use of animals
Is the project summary easily understood by people who do not have a scientific background? Yes✖ No
Are the aims clearly stated? Yes✖ No
Is the significance of the work clear? Yes✖ No
Broadly what is going to be done to the animals? Yes✖ No
Replacement
Is it clear why alternatives are not being used? Yes✖ No
Reduction
Are the numbers requested justified? Yes✖ No
Refinement
Do I know...
The meaning of all terms used? Yes✖ No
Where will the animals be housed and who will care for them at all stages of the project? Yes✖ No
Whether any genetically modified animals have phenotypes which require special care? Yes✖ No
The details of what will happen to each individual animal or group of animals from the beginning to 
the end of the project? (agents, dose rates, routes and frequency of administration, actions, 
anaesthesia, surgery, number of procedures per animal, etc.).
Yes✖ No
The potential impact on the animals' welfare of each procedure? Yes✖ No
What criteria will be used to monitor the animals? Yes✖ No
What will be done if welfare problems are identified? Yes✖ No
How the animals will be killed and disposed of? Yes✖ No
Whether early and subsequent inspections of the work are needed? Yes✖ No
Investigators 
Do I know...
Who will be doing the work? Yes✖ No
What experience the named personnel have in the specific techniques described in the proposal? Yes✖ No
What training is needed? Yes✖ No
Who will provide the training? Yes✖ No
How the training will be provided? Yes✖ No
Have I consulted with the Animal Welfare Officer in the design of this project? Yes✖ No
Animals Requested VLAHOS AEC #1521 
 1 
Provide an explanation for the number of animals being requested. This explanation should 
be based on statistical analysis and/or other considerations in the experimental design 
(e.g., multiple time points, quantity of tissue required). Where appropriate, present the 
numbers in table form. 
 
The group size of 12 per group (8 [biochemistry] + 4 [histology]) has been based on power 
calculations to ensure a maximum likelihood of detecting real differences in parameters between 
control and treated mice based on historical variances in our laboratory for similar protocols 
(University of Melbourne AEEC #02084, 02085, 05097, 05107, 06199, 0810912, 1011596, 
1112185).  The experiments have been designed to extract the maximum information from as few 
mice as possible.  While the animal numbers listed below seem large, each experiment has been 
designed to produce definitive outcomes preventing possible repeats of experiments. 
 
Experiment outline 
In the tables below we have outlined the experimental approach and the two main analyses 
required for our work which include the assessment of the lung by either biochemical analysis or 
via histopathology.  Therefore our experimental endpoints require using separate animal groups 
due to the incompatibility of the techniques used.  Animals used for histopathology cannot be 
bronchoalveolar lavaged (BAL) to prevent damage to the delicate alveolar and other lung 
structures.  In addition the fixative used to preserve the lung tissue in the histopathological process 
prevents the assessment of genes and other cytokines due to tissue processing. 
 
Analyses 1: Determination of inflammation and COPD in the lung by biochemical analyses. 
One important aspect to inflammatory lung disease, COPD and AE-COPD is the profile of 
inflammatory cells which enter the pulmonary system.  In order to assess whether the potentially 
therapeutic agents are effective, we look at the BAL to evaluate cytokine levels and cell profiles.  
Furthermore, the lungs from the same mice are tested for gene expression and for protein content 
on various disease mediators.  We are therefore unable to assess lung architecture from animals 
which are used for BAL, gene and cytokine assessment. 
 
Analyses 2: Determination of inflammation, airway space enlargement and COPD in the lung by 
histological assessment in tissue. 
For this technique we need separate animals from the biochemically assessed for histology to 
determine any structural changes that have occurred in response to cigarette smoke.  These lungs 
cannot be used for the above analyses as the lungs are fixed with paraformaldehyde (fixative) and 
thus cannot be used for molecular profiling as the fixative destroys the genes of interest.  In 
addition, lungs that have been lavaged cannot be used for histological analyses because the 
pressures produced by the lavage process disrupt the lung structure.  Therefore, two separate 
analyses (and hence groups of animals) are required for our experiments due to the incompatibility 
of the techniques used.  This incompatibility in techniques does not allow both analyses to be 
performed on the same animal.  Although the numbers required appear large, each experiment 
has been designed to produce definitive outcomes such that there is no need to go back and 
repeat experiments and we therefore in fact minimise the number of animals used. 
 
Animals Requested VLAHOS AEC #1521 
 2 
Table 1: Smoke exposure protocol  
Cigarette smoke exposure will be for 4 days (acute smoke protocol) or up to 6 months (chronic smoke 
protocol) as established from our previous work (AEEC # 02085, 05097, 0810912, 1112185). 
 
Mouse Treatment n Analysis 
Balb/c Sham control 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Sham + Vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Sham + drug dose 3 
(highest dose in the smoke animals) 
12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Smoke control 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Smoke + Vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Smoke + drug dose 1 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Smoke + drug dose 2 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Smoke + drug dose 3 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Pair fed to smoke control 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Pair fed to smoke vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Pair fed to smoke drug dose 3 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
 Sub-total 132  
 
The 12 animals per group will be divided into two subsections 
8 animals per group for biochemistry and cell assessment 
4 animals per group for histopathological assessment 
 
However this will be done with 7 agents so 132 x 7 = 924 mice total 
Agents will be tested in both acute (4-day) and chronic (up to 6 month) protocols, therefore 2 
timepoints. 
924 mice x 2 = 1848 mice 
 
*Agents = small molecular weight compounds or neutralising antibodies  
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Table 2: Smoke exposure protocol in gene-modified mice 
Based on our past research, we have acquired considerable evidence implicating oxidative 
stress enzymes (Gpx-1, NOX-1, NOX-2, NOX-4), and cytokines (IL-17) in COPD.  We now 
wish to test the universality of oxidative stress enzymes and the cytokines by exposing 
mice lacking these genes to cigarette smoke. 
 
 
Mouse  Treatment n Analysis 
Wild-type C57Bl/6  sham  12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6  Sham + vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6 Sham + drug 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6  Smoke control 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6  Smoke + vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6 Smoke + drug 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6  Pair fed to smoke  12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6  Pair fed to Smoke 
+ vehicle 
12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
Wild-type C57Bl/6 Pair fed to smoke  
+ drug 
12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO  sham  12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO Sham + vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO Sham + drug 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO  Smoke control 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO Smoke + vehicle 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO Smoke + drug 12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO  Pair fed to smoke  12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO Pair fed to Smoke 
+ vehicle 
12 8 x Cellular inflammation and gene profiling 
4 x Histopathological assessment 
KO Pair fed to smoke  12 8 x Cellular inflammation and gene profiling 
Animals Requested VLAHOS AEC #1521 
 4 
+ drug 4 x Histopathological assessment 
 Total 216  
 
 
These studies will be conducted in 5 different mouse strains genetically deficient in genes 
that we have identified as being involved in oxidative stress responses and the 
development of COPD. 
 
Therefore the total number of mice for KO mouse studies = 216 x 5 = 1080 
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Intervention Criteria VLAHOS 
Section 5.4 – Intervention Criteria 
Steps: 
1. Determine the severity of abnormalities seen, using the Severity Table below. 
2. Contact the project supervisor or animal house staff for advice if appropriate or required. 
3. Take action in accordance with the Intervention Criteria below. 
 
Intervention Criteria 
Criteria are based on the severity of signs, as classified by the table below: 
Observations (based on the Severity 
Table below) 
Action required 
Normal (√ on monitoring sheet) None 
1 or more “mild to moderate” signs 
(based on below) 
 
Increase frequency of observations to twice daily 
(seek AFM/AWO advice where appropriate so that 
treatment and care can be given) 
1 or more “severe” signs (based on 
below) 
Euthanasia 
 
Severity Table for Mice 
 Mild to Moderate Severe 
Non-specific sign(s): 
Appearance Slight to moderate piloerection with 
no dehydration (skin tenting). 
Piloerection with dehydration (skin 
tenting). 
Weight 
changes  
Slight to moderated weight decrease 
(<20% compared to starting weight 
for influenza-treated mice and <15% 
compared to starting weight for all 
other mice). 
Weight decrease (>20% compared 
to starting weight for influenza-
treated mice and >15% compared to 
starting weight for all other mice). 
Behaviour Subdued but responsive, decreased 
interaction with peers. 
Unresponsive to activity and 
provocation. 
Specific conditions or abnormal clinical sign(s): 
Malocclusion 
 
 
If no to minimal oral trauma & no to 
minimal weight loss, 
seek AFM/AWO advice: consider 
trimming & providing powdered diet. 
If oral trauma & weight loss seen, or 
if not responsive to treatment, 
euthanize. 
Skin lesion(s) 
 
If very superficial and <1cm, seek 
AFM/AWO advice: consider treating 
with topical or systemic antibiotics. 
If deeper layers of skin are exposed, 
or if not responsive to treatment, 
euthanize. 
Fight 
wound(s) 
If very superficial and <5mm, seek 
AFM/AWO advice: consider treating 
with topical or systemic antibiotics. 
Recheck compatibility with 
cagemates. 
If deeper layers of skin are exposed, 
or if not responsive to treatment, 
euthanize. 
Rectal or 
Vaginal 
prolapse 
 
If has occurred very recently and the 
tissue is not necrotic, seek AWO 
advice: replacement sometimes 
possible under anaesthesia. 
If has occurred more than several 
hours ago or tissue is necrotic, 
euthanize. 
Eye 
discharge or 
conjunctivitis 
If mild and no other signs, seek AWO 
advice re treatment. 
If other signs noted, or not 
responsive to treatment, euthanize. 
Swelling(s) If not ulcerated, no other signs noted 
and does not impair movement, 
observe. 
If has occurred more than several 
hours ago or tissue is necrotic, 
euthanize. 
Other signs Hunched appearance, laboured breathing, loss of grooming. 
Seek AFM/AWO advice re: appropriate action  
or euthanize if animal is in moderate or severe pain or distress 
AFM = Animal Facility Manager, AWO = Animal Welfare Officer 
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APPROVED RESEARCH PROJECT
1.     ADMINISTRATION DETAILS
SPPL: Physiology (031) ETHICS ID: 1212675.3
AEC: Anatomy & Neuroscience, Pathology, 
Pharmacology, and Physiology
PROJECT 
SUPERVISOR &
DEPARTMENT:
Prof Mary Wlodek
Physiology
PRIMARY
CONTACT &
DEPARTMENT:
Mr Andrew Jefferies
Physiology
TITLE: Impact Of Exercise Early In Life On The Adult Heart
APPROVAL 
DATE:
07 October 2014
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1. 2    AMENDMENT SUMMARY
'Yes' answers in this section indicate amendments have been made to that section of the following application:
Project Overview - SPPL or Title?
No
Risk Management/Permits?
No
Project Summary - Outline, Aims and Design?
Explain briefly why an amendment to the project is need, then give details in Project Summary Steps.
Yes - Addition of tail vein blood sampling at 9, 16, 20 & 24 weeks.
JUSTIFICATION FOR THE USE OF ANIMALS
Potential Benefits or Impact?
No
Repeated Studies/Use of Animals?
No
The 3Rs - Replacement, Reduction, Refinement?
Any request for more animals or revisions to project design will require an answer to this section in addition to
reconsideration of all remaining Steps under the category of Refinement, Animals Requested, Transport and Location,
Project Description, Personnel, Monitoring and Fate of Animals.
No
Animals Requested?
State briefly the changes made and complete new details in Animals Requested Step. Note: Both original approval and
amended animal numbers and details will appear in the amended application. Please attach a table listing accumulated
totals of each species/strain used to date.
Yes - We request an additional 55 male WKY rats.
N=20 to be killed at 9 weeks of age (N=10 exercised & N=10 sedentary)
N=30 to be killed at 24 weeks of age (N=10 sedentary, N=10 early exercise, N=10 late exercise)
We also request an additional 5 animals to account for animal ill health or equipment failure.
Transport and Location?
No
Project Description?
Briefly explain how in this amendment the new experimental design or the change to animal numbers can be reconciled
with the original approved application. Include full details at Project Description Step.
Yes - Addition of tail vein blood sampling at 9, 16, 20 & 24 weeks.
Timeline for 9 week and 24 week animals for molecular and hormone studies.
PERSONNEL?
List here names of any new person being added and/or existing person being removed and a brief reason for doing so.
Page  - 3 - Date: 05 November  2014 08:11:05
Then complete all changes in Personnel Step.
Yes - Delete Kristina Anevska, Isobelo Pre and Tina Hosseini. Addition of tail vein blood sampling for some staff and 
students.
Monitoring or Management of Emergencies?
No
Fate of the Animals?
No
Attachments or Supporting Documents?
What is being added or taken out and why? E.g., updated monitoring sheet which incorporates new procedures being
proposed.
Yes - Addition of updated experimental timeline and amendment letter.
2.     PROJECT SUMMARY
BACKGROUND, AIMS AND OUTLINE
2.1 Provide a brief discussion of the background of the project and describe the progress of the project to
date.
Cardiovascular disease is the largest cause of mortality in Australia and physical activity is a key protective factor 
in the prevention of cardiovascular disease and all-cause mortality. Many studies in adult rats and adult humans 
have shown that endurance exercise training is beneficial to the heart, but these effects are only temporary and 
lost several weeks after training is stopped. Because of this it has generally been assumed that the beneficial 
effects of exercise for the heart are also temporary for children. However we have exciting preliminary data from a
previous study in rodents (AEC 0006228) suggesting that when young rats do exercise training before they reach 
puberty, their hearts become bigger (physiological hypertrophy) and possibly healthier and this beneficial effect 
lasts well into adulthood. Furthermore, this beneficial effect appears permanent, despite these rats being 
sedentary throughout their adult life. This project will test our hypothesis, that the juvenile period in rats is a 
unique stage of development amenable to long-term cardiac programming by short-term endurance training. At 
this formative stage of research, it is not possible to identify such a novel link in the heart using human models. 
Very little is known in humans about the long-term beneficial effects of endurance training during childhood on 
adult health. Support for our hypothesis is found in the few human epidemiology studies on earlier childhood that 
have been undertaken -an example being that the most active children at 5 years of age have lower fat mass at 8 
and 11 years of age, even if they are sedentary after 5 years of age. This human study and our preliminary rodent
findings support a role for endurance training during early life as being beneficial to adult health -despite a 
sedentary adult lifestyle. Well controlled animal studies free from confounding environmental and social factors 
are now needed to establish this proof of principle prior to human translation. Therefore, using a rodent 
endurance-training model that is well established by our research team the aims of this project are listed below:
2.2 State the aims of the project.
Aim 1: To investigate if Early Exercise increases adult cardiac function, dimensions, capillarisation, protein 
synthesis, and cardiomyocyte size and number consistent with physiological cardiac hypertrophy.
 A) Assessment of cardiac function (M-mode and colour guided Doppler echocardiography in lightly anesthetised 
rats) 
B) Measurement of ventricular wall thickness and lumen area (digital imaging) 
C) Stereological assessment of capillarisation within the myocardium (stereological techniques) 
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D) Assessment of cardiac fibrosis (image analysis) 
E) Assessment of cardiomyocyte growth (confocal microscopy, stereological measurement of the number of 
cardiomyocyte nuclei) 
Aim 2: To establish if the juvenile period in rats is a unique stage of cardiac development amenable to 
physiological cardiac hypertrophy into adulthood by short-term endurance training. 
Aim 3: To examine if there are gender-specific effects of Early Exercise on adult heart mass, cardiac function and
heart health.
2.3 Briefly outline what will happen to the animals to be used in the amended protocols. It is important to
note that this section is a summary only. Expanded detail of procedures on animals is required in the
Project Description.
Housing: Rats are obtained from the ARC in Perth and are housed in plastic cages of 3-4 rats/cage, 12hr light 
cycle, standard environmental conditions and unrestricted pellets and water. 
Exercise training protocol 6mo cohort: Exercise training consists of running on a motorized treadmill 5 
days/week for four weeks. The 4 week exercise training intervention will be completed at different ages 
throughout the animals life. Some rats will do no exercise training (Sedentary), some rats will complete the 
exercise training early in life (at 5-9 weeks of age), other rats after puberty (at 11-15 weeks old) or later in life (at 
20-24 weeks old). 
Metabolism Cage protocol: At 5.5 months all animals will undergo acclimitisation to a metabolism cage over 
several days. The animals will have a final 24hr met cage measurement, where food and water intake will be 
measured and urine and faeces output recorded. 
Echocardiography: At 6 months of age, all animals will be placed under anaesthetic and an echocardiographic 
(ECG) assessment will be made. 
Post mortem: Following ECG assessment at 6 months of age all rats will be killed by an overdose of anaesthetic 
and a post mortem conducted.
Exercise training protocol 9wk cohort: Exercise training protocol consists of running on a motorized treadmill 5 
days/week for four weeks. Half of the 9 week animals will enter this protocol, the remaining animals will do no 
exercise (Sedentary).
Echocardiography 9wk cohort: At 9wks of age all animal will be placed under anaesthetic and an 
echocardiographic assessment made.
Post mortem 9wk cohort: Following ECG assessment all rats will be killed by an overdose of anaesthetic and a 
post mortem conducted.
Tail vein blood sampling: A tail vein blood sample will be obtained at 9, 16, 20 &amp; 24 weeks to use for 
microRNA and hormones.
JUSTIFICATION FOR THE USE OF ANIMALS
2.4 Explain the significance and the potential benefit of the proposed project.
The innovation of this project is that it will establish that short-term endurance exercise during early life can 
permanently program improved adult heart health in rats. The significance of this project for human health is that 
should our findings translate into humans, it would mean that regular physical activity during childhood could 
result in improved adult heart health, even if people were sedentary during adulthood. Importantly, childhood 
represents a stage in life in which government intervention in physical activity levels is more feasible than during 
adulthood. For example, the amount and type of physical activity could be mandated by changes to the school 
curriculum. The outcomes from this proof of principle project would mean that short-term, practical public health 
interventions in childhood could improve adult heart health and dramatically reduce the burden of disease on the 
Australian health system.
2.5 Will the degree of pain or distress experienced by animals be the same as outlined in the original project.
The echocardiography of the heart occurs under anaesthetic. There are no ill effects of the echo probe procedure.
The animals will be killed by anaesthetic overdose following the ECG procedure.
We have used this exercise training protocol in previous rodent exercise studies (0006228). Based on our 
previous experience, rats cope well with treadmill running exercises such as those proposed in the present study 
as they are naturally physically active animals. Some rats require encouragement such as gentle tapping or 
blowing some medium pressure air onto their "backsides" in order for them to complete the exercise procedure. 
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This could be interpreted as a mild form of discomfort, similar to what humans feel when they are exercising.
Blood will be sampled directly from the tail vein. This involves gently warming the rat using a temperature 
controlled heat lamp. The rat is exposed to heat for no longer than 10 minutes at a cage temperature of 35-37C. 
During this time the rat is visually monitored to ensure that the temperature is not causing discomfort or 
considerable stress. The rats cope well with heating, and usually exhibit no distress. Rats are then wrapped 
gently and blood is sampled from the caudal vein. The rats remains wrapped for approximately 1 minute for the 
tail vein blood sample. The rats will flinch and often squeal when the needle is inserted, to ensure sample is done 
efficiently they are gentle restrained. Once the sample is taken the rat is unwrapped and returns to normal 
behaviour. Staff have extensive experience in this technique to ensure that the stress caused and time taken is 
minimal. The pain caused to the rat is similar to that experienced when humans have a needle inserted for blood 
sampling. Rats are returned to the box and monitored for normal behaviour and to ensure the tail is not bleeding.
2.6 Does this project duplicate work that has been carried out previously? If so, please explain why it is
necessary to duplicate the work.
No
2.7 Have any of the animals been the subject of a previous research or teaching activity? If yes, provide AEC
Register Number/s of the other project/s, describe what was done to the animals previously, and justify
their use in this project.
No
REPLACEMENT
3.     ALTERNATIVES
3.1 Have alternatives that totally or partially replace the use of animals been incorporated into this project? If
no, identify potential alternatives and explain why they are unsuitable for use in this project. If yes,
please describe what alternatives are to be used in this project.
No - This project considers the effects of exercise early in life on the adult heart. There is no alternative to the use
of the whole animal.
REDUCTION
4.     ANIMALS REQUESTED
APPROVED NUMBER  OF ANIMALS
Type/Species Breed/Strain Sex Age Total 
Number
Source
 Rat Wistar M 4 weeks 90 Other - ARC  
 Rat Wistar F 4 weeks 90 Other - ARC  
AMENDED NUMBER OF ANIMALS REQUESTED 
Type/Species Breed/Strain Sex Age Total 
Number
Source
 Rat Wistar M 4 weeks 55 Other - Animal Resources Centre 
 Rat Wistar M 4 weeks 90 Other - ARC  
 Rat Wistar F 4 weeks 90 Other - ARC  
NOTE: refer to section 6.2 for details of genetically modified and/or cloned animals
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5.     JUSTIFICATION FOR NUMBER OF ANIMALS REQUESTED
5.1 Provide an explanation for the number of animals being requested. This explanation should be based on
statistical analysis and/or other considerations in the experimental design (e.g., multiple time points,
quantity of tissue required). Where appropriate, present the numbers in table form.
Please refer to Appendix one for description of animals required.
5.2 To reduce animal use, would the animals or their tissues be suitable for use in another project at the end
of your experiment/s? Identify the suitable project, if known.
Yes - We will be taking a complete range of tissues at post mortem from these animals.  We have strong 
collaborations both nationally and internationally and will be further examining if the tissues from this study which 
we ourselves do not use could form the basis of further study for collaborators.
REFINEMENT
6.     USE OF ANIMALS
6.1 Justify your choice of animal (species/strain/sex/age).
The Wistar Kyoto rat strain is used as it is the same strain that we have used in our previous studies where we 
have established our preliminary findings. Therefore it is critical that the study be conducted in the same strain of 
rats.  Mice are also commonly used in exercise experiments; however the tissue available from each mouse is 
much less. Therefore, by using rats instead of mice, fewer animals are needed to be killed in order to perform all 
of the planned analyses.
6.2 Genetic Modification or Cloning of Animals.
This project does not involve the use or production of genetically modified animals.
This project does not involve the use or production of cloned animals.
6.3 Transport
6.3.1 Will animals need to be transported from the source location/s to the location where they will be
held for this project?
No
6.3.2 Where will procedures be performed? If animals need to be transported from where they are
housed to where the procedures are carried out, provide details of transport and acclimatisation
procedures.
ECG assessment will be performed within the Biological Research Facility. The animals will be 
transported in appropriate transport boxes containing their own bedding in the morning of the day of post 
mortem to the research laboratory on Level 6 of the Department of Physiology. They will be euthanized in 
this laboratory.
6.4 Location & Housing
6.4.1 Where will animals be housed?
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Type/Species Breed/Strain Housing
 Rat Wistar Biological Research Facility  
 Rat Wistar Biological Research Facility  
 Rat Wistar Biological Research Facility  
6.4.2 Will any animals be housed outdoors? If, contrary to the needs of the species, no shelter is
provided, justify the lack of shelter.
No
6.4.3 What type of housing will be used? Describe any special housing requirements.
Rats will be housed in plastic cages containing sawdust. They have constant access to water and food. 
Shredded paper and environmental enrichments are also provided for rats to prepare nests with.
6.4.4 Will any animals be housed individually? If yes, explain why, for how long and how the impact of
social isolation will be minimised.
Yes - They will have a 24 hour metabolic measurement in which they are housed individually in a 
metabolic cage. This is necessary to ensure accurate measurement of food and water intake and energy 
expenditure during this experiment. This will occur on two separate occasions 3 days apart when they are 
5 months old.
7.     PROJECT DESCRIPTION
Housing and food: Rats will be obtained from the ARC and housed in the BRF. They will be kept in plastic cages of 3-4. 
The rats are exposed to a 12 hour light/dark cycle at a room temperature of 18-22 degrees C and 50% relative humidity. 
All rats have food available ad libitum as mouse cubes and unrestricted drinking water access. All rats have nesting 
materials available and enhancement items.
Measurement of body weight and dimensions (AEC 1011865, 1112130): Measurement of weight and dimensions 
(crown rump length, head width, limb length and abdominal circumference) 2, 4, and 6 months. Measurement of 
dimensions requires short animal restraint (30 seconds) and has no adverse effects on the rat.
Exercise Training: The exercise training protocol consists of running on a motorized treadmill 5 days/week. To allow for 
improvements in fitness and familiarity with the procedure, the running duration progressively increases in 10 minute 
increments each day from 20 to 60 minutes, with speed set at 15m/min for the first week and 20m/min thereafter. The 
Sedentary rats are placed on a stationary treadmill for an identical amount of time during weeks 5-9 of life. This is the 
same exercise training protocol as we have employed in our previous study (0006228). Although voluntary exercise with 
the use of running wheels is an alternative exercise option, the precise control of exercise intensity is only possible with 
treadmill exercise and the low variation within the groups allows for our physiologically meaningful changes to be 
detected. Time line for exercise training: There are 4 treatment groups of rats, with all rats being killed at 6 months of age.
Treatment group 1 (Sedentary) are sedentary and are not subjected to any endurance training. Treatment group 2 (Early 
Exercise) complete the exercise training protocol during weeks 5-9 of age. Treatment group 3 (Mid Exercise) complete the
exercise training protocol at weeks 11-15 of age. Treatment group 4 complete the exercise training protocol at weeks 
20-24 of age. We will also study a cohort of 9wk rats. These animals will enter the exercise program at 5wks of age, and 
will exerise for 4 weeks using the same speed and duration of exercise as the early exercise group of the 6mo cohort. 
Only half of these 9wk animals will exrecise, the remaining animals will have no exercise (sedantary).
Renal function testing (AEC 1011865, 1112130): At approximately 5.5 months rats undergo renal function testing using 
a metabolism cage. Prior to a 24hr measurement in the cage, the rats are acclimatised to the metabolism cage over 11 
days. Day 1- 3hrs in metabolism cage, day 4- 8hrs, day 7- overnight, at day 11 the rats have a final 24hr measure. 
Echocardiography (AEC 1011865, 1112130) (Aim 1): The assessment of left ventricular function will be assessed 
echocardiographically, using a GE Vivid E9 and rat cardiac probe at 6 months and 9 weeks of age. Examination requires 
a short period of isoflurane anaesthesia (approx 30 mins) using the Univentor 400 anaesthetic unit, using an induction 
concentration of 3-5% oxygen, at a flow-rate of 3L min, followed by a maintenance concentration of 1.5-3% (isoflurane) 
delivered by a head funnel. The animal will then be placed supinely onto a warming pad, and the chest shaved to remove 
fur. Ultrasound imaging is obtained with gentle application of the probe onto the chest wall, with medical ultrasound gel 
used as a coupling fluid. Measurement of left ventricular fractional shortening, ejection fraction and wall thickness will be 
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made. 
Post mortem: Following ECG assessment rats will be killed with an overdose of an anaesthetic administered 
intraperitoneally (Ketamine (300mg/kg) and Illium Xylazil-20 (30mg/kg) causing a loss of consciousness and subsequent 
collection of blood and tissues for further analysis.
Tail Vein Blood Sampling: Blood will be sampled directly from the tail vein. This involves gently warming the rat using a 
temperature controlled heat lamp where the temperature can not increase above 38C. We use gentle heat for a longer 
period so as to minimise the stress to the animal during this procedure. The rat is exposed to heat for no longer than 10 
minutes at a cage temperature of 35-37C. During this time the rat is visually monitored to ensure that the temperature is 
not causing discomfort or considerable stress. Rats are then wrapped gently and blood is sampled from the caudal vein 
using a 27 gauge needle on a 1ml syringe. Maximum volume sampled is 400μl. The rat remains wrapped for 
approximately 1 minute for the tail vein blood sample.Staff have extensive experience in this technique to ensure that the 
stress caused and time taken is minimal. Rats are returned to the box and monitored for normal behaviour and to ensure 
the tail is not bleeding. Blood samples will be obtained at 9, 16, 20 and 24 weeks.
Timeline for 9 weeks cohort (for molecular and hormone analysis):  Animals will arrive at the BRF at 4 weeks of age 
and be allocated to one of two groups; sedentary and exercise. Those animals allocated to the exercise group will 
commence treadmill exercise at 5 weeks of age using the protocol outlined above. The sedentary group will have no 
exercise. At 9 weeks all animals from this cohort will have blood sampled from the tail vein and then be killed and tissues 
collected and weighed. Please see attached experimental timeline.
Timeline for 24 weeks cohort (for molecular and hormone analysis): Animals will arrive at the BRF at 4 weeks of age 
and be allocated to one of three groups; sedentary, early exercise or late exercise. Animals for the early exercise group 
will commence treadmill exercise at 5 weeks using the above protocol. Animals allocated to the late exercise group will 
commence treadmill exercise at 20 weeks using the above protocol. All animals allocated to this group will have blood 
sampled at 9, 16, 20 and 24 weeks of age via the tail vein. At 24 weeks of age all animals will be killed and tissues 
collected and weighed. Please see attached experimental timeline.
8.     PERSONNEL
PROJECT SUPERVISOR
Name Wlodek, Prof Mary
Qualifications Bachelors Degree, University of Western Ontario, PhD, Monash University, Masters (Research), 
University of Western Ontario
Department Physiology
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
OTHER INVESTIGATOR
 Name Jefferies, Mr Andrew
Qualifications Bachelors Degree, La Trobe University, Post Graduate Diploma, La Trobe University
Department Physiology
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Rat Tail vein blood 
sampling
more than
20
No   
 Rat Monitoring of rats for 
health and well being
more than
20
No   
 Rat Intraperitoneal 
Injection for 
euthanasia
more than
20
No   
 Rat Weights and 
dimensions
more than
20
No   
 Rat Euthanasia by CO2 
asphyxiation
more than
20
No   
 Rat Treadmill exercising of
rats
0 Yes Dr Glenn 
Wadley
Dr Wadley has over 10 
years experience with 
rodent exercise 
experiments and has 
performed the procedure in 
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over 200 rats and mice.  
 Name Wadley, Dr Glenn
Qualifications Dr Wadley is Senior Lecturer at Deakin University in Burwood. He has over 10 years experience in
using the motorized treadmill to exercise rats. He will be responsible for teaching staff and 
students in the Wlodek laboratory the rat exercise protocol.
Department Deakin University
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Rat Treadmill exercising of
rats
more than
20
No   
 Name Asif,  Yasmin
Qualifications
Department Deakin University
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Rat Tail vein blood 
sampling
0 Yes Andrew 
Jefferies
Andrew has over 7 years 
experience in sampling 
blood from rats using the 
tail vein method  
 Rat Monitoring of rats for 
health and well being
more than
20
No   
 Rat Intraperitoneal 
Injection for 
euthanasia
more than
20
No   
 Rat Treadmill exercising of
rats
more than
20
No   
 Rat Weights and 
dimensions
more than
20
No   
 Rat Euthanasia by CO2 
asphyxiation
more than
20
No   
 Rat echocardiography of 
heart
more than
20
No   
 Name Mahizir, Nurul
Qualifications Nurul has completed her BSc with honours in 2012, and intends to commence her PhD in 2013 
within the Wlodek Laboratory.
Department Physiology
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Rat Tail vein blood 
sampling
more than
20
No   
 Rat Monitoring of rats for 
health and well being
more than
20
No   
 Rat intraperitoneal 
Injection for 
euthanasia
more than
20
No   
 Rat Euthanasia by CO2 
asphyxiation
more than
20
No   
 Name Cheong, Jean
Qualifications Jean completed her BSc with honours in 2012, and intends on commencing her PhD in 2013 
within the Wlodek Laboratory.
Department Physiology
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 Rat Tail vein blood 
sampling
more than
20
No   
 Rat Monitoring of rats for 
health and well being
more than
20
No   
 Rat intraperitoneal more than No   
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Injection for 
euthanasia
20
 Rat euthanasia by CO2 
asphyxiation
more than
20
No   
ANIMAL FACILITY MANAGER
 Name Kesar, Ms Marica
Qualifications Applied Diploma, Victoria College
Department School Of Biomedical Sciences
Species Technique /Procedure Times 
Performed
Training 
Required
Training 
Provided by
Expertise of Trainer
 
9.     MONITORING
9.1 Day-to-day monitoring during the project.
Who will monitor the animals on weekdays?
Jean Cheong, Mr Andrew Jefferies, Nurul Mahizir, Yasmin Asif
Who will monitor the animals after hours (incl. Weekends and holidays)?
Jean Cheong, Mr Andrew Jefferies, Nurul Mahizir, Yasmin Asif
9.2 Day-to-day monitoring during the project: What specific signs will be monitored and how frequently?
Attach a copy of the monitoring checklist you will use to record these observations.
We will monitor the daily health of the animals with visual checks to ensure they are active and appear healthy 
(ie.Eyes clear, no secretions, smooth hair, normal behaviour). BRF staff also handle the rats at least twice weekly 
and are trained to observe and act on any inappropriate behaviour or activity of the rat. On weekends and public 
holidays the animals will be checked once daily by a member of the research team. In addition, rats are checked 
daily by the staff of the BRF facility and immediate contact is made with an investigator should any animals 
appear unwell. In addition, the staff of the BRF change bedding two times each week and visually check the rats.
All staff and students that have not been trained will be fully supervised at all times by Andrew Jefferies. No staff 
or students will be rostered onto weekend duties until they are fully trained.
9.3 Monitoring during and after procedures/interventions: What specific signs will be monitored and how
frequently? Attach a copy of the monitoring checklist you will use to record these observations.
Throughout all study times observations are made visually and any activity which seems to be non-typical is 
recorded on our animal record sheets and reported to senior staff for assessment. Monitoring sheets are attached
for these procedures.Rats will be continuously monitored during all treadmill running procedures for changes in 
running style (indicating fatigue). Rats will also be withdrawn if they are unable or unwilling to complete the 
running tasks without a small amount of encouragement as detailed in the project description.
9.4 What clinical, behavioural or other signs will be used to indicate that intervention is needed to alleviate an
animal's pain or suffering? What action will be taken if these indicators are reached?
The rats will be monitored for changes in body mass (i.e. loss of appetite) and general coat condition (lack of 
grooming). If any animal shows signs of distress (losing body mass, scruffy coat, no grooming, not feeding or 
drinking, very aggressive or withdrawn behaviour etc) the animal will be euthanised. In our experience this is very 
uncommon in our healthy cohort of rats. Animals will be weighed and monitored daily whilst exercising, and if an 
animal loses weight over 3 days or max >15% weight loss the animal will be removed from the study.  To 
approach with treatment is often not possible and would most likely further affect the study results, so euthanasia 
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is the most common approach.
9.5 Who is responsible for the management of emergencies?
Prof Mary Wlodek, Mr Andrew Jefferies
10.     FATE OF ANIMALS
10.1 What will be the maximum period of time that an individual animal or group of animals will be used in this
project?
Rats will be in the experimental protocol for up to 6 months.
10.2 What will happen to the animals at the completion of the project?
The animals are killed and relevant tissues collected.
10.3 If the animals are to be killed, how will this be done and by whom? Include information about agents,
dose rates, method and route of administration and experience of personnel.
Animals for post mortem tissue collection are killed via intraperitoneal overdose of Ketamine (300mg/kg) and 
Illium Xylazil-20 (30mg/kg) using a 27G needle and final volume of no more than 500ul. After the overdose of 
Ketamine and Xylazine a thoracotomy will be performed to ensure death. All staff and students are proficient in 
these techniques, or will be thoroughly taught.
10.4 What will be the method of disposal of dead animals?
Animals are wrapped in black plastic bags and placed in the freezer in the BRF on level 9 for appropriate later 
disposal.
11.     ADDITIONAL DETAILS
11.1 Risk Management
11.1.1 Does the research involve procedures or agents that might pose a health risk to other animals
and/or personnel? If Yes, please explain the risk and describe what precautions will be taken.
Yes - Aerrane (Isoflurane) is an anaesthetic that is not considered hazardous according to criteria of 
Worksafe Australia. Although not hazardous, we take the following precautions to in minimise risk to 
otheranimals and personnel; scavenger system to remove excess anaesthetic and PPE (lab coats, gloves
and safety glasses).
11.1.2 Is the acquisition, holding, or use of the animals subject to any permit, law or regulation of the
State or Commonwealth (e.g., OGTR, protected native or imported)? If yes, please specify permit
numbers.
No
11.2 Glossary of Scientific Terms
Scientific Term Lay Description
 Cardiomycocyte Muscle cells that make up the cardiac muscle  
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11.3 Attachments
The following attachments should accompany this application:
Category Description Attached 
Via Themis
Hard Copy
Only
 Extension to question in 
application
Animal request explanation Yes No  
 Extension to question in 
application
Experimental Timeline Yes No  
 Monitoring checklist 
proforma
Echo monitoring sheet Yes No  
 Monitoring checklist 
proforma
Exercise monitoring sheet Yes No  
 Extension to question in 
application
Amendment Letter Yes No  
 Extension to question in 
application
Experimental Timeline Yes No  
11.4 Funding and Contracts
11.4.1 Identify the principal source of funding for this project (internal/external/commercial or private).
External funding agency
11.4.2 Is this project Commercial in Confidence?
No
11.4.3 Is this project covered by a research contract?
No
12.     GENETIC MODIFICATION OR CLONING OF ANIMALS
None Specified.
13.     AUTHORISATIONS
The Research Office has verified that the following nominated personnel have signed off on this project
application online through THEMIS on the given date/s:
 Project Supervisor Wlodek, Prof Mary 18 September 2014  
 Investigator Jefferies, Mr Andrew 16 September 2014  
 Investigator Mahizir, Nurul 16 September 2014  
 Investigator Cheong, Jean 17 September 2014  
 Animal Facility Manager Kesar, Ms Marica 18 September 2014  
The Project Supervisor has acknowledged that all trainers listed on this application have the relevant expertise
and that they have accepted responsibility to train their nominated researcher/s to be competent in the necessary
procedures.


